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Newborn brain injury is the leading cause of childhood neurodisability, including cerebral 
palsy (CP). Cystic periventricular leukomalacia (cPVL) selectively affects preterm newborns. 
Hypoxic-ischemic encephalopathy (HIE) affects term newborns with childbirth complications 
disrupting blood/oxygen supply to the brain. Glutamate excitotoxicity and inflammation are 
key mechanisms of injury. The role of genetic and epigenetic factors in regulation of 
glutamate transport and inflammation is unclear.
Hypotheses:
1) Preterm survivors with risk variants at the glutamate transporter (EAAT2) and key pro-
inflammatory cytokines (TNFα, IL1ß, IL6) have higher risk of impairment vs those with 
either variant or none 
2) Hypoxia-ischaemia (HI) alters transcription of these genes in the term-equivalent rat brain 
3) This is mediated by a DNA methylation change in the brain, which correlates with 
methylation in blood
Methods:
In the APIP cohort (n=308), genotypes were tested for association with CP at 2y; secondary 
outcomes included cPVL, and standardised motor and cognitive assessments at 2y (Griffiths 
Scales) and 5y (Movement ABC; British Ability Scales, BAS).
In the rat study (n=42), the effects of HI on transcription of these genes were assessed in the 
cortex and hippocampus (qPCR), alongside DNA methylation of EAAT2 and TNFα in cortex 
and blood (bisulfite pyrosequencing)
Results:
Cytokine variants are associated with cPVL and CP (TNFα -308) and the BAS cognitive 
score (IL1ß -511). Evidence was weaker for white matter injury (IL6 -174), the non-verbal 
and verbal BAS subscales (IL1ß -511 and EAAT2 -200/-181 respectively). 
HI induced cytokine transcription in the rat brain, accompanied by astrogliosis and myelin 
injury. Evidence of suppression of glutamate transport in the cortex was very weak and not 
associated with DNA methylation changes. 
Conclusions: 
These exploratory studies support a role for neuroinflammation in neurological and 
neurodevelopmental impairment. Genetic and epigenetic biomarkers may facilitate early 




Early life stresses such as prematurity, infections and complicated childbirths can damage the 
delicate developing brain. Newborn brain injury is the leading cause of childhood disabilities 
affecting movement (e.g. cerebral palsy), perception (e.g. blindness, deafness) and cognition 
(e.g. learning, language and memory). A better understanding of how brain injuries occur is 
needed to develop strategies to protect the brain. Two mechanisms are emerging as central: 
brain inflammation and disruption of the neurotransmitter glutamate, which enables 
communication between neurons. Neonatologists often observe that some babies cope worse 
than others upon similar stresses, raising the question of whether genetic differences might be 
important. For example, genetic make-up could affect the strength of inflammatory responses 
or the extent of glutamate transport disruption. Another unanswered question regards the 
actual mechanisms through which early life stresses trigger changes in the brain’s responses, 
e.g. after a severe interruption of blood and oxygen flow (hypoxia-ischaemia) seen in 
complicated childbirths. DNA methylation is an interesting candidate mechanism, acting like 
a signature or molecular memory left on the DNA by stressful events. This signature can turn 
the dial up or down on the brain’s responses and potentially trigger stronger inflammation or 
greater disruption of glutamate transport. Since it is not possible to carry out such 
investigations in babies, animal models become valuable. 
Questions:
1) Do genetic variants affecting inflammation and glutamate transport influence the risk of 
brain injury and disability in a cohort of newborns born very prematurely in Bristol?
2) Does hypoxia-ischaemia alter inflammation and glutamate transport in the rat brain? Is 
this mediated by DNA methylation changes? Can DNA methylation changes reflecting 
the early stages of brain injury be picked up in blood (which is accessible in newborns)?
Results:
1) Genetic variants affecting the strength of inflammation are associated with risk of severe 
brain injury at birth, cerebral palsy at 2y and poorer cognitive scores at 5y. Evidence was 
more uncertain for genetic variants affecting glutamate transport in relation to verbal 
skills at 5y. 
2) Hypoxia-ischaemia caused inflammation in the rat brain, at the beginning of the injury 
process. DNA methylation related to inflammation could not be assessed because of 
COVID-19-related disruptions and remains a priority for future work. Evidence was more 
uncertain for disruption of glutamate transport, and DNA methylation was not affected in 
brain or blood. 
Conclusion:
The study supports a key role for inflammation in newborn brain injuries and related 
disability, as well as a contribution of genetic factors to risk, and encourages further research 
in this direction. Having this type of information ahead of time might help the family and 
healthcare professionals produce a personalised plan of care, which makes the most of the 
available prevention strategies and treatments to protect the brain (e.g. more frequent 
monitoring during pregnancy, labour, and childbirth; plan childbirth in a specialised hospital 
to avoid last minute transfers).
v
Acknowledgments
This work is dedicated to my sister Sara, my lifelong ally, without whom none of this would 
have been possible. 
I would like to thank Prof Karen Luyt, for being an inspirational mentor. She shared her 
vision with me from day one, supported me in becoming a part of the scientific community, 
and consistently fuelled my passion for research. She guided me by sharing expert 
knowledge, asking insightful questions, and offering plenty of positive encouragement. She 
challenged me when I needed it and encouraged me to develop my own path.
I would like to thank Prof Anthony Isles, for sharing so much insight and knowledge with 
such kindness and approachability. I have truly appreciated being able to knock at his door 
during my time in Cardiff whenever I got stuck, and every time leaving with a clear mind and 
a better understanding. I am also thankful for his ability to bring me back to planet Earth 
whenever I went off on a tangent, both in the lab and in my writing.
I would like to thank Dr Ela Chakkarapani, for his sharp questions, constructive comments, 
and high standards, which have regularly pushed me to do better. For giving me the 
invaluable opportunity to learn about many of the things behind working with animal models, 
both in the outlook and in the practice. For enabling a wonderful collaboration with Dr 
Hemmen Sabir and coming to Essen with me.
Thanks to Dr Hemmen Sabir for agreeing to help with the animal work, for opening the doors 
of his lab and his house and sharing his expertise and resources, all with a brilliant sense of 
humour. Thanks to Dr David Harding for sharing the clinical data and cytokine genetic data 
he obtained from the Avon Premature Infant Project. Thanks to Prof Aniko Varadi and Dr 
Shavanthi Rajatileka for sharing the genetic data for the glutamate transporter they obtained 
for the Bristol Neonatal Gene Study. 
Thanks to Dr Santi Rodriguez and Dr Adam Smith-Collins for concentrating so much helpful 
feedback during our yearly reviews and triggering interesting ideas for the future. Thanks to 
Dr David Odd and Prof Peter Blair for helping me get a better understanding of statistics and 
develop critical thinking. Thanks to Dr David Carslake for offering advice on statistics and 
genetic epidemiology concepts in his free time. Thanks to Dr Jennifer Palmer for her advice 
on the qPCR methodology. Thanks to Dr Sally Jary, Dr Helen Miller and Ms Satomi Okano 
for helping me see how the cooperation between different professions enables a true impact 
for children and their families. 
Thanks to Dr Kira Rienecker for helping me get started with the pyrosequencing 
methodology in Cardiff and for sharing her tried and tested common primer sequence. 
Thanks to Dr Ngoc-Nga Vinh for helping me troubleshoot with the temperamental 
pyrosequencing equipment in the Cardiff lab. 
Thanks to Dr Gavin Welsh, for his kindness and support at a difficult time, these things make 
a difference. Thanks to Ms Sharen O’Keefe for being so patient with me and being my expert 
point of reference for anything admin. Thanks to my friend and fellow PhD student Manuela 
Rosa Kouakou for the rants, the chocolate, the laughter and generally being present 
throughout this experience and beyond. Finally, thanks to the GW4 BioMed DTP not only for 
funding this project but also for supporting their students through this difficult pandemic. 
Away from academia, my first thank you goes to my family and friends, both here in Bristol, 
Milan and around the world. Thank you for being my rocks and for your unconditional love 
vi
and support: you are my centre. Thanks to the newly born PMDD Support Bristol group, for 
actively promoting a much needed shift in awareness and providing fellow PMDD warriors 
with a space to connect before going back out there to fight our battles and work towards our 
goals.
Finally, I would like to thank Prof Pierre Gressens and Dr Michael Ashby for their time and 
help in evaluating this project.
vii
Author’s Declaration
I declare that the work in this dissertation was carried out in accordance with the 
requirements of the University's Regulations and Code of Practice for Research Degree 
Programmes and that it has not been submitted for any other academic award. Except where 
indicated by specific reference in the text, the work is the candidate's own work. Work done 
in collaboration with, or with the assistance of, others, is indicated as such. Any views 
expressed in the dissertation are those of the author.
SIGNED: Silvia Pregnolato              DATE: 16/12/2020
viii
Plagiarism Statement 
Excerpts from chapters 1 and 5 have been published in a review article co-authored by Prof 
Karen Luyt, Dr Ela Chakkarapani, Prof Anthony Isles (see Appendix). The first draft of the 
manuscript was written by me. Prof Karen Luyt and I contributed to the conception and 
design of the review. All authors revised, read, and approved the submitted version of the 
manuscript.
SIGNED: Silvia Pregnolato              DATE: 16/12/2020










List of Figures ..................................................................................................xvi
Abbreviations ...................................................................................................xix
1 Background ..................................................................................................22
1.1 Historical and global perspective on the care of the vulnerable newborn ..........22
1.2 Short-term morbidities in the vulnerable newborn: perinatal brain injuries ....26
1.2.1 The burden of morbidities: focus on perinatal brain injuries .......................................26
1.2.2 Neuroimaging and brain injury patterns .......................................................................28
1.3 Long-term morbidities in the vulnerable newborn: neurodevelopmental 
impairment.........................................................................................................................30
1.3.1 Cerebral palsy and related comorbidities .....................................................................30
1.3.2 Cognitive and behavioural impairment ........................................................................34
1.4 Clinical challenges: molecular data and precision medicine ................................36
1.4.1 Identification, diagnosis, and treatment in childhood...................................................36
1.4.2 Identification, diagnosis, and treatment in the neonatal period ....................................38
1.4.3 Integration of molecular data may assist with earlier risk stratification and more 
tailored treatment ......................................................................................................................41
1.5 Pathogenesis of perinatal brain injuries .................................................................42
1.5.1 Developmental vulnerability: preterm birth .................................................................43
1.5.2 Upstream environmental triggers .................................................................................45
1.5.3 Downstream mechanisms .............................................................................................50
1.5.4 Genetic factors ..............................................................................................................69
1.5.5 Epigenetic factors .........................................................................................................75
1.6 Thesis angle: (dys)regulation of the glutamate transporter and pro-
inflammatory cytokines by genetic and epigenetic factors ............................................80
2 Association between candidate genetic variants affecting glutamate 




2.3 Materials and methods .............................................................................................84
2.3.1 Study sample.................................................................................................................84
2.3.2 Genetic variants ............................................................................................................84
2.3.3 Clinical outcomes .........................................................................................................86
2.3.4 Clinical covariates ........................................................................................................87
2.3.5 Statistical analysis.........................................................................................................87
2.3.6 Comparison with 1000 Genomes Project .....................................................................88
x
2.4 Results ........................................................................................................................89
2.4.1 Complete cases .............................................................................................................89
2.4.2 Distribution of alleles and genotypes ...........................................................................89
2.4.3 Characteristics of the cohort .........................................................................................92
2.4.4 Outcomes ....................................................................................................................100
2.5 Discussion ................................................................................................................124
2.5.1 Genetic models ...........................................................................................................125
2.5.2 Missing data................................................................................................................125
2.5.3 Characteristics of the study population.......................................................................127
2.5.4 The study is underpowered to assess the combinations of glutamate transporter 
variants and their interaction with cytokine variants ..............................................................128
2.5.5 TNFα -308 is associated with cPVL at birth and cerebral palsy at 2y .......................130
2.5.6 IL1β -511 is associated with cognitive skills at 5y.....................................................131
2.5.7 IL6 -174 may be associated with cPVL at birth .........................................................132
2.5.8 EAAT2 variants are in Hardy-Weinberg disequilibrium............................................133
2.5.9 EAAT2 variants remain suitable candidates for future studies ..................................135
2.5.10 Considerations on SNP-outcome and SNP-clinical covariate-outcome associations
136
2.5.11 Strengths and limitations ..........................................................................................139
2.6 Conclusion ...............................................................................................................140
3 Transcriptional regulation of key pro-inflammatory cytokines and the 




3.3 Materials and methods ...........................................................................................142
3.3.1 Study design................................................................................................................142
3.3.2 Rice Vannucci rat model of moderate hypoxic-ischemic brain injury at term...........146
3.3.3 Downstream molecular analyses ................................................................................151
3.3.4 Statistical analysis.......................................................................................................157
3.4 Results ......................................................................................................................160
3.4.1 Housekeeping genes ...................................................................................................160
3.4.2 Cortex .........................................................................................................................161
3.4.3 Hippocampus ..............................................................................................................183
3.4.4 Comparison across regions .........................................................................................204
3.5 Discussion ................................................................................................................207
3.5.1 Hypoxia-ischaemia induces astrogliosis and myelin injury in both regions ..............208
3.5.2 Hypoxia-ischaemia induces an early neuroinflammatory response in both regions ..210
3.5.3 Hypoxia-ischaemia may suppress Glt1 in the cortex .................................................212
3.5.4 Methodological refinement for future studies ............................................................213
3.5.5 Strengths and limitations ............................................................................................214
3.6 Conclusion ...............................................................................................................215
4 Promoter DNA methylation at the glutamate transporter in a rat model 
of hypoxic-ischemic brain injury at term .....................................................216
4.1 Introduction.............................................................................................................216
4.2 Hypothesis ...............................................................................................................218
4.3 Materials and methods ...........................................................................................218
4.3.1 Study design................................................................................................................218
4.3.2 Rice Vannucci rat model of moderate hypoxic-ischemic brain injury at term...........218





4.4.2 Glutamate transporter .................................................................................................234
4.5 Discussion ................................................................................................................245
4.5.1 Peg3 data supports accuracy and precision of DNA methylation methodology ........245
4.5.2 There is no evidence that DNA methylation in the promoter of Glt1 is affected by 
hypoxia-ischaemia ..................................................................................................................246
4.5.3 Strengths and limitations ............................................................................................248
4.6 Conclusion ...............................................................................................................249
5 General discussion .....................................................................................249
5.1 Genomic studies of cerebral palsy and newborn brain injuries.........................250
5.1.1 Understanding genetic effects: from single SNP to haplotype analyses ....................251
5.1.2 Choice of study design: from candidate gene to genome-wide approaches ...............253
5.1.3 Choice of outcomes: integrating short-term and long-term outcomes .......................256
5.1.4 Translational value of genetic studies.........................................................................257
5.2 Epigenetic and transcriptional studies of hypoxic-ischemic brain injury.........258
5.2.1 Neuroinflammation in hypoxic-ischemic brain injury ...............................................258
5.2.2 Glutamate transporter regulation following hypoxia-ischaemia remains worth further 
attention ..................................................................................................................................262






Table 2.1. List of candidate SNPs............................................................................................83
Table 2.2. Complete cases cohorts for each EAAT2 SNPs-cytokine SNP pair........................87
Table 2.3. Genotype distributions ............................................................................................87
Table 2.4. Allele frequencies ...................................................................................................88
Table 2.5. Hardy-Weinberg disequilibrium testing for the EAAT2 SNPs................................89
Table 2.6. Distribution of the EAAT2 -200/-181 genotype combinations................................90
Table 2.7. Clinical and demographic characteristics of the cohort ..........................................91
Table 2.8. Distribution of gestational ages...............................................................................91
Table 2.9. Clinical and demographic characteristics by EAAT2 -200 genotype......................92
Table 2.10. Clinical and demographic characteristics by EAAT2 -181 genotype....................93
Table 2.11. Clinical and demographic characteristics by number of A alleles at EAAT2 -200/-
181............................................................................................................................................94
Table 2.12. Clinical and demographic characteristics by TNFα -308 genotype ......................95
Table 2.13. Clinical and demographic characteristics by IL1β -511 genotype........................96
Table 2.14. Clinical and demographic characteristics by IL6 -174 genotype..........................97
Table 2.15. Outcome distributions ...........................................................................................98
Table 2.16. Univariable tests of association between the EAAT2 SNPs and all outcomes......99
Table 2.17. Univariable tests of association between the cytokine SNPs and all outcomes..100
Table 2.18. Univariable tests of association between all SNPs and cerebral palsy ...............101
Table 2.19. Combined EAAT2-cytokine genotype distributions in relation to cerebral palsy
................................................................................................................................................103
Table 2.20. Stratification of the children with cerebral palsy by both genotype and perinatal 
inflammatory exposures .........................................................................................................107
Table 2.21. Univariable tests of association between all SNPs and cystic periventricular 
leukomalacia ..........................................................................................................................109
Table 2.22. Sensitivity analysis of the SNP effects on risk of any moderate to severe white 
matter injury ...........................................................................................................................110
Table 2.23. Combined EAAT2-cytokine genotype distributions in relation to cystic 
periventricular leukomalacia ..................................................................................................111
Table 2.24. Univariable tests of association between all SNPs and the Griffiths aggregate 
general quotient at 2 years......................................................................................................112
Table 2.25. Combined EAAT2-cytokine genotype distributions in relation to the number of 
children with the Griffiths score at 2 years ............................................................................113
xiii
Table 2.26. Univariable tests of association between all SNPs and the BAS score at 5y......114
Table 2.27. Sensitivity analysis of the effects of IL1β -511, EAAT2 -200 and -181 on the 
subscales of the BAS score at 5 years ....................................................................................116
Table 2.28. Combined EAAT2-cytokine genotype distributions in relation to the number of 
children with the BAS score at 5 years ..................................................................................118
Table 2.29. Univariable tests of association between all SNPs and the M-ABC score at 5 
years .......................................................................................................................................119
Table 2.30. Combined EAAT2-cytokine genotype distributions in relation to the M-ABC 
score at 5 years .......................................................................................................................120
Table 2.31. Sensitivity analysis of the SNP effects on the M-ABC score at 5 years.............121
Table 3.1. qPCR primers........................................................................................................153
Table 3.2. qPCR recipe ..........................................................................................................154
Table 3.3. qPCR protocol.......................................................................................................154
Table 3.4. Markers of Injury (Cortex): descriptive statistics .................................................158
Table 3.5. Markers of injury (cortex): primary analyses .......................................................159
Table 3.6. Markers of injury (cortex): secondary analyses ....................................................163
Table 3.7. Gfap expression (cortex): sensitivity analyses......................................................165
Table 3.8. Inflammation (Cortex): descriptive statistics ........................................................166
Table 3.9. Inflammation (cortex): primary analyses ..............................................................167
Table 3.10. Inflammation (cortex): secondary analyses ........................................................171
Table 3.11. Inflammation expression (cortex): sensitivity analyses ......................................173
Table 3.12. Glt1 (cortex): descriptive statistics .....................................................................175
Table 3.13. Glt1 (cortex): primary analyses...........................................................................175
Table 3.14. Glt1 (cortex): secondary analyses .......................................................................176
Table 3.15. Top 10 rats ranked by most extreme gene expression for each gene (cortex) ....179
Table 3.16. Markers of Injury (Hippocampus): descriptive statistics ....................................180
Table 3.17. Markers of injury (hippocampus): primary analyses ..........................................180
Table 3.18. Markers of injury (hippocampus): secondary analyses.......................................185
Table 3.19. Inflammation (hippocampus): descriptive statistics ...........................................187
Table 3.20. Inflammation (hippocampus): primary analyses.................................................188
Table 3.21. Inflammation (hippocampus): secondary analyses .............................................192
Table 3.22. Inflammation expression (hippocampus): sensitivity analyses...........................194
Table 3.23. Glt1 (hippocampus): descriptive statistics ..........................................................196
Table 3.24. Glt1 (hippocampus): primary analyses ...............................................................196
xiv
Table 3.25. Glt1 (hippocampus): secondary analyses............................................................197
Table 3.26. Top 10 pups ranked by most extreme gene expression for each gene 
(hippocampus)........................................................................................................................200
Table 3.27. Gene expression: findings surviving Benjamini-Hochberg False Discovery Rate 
(7%) correction (shaded)........................................................................................................204
Table 4.1. DNA methylation primers.....................................................................................224
Table 4.2. Peg3 – Percentage DNA methylation at individual CpG sites .............................230
Table 4.3. Glt1 (CpG island) – Percentage DNA methylation at individual CpG sites.........231
Table 4.4. Glt1 (CpG island): descriptive statistics ...............................................................233
Table 4.5. Glt1 (CpG island): primary analyses ....................................................................234
Table 4.6. Glt1 (CpG island): secondary analyses .................................................................235
Table 4.7. Glt1 (proximal promoter) – Percentage DNA methylation at individual CpG sites
................................................................................................................................................235
Table 4.8. Glt1 (proximal promoter): descriptive statistics ...................................................236
Table 4.9. Glt1 (proximal promoter): primary analyses ........................................................238
Table 4.10. Glt1 (proximal promoter): secondary analyses ...................................................238
Table 4.11. Glt1 (distal shore) – Percentage DNA methylation at individual CpG sites ......239
Table 4.12. Glt1 (distal shore): descriptive statistics .............................................................240
Table 4.13. Glt1 (distal shore): primary analyses ..................................................................241
Table 4.14. Glt1 (distal shore): secondary analyses...............................................................241
Table 4.15. DNA methylation: findings surviving Benjamini-Hochberg False Discovery Rate 
(5%) correction (none) ...........................................................................................................242
Table 5.1. Research questions and main findings of this project...........................................247
Table 8.1. Literature review of candidate cytokine SNP-relevant outcome studies ..............334
Table 8.2. Regression modelling of the EAAT2-TNFα SNP effects on cerebral palsy ........341
Table 8.3. Regression modelling of the EAAT2-TNFα SNP effects on the BAS cognitive 
score at 5 years .......................................................................................................................342
Table 8.4. Generalised linear model of the EAAT2-TNFα SNP effects on the M-ABC motor 
score at 5 years .......................................................................................................................344
xv
List of Figures
Figure 1.1 Global causes of under-5 deaths in 2015: focus on preterm birth complications and 
intrapartum-related complications (37)....................................................................................23
Figure 1.2. Cerebral Palsy infographic (156)...........................................................................30
Figure 1.3. Diagram of the proposed pathogenetic mechanisms of newborn brain injuries and 
candidate genes examined in this project.................................................................................41
Figure 1.4. Multiple hit hypothesis for brain injuries in the vulnerable newborn (adapted from 
(494, 502))................................................................................................................................48
Figure 1.5. Primary, secondary and tertiary phases of brain injury leading to cerebral palsy 
(655) .........................................................................................................................................55
Figure 1.6. a) topology; b) stoichiometry of EAAT2 transport derived from prokaryotic 
homologue aspartate transporter GltPh as a model for mammalian EAATs (672)...................60
Figure 1.7. Glutamate signalling under a) physiological and b) excitotoxic conditions in the 
immature brain .........................................................................................................................61
Figure 1.8. Model for the potentiation between hypoxia-ischaemia and 
infection/inflammation (375) ...................................................................................................65
Figure 1.9. Molecular mechanisms by which TNFα links glutamate excitotoxicity and 
inflammation (544)...................................................................................................................66
Figure 1.10. Types of genetic variation ...................................................................................69
Figure 1.11. Regulation of gene expression from DNA to protein and context for this project 
(readapted from (1022)) ...........................................................................................................79
Figure 2.1. Linkage disequilibrium plots from Haploview. D’ (left) and r2 (right) .................89
Figure 2.2. Combined EAAT2-TNFα genotype distributions in relation to cerebral palsy ....104
Figure 2.3. Combined EAAT2-IL1β genotype distributions in relation to cerebral palsy......105
Figure 2.4. Combined EAAT2-IL6 genotype distributions in relation to cerebral palsy........106
Figure 2.5. Scatterplot of the Griffiths score at 2 years by the number of A alleles at EAAT2 -
200/-181 .................................................................................................................................113
Figure 2.6. Scatterplot of the BAS score at 5 years by the number of A alleles at EAAT2 -
200/-181 .................................................................................................................................117
Figure 2.7. Proposed model for differential effects of EAAT2 genetic variants in acute and 
chronic hypoxia-ischaemia.....................................................................................................133
Figure 2.8. Directed acyclic graph showing that clinical covariates cannot confound genetic 
effects on neurodevelopmental outcomes ..............................................................................134
xvi
Figure 2.9. Directed acyclic graph of the SNP-cerebral palsy association with clinical 
covariates as mediators ..........................................................................................................135
Figure 2.10. Directed acyclic graph of the SNP-cerebral palsy association with clinical 
covariates as effect modifiers.................................................................................................135
Figure 3.1. Experimental design of the pilot study ................................................................142
Figure 3.2. Marking of pups with numerical IDs for assignment to experimental groups ....143
Figure 3.3. Surgery station .....................................................................................................144
Figure 3.4. Anaesthesia chamber ...........................................................................................145
Figure 3.5. Rat pup under the dissecting microscope ............................................................146
Figure 3.6. Brain on slicer matrix ..........................................................................................148
Figure 3.7. Mbp expression (cortex): plots ............................................................................160
Figure 3.8. Gfap expression (cortex): plots............................................................................161
Figure 3.9. Map2 expression (cortex): plots ..........................................................................162
Figure 3.10. Mbp expression (cortex): plot of secondary analyses........................................164
Figure 3.11. Gfap expression (cortex): plot of secondary analyses .......................................164
Figure 3.12. Map2 expression (cortex): plot of secondary analyses......................................165
Figure 3.13. Gfap expression (cortex): plot of sensitivity analyses .......................................166
Figure 3.14. Tnfα expression (cortex): plots ..........................................................................168
Figure 3.15. Il6 expression (cortex): plots .............................................................................169
Figure 3.16. Ilβ expression (cortex): plots .............................................................................170
Figure 3.17. Tnfα expression (cortex): plot of secondary analyses........................................171
Figure 3.18. Il1β expression (cortex): plot of secondary analyses.........................................172
Figure 3.19. Il6 expression (cortex): plot of secondary analyses...........................................172
Figure 3.20. Inflammation expression (cortex): plots of sensitivity analyses........................174
Figure 3.21. Glt1 expression (cortex): plots...........................................................................176
Figure 3.22. Glt1 expression (cortex): plot of secondary analyses ........................................177
Figure 3.23. Matrix of pairwise correlations in gene expression (ΔCt) (cortex) ...................178
Figure 3.24. Mbp expression (hippocampus): plots ...............................................................182
Figure 3.25. Mbp expression (hippocampus): plot by time ...................................................182
Figure 3.26. Gfap expression (hippocampus): plots ..............................................................183
Figure 3.27. Map2 expression (hippocampus): plots .............................................................184
Figure 3.28. Mbp expression (hippocampus): plot of secondary analyses ............................185
Figure 3.29. Gfap expression (hippocampus): plot of secondary analyses............................186
Figure 3.30. Map2 expression (hippocampus): plot of secondary analyses ..........................186
xvii
Figure 3.31. Tnfα expression (hippocampus): plots ...............................................................189
Figure 3.32. Ilβ expression (hippocampus): plots..................................................................190
Figure 3.33. Il6 expression (hippocampus): plots ..................................................................191
Figure 3.34. Tnfα expression (hippocampus): plot of secondary analyses ............................193
Figure 3.35.Il1β expression (hippocampus): plot of secondary analyses ..............................193
Figure 3.36. Il6 expression (hippocampus): plot of secondary analyses ...............................194
Figure 3.37. Inflammation expression (hippocampus): plots of sensitivity analyses ............195
Figure 3.38. Glt1 expression (hippocampus) .........................................................................197
Figure 3.39. Glt1 expression (hippocampus): plot of secondary analyses.............................198
Figure 3.40. Matrix of pairwise correlations in gene expression (ΔCt) (hippocampus) ........199
Figure 3.41. Pairwise correlations (between bran regions)....................................................203
Figure 4.1. Diagram of the candidate promoter regions in Glt1 chosen for DNA methylation 
analysis by bisulfite conversion followed by pyrosequencing...............................................214
Figure 4.2. DNA methylation analysis: bisulfite conversion, two-step PCR, and 
pyrosequencing ......................................................................................................................221
Figure 4.3. Pyrosequencing cascade as illustrated on the Pyromark Gold Q96 Reagents 
handbook (1299) ....................................................................................................................226
Figure 4.4. Peg3 – Percentage DNA methylation at individual CpG sites ............................231
Figure 4.5. Glt1 (CpG island) – Percentage DNA methylation at individual CpG sites .......232
Figure 4.6. Glt1 (CpG island) DNA methylation: plots.........................................................234
Figure 4.7. Glt1 (proximal promoter) – Percentage DNA methylation at individual CpG sites
................................................................................................................................................236
Figure 4.8. Glt1 (proximal promoter) DNA methylation: plots.............................................237
Figure 4.9. Glt1 (distal shore) – Percentage DNA methylation at individual CpG sites .......239
Figure 4.10. Glt1 (distal shore) DNA methylation: plots.......................................................240
Figure 8.1. Plots of model predictions of the effect of the increasing number of A alleles at 
EAAT2 -200/-181 on the BAS score by TNFα -308 risk genotypes .....................................343
xviii
Abbreviations
ADHD Attention deficit hyperactivity disorder
aEEG Amplitude-integrated electroencephalography
APIP Avon Premature Infant Project
ASD Autism spectrum disorders
BAS British Ability Scales
bp Base pair
bcDNA Bisulfite converted DNA
BGT Basal ganglia thalamus 
cDNA Complementary DNA
cffDNA Cell free fetal DNA
CNS Central nervous system
CNV Copy number variant
CP Cerebral palsy
cPVL Cystic periventricular leukomalacia
CSF Cerebrospinal fluid
Ct Cycle threshold
DAMPs Danger associated molecular patterns
dNTP Deoxyribonucleotide triphosphate
eQTL Expression quantitative trait locus
EWAS Epigenome-wide association study
FACS Fluorescent-activated cell sorting
FDR False discovery rate
FIRS Fetal inflammatory response syndrome
GMFCS Gross Motor Function Classification System
GWAS Genome-wide association study
HI Hypoxia-ischaemia






M-ABC Movement ABC Score
MACS Magnetic-activated cell sorting
MAF Minor allele frequency
mQTL Methylation quantitative trait locus
MRI Magnetic resonance imaging
mRNA Messenger RNA
MRS Magnetic resonance spectroscopy
NEC Necrotising enterocolitis
NICU Neonatal intensive care unit
NTC Non-template control
P7 Postnatal day 7
PCR Polymerase chain reaction
qPCR Quantitative polymerase chain reaction
RCT Randomised controlled trials
RNS Reactive nitrogen species
ROS Reactive oxygen species
xix
RT Room temperature
SNP Single nucleotide polymorphism
SNV Single nucleotide variant






1.1 Historical and global perspective on the care of the vulnerable 
newborn
Perinatal medicine has undergone remarkable advances in the last 70 years and has improved 
survival and quality of life of many vulnerable newborns, making neonatology the most 
rapidly developing specialty in paediatrics (1). While protection of the newborn brain is at the 
very core of these improvements, perinatal brain injuries are still leading causes of mortality 
and morbidity. This project focuses on the two of the most vulnerable populations of 
newborns. The first is represented by term newborns suffering from complications during 
labour and/or childbirth causing interruption in the supply of blood and oxygen to the brain 
leading to hypoxic-ischemic encephalopathy (HIE). The definition of HIE adopted in this 
project adheres to the current international consensus, which requires integration of clinical, 
biochemical, electrophysiological and neuroimaging data evidencing the intrapartum timing 
of the acute hypoxic-ischemic event leading to the encephalopathy (2, 3). The second 
population is represented by preterm newborns, who are often born with a variety of 
comorbidities, challenging an already vulnerable immature body and brain. The impact of 
prematurity on the brain involves a spectrum of abnormalities of the white and grey matter, 
collectively known as encephalopathies of prematurity. At the most severe end of the 
spectrum is cystic periventricular leukomalacia (cPVL), a severe form of preterm white 
matter injury characterised by necrotic cysts in the periventricular white matter large enough 
(≥2 mm) to be observed by cranial ultrasound at birth (4), and for which no postnatal 
treatment is currently available. 
The care of the vulnerable newborn changed drastically from the 1950s and 1960s with the 
introduction of modern state-of-the-art neonatal intensive care units (NICUs) (5). Scientific 
and technological advances allowed substantial improvements in thermoregulation and 
supporting breathing and, as a consequence, sick newborns could be saved in intensive care 
rather than letting them die. Strict hygienic rules for staff and parents in handling the sick 
newborn, especially the most premature, were introduced to prevent spread of infections (6). 
In the 70s, collaborations between pioneering neonatologists and developmental 
psychologists led to the first preterm developmental programmes, focusing on optimising the 
postnatal environment to mimic the intrauterine environment, prevent the iatrogenic sequelae 
of the NICU, and ultimately improve wellbeing and development of these newborns (7-9). 
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This approach was further developed in the 80s, with implementation of the Newborn 
Individualized Developmental Care and Assessment Program (NIDCAP), which promoted an 
understanding of the importance of family involvement, mother-infant bonding, and kangaroo 
care, as well as a shift towards individualisation of care for each newborn based on detailed 
observation of behavioural cues during care (10, 11). By the late 1990s, technological 
advances in neonatal intensive care facilitated survival of neonates born as early as 23 weeks 
gestational age or as small as 500 g. This coincided with increased rates of preterm birth 
globally, possibly due to factors including increased maternal age, pregnancies complicated 
with maternal diabetes and hypertension, multiple pregnancies due to in vitro fertilisation and 
changes in obstetric practices (e.g. increase in c-sections) (as well as improved data 
collection) (12). While most preterm survivors grow into healthy children and adults, the 
preterm population as a whole is at risk for a variety of short- and long-term complications 
including brain injuries and impaired development, respiratory distress syndrome, retinopathy 
of prematurity and infection/inflammation (see 1.2). Preterm births represent a global health 
priority, not only because of the rising rates but also because of the lack of preventative 
treatments and effective screening strategies. Although there are general maternal health 
strategies (e.g. prenatal care, smoking cessation, pregnancy spacing, nutritional supplements 
during pregnancy) and some interventions in women with preterm labour (e.g. progesterone, 
cervical cerclage, antibiotics, tocolytics to slow contractions) that can reduce risk of preterm 
birth, the majority occurs unexpectedly in apparently low-risk women (13, 14). Nowadays, 
amongst preterm births, 60-70% are near term (34-36 weeks), 20% are moderately preterm 
(32-33 weeks), 10-15% are very preterm (28-31 weeks) and 5% are extremely preterm (<28 
weeks) (15, 16). About 30% preterm births are medically induced (e.g. induction of labour or 
caesarean section) due to maternal or fetal indications (e.g. infection, pre-eclampsia); 45% 
preterm births occur due to spontaneous preterm labour, with onset of contractions preceding 
rupture of the fetal membranes; finally, 25% preterm births occur due to premature rupture of 
the membranes (PPROM) preceding onset of contractions (1, 15). 
Despite the increase in rates of preterm birth, mortality of preterm newborns has decreased 
steeply in the last 70 years thanks to advances in perinatal care (17-22). This is most obvious 
when considering survival at the earliest gestational ages. In England, the EPICure studies 
showed that survival to discharge of extreme preterm newborns (22-25 weeks) improved 
from 40% in 1995 to 53% in 2006 (23, 24). In 2016, 8% of the newborns born alive at 22 
weeks survived to 1 year in the UK; this reached 34% for those born at 23 weeks, 59% at 24 
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weeks, 74% at 25 weeks and 82% at 26 weeks (25). When the proportions are calculated 
based on the numbers of admissions to NICU rather than live births, they reach 54% for the 
newborns born at 22 weeks, 45% at 23 weeks, 63% at 24 weeks, 77% at 25 weeks and 84% at 
26 weeks, highlighting the impact of intensive care for survival at the lowest gestational ages. 
Importantly, differences in active perinatal management exist from country to country, with 
lower survival (<1% at 22-23 weeks) in France, where the general policy is to provide 
palliative but not intensive care before 24 weeks (22). Nonetheless, the general trend for 
improved survival of preterm newborns has been observed not only in England, but also in 
France (EPIPAGE studies) (22, 26), Sweden (27, 28), the US (Neonatal Research Network 
studies) (29), Canada (30) and Japan (31), with relatively stable survival rates in Australia 
(32). The majority of newborns born very preterm (between 28 and 32 weeks, i.e. before 7 
months of gestation) survive preterm birth, and, altogether, represent 85% of surviving 
preterm infants (33). 
The more advanced type of data that could be obtained in the state-of-the-art NICU also 
allowed progress in the care of the term newborn suffering from birth-related complications. 
Until the 90s, a diagnosis of birth asphyxia had been based on the symptoms (e.g. breathing 
difficulties, bradycardia, low Apgar score, manifestation of the neurological syndrome) and 
the assumption that this was due to an interruption of oxygen and blood flow to the brain 
(hypoxia-ischaemia, HI) during labour and childbirth (intrapartum). It became increasingly 
clear that that these were non-specific signs of fetal compromise and that the proportion of 
cases with a true intrapartum HI insult preceding encephalopathy was much smaller (34). A 
diagnosis of HIE was introduced to describe these cases, with the requirement of objective 
clinical, biochemical and neuroimaging evidence of the intrapartum HI insult (2, 3). A 
generic diagnosis of neonatal encephalopathy was recommended for the remaining cases 
where causation was more ambiguous, including perhaps multiple hits of milder and 
intermittent or chronic hypoxia-ischaemia across the perinatal period, and/or a variety of 
infectious, genetic, metabolic or traumatic triggers (35). 
Reflecting advances in perinatal care, the global neonatal mortality rate has halved from 5 
million in 1990 to 2.5 million (7,000 neonatal deaths/day) in 2018 (36). Nonetheless, preterm 
birth complications and intrapartum-related complications remain the two leading causes of 
neonatal mortality globally, accounting for 35% (900,000) and 24% (600,000) neonatal 
deaths respectively (Figure 1.1). Next in line are sepsis (15%) and congenital abnormalities 
(11%) (36, 37). Amongst the 140 million newborns born alive every year, 15 million are born 
23
preterm (<37 weeks of gestation), corresponding to 1 in 10 live births (12, 38). Of the 10 
million newborns requiring some form of assistance to breathe in 2010, 1.15 million 
developed neonatal encephalopathy (8.5/1,000 live births), of which at least half died and at 
least a quarter developed some form of neurodevelopmental impairment (39). Asia and Sub-
Saharan Africa account for the majority of neonatal deaths (90%), preterm births (80%) and 
neonatal encephalopathies (93%) (36, 38, 40). In high-income settings including Europe and 
North America neonatal mortality rates are much lower (1.5%) due to availability of 
advanced perinatal care. In the UK, intrapartum-related deaths have halved since the 90s due 
to such advances, and currently account for 5% neonatal deaths (41). In England and Wales, 
neonatal mortality has been in decline since records began in the 80s reflecting healthcare 
improvements, although a plateau was reached between 2017 and 2018 (2.8 deaths/1,000 live 
births). Preterm birth complications remain the leading cause of child mortality in England 
and Wales, accounting for nearly 50% neonatal deaths (42). 
Figure 1.1 Global causes of under-5 deaths in 2015: focus on preterm birth 
complications and intrapartum-related complications (37)
Despite the trend for reduction in absolute numbers of neonatal deaths, the decline in 
neonatal mortality in high income-settings has been slower than that of older children (1-59 
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months) and the proportion of neonatal deaths amongst child deaths has actually increased 
from 40% in 1990 to 47% in 2018 (36). This has been an important obstacle in failing to meet 
the United Nations Millennium Development Goal to reduce childhood mortality by two-
thirds in 2015 (43). In the UK, progress in reducing neonatal mortality has been slower than 
in comparably wealthy countries (EU15+: 15 Western Europe EU members in 2004, Norway, 
Canada and Australia) since the 00s, and specific UK Child Survival Goals have been set to 
address to improve UK survival by 2030 (44). Since the proportion of child mortality caused 
by neonatal deaths is increasing globally, the UN emphasise that “focusing on newborns is 
critical to further accelerating progress in child survival” (43). Moreover, since about a third 
of neonatal deaths occur in the first day of life and nearly three quarters in the first week (45, 
46), “focusing on the critical periods before and immediately following birth is essential to 
saving more newborn lives” (36). 
Survival of vulnerable newborns is highly dependent on place of birth and 
availability/practice of active perinatal management (47). Integration of multiple strategies 
will be required for progress, ranging from implementation of simple and cost-effective 
interventions, such as kangaroo care, support for breastfeeding and basic care for infections 
and breathing difficulties (12), to increased availability of more comprehensive obstetric and 
neonatal intensive care and specialised equipment (39, 48-50). In settings where advanced 
perinatal care is available, precision medicine may provide an opportunity for further 
improvement (51). Integrating molecular data (e.g. genomic, epigenomic, transcriptomic and 
proteomic data) alongside clinical and neuroimaging data has the potential to maximise 
tailoring of care to each newborn, extend the window for active management, improve the 
chances of prevention, and enable identification of novel neuroprotective approaches. 
1.2 Short-term morbidities in the vulnerable newborn: perinatal brain 
injuries
1.2.1 The burden of morbidities: focus on perinatal brain injuries
A premature newborn is deprived of a crucial period of intrauterine growth and is born with a 
body that is immature in all its components. The consequences of these immaturity are 
particularly severe for organs that undergo crucial periods of growth in the third trimester of 
pregnancy, including the brain, lung, gut, and eye. Accordingly, common morbidities 
affecting the preterm newborn include respiratory distress syndrome, neonatal sepsis, 
necrotising enterocolitis, seizures, vision and hearing loss, and haemorrhagic and non-
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haemorrhagic brain injuries (17, 38, 52-60). Term newborns tend to be less susceptible to the 
widespread multi-organ consequences and comorbidities of excessive immaturity, but more 
vulnerable to complications during labour and childbirth due to higher gestational length and 
birth weight. Indeed, an acute HI insult during a problematic labour and childbirth can have 
devastating and life-long consequences on the brain, especially in newborns exposed to other 
perinatal risk factors, such as infections or intrauterine growth restriction (61). The huge 
impact of preterm birth complications and intrapartum-related complications on morbidity is 
clear from WHO global estimates, which place these conditions in fourth and ninth place as 
leading causes of years of healthy life lost due to disability (i.e. over 102,000 and 67,000 
disability-adjusted life years respectively), above causes such as congenital anomalies, HIV 
and tuberculosis (62). The societal burden is also economic, with an estimated £2.9 billion 
cost of preterm birth complications to the public sector in England and Wales in 2006 (63).
The human brain develops substantially after birth, especially in the first months and years of 
life, with the intracortical fibres of the cortex completing their myelination well into the third 
decade (64). Hence, all newborns are born with a brain that is inherently immature and 
vulnerable. While there are other causes of neurodevelopmental impairment (e.g. congenital 
abnormalities, e.g. chromosomal and genetic abnormalities or defects due to exposure to 
neurotoxins, stroke), as well as a range of risk factors (e.g. socioeconomic status, nutrition, 
cognitive stimulation, polygenic risk), perinatal brain injuries remain the leading cause of 
childhood neurodisability (65-67). 
In 2015, a Brain Injuries Expert Working Group was formed and agreed on pragmatic 
definitions and classifications of perinatal brain injuries to be set as a standard in the UK 
(68). The aim was to facilitate systematic data collection for monitoring of trends in perinatal 
brain injuries and effectiveness of neuroprotective strategies. The consensus definition 
excluded congenital abnormalities and included all brain injuries detected during the neonatal 
unit stay, i.e. seizures, intracranial haemorrhage, perinatal stroke, hypoxic-ischemic 
encephalopathy, central nervous system (CNS) infections, bilirubin encephalopathy and 
periventricular leukomalacia. Since clear evidence of injury often emerges as the child grows 
older, it was acknowledged that an accurate measure of brain injuries is based on integration 
of short-term (neonatal) and long-term (childhood) outcomes. Using routinely collected NHS 
data, the group reported that the current rate of perinatal brain injuries in England, Wales and 
Scotland is 5 brain injuries/1,000 live births and that this rate has remained relatively stable 
26
between 2010 and 2015. The national ambition announced by the UK Secretary of State for 
Health to halve this by 2030 places particular urgency on neuroprotection research (69, 70). 
The vulnerability of preterm newborns is highlighted by the high incidence of brain injuries 
in this group (26 brain injuries/1,000 preterm live births) compared to term-born newborns 
(3.5 brain injuries/1,000 term live births) (68). On the other hand, term births represent the 
majority of births, making HIE the most common type of brain injury, with a rate of 
2.6/1,000 live births in England. Next in line are seizures (1.9/1,000 live births), intracranial 
haemorrhage (1.1/1,000 live births), CNS infections (e.g. meningitis) (0.70/1,000 live births), 
bilirubin encephalopathy (0.60 /1,000 live births), perinatal stroke (0.14/1,000 live births) and 
finally cystic periventricular leukomalacia (cPVL) (0.3/1,000 live births). While most of 
these brain injuries affect both preterm and term newborns, over 80% HIE occurs in term 
newborns, whereas intracranial haemorrhage and cPVL disproportionally affect preterm 
newborns. Nearly all of the over 180 newborns who developed with cPVL in 2015 were born 
≤ 33 weeks, and the rate of cPVL in this group reaches 12.4/1,000 live births. This is slightly 
lower than cPVL rate of 1.8% (18/1,000 live births) reported in preterm newborns born <34 
weeks by the French EPIPAGE-2 study in 2011 (22). In clinical practice, a considerable 
degree of overlap is observed and newborns are often diagnosed with multiple types of brain 
injury (68), as for severe intraventricular haemorrhage (IVH) and cPVL (71-75).
1.2.2 Neuroimaging and brain injury patterns
Progress in neuroimaging techniques, with the introduction of MRI techniques alongside 
cranial ultrasound, has been key in understanding the structural correlates of childhood 
neurodevelopmental outcomes in the newborn period (76, 77). 
1.2.2.1.1 Hypoxic-ischemic encephalopathy in the term newborn
Two main patterns of injury are associated with moderate to severe HIE (78). The first 
pattern (25%-75% cases) involves injury to the deep grey matter, including the basal ganglia 
and thalamus (“BGT pattern”), hippocampus and somatosensory cortex (which receives 
output from the motor cortex and integrates external sensory signals before movement 
initiation) (79-81). Injury may also involve the white matter, anterior and posterior limbs of 
internal capsule (ALIC and PLIC), brain stem and cerebellum, and extends further into the 
cortex in the most severe cases (79, 82-88). The BGT are regions of high metabolic demand 
and are therefore most affected by acute HI (89). Accordingly, the BGT patterns is often seen 
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in association with an acute sentinel event, such as prolapse of the umbilical cord or placental 
abruption and is associated with more severe neurodevelopmental impairment (79, 80). 
The second pattern (15-45% cases) involves injury in the watershed areas (“WS pattern”), i.e. 
the vulnerable border areas of the white matter and cortex supplied by the anterior and middle 
cerebral arteries or the middle and posterior cerebral arteries. Injury extends from the white 
matter to the overlying cortex in the most severe cases. WS injury is generally considered to 
be related to prolonged partial HI, since in these instances blood is redistributed to the regions 
with high metabolic demand (e.g. BGT). Newborns with WS injury tend to have normal 
motor outcomes in early childhood, however they are at risk of cognitive and language 
impairment (80, 90, 91). In clinical practice, a considerable degree of overlap is observed 
between brain injury patterns (79, 80, 89).
1.2.2.1.2 Periventricular leukomalacia in the preterm newborn
Progress in neuroimaging techniques also greatly benefitted our understanding of preterm 
white matter injury. In the 1980s, cranial ultrasound could only detect large haemorrhages 
and the most severe cystic type of white matter injury (cPVL), characterized by focal 
macroscopic cysts due to tissue necrosis in the white matter around the ventricles (4, 76, 92). 
This severe form of white matter injury almost inevitably leads to cerebral palsy (93-97). 
Necrotic white matter injury can also evolve into microscopic glial scars, which may not be 
visible with traditional ultrasound. These are a more common type of injury and are sufficient 
to cause a loss in brain volume (76, 98). Necrosis of the periventricular white matter can 
affect white matter tracts that are rapidly developing at the time of injury, including those 
connecting the thalamus to the cortex and different regions of the cortex with each other (99). 
With the development of MRI techniques, a diffuse type of PVL has increasingly been 
recognized, characterised by non-focal and non-necrotic disturbances of myelination in the 
periventricular white matter, typically detected as excessive high signal intensity (DEHSI) on 
MRI (100). This is thought to be due to diffuse gliosis, with typical neuropathological 
features including impaired pre-oligodendrocyte development, astrogliosis and microgliosis, 
and is distinct from the necrotic injury with destruction of all cellular elements that 
characterises cPVL (101). This diffuse white matter injury is associated with reduced white 
matter volume, ventricular dilatation and altered white matter microstructure (detected via 
diffusion tensor imaging) (102-105). Diffuse PVL has emerged as the predominant type of 
white matter injury, accounting for over 90% PVL cases and occurring in 50% preterm 
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newborns (106). MRI neuroimaging, alongside diffusion-weighted, diffusion tensor, and 
susceptibility weighted imaging have also allowed identification of ischemic punctate lesions 
in the white matter and cerebellum, present in 20% extremely preterm newborns, as well as 
small intraventricular and cerebellar haemorrhages (107, 108). While rates of the more severe 
cystic form have declined to less than 5% (below 1% in some centres) with advances in 
perinatal care, this has not been reflected for the diffuse forms (106, 109-116). The cystic and 
diffuse forms of white matter injury have been proposed to be different manifestations of an 
‘encephalopathy of prematurity’ (76) as well as distinct pathologies (117). Advances in 
neuroimaging have also highlighted that injury in the preterm brain is not limited to the white 
matter but it extends to the deep grey matter, cortex, and cerebellum, all of which contribute 
to the volume loss (76, 118-120). Moreover, functional changes in brain connectivity occur 
even in the absence of structural changes, reflecting global differences in brain development 
following preterm birth, and are associated with neurodevelopmental impairment (121, 122). 
Crucially, altered functional connectivity in the preterm brain has now been identified during 
pregnancy using fetal resting-state functional MRI, providing evidence that neurological 
damage in the preterm newborn starts in utero (123).
1.3 Long-term morbidities in the vulnerable newborn: 
neurodevelopmental impairment
Survivors of perinatal brain injuries are at risk of a range of neurodevelopmental impairments 
affecting movement, cognition, perception, and behaviour, with potentially lifelong impact 
(124, 125). 
1.3.1 Cerebral palsy and related comorbidities
1.3.1.1 Classification of cerebral palsy
While moderately rare in the population, with a prevalence of 1/500 live births, cerebral palsy 
(CP) is the most common physical disability in childhood in high-income countries, affecting 
17 million people globally (126-130). CP is currently defined as “a group of permanent 
disorders of the development of movement and posture, causing activity limitation, that are 
attributed to non-progressive disturbances that occurred in the developing fetal or infant 
brain. The motor disorders of cerebral palsy are often accompanied by disturbances of 
sensation, perception, cognition, communication, and behaviour, by epilepsy, and by 
secondary musculoskeletal problems” (131, 132). CP is an umbrella term assigned at the 
diagnosis stage by the clinician based on observation of signs and symptoms. It includes 
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multiple causes and risk factors (many of which are still emerging), neuroimaging patterns 
and clinical subtypes (133-137). 
CP can be classified based on types of motor impairment (spastic, dyskinetic, ataxic and 
mixed), parts of the body affected (quadriplegia, diplegia, hemiplegia), as well as severity 
(Figure 1.2) (127, 138). The latter is described by the five grades of the Gross Motor 
Function Classification System (GMFCS), with grades III to V indicating the inability to 
walk without a waking aid, including wheelchair use (139). Children with spastic hemiplegia 
and diplegia represent 75-80% of the total (approximately 40% for each subtype) in high-
income countries, with 1-2% requiring a wheelchair. The remaining 20-25% children have 
quadriplegia (GMFCS grades IV-V), and three quarters require a wheelchair (140). Overall, 
40% children with CP are unable to walk independently (10% walk with an aid, 30% use a 
wheelchair) (140, 141). Evidence from low-income settings is scarce but suggests a higher 
prevalence of severe forms of CP and additional impairments (142, 143). The most common 
CP subtypes associated with HIE are spastic quadriplegia and dyskinetic CP (144, 145), those 
associated with cPVL are spastic diplegia and quadriplegia; vascular causes including 
haemorrhagic brain injuries and perinatal stroke are typically associated with hemiplegia 
(106, 137). Importantly, 25-50% of the newborns developing CP have a range of additional 
neurodevelopmental impairments, including chronic pain, epilepsy, speech impairment, 
behavioural, sleeping and eating issues, blindness, and deafness (Figure 1.2) (140, 141, 146-
148). Notably, approximately half of these children have some degree of cognitive 
impairment (e.g.  IQ, executive function, language). The health complications of CP extend 
to the entire lifespan and include higher risk of chronic diseases and mortality, likely due to 
reduced physical activity, poor nutrition, accidents, and poor detection/treatment, as well as 
lower perceived quality of life for physical functions and social engagement (149-155).
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Figure 1.2. Cerebral Palsy infographic (156)
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1.3.1.2 Risk factors for cerebral palsy
Since it was first proposed by William Little in 1861 as the consequence of birth asphyxia 
(157), the definition of CP has continued changing reflecting the evolving understanding of 
this group of conditions (137). It is now known that HIE is a cause of CP in important but 
limited proportion of cases, i.e. 10% in high-income countries (2, 61, 145, 158-160). 
Antenatal risk factors interfering with development throughout pregnancy are estimated to 
contribute to CP in 70-80% cases, including preterm birth, male sex, maternal infections, 
placental pathologies leading to intrauterine growth restriction, multiple pregnancies, pre-
eclampsia, in utero exposure to neurotoxins, post-term birth, congenital malformations and 
genetics. Postnatal events, such as neonatal infections, strokes, traumatic brain injuries and 
metabolic disorders make-up the remaining 10-20%, or more in settings with higher infection 
rates (e.g. in areas where cerebral malaria with febrile seizures is endemic) (129, 161-172). 
Moreover, the roles of maternal obesity, maternal education, maternal stress during 
pregnancy, race, ethnicity, and socioeconomic factors are also being explored as risk factors 
for CP, although disentangling correlation from causation is difficult here since these 
variables are often correlated to each other and with preterm birth and access to perinatal care 
(173-189). Overall, it is now recognised that CP results from a combination of multiple 
predisposing factors and causal pathways more frequently than from a single event (134). 
Children born preterm represent 30-50% CP diagnoses, making preterm birth a leading cause 
of CP in high-income settings (172, 190). The risk of CP increases with decreasing 
gestational age (191), and children born before 33 weeks have 30 times higher risk compared 
to their peers born at term (192). The current international estimates of CP prevalence by 
gestational age are 0.1% (1/1,000) live births for children born at term, 0.4-0.7% (4-7/1,000) 
live births for children born moderately preterm, 3-5% (30-50/1,000) live births for children 
born very preterm, and 7-10% live births (70-100/1,000) for children born extremely preterm 
(130, 191, 193-195). 
Amongst preterm newborns, the strongest predictor of death or major disability, including 
disabling CP, blindness and deafness is cPVL (148, 196-199). Up to 90% preterm newborns 
with CP have some form of white matter injury, whether diffuse or cystic (200). Compared to 
cPVL, diffuse PVL and punctate lesions are associated with less severe neurological and 
neurodevelopmental impairment, largely affecting cognitive functioning and risk of 
psychiatric disorders (102, 201-204), although higher risk of CP has also been reported (199). 
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Thus, while brain injuries associated with HIE and cPVL are not the only causes of CP, 
newborns suffering from these two types of brain injuries are very high risk populations: 
without treatment, 30-40% newborns with HIE (205-211) and 80-100% newborns with cPVL 
will develop CP (93-96).
1.3.1.3 Other forms of motor impairment 
Preterm newborns are 3-4 times more likely to develop deficits in finer motor skills and 
coordination vs term newborns, with 20% developing moderate impairment and 40% mild to 
moderate impairment (212-214). Assessing non-CP motor impairment with the Movement 
Assessment Battery for Children (M-ABC) assessment is essential (215-217), since even mild 
motor impairment is associated with comorbidities, e.g. cognitive impairment, poorer 
academic achievement, behavioural problems, and lower social engagement (212, 218-221). 
1.3.2 Cognitive and behavioural impairment
1.3.2.1 Preterm newborns as a high risk population
While the majority of preterm children grow up without any difficulties, it is well recognised 
that the preterm population as a whole is at high risk for a range of cognitive, behavioural, 
and socio-emotional impairments. Cognitive impairment is indeed the most frequent long-
term consequence of preterm brain injury, whether in combination with motor impairment or 
alone (222). Several international studies have reported a trend for lower cognitive scores 
with decreasing gestational age and preterm birth to be a risk factor for intellectual 
disabilities (24, 26, 28, 29, 31, 223-229). Compared to a 1-2% absolute risk of any (mild to 
severe) cognitive impairment in the general population, very preterm children have 15% risk, 
rising to 30-40% for extreme preterm children (191, 228, 230, 231). Meta-analyses found that 
children born very preterm score on average 10-12 points lower (0.7-0.8 standard deviations) 
than their term born peers, reaching 14-20 points (>1 standard deviation) for children born 
extremely preterm (232-234). Cognitive and behavioural impairment in late preterm children 
is less obvious but has nonetheless been reported (235, 236), with a large meta-analysis of 74 
studies including over 64,000 children recently confirming a correlation between gestational 
age and cognitive scores at all preterm gestational ages (237). The study highlighted the 
extent of impairment, with variation in gestational age accounting for 40% variation in IQ, 
and differences in IQ between preterm and term children persisting from before to after 
school. Preterm children also had lower performance in reading, spelling, and maths than 
their term-born peers, with differences for reading and spelling persisting to secondary 
school. Additionally, preterm children had doubled risk of attention deficit hyperactivity 
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disorder (ADHD) (237), alongside an increased risk of autism spectrum disorders that is 
inversely related to gestational age (238-240). Alongside cognitive impairment, socio-
emotional problems (e.g. social competence, self-esteem, emotional regulation) and increased 
risk of psychiatric disorders (e.g. anxiety, depression, schizophrenia, bipolar disorder) have 
also been described in very preterm newborns, with proposed mechanisms including 
interactions between impaired brain development, early life stresses (e.g. pain, maternal 
stress/depression) and early parental behaviour (241). 
1.3.2.2 Risk factors for cognitive impairment
As for motor impairment, cognitive impairment is multifactorial and many of the risk factors 
overlap. Risk factors include perinatal complications (perinatal brain injuries, preterm birth, 
neonatal infections, intrauterine growth restriction, bronchopulmonary dysplasia), biological 
male sex, low socio-economic status, and low maternal education, with the impact of 
perinatal risk factors diminishing over time as environmental factors (e.g. maternal education, 
socioeconomic status) gain importance (91, 197, 228, 242-247). The cumulative effect of 
perinatal risk factors is evidenced by the fact that preterm newborns with multiple risk 
factors, including intrauterine growth restriction, perinatal infection/inflammation, and 
socioeconomic disadvantage, have a higher risk of developing executive function deficits at 
school age (248, 249). Importantly, genetic and epigenetic factors are emerging as important 
contributors to cognitive impairment and intellectual disabilities (250-252). 
cPVL remains the strongest predictor of death or major disability amongst preterm newborns 
(148, 196, 197), and this includes cognitive impairment (253, 254). Children born preterm 
with cPVL have on average 10 points lower IQ at school age (255), as well as visuo-spatial 
impairment (256) and deficits in social cognition (257) compared not only to their term but 
also to their preterm peers. 
Cognitive impairment is a significant problem also in children born at term with HIE. Some 
degree of cognitive impairment was identified in all trials of therapeutic hypothermia (205-
211). Amongst cooled newborns in the NICHD Neonatal Research Network, nearly all the 
survivors with CP (96%) had moderate to severe cognitive impairment (IQ<70) at school age, 
as well as a small percentage of those without CP (9%); additionally, about a third of the 
survivors without CP had milder cognitive delays (IQ 70-84) (243). A systematic review of 7 
studies confirmed that even in the absence of CP, 25-60% HIE survivors develop some 
degree of cognitive impairment by school age (258). Impairment of both general cognitive 
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outcomes and specific subdomains (executive function, memory, attention, language) is 
higher for the newborns with moderate to severe HIE (259-261), although even mild HIE 
may have an effect (260-264). HIE newborns are also at higher risk of behavioural issues, 
such as hyperactivity and attention problems, which in turn affect educational achievement 
(258). Importantly, at least 20% of the children identified as having mild or no cognitive 
impairment still required special educational support (243). 
1.4 Clinical challenges: molecular data and precision medicine 
1.4.1 Identification, diagnosis, and treatment in childhood
While major disabilities (e.g. severe CP, severe cognitive impairment, epilepsy, blindness, 
deafness) tend to emerge early in the first years of life, milder forms of impairment might 
become noticeable only as the child grows to preschool and school age (e.g. milder CP, finer 
motor skills and coordination problems, milder cognitive impairment, speech impairment, 
autism spectrum disorders) (140, 141, 146-148). Identification of children affected by 
neurodisabilities relies on integration of clinical and neuroimaging data from the neonatal 
period with standardised neurological and neurodevelopmental assessments administered by 
clinicians during childhood. The majority of neonatal services in England currently offer 
follow-up until at least 2 years of life (228). A combination of standardised neurological and 
motor assessments can aid in diagnosis of CP, including the Hammersmith Infant 
Neurological Examination, the General Movements Assessment, and the Developmental 
Assessment of Young Children (97, 265, 266). With regard to broader neurodevelopmental 
assessments at toddler age, the most widely used are the Bayley Scales of Infant 
Development and the Griffiths Mental Development Scales, which assess strengths and 
weaknesses in all developmental areas and recommend the most appropriate interventions. As 
the child grows to preschool and school age, a range of age-adequate tests can be used to 
assess specific domains, such as the British Ability Scales (BAS)/Differential Ability Scales 
(DAS), the Kaufmann Assessment Battery for Children (KABC) and the Wechsler 
Intelligence Scale for Children (WISC-IQ) assessing cognition and basic educational 
achievement; the Social Skills Rating System and other assessments for social and emotional 
functioning (267); and the Movement Assessment Battery for Children (M-ABC), assessing 
fine motor skills, balance and coordination. 
The earlier the identification of the brain injury or neurodevelopmental impairment, the 
earlier the child and family can access a diagnosis and all available neuroprotective strategies 
both in the short- and long-term (268). The neuroprotective benefit of developmental 
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strategies during childhood is under investigation. A few studies have assessed the effect of 
developmental interventions (e.g. physical therapy) specifically in children with CP or cPVL 
and have mostly suffered from low power or overlap in content of interventions in study and 
control group (269-271). Most studies have focused on populations at high-risk for 
neurodevelopmental impairment instead, mostly the preterm population (272, 273). Family-
centred programmes that stimulate all aspects of development in high-risk newborns via 
family coaching have shown clinically meaningful effects in the first 2 years which are 
attenuated by 5 years (270, 274). Such dissipation of positive effects of home-based 
developmental intervention was seen in the Avon Premature Infant Project, a prospective 
study which followed children born very preterm in two Bristol hospitals in the 90s up to 5 
years of age (275, 276). In terms of general early developmental interventions (e.g. 
physiotherapy, speech and language therapy and visual and tactile stimulation), a Cochrane 
review and meta-analysis reported a significant impact on cognitive and motor outcomes in 
preterm newborns at toddler age, with cognitive but not motor improvements persisting up to 
preschool age and neither persisting any further (273). Overall, while more evidence is 
needed of the long-term effects of developmental interventions, the existing evidence of 
beneficial effects in early childhood highlights the importance of early identification. 
Experimental research in developmental neuroscience further supports starting interventions 
as early as possible, based on evidence of greater plasticity of the brain in the early periods 
and the existence of sensitive periods, and therefore potential therapeutic windows, for 
different areas of development (268, 277). Investing in early human development has indeed 
been proposed as a strategic economic investment for healthcare and society (277). 
A change in diagnostic practice has been proposed in the last decade, whereby referral to 
intervention is not made after a CP diagnosis but as soon as a child is considered at risk 
(278). This risk-based approach can be extended to all forms of developmental impairment. 
Notably, a systematic review of reviews recently highlighted that a CP diagnosis can now be 
accurately made well before the classic 12-24 months period and even before 6 months’ 
corrected age. This can be achieved by combining clinical history with a range of 
standardised tools including MRI scans (with or without serial ultrasound scans) and 
assessments of motor skills (General Movements, Hammersmith Infant Neurological 
Examination, Developmental Assessment of Young Children) (266). Hence, the current 
translational challenge lies in identifying and integrating as much information as possible 
36
about modifiable and non-modifiable risk factors from before conception all the way to 
childhood. 
1.4.2 Identification, diagnosis, and treatment in the neonatal period
The state-of-the-art NICU represents the first tier of neuroprotection for the vulnerable 
newborn in the perinatal period, despite also having iatrogenic effects. The real-world impact 
of perinatal neuroprotective strategies introduced in the last 50-70 years is evidenced by 
changes in global trends in prevalence of CP and cognitive impairment. Following an initial 
increase with the introduction of modern NICUs and improved survival (279-281), the 
prevalence of CP has declined for all gestational ages including extreme preterm newborns 
(137, 282), and has reached stability since the beginning of the century in Europe (283-286), 
Australia (193), Canada (287), Japan (288) and China (289, 290), with a slight increase to 
3/1,000 live births in the US (291-297). The impact of the improvements in perinatal care and 
neuroprotection is also evident when considering outcomes of extreme preterm newborns. In 
2019, a meta-analysis of 65 cohort studies published between 2000 and 2017 concluded that 
the improved survival in newborns born between 22 and 27 weeks gestation has been 
accompanied by a decrease in severe disability (from 36% to 19% for 22-24 weeks, from 
14% to 4% for 25-27 weeks) and an increase in disability-free survival (from 1% to 9% for 
22-24 weeks, from 41% to 64% for 25-27 weeks) (298).
Two milestones in neuroprotection were achieved in the last decade: the introduction of 
therapeutic hypothermia for term HIE (≥36 weeks), recommended internationally in 2010 
(299-302); and the introduction of magnesium sulphate administered to the mother during 
preterm labour (<34 weeks) for protection of the preterm brain, recommended internationally 
in 2015 (303, 304). Meta-analyses show that both therapies reduce risk of CP by 
approximately a third in their respective populations (303, 305, 306). Currently, these are the 
only two perinatal interventions with high-quality evidence of effectiveness for prevention of 
CP, as evidenced by two Cochrane systematic reviews (307, 308). 
Currently, 5-10% newborns born before 33 weeks still develop CP and 15-20% develop some 
form of cognitive and motor impairment (130, 191, 193-195). Moreover, rates of non-CP 
motor impairment (e.g. developmental coordination disorder) in extreme preterm newborns 
have nearly doubled (from 23% to 37%) in Australia between 1991 and 2005 (215). For the 
preterm newborns developing brain injuries, the DRIFT trial (drainage, irrigation, and 
fibrinolytic therapy) recently reported neuroprotective effects for severe IVH, with evidence 
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of better cognitive outcomes at 2 and 10 years (309, 310). Crucially, no postnatal treatment 
for cPVL exists, and the majority of these newborns still inevitably develop motor and 
cognitive impairment. The highest level of neuroprotection for this population is currently 
achieved by maximising access to all available interventions for global care of the preterm 
newborn, which minimise the risk of mortality and severe brain injury (e.g. planned delivery 
in a tertiary centre, magnesium sulphate, antenatal steroids, prophylactic antibiotics following 
premature rupture of membranes, supported ventilation) (311). This requires the newborn to 
be in the right place and the right time, namely tertiary centres with specialised staff, 
equipment, and medications (312). The impact of being born in the right place has been 
highlighted by studies of extreme preterm newborns in England (EPICure and National 
Neonatal Research Database), reporting that delivery in a tertiary centre improved not only 
the chance of survival but also survival without brain injury and disability (47, 313). A key 
challenge for the preterm population is early identification of newborns at risk and 
appropriate planning.
With regard to HIE, six international trials of hypothermia between 2005 and 2013 have 
shown a reduction in the rate of death or neurodisability by 2 years to 40-50% and the rate of 
CP to 20-30% (205-211). While it is still too early to evaluate changes in the HIE population 
in the post-hypothermia era, there are some encouraging findings suggesting a trend for 
reduced incidence of CP in Sweden, a further drop in rate of death or severe disability to 29% 
in the US (314) and a reduction in CP severity in the UK (145, 282, 315). However, 
approximately 30% cooled newborns with HIE still die or develop a severe disability, and 
approximately 20% still develop CP (314). 
A main issue with hypothermia treatment is missing the 6h-therapeutic window (316, 317). 
Hypothermia treatment requires rapid access to specialised equipment for precise temperature 
control and MRI imaging, which tend to be present mostly in tertiary units. Therefore, a key 
challenge not only for preterm but also term newborns lies in shifting away from a “wait-and-
see” approach where decisions have to be made rapidly based on the clinical course around 
the time of birth, and access to specialised care may not be possible within the short time 
frame. Another key issue is that not all newborns that are treated benefit from hypothermia 
(number needed to treat = 7 (95% CI 5-10)) (306). Treatment may be less or not effective if 
brain injury is too severe (89), and in newborns with different pathologies including neonatal 
encephalopathy with intermittent or prolonged hypoxia during pregnancy (317) or 
misdiagnosed conditions mimicking HIE (e.g. congenital anomalies, neuromuscular 
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conditions and sepsis) (89). To the opposite end, newborns with mild HIE do not currently 
qualify for hypothermia, however 20-30% go on to develop abnormal neurological outcomes 
and it is not clear whether they may also benefit from cooling and further stratification at the 
diagnosis stage (262, 318-322). A key challenge for the term population is refining and 
improving rapidity and accuracy of HIE diagnoses. 
Currently, HIE diagnosis is based on integration of multiple types of evidence, in order to 
distinguish intrapartum hypoxic-ischemic causation from unspecific signs of foetal distress 
(2, 3):
 Biochemical evidence (in the delivery room/NICU): metabolic acidosis in intrapartum 
cord blood/early neonatal blood due to impaired gas exchange in the placenta 
 Clinical evidence
o (in the delivery room): sentinel intrapartum events, sudden and sustained 
bradycardia, low Apgar score at birth, need for prolonged resuscitation 
o (in the NICU): neurological examination with the Sarnat method (e.g. assessing 
seizures, altered consciousness, altered tone and reflexes, inability to start or 
maintain breathing and sucking, multiorgan dysfunction) 
o (childhood follow-up): later diagnosis of spastic quadriplegia or dyskinetic CP
 Electrophysiological evidence (in the NICU): discontinuous or flat trace and/or seizure 
activity on amplitude-integrated electroencephalography (aEEG) 
 Neuroimaging evidence of brain injury (in specialist facilities): MRI in the hours after 
birth 
All of the available biomarkers have some limitations. For example, coupling the Sarnat 
neurological examination with aEEG enhances predictive power, however this is lost during 
hypothermia (323, 324). Magnetic resonance biomarkers in the neonatal period are currently 
the best predictors of long-term neurodevelopmental outcomes and are not affected by 
hypothermia (325-331). These include MRI measurements (e.g. injury in the BGT, PLIC, 
ALIC and watershed) (329, 330, 332, 333), and MRS measurements (e.g. concentration of 
neuronal N-acetyl aspartate (NAA) in the thalamus; Lac/NAA peak-area ratio) (320, 334, 
335). Conventional MRI carried out around 4-6 days has 90% sensitivity (ability to identify 
true positives), however this improves after the first week of life as injury develops; 
moreover, specificity (ability to identify true negatives) is relatively low (around 50%). MRS 
outcomes reflecting oxidative metabolism in the deep grey matter have higher specificity 
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(around 95%) but lower sensitivity (around 82%) (326). Both require advanced equipment 
which is not always available within the required time frame. 
In conclusion, the current clinical challenges for both preterm and term brain injuries lie in 
the need for novel neuroprotective interventions, as well as earlier, more rapid, and more 
accurate identification of newborns at risk. Integration of molecular data (e.g. genomic, 
epigenomic, transcriptomic and proteomic data) has the potential to partly address these 
clinical challenges.
1.4.3 Integration of molecular data may assist with earlier risk stratification and more 
tailored treatment
The molecular field has been developing rapidly in the last two decades, building on the 
sequencing of the human genome in 2003 and the substantial technological advances that 
have followed, which have made these tools increasingly time- and cost-effective. Molecular 
tools currently used primarily within research settings are hoped to become increasingly 
adopted in clinical practice in the future. Genetic variation amongst individuals is emerging 
as an important contributor to risk in complex multifactorial diseases under the influence of 
both genes and environment. Newborn brain injuries are multifactorial, with a central role of 
environmental insults, such as hypoxia-ischaemia, infections, and developmental immaturity 
due to preterm birth (see 1.5). Their genetic architecture is largely unknown, but the common 
observation that some newborns fare better than others upon being exposed to similar insults 
suggests that individual response to such environmental stressors and therefore vulnerability 
to injury may have a genetic component. Moreover, the genetic basis of neurodevelopmental 
impairments that develop during childhood is also emerging (see 1.5.4). In theory, genetic 
risk could be assessed early in pregnancy and provide a layer of information available to the 
family and the neonatologist well before birth and the neonatal stay in the NICU. This has the 
potential to promote a shift towards earlier identification of high-risk pregnancies and 
creation of a tailored care plan that maximises the possibility to intervene on the modifiable 
components of risk at the most appropriate time in the most appropriate place. Extending the 
scope of available information which can be offered by the clinician could also greatly help 
mothers and families, who have increasing control over many choices around birth and often 
little prior objective evidence to support them in the decision-making process (336, 337). A 
better understanding of genetic risk may be particularly relevant for cPVL, for which no 
postnatal treatment exists. 
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The translational value of molecular tools goes beyond assessment of the fixed component of 
risk held within the DNA and extends into exploration of how genes important for brain 
function are dynamically (dys)regulated in response to environmental stressors in their 
journey from DNA to mRNA to proteins. Exploring gene regulation can not only give 
insights into the pathophysiology of injury, but also support candidacy of therapeutic targets 
and molecular biomarkers for rapid diagnosis and risk stratification at birth. This is 
particularly relevant for HIE. The underlying concept is that the acute hypoxic-ischemic 
insult triggering HIE will cause changes in expression of many genes in the brain, some of 
which will have key roles in the injury process. This will lead to measurable changes in gene 
expression in the brain, which may correlate with measurements in easily accessible 
peripheral tissues at birth (e.g. cord blood, early neonatal blood, cerebrospinal fluid) that are 
often collected during routine care. So far, research has focused on measuring serum levels of 
proteins from genes thought to participate in the pathophysiology of injury (e.g. neuronal 
injury, astrocyte injury, neuroinflammation, vascular and blood brain barrier damage, 
oxidative stress, and metabolic intermediates) (see 1.5) (338-347). Clinical studies of HIE 
biomarkers have largely been small, single-centre studies with variable measurement timings 
and outcomes (344), and no single circulating biomarker has yet been identified in this 
relatively new field of research. A type of molecular biomarker which awaits exploration is 
represented by epigenetic marks, which may be laid on DNA following environmental 
stresses (e.g. HI) and potentially disrupt gene regulation both in the short- and long-term, 
acting as a molecular memory (see 1.5.5). Assessing epigenetic biomarkers has the potential 
not only to improve diagnosis at birth but also prediction of long-term outcomes and, more 
broadly, the understanding of the pathogenesis of HIE.
1.5 Pathogenesis of perinatal brain injuries
The aetiology of perinatal brain injuries is multifactorial, including environmental and 
genetic factors, maternal and fetal/neonatal factors, antenatal, intrapartum, and postnatal 
factors, all of which are likely to contribute to short- and long-term outcomes. Half a century 
of research into the mechanisms of perinatal brain injuries has consistently pointed to two 
main upstream triggers, infection/inflammation, and hypoxia-ischaemia (77, 98, 106, 117, 
348, 349). These insults are thought to interact in the vulnerable immature brain and converge 
onto three downstream mechanisms of injury: excessive neuroinflammation and glutamate 
excitotoxicity, which interact and potentiate each other in a bidirectional manner (see 
1.5.3.3), ultimately leading to free radical attack, which directly damages cell components as 
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well as triggering delayed cell death by apoptosis. Severity and temporal profile of hypoxia-
ischaemia (HI) and infection/inflammation (I/I), degree of brain maturity (i.e. gestational 
age), comorbidities, biological sex and genetic background may all contribute to individual 
differences in susceptibility to injury, pathogenesis, and clinical presentation. Thus, brain 
injuries are thought to be induced by complex interactions between environmental triggers - 
cerebral hypoxia-ischaemia and infection/inflammation - developmental and genetic 
vulnerabilities. Disentangling these mechanisms will be key for developing clinical strategies 
aimed at prevention and treatment (101, 350-353). This project focuses on candidate genes 
thought to be involved in the responses to hypoxia-ischaemia and inflammation, namely the 
main glutamate transporter (EAAT2) and three key pro-inflammatory cytokines (TNFα, IL1β 
and IL6), as described below (Figure 1.3).
Figure 1.3. Diagram of the proposed pathogenetic mechanisms of newborn brain 
injuries and candidate genes examined in this project
1.5.1 Developmental vulnerability: preterm birth
The brain undergoes rapid and critical developmental events during the peak time of 
premature brain injury (24-32 weeks), including neuronal migration and proliferation, growth 
of axons and dendrites, synaptogenesis, development of the vascular system and myelination. 
Interference with these trajectories may contribute to selective vulnerability of brain cells and 
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regions and alter subsequent development. Preterm birth itself induced in the baboon by 
elective delivery in the absence of exacerbating factors (e.g. infections, growth restrictions) 
causes subtle brain injury (e.g. white matter gliosis, ventricular dilatation, loss of neurons in 
the hippocampus, and subarachnoid and intraventricular haemorrhages), with the extent of 
injury correlating with the regimen of mechanical ventilation (55, 354).
While neuronal loss in the cortex and deep grey matter is frequently seen in the term 
newborn, in the preterm brain the pre-oligodendrocyte and the periventricular white matter 
are the most vulnerable cellular and regional targets, leading to the classic neuropathology of 
PVL (98, 101). Amongst their functions, oligodendrocytes are responsible for laying the 
highly specialized myelin membrane around axons and are therefore key for development of 
the white matter. Myelination begins before birth and peaks in the first two years of postnatal 
life, with the intracortical fibres of the cortex being myelinated well into the third decade. 
The process of myelination requires that oligodendrocytes first proliferate and develop into 
mature oligodendrocytes and then depose myelin around axons (106). Around the peak time 
of preterm brain injury (28-32 weeks of gestation), the pre-oligodendrocyte stage still 
represents the majority of the oligodendrial pool in the very preterm brain (355, 356). Pre-
oligodendrocytes are more vulnerable than mature oligodendrocytes to hypoxia-ischaemia, 
infection/inflammation, oxidative damage and ultimately cell death (98, 109, 357-363). 
Indeed, a unique feature of diffuse periventricular white matter injury is an arrest in the 
development of oligodendrocytes at the pre-oligodendrocyte stage, leading to the abnormal 
myelination patterns typically seen through MRI (98, 109). In more severe cPVL, necrotic 
injury extends to all cell components leading to cysts and focal axonal degeneration which 
exacerbates myelin injury (77, 364). Certain neuronal populations are also particularly 
vulnerable in the preterm brain, including subplate neurons. Around the peak time for cPVL, 
these neurons send axons to promote and support development of the cortex before the new 
axons projecting from the thalamus, corpus callosum and some regions of the cortex enter the 
cortex itself. Moreover, around this time, GABAergic interneurons migrate to the cortex 
radially from the dorsal telencephalic subventricular zone and tangentially from the ventral 
germinative epithelium of the ganglionic eminence and may therefore find themselves 
travelling through a minefield of activated microglia and astroglia (348, 365). The notion that 
the neonatal brain responds to injury in a way that is dependent on developmental age is 
supported by evidence that moderately preterm newborns (32-35 weeks) and full-term 
newborns with intrapartum HI have different neuromaging and clinical pictures, with the 
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former having a higher incidence of white matter injury and IVH, as well as a higher 
incidence of spastic diplegia (160).
Concurrent developmental vulnerabilities affecting preterm newborns include the inability of 
the immature brain to synthesize appropriate amounts of growth factors needed for brain 
development and endogenous neuroprotection, as well as an immature immune system (366). 
Indeed, preterm newborns have reduced numbers of monocytes and neutrophils and reduced 
ability of these cells to fight infections, as well as lower levels of cytokines; on the other 
hand, perinatal challenges to the immune system can promote an excessive and sustained 
inflammatory response, inducing immune tolerance and reducing immune function in the 
newborn (53). The specific developmental events affecting the immature immune system and 
increasing vulnerability of preterm newborns to infection/inflammation are still largely 
unknown and focus of current research (367). The immature brain is also particularly 
vulnerable to oxidative stress and hypoxia due to lower antioxidant capability, higher content 
of fatty acids vulnerable to lipid peroxidation, and higher content in iron, which is essential 
for growth but can also contribute to free radical generation (368). Overall, it is becoming 
increasingly evident that, aside from the most severe injuries causing necrotic cell death and 
cysts, much of the chronic disability in survivors of preterm birth stems from impaired 
development of brain cells at a critical time for brain growth and establishment of brain 
connectivity (369). This dysmaturation is likely to be multifactorial, with main contributors 
being hypoxia-ischaemia and infection/inflammation, including that triggered by ventilation 
support (370, 371).
1.5.2 Upstream environmental triggers
1.5.2.1 Perinatal infection/inflammation
Since the first studies reporting an association between inflammation, brain injury and CP in 
the 1990s, an active area of research has emerged exploring the role of 
infection/inflammation in newborn brain injuries and neurodevelopment (372-374). 
Currently, a substantial body of epidemiological, neuropathological, and experimental 
evidence supports a causal relationship between local and systemic inflammation and white 
matter injury (and potentially grey matter injury) in the preterm newborn (375-382). 
Substantial evidence also exists that exposure to inflammation sensitises the term brain to 
hypoxic-ischemic brain injury, contributing to HIE (383, 384). 
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Exposure to inflammation can occur across the perinatal period, from the fetal stage (e.g. 
maternal intrauterine infections), to labour and childbirth (e.g. early neonatal sepsis), to the 
neonatal period (e.g. late neonatal sepsis, inflammatory comorbidities such as necrotising 
enterocolitis) (53, 375-379, 382, 385-395).
Maternal genitourinary infections during pregnancy can trigger an inflammatory response in 
the foetus leading to fetal inflammatory response syndrome (FIRS). This syndrome increases 
risk of perinatal death and neurological, pulmonary, and cardiovascular morbidities (396-
402), including CP and cognitive impairment (387, 403-405). Chorioamnionitis is the most 
common antenatal infection and involves a bacterial infection of the placenta arising during 
prolonged labour or premature rupture of membranes. It is the most common cause of 
spontaneous preterm birth, causing up to half of spontaneous preterm births (406-409), and is 
associated with substantial mortality and morbidity (397, 410-413). Clinical studies have 
reported an association with CP in both preterm and term newborns, with the strongest 
association seen in the preterm newborn; indeed, the National Institute for Health and 
Clinical Excellence (NICE) guidelines state it as an independent perinatal risk factor for CP 
at all gestational ages (387, 389, 390, 392, 393, 401, 414-419). There is substantial evidence 
that chorioamnionitis is specifically associated with preterm brain injury, including both 
severe IVH and cPVL (382, 388, 389, 391, 397, 398, 401, 410, 420-428). There is also some 
evidence that chorioamnionitis and maternal fever are associated with neonatal 
encephalopathy in term newborns (429-432). While the FIRS is often seen in association with 
chorioamnionitis, it may also be triggered by maternal blood-borne or respiratory infections. 
Common parasitic (toxoplasmosis) and viral (rubella, cytomegalovirus, herpes simplex) 
extra-amniotic infections are minor causes of CP in high-income countries, nonetheless they 
have been shown to increase risk (433). Some studies related to the Covid-19 pandemic have 
reported that, while the majority of mothers have good outcomes, there may be an increased 
risk of premature rupture of membranes, preterm birth and fetal distress, alongside the 
uncommon but possible risk of vertical transmission (434-437). The inflammatory profile and 
long-term consequences on neurodevelopment in these newborns will have to be followed up 
closely. 
Infection/inflammation can also occur around the time of birth or shortly after. Early onset 
neonatal sepsis is detected from positive microbiological cultures in blood or cerebrospinal 
fluid in the first 3 days of life and assumed to originate from transmission during childbirth, 
while late onset neonatal sepsis is detected after 3 postnatal days and assumed to originate 
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from the postnatal environment (438). Newborns who develop neonatal sepsis are more likely 
to have prolonged hospital stays and neonatal complications and higher mortality (439). 
Preterm newborns are a high-risk population due to the immaturity of their immune system, 
higher incidence of premature rupture of membrane, prolonged labour, prolonged 
hospitalisation, prolonged mechanical ventilation, use of invasive procedures, use of 
antenatal corticosteroids for prevention of respiratory disease (which may be 
immunosuppressive) and postnatal corticosteroids (which have been shown to have both 
benefits and adverse effects, including gastrointestinal, blood pressure and growth problems, 
and neurological abnormalities at high doses) (53, 440, 441).  Moreover, the sickest preterm 
newborns often have comorbidities which potentiate and exacerbate systemic inflammatory 
states. Necrotising enterocolitis (NEC) is an acute inflammation of the gut, due to the lining 
of the intestine becoming invaded with bacteria, leading to sepsis and in the worst cases 
perforation. This devasting condition has proven one of the hardest to eradicate, leading to 
death in 20-40% cases and approaching totality in the sickest newborns (54, 442, 443). More 
than 85% of all NEC cases occur in very premature newborns, pointing to the detrimental 
effect of immaturity, hypoxia-ischaemia, and inflammation not only for the brain and lung, 
but also for the gut (444, 445). The effect of NEC on neurodevelopment has been highlighted 
by a recent systematic review and meta-analysis, which reported that NEC survivors have 
higher risk of both IVH and PVL compared to premature newborns without NEC, and a large 
proportion suffer from neurodevelopmental impairment of which CP is the most common 
(18%); furthermore, the severity of impairment correlates with the severity of gut injury 
(446). Several studies have reported a higher risk of white matter injury, as well as 
neurodevelopmental impairment at 2 years in preterm newborns with neonatal sepsis (386, 
405, 428, 447-454). A recent systematic review and meta-analysis reported that very preterm 
newborns with neonatal sepsis have higher risk of neurodevelopmental impairment, including 
CP and neurosensory deficits, but no difference in cognitive outcomes (455).
The role of neonatal sepsis in term HIE has been explored less than in preterm newborns. In 
the hypothermia trials, the incidence of neonatal sepsis was relatively high (5-14%) and likely 
to be higher in low-income settings (306). A population-based study from South Asia 
reported higher mortality in newborns with encephalopathy also exposed to premature 
rupture of membranes, which is a known risk factor for early neonatal sepsis (456). Presence 
of any perinatal inflammatory marker (including maternal fever in labour, clinical 
chorioamnionitis, fetal tachycardia, prolonged rupture of membranes, early neonatal sepsis, 
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toxoplasmosis, rubella, cytomegalovirus and herpes simplex infection) was found in 
approximately a quarter of over 4,000 term newborns in the Vermont Oxford Network 
Neonatal Encephalopathy Registry (457). A Canadian registry-based cohort studies of 
children with CP found that, while neonatal sepsis was more prevalent in the preterm 
population, term-born children with neonatal sepsis were more likely to have more severe 
motor impairment (spastic quadriplegia and grades IV to V on the Gross Motor Function 
Classification System) (458). 
1.5.2.2 Perinatal hypoxia-ischaemia
The temporal profile of hypoxic-ischemic events is largely different in term and preterm 
newborns. In term newborns with HIE, defined and acute hypoxic-ischemic events during 
problematic labour or childbirth (e.g. placental abruption, cord occlusion, uterine rupture, and 
shoulder dystocia) are usually recognized by the clinician and represent the first step of a 
diagnosis of HIE, aided by objective clinical and neuroimaging criteria. In neonatal 
encephalopathy, an acute hypoxic-ischemic event may act as a second hit on top of an 
existing hypoxic-ischemic condition (e.g. placental abnormalities) with a temporal profile 
that is more difficult to identify. 
In the preterm newborn, a sentinel event is rarely recognized, and hypoxia-ischaemia is 
generally assumed to have a more complex temporal profile, with intermittent or chronic 
nature (364, 459). The foetal brain is adapted for the relatively hypoxic uterine environment 
and is able to compensate and maintain oxygen delivery via changes in cerebral blood flow, 
however beyond a certain threshold cerebral hypoxia-ischaemia can occur (460). Short 
episodes of acute hypoxia can induce labour and preterm birth itself (460). Chronic milder 
hypoxia due to placental insufficiencies can cause growth restriction, accompanied by 
structural and functional brain injuries (55). However, it remains challenging to determine the 
individual contribution of hypoxia-ischaemia amongst several coexistent factors, such as 
infection/inflammation, growth restriction or hyperoxia due to mechanical ventilation (461). 
Physiologically, it is conceivable that the preterm brain is vulnerable to hypoxia-ischaemia 
due to the anatomical and functional immaturity of the periventricular vasculature, which 
would make the periventricular white matter vulnerable to minor drops in cerebral perfusion 
(106, 364, 462-468). The periventricular white matter has lower basal blood flow compared 
to grey matter regions in both humans (469, 470) and the preterm fetal sheep (471-473). 
Further drops in blood flow are common in sick premature infants with respiratory disease 
due to lung immaturity (474). Mechanical ventilation may also contribute to ischaemia due to 
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the vasoconstrictive effect of the induced cumulative hypocarbia (475). A meta-analysis 
recently reported an association between preterm brain injury and perinatal risk factors 
related to hypoxia-ischaemia, including oligohydramnios, acidaemia, low Apgar scores, 
apnoea, respiratory distress syndrome and seizures (476). However, the link between regional 
differences in blood flow and vulnerability to severe white matter injury is not consistent and, 
even in moderate ischaemia, some regions of white matter are spared. This suggests that 
ischaemia is necessary but not sufficient in isolation (77, 352, 472). Indeed, it has been 
suggested that more consistent evidence is needed to ascertain the specific role of hypoxic 
and ischemic events in preterm brain injury altogether, and that future research should take 
into account contributions and interactions with other biological processes, including 
infection/inflammation and developmental vulnerability (366, 369, 370). 
1.5.2.3 Multiple hits
Several experimental studies have shown that a combination of hypoxia-ischaemia and 
infection/inflammation leads to worse brain injury, gross and fine motor impairment, as well 
as memory, learning, and behavioural impairment (477-484). Importantly, mild insults that 
are individually insufficient to cause injury can lead to brain injury when combined (383, 
485-493). In the multiple hit paradigm, hypoxia-ischaemia and neuroinflammation interact 
and potentiate each other in a bidirectional manner, sensitising the brain to subsequent insults 
and contributing to brain injury (369, 375, 383, 485, 486, 494-496). This is reflected by 
clinical evidence that multiple perinatal inflammatory and hypoxic-ischemic risk factors (e.g. 
antenatal or postnatal infection/inflammation, pre-eclampsia, placental pathologies, growth 
restriction, complicated neonatal course) cumulatively increase risk of brain injury and 
neurodisability compared to single hits (61, 121, 417, 497-501). The immature neonatal brain 
is particularly vulnerable to the detrimental effect of these multiple inflammatory and 
excitotoxic hits, as evidenced by the fact that mild intrauterine infection/inflammation confers 
protection to subsequent hypoxia-ischaemia in the adult brain but exacerbates injury in the 
neonatal mouse brain (479). 
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Figure 1.4. Multiple hit hypothesis for brain injuries in the vulnerable newborn 
(adapted from (494, 502))
1.5.3 Downstream mechanisms
1.5.3.1 Neuroinflammation and systemic inflammation: focus on TNFα, IL1β and IL6
1.5.3.1.1 Infection/inflammation, brain injuries and pro-inflammatory cytokines
Experimental evidence supports a causal role of infection/inflammation in brain injury. As a 
standalone insult, infection/inflammation has been studied largely in the context of preterm 
brain injury, with evidence supporting the developing oligodendrocyte as a key cellular target 
(494). An acute and severe intrauterine inflammatory insult, caused by injecting bacteria or 
bacterial endotoxin lipopolysaccharide (LPS, which crosses the placenta) in pregnant 
animals, causes a fetal inflammatory response, leading to white matter injury and behavioural 
abnormalities in mice, rats, rabbits, sheep, and macaques (495, 503-509). Chronic intrauterine 
inflammation also causes a fetal inflammatory response, leading to milder non-cystic injury, 
nonetheless involving axonal disruption, astrogliosis and remodelling of the cerebral 
vasculature in the preterm sheep (510, 511). A more recently developed mouse model with 
intraperitoneal injection of IL1β in the preterm-equivalent pup has shown that even moderate 
systemic inflammation, which is likely more relevant to the preterm newborn, is capable of 
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altering the developmental programmes of the white matter. The insult is sufficient to 
produce myelination defects, with reduced number and diameter of myelinated neurons, 
partial blockade of oligodendrocytes at the non-myelinating pre-oligodendrocyte stage, 
altered expression of relevant transcription factors, neuroimaging, and behavioural 
abnormalities (494, 512). Infection/inflammation has also been explored within a multiple-
hits paradigm in the context of HIE (see 1.5.3.3).
Systemic inflammation caused by perinatal infections or inflammatory comorbidities can 
propagate to the brain via infiltration of peripheral immune cells through the disrupted blood 
brain barrier and local recruitment of peripheral immune cells (494, 513). Moreover, 
peripheral cytokines can stimulate vascular endothelial cells in the brain to release pro-
inflammatory prostaglandins in the brain parenchyma, which in turn activate microglia and 
trigger local inflammatory responses (514, 515). Neuroinflammation with glial activation and 
increase in pro-inflammatory cytokines can also be triggered locally as a result of hypoxic-
ischemic injury of brain cells, especially the developing neuron and oligodendrocyte in the 
term and preterm brain respectively (375, 516). Local and systemic stresses can therefore 
converge on neuroinflammation and cytokines are key molecular mediators at the core of 
these processes. 
Cytokines are emerging as potential therapeutic targets as well as early biomarkers of injury 
in both preterm and term brain injuries, since different perinatal stressors (e.g. perinatal 
infection/inflammation, hypoxia-ischaemia, intrauterine growth restriction, coagulation 
disorders) appear to converge on their dysregulation (381, 517-520). These soluble proteins 
link the nervous system to the endocrine and immune systems, and include interleukins, 
interferons, tumour necrosis factors, chemokines and colony-stimulating factors (521). 
Cytokines are essential for brain homeostasis and development, contributing to 
neuroprotective inflammatory responses, synaptic plasticity, learning and memory, and are 
generally classified into anti- and pro-inflammatory based on their function (522-525). 
Preterm birth itself is associated with a systemic inflammatory status, with elevated cytokine 
levels in cord blood and cerebrospinal fluid (CSF) able to differentiate preterm and term 
newborns (520, 526-529). However, the inflammatory mechanisms relevant to brain injuries 
are at least in part divergent from those leading to preterm birth, as demonstrated by the fact 
that intrauterine inflammation insufficient to cause preterm birth can still induce brain injury; 
moreover, blocking the IL1 receptor prevents brain injury but not preterm birth in mice (530, 
531). There are multiple mechanisms through which inflammation may cause brain injury, 
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including disruption of cerebral blood flow, direct cellular damage mediated by cytotoxic 
pro-inflammatory cytokines and potentiation of glutamate excitotoxicity (101, 532-534). 
For example, TNFα has been proposed to mediate injury via multiple mechanisms: by 
promoting activation of blood coagulators leading to thrombosis and necrosis (535); by 
increasing permeability of the blood brain barrier (536, 537); by direct damage to myelin and 
developing oligodendrocytes (538-542); by activating glial cells and propagating 
neuroinflammation via induction of other cytokines (543); by enhancing glutamate 
excitotoxicity (544), ultimately leading to oxidative stress and damage to immature 
oligodendrocytes and neurons (365, 401, 545, 546); and by affecting blood flow. Indeed, 
TNFα can alter contractility and diameter of cerebral arterioles, with mixed evidence of both 
vasoconstriction with reduced cerebral blood flow (547-549), and vasodilation with increased 
cerebral blood flow (550-554) in newborn piglets, adult rats and rabbits. The underlying 
mechanisms are still unclear and include both endothelium-dependent (e.g. induction of nitric 
oxide synthase, direct modulation of intracellular Ca2+ signals in smooth muscle cells, and 
endothelium-independent (e.g. ceramide signalling) effects (550-554).
1.5.3.1.2 Experimental evidence supporting candidacy of pro-inflammatory cytokines 
Experimental studies support a key role of neuroinflammation in causing brain injury and of 
these cytokines in being key mediators of this process. Major differences in the inflammatory 
response following infection/inflammation, hypoxia-ischaemia or a combination of both are 
seen between preterm- and term-equivalent rats: in the preterm brain, IL1β is the main pro-
inflammatory cytokine released and the anti-inflammatory response is absent or very limited; 
in the term brain, on the other hand, both pro- and anti-inflammatory responses are stronger, 
including both IL1β and TNFα, as is disruption of the blood brain barrier (517).
Several studies have shown that genetic or pharmacological inhibition of IL1 protects the 
newborn rodent brain from hypoxic-ischemic injury (555-561), as well as in combined 
inflammatory and hypoxic-ischemic insults (557, 562, 563). Moreover, knockdown reducing 
but not eliminating IL1β attenuates injury, interestingly in correlation with upregulation of 
IL6 (559). IL6 can have pro- or anti-inflammatory functions depending on the pathological 
context (381, 516, 564). Following HI, it acts as a mediator of inflammation in the acute 
phase, switching to neurotrophic functions in the subacute and long-term phases (564).
Addition of TNFα to mixed glial cultures or overexpression in transgenic mouse exacerbate 
injury (565-567). Genetic knockout or pharmacological inhibition of TNFα after an acute HI 
insult, inflammatory insult or a combined inflammatory/excitotoxic insult are 
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neuroprotective, reducing brain injury by half in some studies (485, 568-573). In term-
equivalent rats exposed to a single inflammatory hit, the Tnfα pathway emerged as being 
associated with cell death/survival in hypothesis-free transcriptome-wide analyses (492). In 
the preterm foetal sheep challenged by prolonged systemic inflammation, blocking TNFα 
delays (but does not stop) the rise of IL6 and markedly attenuates white matter gliosis, while 
also improving recovery of EEG and cardiovascular function (574). TNFα inhibition also 
normalises total oligodendrocyte count, by reducing the proliferation of pre-oligodendrocytes 
stimulated by inflammation, without affecting mature oligodendrocytes or myelin expression, 
though the mechanisms and significance for brain development are still unclear (574). On the 
other hand, TNFα antibody reduces the elevation of IL1β following neuroinfection 
(intracerebral injection of LPS) but does not reverse brain injury, suggesting complex dual 
roles (575). Indeed, mice lacking TNFα receptors are more susceptible to hypoxic-ischemic 
injury (576).
1.5.3.1.3 Clinical evidence supporting candidacy of pro-inflammatory cytokines
Pro-inflammatory cytokines have been found across the three compartments relevant to the 
brain-injured newborn (uterus, fetal/neonatal circulation, fetal/neonatal brain) and are able to 
cross boundaries between them (via the placenta and blood brain barrier) (374). Elevated 
cytokine levels have been found in the post-mortem brains of preterm newborns with cPVL 
(in and around necrotic cysts) as well as in ultrasound-defined diffuse PVL across different 
cell types (including activated microglia, reactive astrocytes, some pre-oligodendrocyte 
populations, macrophages)  (577-584). The role of cytokines in early white matter injury and 
in less severe MRI-defined diffuse white matter injury remains to be ascertained (101). Post-
mortem studies of cytokine levels in term HIE are scarcer but nonetheless include reports of 
elevated expression (especially of IL1β) in the injured regions (e.g. hippocampus), including 
in newborns with seizures (585, 586). Moreover, other inflammatory mediators known to 
regulate these cytokines (e.g. COX2) have been found to be dysregulated in post-mortem HIE 
brains (586-588). 
Cytokines are also found at elevated levels in the systemic circulation of brain-injured 
newborns. Evidence is substantial for preterm newborns, for whom elevated levels in 
amniotic fluid, cord blood, early neonatal blood, CSF and urine are associated with PVL, 
IVH, neurological abnormalities, CP and adverse motor, cognitive, behavioural and 
educational outcomes (independently of gestational age, birth weight and sex) (249, 374, 
589-617). Early cord TNFα is also associated with EEG depression in the newborn period, 
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which is in turn associated with brain injury and neurodevelopmental impairment (618). 
Unsurprisingly, preterm newborns with perinatal infections and inflammatory comorbidities 
(e.g. chorioamnionitis, funisitis, NEC, sepsis, prolonged mechanical ventilation) show 
particularly elevated cytokine levels in cord and neonatal blood (589, 619-628). Fewer 
studies failed to find such an association, and suggested explanations include low power 
(especially for cPVL) and variable time windows for sample drawing and measurement (595, 
599, 627, 629, 630). The association between cytokine levels in neonatal blood and long-term 
neurodevelopmental outcomes is particularly clear in extreme preterm newborns, as shown 
by the ELGAN studies. In this high-risk population, persistency of inflammation (elevated 
levels on multiple days in the first two neonatal weeks) and breadth of inflammation 
(elevated levels of multiple proteins, especially across functional categories) in the first two 
weeks of life seem to have an important impact on neurodevelopment (605). This is reflected 
in a 2- to 3-fold risk of CP (e.g. TNFα and TNFα-r1 with diplegia and IL6 with hemiplegia), 
increased risk of microcephaly, as well as severe motor and cognitive impairment at 2 years 
(604, 607, 611). There is also a clear association between persistently high levels of 3 or 
more inflammatory proteins in early neonatal blood and structural neuroimaging findings, 
including reduced overall brain volume, and reduced volumes for cortex, deep grey matter, 
cerebellum, and brainstem (631). While smaller cerebellum and brainstem are associated with 
impaired cognition, the association between inflammation and cognition is not fully 
explained by reduced brain volumes and other mechanisms are likely to be involved, 
including impaired functional connectivity, and altered epigenetic regulation of gene 
expression (631, 632). Indeed, cytokines may affect neurodevelopment in the absence of 
obvious perinatal brain injuries. This is supported by evidence that the association between 
persistently high levels in early neonatal blood and attention problems at 2 years is not 
mediated by ultrasound evidence of white matter injury or early cognitive impairment (612). 
Interestingly, cytokine levels on day 14 have much higher predictive power than at day 3, 
which may reflect the accumulation of risk factors after birth (611).
Cytokines are also elevated in the peripheral circulation of term newborns. Children born at 
term developing CP have higher TNFα, IL1β and IL6 levels in neonatal blood (372). More 
recently, interest has focused specifically on HIE, with emerging evidence that elevated 
levels in CSF not only predict HIE but also correlate with HIE severity (346, 633-637), as 
well as being associated with death or neurological and neurodevelopmental impairment at 
toddler age (633, 637-639). Cytokine levels in cord blood and early neonatal blood have also 
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been shown to predict HIE (323, 346, 636, 640-643). This includes association with MRI and 
aEEG findings (644, 645), MRS-defined impaired oxidative metabolism in the deep grey 
matter (646) and seizures (647). Once again, elevated levels in blood also predict long-term 
neurological and neurodevelopmental impairment (323, 639, 640, 646, 648-650) and epilepsy 
(647). 
Importantly, the inflammatory response in these newborns may remain altered in the long-
term. Preterm children who had PVL at birth and developed CP maintain an altered 
inflammatory response at-school age, producing higher levels of TNFα both in plasma and in 
peripheral blood mononuclear cells following an inflammatory challenge ex vivo (LPS 
stimulation) compared to control children matched by gestational age (651). Similarly, 
children who had neonatal encephalopathy at birth maintain higher levels of several pro-
inflammatory cytokines in serum at school age, both at baseline (including TNFβ, IL6 and 
IL8) and following LPS stimulation ex vivo (including TNFα, IL1β, IL6 and IL8), with 
elevated TNFβ correlating with low gross motor scores (652). Another study reported that 
children with CP have higher plasma TNFα, although gestational age was not reported (653). 
Interestingly, TNFα levels correlated with CP severity measured using the Gross Motor 
Function Classification System in the subgroups with spastic quadriplegia and diplegia, as 
well as with degree of improvement after rehabilitation therapy. A study with a Han Chinese 
sample reported higher plasma IL6 in term-born male adults with spastic CP (654). These 
findings need to be confirmed by larger studies but suggest that the insults leading to 
perinatal brain injury might program inflammation to be sustained in the long-term, 
potentially offering an extended window for intervention. Tertiary mechanisms of injury, 
mediated by epigenetic modifications, may sustain dysregulation and sensitisation in the long 
term, interfering with remodelling and repair mechanisms (380, 655). 
Amongst pro-inflammatory cytokines, TNFα, IL1β and IL6 are not only the most frequently 
studied, but also the most predictive of neurodevelopmental outcomes, as reported by two 
systematic reviews (613, 656). Candidacy of these cytokines is supported by the finding of 
dysregulation in a range of neurodevelopmental, psychiatric, and neurodegenerative disorders 
(657-661). 
1.5.3.2 Glutamate excitotoxicity: focus on EAAT2
1.5.3.2.1 Hypoxia-ischaemia, glutamate excitotoxicity and brain injuries
An acute HI insult leads to brain injury in first instance via disruption of glutamate 
homeostasis. Glutamate is the main excitatory neurotransmitter in the mammalian brain 
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(662). It is essential for brain function, orchestrating not only fast excitatory 
neurotransmission but also long-lasting neuronal changes necessary for memory, learning and 
cognition. It is also fundamental during brain development, due to its role in regulating 
formation and elimination of synapses, neuronal migration, proliferation, and viability. 
Glutamate is abundant inside brain cells and most neurons and glial cells have glutamate 
receptors distributed across most cellular elements, highlighting the importance of 
glutamatergic systems for normal function (663-667). Stimulation of a glutamatergic neuron 
results in Ca2+-dependent release of glutamate in the synapse by vesicular exocytosis. 
Extracellular glutamate binds to and activates post-synaptic ionotropic (NMDA, AMPA and 
kainate receptors) and metabotropic (mGluR) glutamate receptors, stimulating the post-
synaptic neurons via Ca2+ or Na+ influx. This induces intracellular signalling cascades which 
lead to physiological cellular responses, such as regulation of transcription factors and DNA 
replication (668, 669). The ubiquity of glutamate is a double-edged sword: when homeostasis 
is disrupted, glutamate can turn into a potent neurotoxin. If the concentration of glutamate in 
the extracellular space rises above physiological levels, post-synaptic glutamate receptors are 
overactivated. This excessive activation, or excitotoxicity, leads to cell death via activation of 
suicide cell programs (apoptosis) (669, 670). Since it was first proposed in the late 1960s 
(671), the concept of glutamate excitotoxicity has been implicated in several adult disorders, 
both acute (e.g. ischemic stroke and traumatic brain injury) and chronic (e.g. amyotrophic 
lateral sclerosis, Alzheimer’s, Parkinson’s, major depression and addiction) (672, 673). 
Consistently, injection of glutamate agonists into the cortex, striatum, and periventricular 
white matter of newborn rodents, rabbits and kittens produces patterns of perinatal brain 
injuries similar to those seen in humans (674-680). 
The cascade leading to glutamate excitotoxicity following an acute HI event is well described 
and typically involves an acute phase of injury minutes after the insult, and a delayed phase 
of injury in the hours and days after reperfusion. In the model of HI and inflammatory brain 
injuries leading to CP, the tertiary phase is less clear but is thought to span weeks and years 
after the insult and involve prolonged inflammation, impaired development, impaired repair 
and remodelling mechanisms and epigenetic dysfunction (89, 344, 655, 681, 682). 
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Figure 1.5. Primary, secondary and tertiary phases of brain injury leading to cerebral 
palsy (655)
Following an acute HI insult, a primary energy failure occurs due to blood, oxygen and 
glucose deprivation, causing failure of oxidative phosphorylation and impairment of ATP 
production and tissue energy reserves. Astrocytes, with their unique oxidative capacity and 
ability to upregulate ATP production, are central to maintaining energy metabolism during 
the first stages of ischaemia (683). If the insult is severe, some cells may die at this early 
stage via necrosis, due to influx of ions and water, cell swelling and bursting, with all cellular 
elements dying within hours. This is a key process in the development of white matter cysts 
in the preterm brain (77).
Upon reperfusion and reoxygenation, glucose use is nearly completely restored, as is 
mitochondrial respiration and production of high-energy phosphates including ATP (latent 
phase) (682, 684-686). However, impairment of the ATP-dependent Na+/K+ pumps in the 
early phases leads to loss of the electrochemical gradient across the cell membrane. In 
surviving neurons, depolarization of the cell membrane activates Ca2+ channels in the pre-
synaptic terminal, triggering vesicular release of glutamate in the synapse. In astrocytes, HI 
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leads to a failure in the astrocytic glutamate uptake system, which also relies on Na+/K+ 
gradients. The combination of increased synaptic release and reduced astrocytic uptake leads 
to accumulation of glutamate in the synaptic space and overactivation of post-synaptic 
ionotropic and metabotropic glutamate receptors (106). The subsequent intracellular Ca2+ 
flooding triggers activation of phospholipases, endonucleases, proteases, and nitric oxide 
synthase, with degradation of cellular and extracellular structures, and generation of harmful 
free radicals, reactive oxygen species (ROS) and reactive nitrogen species (RNS). 
Additionally, glutamate leaking outside the synapse activates extra-synaptic NMDA 
receptors, which, contrarily to the pro-survival action of synaptic NMDA receptors, promotes 
excitotoxic cell death even further (687). This excitotoxic-oxidative cascade eventually leads 
to cell damage or death via a continuum of necrosis, apoptosis, and autophagy in the 
secondary phase of injury hours after the insult (76, 77, 671, 688-694). During necrosis, the 
cell swells until the membrane is ruptured, the intracellular contents are released and lysed, 
followed by inflammation and phagocytosis. On the other hand, during apoptosis chromatin 
is condensed, the cell shrinks while the cell membrane remains intact, mitochondria are 
damaged, death genes (e.g. Bax, Caspases, p53, Parp, Cytochrome c, Bid) are activated 
leading to cleavage of DNA at specific sites, and the cells dies without inflammation 
followed by phagocytosis (101). The role of autophagy, a type of cell death mediated by 
lysosomes, is less clear, but evidence of its involvement in HI brain injury is emerging (681, 
692, 695, 696). The predominant cell death mechanism depends on severity of the insult, sex, 
cell type and developmental stage of the cell (101, 697). Importantly, the secondary energy 
failure has been evidenced in vivo in newborns by MRS imaging. Specifically, a depletion of 
high energy phosphates occurs in the brain in the 12h following HI accompanied by a rise in 
lactate, despite maintenance of cardio-respiratory support (685, 698). This secondary energy 
failure correlates with adverse outcomes including death, brain injury and disability (699). 
Therapeutic hypothermia interferes with the secondary injury process, posing the requirement 
for the short time window (700-703).
The different patterns of HI brain injury in the preterm and term brain may be related to 
differential cellular and regional vulnerabilities at different stages of development, alongside 
developmentally-regulated changes in expression of glutamatergic genes (98, 101, 106). The 
white matter in the rat is more vulnerable to HI at preterm-equivalent age, when pre-
oligodendrocytes are predominant, than at term-equivalent age, when mature 
oligodendrocytes are the major form (359, 704, 705). Glutamate is highly toxic to pre-
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oligodendrocytes in cell culture, rapidly leading to cell death via free radical attack (357, 706, 
707). Pre-oligodendrocytes are also strikingly more vulnerable than immature neurons in 
moderate global ischaemia in the preterm fetal sheep (708, 709). Accordingly, the patterns of 
HI white matter injury seem to be determined primarily by the timing of appearance (710) 
and spatial distribution (472) of pre-oligodendrocytes rather than severity of ischaemia itself. 
Immature neurons in the preterm brain are also more vulnerable to excitotoxic injury than in 
the term brain, since NMDA receptors are developmentally upregulated, more permeable to 
calcium and less sensitive to magnesium block (711). In physiological conditions, the 
abundance of glutamate receptors in the white matter is key during early neuronal 
development, contributing to rapid growth and myelination. However, their abundance also 
confers increased vulnerability in excitotoxic conditions (712). The selective vulnerability of 
subplate neurons compared to cortical neurons observed in a preterm model of HI has been 
suggested to originate from a developmentally-regulated increase in glutamate receptors 
associated with early maturation of these neurons (713). Similarly, it has been suggested that 
selective vulnerability of the deep grey matter and sensorimotor cortex in term HIE could be 
related to peaking NMDA receptor expression in these regions around term time and 
proximity to developing glutamatergic circuits (88). 
Cheung et al (714) suggested that glutamate concentration may be key in determining the 
pathways of cell death, with higher glutamate concentrations preferentially triggering 
necrosis and lower concentrations leading to apoptosis. Either way, even transient excess of 
glutamate can start a number of events that can ultimately cause death or damage of 
vulnerable cell populations (715).
1.5.3.2.2 Glutamate
1.5.3.2.2.1 Experimental evidence of dysregulation of glutamate in brain injuries
In the near-term rat, an acute HI insult sufficient to cause mild white matter injury is followed 
by a rise in extracellular glutamate, with oligodendrocytes and axons representing the major 
cellular sources and astrocytes failing to take up excess glutamate (716). In the near-term 
foetal sheep, repeated umbilical cord occlusion sufficient to cause periventricular white 
matter injury is characterised by a delayed rise in extracellular glutamate levels, which 
correlates with the extent of injury and potentially indicates impaired glutamate transport 
function and establishment of reverse transport (see 1.5.3.2.3) (717). In the term piglet, an 
acute global HI insult sufficient to cause brain injury recapitulating HIE is characterised by a 
biphasic pattern of extracellular glutamate levels in the basal ganglia, with an early increase 
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in the first 6 hours followed by transient and slight recovery by 12 hours, possibly due to 
partial compensatory upregulation of glutamate transport; a further increase occurred after a 
day, possibly through cells bursting due to reperfusion injury and reversal of glutamate 
transport in the late stages of disease (718).
The central role of glutamate excitotoxicity in the pathophysiology of HI brain injury is 
demonstrated by the fact that pharmacological blockade of postsynaptic glutamate receptors 
before or immediately after a HI insult is neuroprotective both in preterm (719, 720) and term 
(675, 721) brain injuries. Indeed, one of the mechanisms through which therapeutic 
hypothermia and magnesium sulphate are thought to exert neuroprotection in the term and 
preterm brain respectively is by preventing excitotoxic damage through NMDA receptor 
blockade (722, 723). An interesting and underexplored therapeutic target for neuroprotection 
is represented by glutamate transporters, which are essential to prevent glutamate 
excitotoxicity in physiological conditions.
1.5.3.2.2.2 Clinical evidence of dysregulation of glutamate homeostasis in brain injuries
Clinical evidence of disruption of glutamate signalling following acute HI is provided by 
evidence of elevated glutamate levels in CSF and basal ganglia (MRS spectroscopy) of 
newborns with HIE in the first day of life (724-727). Glutamate levels in CSF can distinguish 
severe from mild or moderate HIE (725). Moreover, glutamate increase in serum is 
significant at 24h of life in newborns with HIE, peaks at day 3 and returns to normal by day 
7, with serum levels correlating with HIE severity (728, 729). Since glutamate is specific to 
the brain, it has been suggested as a sensitive biomarker for brain injury (346). 
Elevated glutamine levels have been found in MRI-defined punctate necrotic white matter 
lesions in the preterm brain (730). Glutamate is taken up into astrocytes for conversion into 
glutamine, which is shuttled back to neurons. The finding of elevated glutamine rather than 
glutamate may be due at least in part to the temporal lag between insult and measurement. An 
important limitation of in vivo glutamate measurements in preterm newborns is that the peak 
window of glutamate changes is probably missed because magnetic resonance measurements 
are likely to be carried out long after the initial insults in newborns that have already become 
sick. With this in mind, these findings more broadly suggest that disrupted glutamate 
homeostasis persists in the subacute phase in moderate necrotic white matter injury. Although 
a relatively small subset of the newborns with punctate lesions also had evidence of cysts, no 
studies to date have measured glutamatergic metabolism specifically in newborns with cPVL. 
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1.5.3.2.3 Glutamate transporter
The brain has no known enzymatic mechanism to metabolise glutamate in the extracellular 
space and it relies on intracellular glutamate uptake by glutamate transporters expressed 
primarily on the membrane of astrocytes (669, 672, 731-735). Within astrocytes, glutamate is 
converted to glutamine, which is shuttled back into the pre-synaptic neuron, ready for 
conversion to glutamate. The glutamate-glutamine cycle is not essential for supplying 
glutamate for neuronal release but is required for homeostasis of glutamate signalling (669, 
672, 736). Astrocytes are in close interaction with neurons: their processes ensheathe 
synapses and are in direct contact with the brain vasculature, forming organised anatomical 
domains; moreover, they communicate with neurons via a range of transporters, receptors, 
ion channels, cytokines and growth factors (737). Given the close interaction with neurons, it 
is not surprising that astrocytes (the most abundant cell types in the brain) are considered part 
of a “tripartite synapsis” alongside pre- and post-synaptic neuron terminals, and that 
disturbances in their function can have catastrophic consequences for neighbouring neurons 
(738).
The five members of the excitatory amino acid transporters (EAATs) family carry out most of 
the glutamate clearance in the central nervous system (739), especially EAAT2 (or SLC1A2, 
rodent orthologue Glt1) and EAAT1 (or SLC1A3, rodent orthologue Glast) (740-742). 
EAAT2/Glt1 is the major glutamate transporter in the forebrain, except in the cerebellum, 
circumventricular organs, and retina, where EAAT1/Glast is prevalent. The structure, function 
and pharmacological properties of the transporter have been studied via a prokaryotic 
homolog of the EAATs which transports aspartate in Pyrococcus horikoshii (GltPh). Thanks 
to these studies, it was possible to characterise the structure of the mammalian transporters 
including EAAT2/GLT1 (Figure 1.6). The transporter is localised to the cell membrane and 
has 8 transmembrane domains, 4 of which make up the central core while the other 4 together 
with two hairpins form the transport domain (734, 743). Glutamate transport is carried out 
through an ATP-dependent process driven by Na+ and K+ gradients, whereby glutamate and 
aspartate are co-transported inside brain cells with 3 Na+ and 1 H+ for the antiport of 1 K+ 
(Figure 1.6). EAAT2 is also a selective anion channel, transporting Cl- anions during 
intermediate conformations, uncoupled from the flux of glutamate (743). 
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Figure 1.6. a) topology; b) stoichiometry of EAAT2 transport derived from prokaryotic 
homologue aspartate transporter GltPh as a model for mammalian EAATs (672)
EAAT2/Glt1 is expressed predominantly by astrocytes in the term and adult brain, as well as 
at lower levels in several neuronal populations at the pre-synaptic axon terminal (e.g. in the 
rodent hippocampus and somatosensory cortex) (669, 736, 744-747). Importantly, it is 
transiently upregulated in pre-oligodendrocytes and some neuronal populations (e.g. layer V 
pyramidal neurons, layer I neurons, interstitial white matter neurons and subplate neurons) 
during mid-late gestation, at the peak time for preterm brain injury (748, 749) (
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Figure 1.7). Accordingly, oligodendrocytes and axons from the rat optic nerve are subject of 
extensive excitotoxic injury upon experimental inhibition of glutamate transport (750). 
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Figure 1.7. Glutamate signalling under a) physiological and b) excitotoxic conditions in 
the immature brain
(A) In the mature healthy brain, glutamate is released by exocytosis from the pre-
synaptic neuronal terminal into the synapse (1), where it binds to post-synaptic 
ionotropic (NMDA, AMPA, kainate) and metabotropic (mGluR) glutamate receptors, 
inducing Ca2+-mediated signalling cascades that result in cellular responses (2). 
Extracellular glutamate is taken up primarily by astroglial EAAT2 (3) and converted to 
glutamine (4), which is shuttled back to the pre-synaptic terminal via glutamine 
transporters (5). Here, glutamine is converted back to glutamate (6). (B) During 
excitotoxicity, a combination of increased neuronal release and decreased astroglial 
uptake leads to a rise in extracellular glutamate levels, overactivation of the post-
synaptic glutamate receptors, Ca2+ overload, and activation of apoptotic pathways. 
Reversal of transport of astroglial transporters may also contribute to the accumulation 
of extracellular glutamate. In the immature brain, upregulation of the glutamate 
transporters in underdeveloped neurons and oligodendrocytes may contribute to their 
selective vulnerability 
GLT1 may be neurotoxic not only when downregulated leading to reduced glutamate 
transport, but also when upregulated if reverse transport is established - both mechanisms 
ultimately leading to increased extracellular glutamate concentrations. Reverse transport has 
an outward direction and is driven by the transmembrane gradient of excitatory amino acids 
independently of ATP and Ca2+ (668, 751, 752). In this scenario, glutamate transporters 
become themselves a major source of extracellular glutamate, potentially turning into key 
contributors of excitotoxic injury (753). Notably, inhibiting reverse GLT1 transport in the rat 
striatum protects against ischemic cell death (754). Moreover, knockout mice lacking GLT1 
are more vulnerable to neuronal death after a short, severe episode of ischaemia than wild-
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type mice, suggesting that GLT1 function is essential for neuroprotection when ischaemia is 
acute; on the other hand, wild-type mice expressing GLT1 are more vulnerable to neuronal 
death than mice lacking GLT1 during extended, chronic ischaemia, suggesting that GLT1 
(via reverse transport) becomes neurotoxic when ischaemia is prolonged (755).
1.5.3.2.3.1 Experimental evidence supporting candidacy of glutamate transporter
Several lines of evidence support the central role of EAAT2 expression/function in 
maintaining extracellular glutamate homeostasis. The high concentration (1 mg/g rat brain 
tissue), ubiquity (1% of total CNS protein in the adult brain), constitutively high expression 
and high degree of conservation across mammalian species are all indications of the 
physiological importance of EAAT2/Glt1 (669, 736, 743, 756). Importantly, selective 
overexpression of GLT1 in astrocytes is neuroprotective during ischaemia (757). On the other 
hand, pharmacological inhibition of glutamate transport, including EAAT2/GLT1, leads to 
rapid extracellular glutamate increase in vitro (758) and overactivation of post-synaptic 
NMDA receptors (759). Genetic deletion via constitutive knockout in the mouse leads to 
lower body weight, seizures, acute cortical injury in the forebrain and increased mortality 
from the second/third postnatal week (760). This delay reflects the dramatic developmental 
upregulation that occurs from the second postnatal week throughout the brain (especially in 
the cortex, striatum, caudate nucleus, and hippocampus) (761-766). Brain tissue from 
knockout mice lacking GLT1 shows much lower (5%) glutamate transport activity compared 
to wild-type, suggesting that GLT1 is responsible for up to 95% of glutamate transport. This 
is confirmed by the ability of GLT1 antibodies to remove 90% of the transport activity in 
forebrain tissue (767). Other GLT1 knockouts have confirmed the obvious phenotype, with 
lower life span, lower body and brain weight, mild loss of CA1 neurons in the hippocampus, 
severe focal neuronal loss in layer II of the neocortex and focal gliosis (768). A conditional 
knockout mouse with selective deletion of GLT1 reproduces this phenotype while ruling out 
developmental adaptations (769). Inhibition with antisense oligonucleotides in vitro and in 
vivo induces a rise in extracellular glutamate, excitotoxic injury and progressive paralysis 
(770). Heterozygote knockouts, on the other hand, show halved concentrations of GLT1, but 
no apparent morphological brain changes, despite an increased risk of traumatic spinal cord 
injury (768, 771). Knocking out neuronal GLT1, which represents no more than 10-20% total 
GLT1 (736, 745), barely affects total GLT1 protein levels and mouse development (772), 
although it has been implicated in adult neuropsychiatric disorders (773). 
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Notably, knocking out both major glutamate transporters (GLT1 and GLAST) in mouse, and 
therefore removing most of the glutamate uptake function, has direct effects on early brain 
development in utero (774). The resulting phenotype involves multiple brain defects (e.g. 
cortex, hippocampus, and olfactory bulb disorganisation), perinatal mortality (including death 
in utero) and impairment of brain developmental processes (e.g. proliferation of stem cells, 
differentiation and migration of neurons, survival of subplate neurons). This highlights the 
indispensability of glutamate transport not only in the postnatal period but also for early brain 
development. This is key, since abnormal brain development at the foetal stage is 
increasingly being recognised as a key contributor of many brain disorders that manifest 
throughout life (55).
1.5.3.2.3.2 Clinical evidence supporting candidacy of glutamate transporter
EAAT2/GLT1 has not been explicitly studied in newborns with HIE. On the other hand, 
elevated levels have been found in reactive astrocytes and macrophages in and around the 
necrotic areas of post-mortem brains of very preterm newborns with cPVL (775). This may 
reflect a response to milder but prolonged hypoxia-ischaemia and/or inflammation, which are 
harder to disentangle in the preterm brain and may involve reverse transport. Candidacy of 
EAAT2 is supported by evidence of dysregulation in several neurological, neurodegenerative 
and psychiatric disorders involving disruption of glutamate signalling, including transient 
cerebral ischaemia, ischemic stroke, epilepsy, traumatic brain injury, amyotrophic lateral 
sclerosis, Alzheimer’s disease, Parkinson’s disease, chronic pain, Huntington’s disease, HIV-
associated dementia, glioma, major depression, schizophrenia, addiction and sleep 
deprivation (669, 672, 743, 773, 776-792). 
1.5.3.3 Potentiation between neuroinflammation and glutamate excitotoxicity: focus on 
EAAT2 and TNFα
Preconditioning and postconditioning with mild hypoxia generate ischemic tolerance in the 
newborn brain (793-798). Similarly, preconditioning with a mild chronic exposure to LPS 
generates immune tolerance, reducing the magnitude of systemic inflammation (574, 799-
802). On the other hand, the mechanisms behind the reciprocal sensitisation between 
inflammation and HI are still largely unresolved. Additionally, they contrast with the 
neuroprotective preconditioning effect observed when the interval between a mild 
inflammatory hit and a subsequent HI hit is intermediate (24h) as opposed to acute (6h) or 
chronic (72h) in term-equivalent rodents, highlighting that the temporal profile of the insults 
matters (491, 803). The detrimental sensitising effect of inflammation is thought to be due to 
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upregulation of pro-inflammatory cytokines and chemokines and activation of apoptotic 
pathways (491, 803). Another mechanism through which inflammation may sensitise the 
brain to HI is by increasing the metabolic demands of the brain, though more studies focusing 
on cerebral oxidative metabolism during inflammation are needed (574, 618, 646).
In the current model for sensitisation, HI and neuroinflammation potentiate each other in a 
bidirectional way, i.e. the excitotoxic injury caused by HI triggers a local inflammatory 
response in the brain, which in turn further sensitises the brain to HI by exacerbating 
glutamate excitotoxicity (e.g. impairment of glutamate transport) and further disruption of the 
blood brain barrier (375, 383, 804). More in detail, neurons and oligodendrocytes injured via 
excitotoxicity release danger associated molecular patterns (DAMPs) in the 
microenvironment, which activate microglia inducing cytokine release (1 in Figure 1.8) (375, 
805). Microglia can also be activated by peripheral cytokines stimulating endothelial cells to 
release prostaglandins locally (514, 515), and by cytokines infiltrating from the periphery via 
the disrupted blood brain barrier and recruiting more peripheral immune cells (494, 513). The 
net result is a “cytokine storm”, whereby the upregulation of pro-inflammatory cytokines is 
not matched by upregulation of anti-inflammatory cytokines and neurotrophic factors (374, 
375, 381, 613, 806-809). The excess pro-inflammatory cytokines further disrupts the blood 
brain barrier (3 in Figure 1.8), allowing infiltration of more peripheral cytokines and immune 
cells (4 in Figure 1.8) (375, 544, 810). The excess cytokines and free radicals further damage 
the developing neurons and oligodendrocytes by enhancing glutamate excitotoxicity (2 in 
Figure 1.8). Mechanisms are thought to include overactivation of post-synaptic metabotropic 
glutamate receptors (494, 811, 812), further release of glutamate by activated microglia (813) 
and failure of the glutamate uptake system, already challenged by the primary energy failure 
induced by HI. 
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Figure 1.8. Model for the potentiation between hypoxia-ischaemia and 
infection/inflammation (375)
1) Cells damaged through excitotoxic injury release endogenous ligands (DAMPs) that 
generate an inflammatory response. Excess pro-inflammatory cytokines and free 
radicals further damages 2) neurons and pre-OLCs, via enhancement of glutamate 
excitotoxicity 3) the vascular bed. This allows 4) infiltration of immune cells from the 
periphery, which further contribute to the cytokine storm
PPR: pattern recognition receptors of the innate immune system, which recognise both 
pathogens and DAMPs released by injured cells (375)
One such mechanism of potentiation may involve an interaction between TNFα and EAAT2. 
TNFα potentiates glutamate excitotoxicity in vitro via complex and interacting mechanisms 
involving crosstalk between neurons, glial cells, and peripheral immune cells, leading to 
vicious circles of glutamate and cytokine release (Figure 1.9) (544).
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Figure 1.9. Molecular mechanisms by which TNFα links glutamate excitotoxicity and 
inflammation (544)
Infiltrated T cells release IFN-ϒR, which promotes microglial release of TNFα (544). 
In pre-oligodendrocytes, TNFα alters glutamate receptor expression and configuration, 
although AMPA and NMDA blockade is not sufficient to prevent cell death in fetal ovine cell 
cultures (814).
In neurons, TNFα (via TNFR1) increases glutamate receptor expression and alters their 
chemical composition making them more permeable to Ca2+, while also decreasing 
expression of inhibitory GABAA receptors (544). The net result is an increase in the 
excitatory strength at the synapsis, which can make neurons more vulnerable to injury in the 
setting of rising extracellular levels of glutamate and TNFα. 
In microglia, two autocrine vicious circles potentiate release of both TNFα and glutamate: 
firstly, TNFα directly promotes release of more TNFα via TNFR1 signalling (815); secondly, 
TNFα induces glutamate release by activated microglia by upregulating glutaminase and 
glutamate release via hemichannels of gap junctions (816). In turn, glutamate activates 
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glutamate receptors on microglia and induce more TNFα release (817, 818). Dying and 
injured neurons maintain microglia active.
In astrocytes, TNFα binds to TNFR1, activates COX2 and generates prostaglandin E2, which 
induces intracellular Ca2+ and leads to extracellular glutamate release by astrocytes (814, 819, 
820). As well as inducing glutamate release by astrocytes, TNFα impairs astrocytic glutamate 
transport by selectively suppressing EAAT2 via NFκB (821). Indeed, TNFα causes a dose-
dependent suppression of glutamate uptake in human fetal astrocytes in vitro sufficient to 
cause excitotoxicity (821-825), as well as in term-equivalent rat astrocytes during hypoxia 
(826). Accordingly, inhibiting NFκB is neuroprotective (827). EAAT2 is a double target 
during hypoxia in vitro: not only does hypoxia suppress EAAT1 and EAAT2 directly via 
disruption of the Na+/K+ gradients, but also it promotes TNFα release, which in turn 
selectively suppresses EAAT2 via NFκB (826). Therefore, it can be hypothesised that other 
mechanisms leading to upregulation of TNFα (e.g. infection/inflammation, genetically 
determined high expression) may contribute to suppression of EAAT2 and further exacerbate 
excitotoxic injury. The relationship between EAAT2 and TNFα appears to be complex, since 
exposing mouse astrocytes, rat microglia and human blood macrophages to an inflammatory 
challenge (LPS or TNFα) enhances EAAT2 expression and glutamate uptake function in 
vitro (828-830). 
Thus, while the specific mechanisms are largely not known, it is clear that the sensitisation 
between neuroinflammation and HI-induced glutamate excitotoxicity involves complex 
interactions between brain cells and a range of mechanisms which result in accumulation of 
pro-inflammatory cytokines and glutamate in the extracellular space, coupled with loss of 
normal homeostatic and developmental functions. 
1.5.4 Genetic factors
Given the key role of HI and infection/inflammation, it is clear that newborn brain injuries 
and CP are largely environmental in their causation. However, in the neonatal unit, it is 
commonly observed that some newborns are more resilient to brain injury than others when 
exposed to similar insults. Similarly, as many as a third of children diagnosed with CP lack 
obvious environmental risk factors, while others do particularly well with seemingly 
complicated clinical histories (831). Not all newborns exposed to perinatal HI and 
infection/inflammation develop brain injuries and not all newborns with brain abnormalities 
in the newborn period develop a neurological sequela in childhood. Genetic factors are 
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thought to lie at the heart of these discrepancies, with genetic background contributing to the 
individual response to environmental insults and therefore interindividual differences in 
vulnerability to injury and impairment. This is analogous to other perinatal disruptions, such 
as foetal alcohol syndrome, whereby the effects of clear environmental risk factors seem to 
manifest differentially depending on susceptibility genes (832). Another line of evidence 
supporting a role for genetic factors in contributing to vulnerability to newborn brain injuries 
is provided by animal studies, i.e. responses to the same environmental insult (e.g. in utero 
hypoxia) are different between mice and rats (e.g. changes in expression of glutamate-
receptor subunits seen in fetal mice but not rats), which are known to have inter-species 
genetic differences (e.g. extra genes in rats compared to mice, including genes involved in 
immunity and protein breakdown) (833).
Studies assessing the genetic architecture of neuroimaging outcomes related to brain injuries 
in the neonatal period are considerably scarcer than classical studies of neurodevelopmental 
outcomes during childhood. Indeed, enormous progress has been made in the last two 
decades in our understanding of the genetic basis of neurodevelopmental disorders, including 
intellectual disability, attention deficit hyperactivity disorder (ADHD) and autism spectrum 
disorders (ASD) (834). Studies exploring the genetic factors causing or contributing to CP 
have also started accumulating (192, 831, 835-841), although they have lagged behind 
compared to those of other neurodevelopmental disorders, not least because of the difficulty 
in obtaining large samples. A likely genetic contribution to CP is supported by several lines 
of evidence. Firstly, the clinical observation that CP often occurs together with neurological 
and neurodevelopmental comorbidities (e.g. intellectual disability, autism spectrum disorders, 
epileptic encephalopathies and congenital anomalies) that may overlap not only in the 
environmental but also in the genetic component, with genetic pleiotropy described for 
multiple candidate CP genes (837, 842). Early twin and family studies provided evidence of 
familial aggregation and heritability (843). Some studies have reported a higher CP risk for 
monozygotic twins (sharing 100% genome) compared to dizygotic twins (sharing 50% 
genome) (844-846), while others have found higher risk of mortality but no difference in CP 
rate (847-849). A Swedish population-based study of familial data shows that parents of a 
child with CP have a 5-fold risk of having a second affected child, with risk reaching 29-fold 
for twins (850). CP risk is considerably higher in consanguineous families, due to the 
increased risk of inheriting identical copies of detrimental autosomal recessive genes (851-
854). Another line of evidence is provided by studies of parental age, suggesting that older 
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parental age may increase risk of certain CP subtypes (e.g. dyskinetic cerebral palsy) as the 
risk of new dominant mutations arises with age (855, 856). Through mathematical modelling 
in a Swedish study of idiopathic congenital CP, genetic factors were estimated to be likely 
causes of CP in up to 48% term and 24% preterm cases (857). The advancement in genetic 
technologies has allowed generation of the first positive evidence of genetic causation in 
monogenic and copy number variant forms of CP, as well as exploration of the polygenic 
forms of CP. 
Uncovering the genetic architecture of a trait, including cystic and diffuse preterm white 
matter injury, HIE and CP, means understanding the proportion of variation in each of these 
traits that is due to genetic factors. This includes identifying all genetic variants affecting 
disease, their effect size, their frequency in various populations as well as their interactions 
with each other and the environment (858). This broad-sense heritability can in turn be 
divided into additive genetic effects (independent and direct effect of each variant, i.e. the 
narrow-sense heritability), dominance genetic effects (interaction between variants at the 
same locus) and epistatic genetic effects (interaction between variants at different loci) (859). 
Genetic variants may be variations at single base pairs in the genome (single nucleotide 
variants, SNVs), which in turn can be common or rare. Common single nucleotide variants 
(single nucleotide polymorphisms, SNPs) are present in 5% or more of the population (i.e. 
the minor allele frequency, or MAF, is ≥ 0.05). Low frequency variants are present in 1-5% 
of the population and rare variants are present in less than 1% of the population. Genetic 
variants can also be small (<1,000 bp) insertions or deletions (indels), duplications or 
inversions of multiple base pairs , as well as large structural changes at the chromosomal 
level, including copy number variants (CNVs, >1,000 bp) and translocations (860) (see 
Figure 1.10).
Figure 1.10. Types of genetic variation
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1.5.4.1 Rare monogenic forms of cerebral palsy
In monogenic forms of CP, a single mutation is deterministic and responsible for the 
observed disease outcome. Here, the trait is proximal to the genome, as there are no other 
contributions other than the genetic variant, which generally results in impaired production of 
a protein. These mutations are likely to be recent in evolutionary terms, as the large 
detrimental effects have not yet had time to be selected against (858). Developmental 
abnormalities deriving from these highly penetrant, large effect variants are more likely to 
become obvious and be detected earlier in individual patients, often in the absence of MRI 
evidence of injury (838, 861).
Rare mutations identified in pedigree studies (e.g. AP4M1, GAD1, AP4, ADD3, TUBA1A, 
SCN8A, KDM5C, NT5C2) often have autosomal recessive mode of inheritance and lead to 
specific CP subtypes, e.g. quadriplegia with severe intellectual disability, ataxic CP and 
spastic diplegia (862-869). An imprinted gene mode of inheritance has also been shown in a 
family with repeated congenital CP (quadriplegia with cognitive impairment), whereby the 
mutation spans a maternally imprinted gene (KANK1) and is expressed only when inherited 
from the father (870). 
Single-gene forms of CP were initially thought to be rare, representing 1-2% of CP cases 
(850). However, the most recent estimates from the largest whole-exome sequencing study to 
date have risen to 14%, with several novel genes being discovered (AGAP1, JHDM1D, 
MAST1, NAA35, RFX2, WIPI2) (136). At the time of writing, there are 63 genes associated 
with monogenic forms of CP in the Online Mendelian Inheritance in Man (OMIM) database 
(https://www.omim.org). This suggests that these numbers are likely to increase with 
increasing sample sizes, favoured by the drop in next-generation sequencing costs and larger 
collaborations between research study groups. Whole-exome sequencing (WES) allows 
identification of rare variants in the 1% regions of the genome which code for proteins and 
are therefore more likely to directly result into a functional protein change (871). Whole-
genome sequencing (WGS) can measure nearly all variation in the genome, including large 
structural variants (see 1.5.4.2), but the high costs have so far limited its uses to research 
settings. Despite the cost and sample size limitations, sequence data may have immediate 
clinical applications when causal variants of large effects are identified, in terms of screening, 
diagnosis, prognosis and therapy. It has been recently suggested that if a genetic cause of CP 
is discovered via sequencing, the diagnosis of CP should not be changed, since CP remains a 
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diagnosis based on clinical signs and symptoms, but rather trigger appropriate 
subclassification based on causation (872). 
Interestingly, two de novo mutations in the coding regions of EAAT2 have been reported in 
association with the relevant outcome of early-onset epileptic encephalopathies (873). De 
novo mutations arising for the first time in the egg, sperm, or fertilised egg (i.e. not inherited 
by either parent) are emerging as more important than expected in neonatal and paediatric 
neurological diseases, highlighting that causation goes beyond in utero disturbances and birth 
trauma (874).
1.5.4.2 Rare structural variations in cerebral palsy
Copy number variants (CNVs) are rare large structural variations (insertions or deletions) 
spanning 1000 base pairs (bp) or more, affecting entire chromosomal regions and therefore 
multiple genes. While studies of CNVs in CP have only recently started to emerge, it is clear 
that structural variants provide a significant causal contribution to CP. Current estimates 
suggest that CNVs are responsible for 10-30% CP cases and are likely to be more precisely 
defined as more studies with larger sample sizes accumulate (192, 875-878). The role of 
CNVs is better recognised in other neurodevelopmental disorders which have been studied 
for longer, such as autism, intellectual disability, epilepsy, and schizophrenia (879-882). 
Indeed, several of the CNVs identified for CP encompass genes that are important for 
neurological function and are shared with other neurodevelopmental disorders (875, 877). 
Studies from other neurodevelopmental disorders point to a trend for larger CNVs, which are 
more likely to arise de novo, to be associated with more severe neurodevelopmental 
impairment (e.g. severe intellectual disability), while smaller inherited variants tend to be 
associated with less severe impairment (e.g. autism) (883). Accordingly, larger CNVs, 
including several de novo variants, have been found in association with more severe forms of 
CP based on the Gross Motor Function Classification System (876, 877). This is a very 
young field and our understanding of the role of CNVs as causes of CP is likely to improve 
rapidly in the near future, especially as cost of microarray and next generation sequencing 
technologies continues to drop. CNVs are also emerging in relation to neuropsychiatric 
disorders in adults born preterm and a prospective neonatal cohort of very preterm newborns 
is currently being recruited from the National Neonatal Research Database (SPRING cohort) 
to assess the role of CNVs spanning neurodevelopmental genes (884, 885).
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1.5.4.3 Multifactorial polygenic forms of cerebral palsy and common single nucleotide 
polymorphisms
While some forms of CP are thought to be due to highly penetrant genetic mutations of large 
effects, other forms of CP are thought to be multifactorial and polygenic. In this different 
type of genetic architecture, risk can be thought of as an underlying continuous variable, the 
“disease liability”, whereby multiple genetic, developmental, and environmental factors bring 
a contribution, individually and interactively (886). This includes the collective effect of 
many common, ancient genetic variants, whose individually small effect is neither sufficient 
nor necessary, but cumulatively contribute to genetic risk. The disease is manifested when the 
overall burden of genetic and environmental factors surpasses a threshold of liability (886). 
Thus, each foetus/newborn will have a different response to adverse environmental risk 
factors (e.g. perinatal infection/inflammation and hypoxia-ischaemia) due to their underlying 
genetic background, and therefore a different risk of brain injury and subsequent 
neurodevelopmental impairment. Polygenic traits encompass many biological processes and 
causal variants and are therefore distal to the genome (858). 
Polygenic traits require large population-based studies to uncover common genetic variants 
contributing to risk. Genome-wide association studies (GWAS) are currently the standard 
design to test the direct association (additive, not through interactions) between common 
genetic variants and a disease outcome (887). In this type of genetic study design, the genome 
is scanned for variants that are found more frequently in cases than controls, without 
requiring any a priori hypotheses. GWAS have successfully identified many common genetic 
variants (SNPs) associated with adult disorders, including diabetes, schizophrenia, 
depression, and bipolar disorder, highlighting the polygenic architecture of many complex 
traits (888-891). Indeed, the emerging genetic evidence in studies of neurodevelopmental and 
neuropsychiatric disorders is blurring the lines amongst historically distinct clinical diagnoses 
and prompting towards a redefinition which takes into account overlapping genetic 
architectures (892-894). For example, a recent study highlighted a genetic overlap between 
early motor and sensory development and autism spectrum disorders by school age (895, 
896). Given the hypothesis-free design, GWAS require samples in the order of thousands to 
allow for sufficient power following stringent statistical correction for multiple testing. This 
has slowed down exploration of childhood neurodevelopmental disorders. While the first 
significant GWAS findings now exist for autism spectrum disorders and attention deficit 
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hyperactivity disorder (834, 897, 898), studies of CP have not yet reached sufficiently large 
samples nationally or internationally.
Candidate-gene studies represent an alternative way to explore potential association based on 
educated guesses about which genes (or variants in a gene) may be causally involved in 
disease pathophysiology. These studies have historically preceded hypotheses-free GWAS 
designs before sufficiently large sample sizes could be achieved. Indeed, several candidate 
SNP studies have been accumulating in the last 15 years, exploring the association between 
CP and SNPs affecting selected pathways thought to be central to perinatal brain injuries, 
namely inflammation, blood coagulation, lipid metabolism, glutamate signalling, nitric oxide 
metabolism and cell death (162, 163, 654, 836, 840, 899-921). Given the genetic and clinical 
heterogeneity that characterises CP, a potentially useful approach is to focus on specific 
populations and pathophysiologies, such as term newborns with HIE or preterm newborns 
(922-924). The disadvantage of this approach is that it is further penalising in terms of sample 
size and power. Findings from candidate SNP studies have been inconsistent, highlighting the 
limitations of current study designs, including small sample sizes, poor replication, clinical 
and genetic heterogeneity, as well as limited understanding of the underlying disease 
pathophysiology. Nonetheless, evidence of genetic risk is accumulating and encouraging 
further exploration with larger sample sizes and integration of different genetic study designs. 
Amongst the candidate SNPs explored, regulatory SNPs ultimately affecting regulation of 
gene expression, and hence the amount rather than the quality of function of the protein, have 
been amongst these variants. These include common genetic variants in the regulatory 
regions of cytokines, affecting the magnitude of inflammatory responses to infections, 
inflammatory comorbidities, and HI (see chapter 2). Despite the evidence of potentiation 
between inflammation and glutamate excitotoxicity, no studies to date have jointly assessed 
genetic variants affecting inflammation and glutamate transport in relation to preterm brain 
injury and neurodevelopmental impairment. 
1.5.5 Epigenetic factors
1.5.5.1 Epigenetic mechanisms as mediators of the interaction between genes and 
environment
Epigenetic mechanisms have been defined as “the structural adaptation of chromosomal 
regions so as to register, signal, or perpetuate altered activity states “ (925). This definition 
encompasses transient epigenetic marks (e.g. those enabling DNA repair) alongside the more 
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stable marks, including those inherited from generation to generation. DNA methylation and 
histone modifications control the transcription of genes from DNA to mRNA by affecting 
DNA accessibility to the transcriptional machinery. This is achieved via addition or removal 
of chemical modifications to the DNA sequence or the histone proteins which package DNA 
into chromatin. Non-coding microRNAs, including different classes of small RNAs (e.g. 
miRNAs) and long non-coding RNAs (lncRNAs), interact with DNA, mRNA and proteins 
and provide an additional layer for regulation of expression, for example by controlling 
transcription, different aspects of mRNA life (e.g. stability, splicing and translation) and 
chromatin architecture (e.g. direct decompaction, binding of chromatin-remodelling proteins) 
(926-928). All of these epigenetic mechanisms interact with each other to cooperatively 
regulate gene expression. Cell function relies on maintenance of epigenetic homeostasis, as 
highlighted by evidence of epigenomic perturbations in human diseases, such as cancer (929).
Within each cell, the epigenome is highly dynamic and is regulated by a complex interplay of 
genetic, environmental and stochastic factors (930). Genetic background contributes to 
methylation differences amongst individuals, e.g. SNPs at CpG sites or near CpG sites 
altering binding of transcription factors or of protein regulating chromatin structure 
(methylation quantitative trait locus effects, or mQTL) (931, 932). Importantly, epigenetic 
mechanisms can respond to cues from the environment, including environmental stresses 
disrupting cellular homeostasis. Such environmentally-induced changes can be propagated 
from cell to cell within an individual, providing a path to solidification of the gene expression 
change in the long-term and long after the initial trigger, resulting in maintenance of the 
phenotype in the organism (933, 934). As well as being propagated from cell to cell within an 
individual or last for the lifespan in terminally differentiated cells, some epigenetic marks can 
also be passed onto the next generation without requiring a change in the DNA sequence. For 
these reasons, epigenetic mechanisms are emerging as the biological mediators linking the 
effects of genes and environment on cell function, mediating the physical changes induced by 
the environment on genes and leading to downstream phenotypes in both health and disease 
(934-937). Effectively, epigenetic mechanisms act as a code of previous experience that 
results in a differential response to a future exposure (938). 
With regard to the vulnerable newborn, this means that: 1) early life stresses, such as the 
acute hypoxia-ischaemia leading to HIE, may alter the epigenetic landscape in the developing 
brain and have long-term consequences on brain development and function 2) newborns with 
the same genetic variants may have different outcomes because of epigenetic differences; 3) 
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there is a heritable component of risk that is systematically missed out by conventional 
genetic analyses (939). 
1.5.5.2 DNA methylation
Amongst epigenetic mechanisms, DNA methylation has been studied for the longest and 
benefits from the availability of high-throughput methodologies for profiling (933). It is 
highly conserved from plants to mammals as a key mechanism for fine spatial and temporal 
control of gene expression, including during development (940). The observation that 
promoter DNA methylation correlates with transcriptional repression has led to the notion 
that cells use this molecular tool to silence gene expression (941).  Promoter methylation is 
thought to inhibit transcription either directly, by inhibiting binding of transcription factors to 
the promoter, or indirectly, by recruiting methyl-binding proteins that alter chromatin 
compaction and accessibility to transcription factors (942, 943). Aside from regulation of 
gene expression, DNA methylation is also key for genomic imprinting of genes, where one 
parental allele is permanently silenced, inactivation of the X-chromosome, inactivation of 
transposable elements, and genome stability (944). Relevance to the brain and neurological 
diseases is highlighted by the fact that, other than the thymus, the brain is the organ with 
highest levels of DNA methylation (945, 946). Dynamic regulation of DNA methylation is 
indeed key for brain function across the life span, including neurogenesis, neuronal plasticity, 
memory formation and maintenance (947-951). Moreover, abnormal DNA methylation 
patterns are emerging in a range of brain disorders, including autism, schizophrenia and 
bipolar disorder, stress, anxiety, and addiction (926, 952-961). 
DNA methylation represents a suitable candidate mechanism in terms of pathophysiology, 
due to its ability to alter transcription typically leading to gene silencing, its ability to be 
propagated from cell to cell and its relative stability over time (933, 962, 963). Despite its 
general stability, DNA methylation changes occur physiologically in early life and continue 
to occur during the lifetime in response to environmental stimuli as well as by chance (964, 
965). Importantly, epigenetic plasticity and responsiveness to the environment appear to be 
higher in the earliest and latest stages of life, providing a window of vulnerability in the 
perinatal period and early childhood (932). Therefore, epigenetic modifications induced by 
the early life stresses of HI and infection/inflammation may mediate long-term alterations in 
glutamatergic and inflammatory responses and contribute to long-term neurodevelopmental 
impairment (966). The relative stability and ease of measurement are also attractive 
properties for use as a molecular biomarker, while its reversibility introduces the interesting 
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possibility of pharmacological manipulation for neuroprotection, potentially extending the 
therapeutic window (743).  
DNA methylation involves addition of a methyl group (-CH3) to the carbon 5 position on the 
pyrimidine ring of cytosines, resulting in 5-methylcytosines (5-mC) (967). It occurs primarily 
at cytosines followed by guanines, i.e. CpG sites (cytosine-phosphate-guanine). 60-70% 
mammalian gene promoters, including those of housekeeping genes, developmental genes, 
and tissue-specific genes, contain CpG-rich regions of 1-2 kilobases (kb) near the 
transcription start site (TSS), known as CpG islands. 95% of promoter CpG islands are 
unmethylated and therefore protected from permanent gene silencing. This is in contrast with 
the scarce and largely methylated CpG sites scattered throughout the rest of the genome, e.g. 
in gene bodies (939, 968-973). CpG shores within 2 kb of a CpG island show more variable, 
dynamic, tissue- and region-specific methylation, and their effect on gene expression is less 
understood (974-977). Less understood alternative forms of methylation specific to the brain 
are also emerging, i.e. non-CpG (CpH) methylation and hydroxymethylation (5-hmC) (978-
980).
Most of an individual’s DNA methylation patterns are established during embryonic and fetal 
development (939, 981). Gametes carry DNA methylation marks which are largely (though 
not completely) erased in the zygote immediately after fertilisation, to ensure totipotency for 
the next generation. Epigenetic marks are subsequently re-established in the primordial germ 
cells, with partial retention of parental marks (> 40% of all 5-mC), providing a pathway for 
inheritance of parental DNA methylation in the offspring’s sperm and oocytes (982, 983). 
DNA methylation marks are also re-established in the somatic cells of the zygote after each 
mitotic DNA replication cycle, where they persist throughout each cell’s lifetime ensuring 
maintenance of cellular identity and function (e.g. neurons and astrocytes from neural 
progenitor cells) (984, 985). While DNA methylation was originally thought to be stable 
except for demethylation during early development, it is now clear that it is a dynamic 
mechanism during development (986).
The “writers” of DNA methylation are DNA methyltransferases (DNMTs), which can 
establish DNA methylation de novo (DNMT3A, DNMT3B, DNMT3L) or identify and 
maintain existing DNA methylation (DNMT1) (939, 987-991). DNA methylation is 
subsequently “read” by methyl-CpG-binding proteins (MBDs), such as MECP2, which 
identify methylated sites and cooperatively recruit histone deacetylases to repress 
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transcription. Methylation can be erased enzymatically or non-enzymatically. The enzymatic 
“erasers” of DNA methylation are the ten-eleven translocation (TET) dioxygenases, which 
actively demethylate DNA by adding a hydroxyl group to 5 methyl cytosine (5-mC) and 
processing to 5-hydroxymethyl cytosine (5-hmC). While much remains to be uncovered 
about the functional implications of 5-hmC, we known that 5-hmC is not recognised by 
DNMTs and methylation status is therefore lost in the daughter cells when DNA is replicated. 
Demethylation can also occur passively with direct processing to 5-hmC and “methylation 
dilution” at each DNA replication cycle. Finally, DNA methylation can be inhibited 
indirectly via destabilisation of the DNMT1 enzyme (939, 984, 992-996). 
Global passive DNA demethylation has only been observed during early development in the 
zygote and primordial germ cells (997). One exception are imprinted genes (e.g. PEG3), 
which have one parental allele permanently methylated across the lifespan resulting in 
expression of one parental allele only. Active demethylation has been reported in somatic 
cells, though only at specific genomic locations and in response to specific stimuli, e.g. active 
demethylation at BDNF (involved in neural plasticity) following neuronal stimulation, and of 
the IL2 promoter following T lymphocytes stimulation (997-999). Expression of both the 
“writers” and “erasers” of DNA methylation has been explicitly shown in during brain 
development in rodent brain (989, 1000-1002). 
1.5.5.3 Perinatal hypoxia-ischaemia and disruption of DNA methylation
Since Barker’s hypothesis of the developmental origins of disease, an entire field of research 
has emerged focusing on the long-term effects of early life stresses on disease (1003-1005). 
Robust epidemiological studies have generated the hypothesis that adverse environments in 
utero or early childhood can impact later disease outcomes, in a phenomenon known as 
developmental programming (1006). Landmark studies have linked prenatal exposure to 
famine (Dutch hunger winter of 1944-45) to risk of schizophrenia and cardiovascular disease 
(1007-1009). Supported by both epidemiological and experimental studies, epigenetic 
changes are emerging as the candidate biological mechanisms for such molecular memory 
(1010-1015). 
Perinatal hypoxia is one of the most common early life stresses and the effects of chronic 
hypoxia during pregnancy on the epigenetic landscape are starting to emerge from 
experimental studies (985, 1016, 1017). In humans, it is difficult to disentangle the effects of 
HI from those due to other perinatal exposures in sick newborns. It is also difficult to 
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understand which DNA methylation changes are causes or consequences of disease. This is 
because the temporal sequence between exposure, DNA methylation change and outcome is 
often not known, and neither is where DNA methylation measurement fits into this temporal 
sequence (1018). Moreover, assessment of brain methylation is generally not feasible in live 
newborns and peripheral methylation (e.g. blood) may have limited relevance to the brain 
(1019). Animal model studies allow evaluation of the causal effect of an insult on the brain’s 
epigenome, providing direct evidence that may translate to humans. These types of studies 
have shown that epigenetic changes mediate the causal effects of exposure drugs on drug 
addiction and of maternal care and offspring’s stress response (1020, 1021). Crucially, the 
potential epigenetic consequences of acute peripartum HI leading to HIE have not been 
explored. This may be achieved by assessing DNA methylation at the candidate 
glutamatergic and inflammatory genes in the most established rat model of HIE, the Rice 
Vannucci model (Chapter 3).  
1.6 Thesis angle: (dys)regulation of the glutamate transporter and pro-
inflammatory cytokines by genetic and epigenetic factors 
This project takes a candidate gene approach focusing on the glutamate transporter 
(EAAT2/Glt1) and three key pro-inflammatory cytokines (TNFα, IL1β and IL6). The potential 
role of dysregulation of these genes in perinatal brain injuries and neurodevelopmental 
impairment is assessed in multiple ways: firstly, by evaluating the effect of regulatory genetic 
variants on risk of cPVL, motor and cognitive impairment at toddler and pre-school age in a 
prospective cohort of very preterm newborns (chapter 2); secondly, by evaluating the effects 
of an acute HI insult on transcription of these genes in an established rat model of HIE at 
term (chapter 3). Finally, DNA methylation at the promoter of these genes was also assessed 
as a candidate epigenetic mechanism mediating these transcriptional changes in the brain. 
Clinical relevance was added by additionally assessing DNA methylation in blood as a 
potential early biomarker of injury in newborns with HIE (chapter 4). Thus, both genetic and 
environmental influences on regulation of glutamate transport and inflammation were 
assessed in relation to two of the most clinically relevant types of newborn brain injuries and 
subsequent neurodevelopmental impairment. The genetic association study (chapter 2) and 
the DNA methylation study (chapter 4) are set at the level of the DNA, with the former 
focusing on changes in the DNA sequence and the latter focusing on chemical modifications 
laid onto DNA without affecting the sequence. The transcriptional study (chapter 3) assesses 
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levels of mature mRNA transcripts, which are under both genetic and epigenetic regulation 
(Figure 1.11).
Figure 1.11. Regulation of gene expression from DNA to protein and context for this 
project (readapted from (1022))
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2 Association between candidate genetic variants affecting 
glutamate transport and inflammation and 
neurodevelopmental outcomes in children born preterm 
2.1 Introduction
One of the interesting developments from 15 years of genome-wide association studies 
(GWAS) of complex diseases is that nearly 90% phenotype-associated variants are located in 
non-coding regions of the genome and are particularly enriched in the regulatory regions, 
including gene promoters (887, 1023-1025). Regulatory genetic variants influencing gene 
expression are known as expression quantitative trait loci (eQTL) and underlie genetically 
programmed differences in mRNA transcription between individuals, via effects on 
transcription factor binding and epigenetic regulation (1023, 1025). 
An approach that can help pinpointing the true causal genetic variants consists in 
triangulating evidence of: 
1) association between altered gene expression and disease, i.e. dysregulated levels of 
pro-inflammatory cytokines and glutamate transporter in preterm brain injury and 
neurodevelopmental impairment (see 1.5.3)
2) association between the regulatory SNP and disease, i.e. genetic variants affecting 
regulation of cytokines and glutamate transporter found at different frequencies in 
newborns with brain injuries and children with neurodevelopmental impairment
3) association between the regulatory SNP and altered gene expression, i.e. SNP 
associated with differential gene expression in a relevant cell type, tissue, and 
developmental stage
With regard to 2), genetic variants in the promoter of three classically studied pro-
inflammatory cytokines (TNFα -308 G>A, IL1β -511 C>T, IL6 -174 C>G) have been 
reported in association with poor neurodevelopmental outcomes, including CP, cPVL and 
neurodevelopmental impairment (see Appendix, Table 8.1 for a literature review) (162, 163, 
654, 905, 906, 908, 912, 917-919, 1026-1032). Candidacy is supported by evidence of 
association with adult autoimmune, infectious, neurological, cardiovascular, and oncological 
diseases featuring elevated cytokine levels (1033-1040). 
SNPs affecting glutamatergic signalling have been historically overlooked. Nonetheless, 
variants in the glutamate ionotropic NMDA receptor subunits have been reported in 
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association with motor, cognitive and behavioural outcomes, as well as electrophysiological 
parameters (921, 1041-1044). Our research group recently reported first evidence of an 
association between regulatory SNPs in the glutamate transporter (EAAT2 -200 C>A, -181 
A>C) and adverse neurodevelopmental outcomes in very preterm newborns, including CP 
and low Griffiths/Bayley scores at 2 years (911). Candidacy of the more studied -181 is 
supported by evidence of association with adverse adult neurological and neuropsychiatric 
outcomes (e.g. worse neurological outcome after ischemic stroke, bipolar disorder episode 
recurrence, lower grey matter volumes in bipolar disorder and schizophrenia) (1045-1051).
With regard to 3), SNP functionality has been experimentally demonstrated for the cytokine 
SNPs via reporter gene assays transfecting mutated promoters in immune cells and assessing 
promoter activity in vitro (1052-1054), and by assessing patients’ immune cells ex vivo 
(1055-1059). SNP functionality has been shown also for the EAAT2 -200 and -181 variants, 
via a reporter gene assay in fetal rat astrocytes in vitro (911), and in vivo evidence of -181 
association with higher blood glutamate levels in adults with relapsing multiple sclerosis and 
stroke (1046, 1060). 
Given the substantial evidence of potentiation between infection/inflammation and glutamate 
excitotoxicity (see Chapter 1), it is plausible that newborns with detrimental genetic variants 
affecting both inflammation and glutamate transport may be particularly vulnerable. In this 
study, alongside replicating individual SNP-disease outcome associations, we specifically 
sought to explore the interaction effects (epistasis) between inflammatory SNPs and 
glutamate transport SNPs on disease risk. This is a secondary analysis using historical genetic 
and clinical data from the Avon Premature Infant Project (APIP) cohort. This was a Bristol-
based prospective cohort of very preterm newborns who participated in a trial assessing the 
neuroprotective effects of a family-based developmental education programme for parents 
continued for up to 2 years of life (275, 276). The intervention showed a small positive effect 
on cognition at 2 years independent of social confounders, which had however attenuated by 
5 years.
2.2 Hypothesis
The main hypothesis is that there is an interaction between candidate regulatory SNPs in the 
glutamate transporter (EAAT2 -200 and -181) and in three key pro-inflammatory cytokines 
(TNFα -308, IL1β -511 and IL6 -174), so that survivors of very preterm birth (≤32 weeks) 
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who have risk genotypes at both pathways have a higher risk of CP than those with risk 
genotypes at either pathway or none.
Additional objectives included: 
 Exploring individual SNP-outcomes associations in univariable analyses, including 
the previously replicated cytokine SNPs and the largely unexplored EAAT2 SNPs
 Expanding the research question to secondary outcomes including severe white matter 
injury at birth (cPVL), non-CP motor impairment and cognitive impairment at 2 and 5 
years of age
2.3 Materials and methods
2.3.1 Study sample
This is a prospective cohort study using historical genetic and clinical data from the APIP 
trial (275, 276). This was a cohort of 328 very and extreme preterm newborns (≤32 weeks of 
gestation) born consecutively in two Bristol hospitals (St Michael’s and Southmead 
Hospitals) between 1990 and 1993. Children with major congenital anomalies of the central 
nervous system and genetic syndromes known to cause CP or neurodevelopmental 
impairment were excluded from the original trial. All families spoke English as the first 
language at home. Of the original 328 APIP newborns, the current analysis excluded the 20 
newborns who died before discharge and included the 308 survivors. 
2.3.2 Genetic variants
Genetic data originated from routine blood spot screening card collected within the first 5-8 
days after birth as part of the UK Newborn Screening Programme 
(http://newbornbloodspot.screening.nhs.uk). The 5 candidate SNPs were genotyped in the 
APIP cohort in 2004 (inflammatory SNPs) and 2014 (glutamatergic SNPs) (Table 2.1). 
Genotypes for the 308 survivors were obtained directly from the authors in text format.
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Table 2.1. List of candidate SNPs






g.-200 C>A rs111885243 (911, 1061)
EAAT2 11
g.-181 A>C rs4354668
TNFα 6 g.-308 G>A rs1800629 Harding, D 
(unpublished)
IL1β 2 g.-511 C>T rs16944 Harding, D 
(unpublished)
IL6 7 g.-174 C>G rs1800795 (1030)
Genetic data was obtained by the original authors using different DNA extraction and 
genotyping methodologies since the studies were conducted by separate research groups a 
decade apart. For the cytokines, DNA was extracted by boiling blood spots in sterile water 
followed by phenol extraction. The regions of interest in the cytokine promoters were 
amplified by polymerase chain reaction (PCR) using commercially available primers and the 
PCR products digested with restriction enzyme NLaIII (Restriction Fragment Length 
Polymorphism analysis, RFLP analysis). Resulting amplified products are cut or uncut 
depending on the presence of the allele and can be separated by size. This was achieved using 
microtiter array diagonal gel electrophoresis (MADGE), which allows to run multiple 
samples simultaneously in a 96-well plate. 
For the glutamate transporter, DNA was extracted from blood spots using a commercial kit 
with extraction columns (QIAamp DNA Micro Kit, Qiagen) (1062). The region of interest in 
the promoter was amplified by PCR using custom primers, including a biotinylated forward 
primer. After denaturation of amplified DNA, the single strands tagged with biotin were 
selectively bound to streptavidin-coated beads, ready for pyrosequencing. This technique 
generates a light signal every time a nucleotide complementary to the target sequence is 
incorporated, allowing sequencing by synthesis in real-time. 
Due to their high but incomplete linkage disequilibrium (LD), the EAAT2 SNPs were 
additionally coded as nine -200/-181 genotype combinations, as previously described (911). 
Moreover, a new exposure variable was created for the number of A alleles at the -200/-181 
genotype combination, based on previous evidence of association with adverse 
neurodevelopmental outcomes in a larger sample including APIP (911).
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Linkage disequilibrium between all genetic variants was measured in the complete cases 
cohort using the Haploview 4.2 software (https://www.broadinstitute.org/haploview/). A 
linkage and a marker file were created in tab-delimited text format 
(https://www.broadinstitute.org/haploview/input-file-formats). The linkage file contained the 
newborns’ IDs and genotypes, the marker file contained the SNPs IDs and genomic locations. 
Both files were uploaded on Haploview, deselecting the default settings of removing 
individuals with <50% genotypes and SNPs >500 kb apart. LD was reported with both D’ 
(ranging -1 to 1) and r2 (ranging 0 to 1) coefficients. Both coefficients measure the amount of 
LD in a sample from the population. The consideration for both D’ and r2 allows to 
discriminate between perfect LD (D’=1; r2=1) and complete LD (D’=1; r2<1).
2.3.3 Clinical outcomes
The primary outcome measure was a diagnosis of CP at 2 years, assigned by a clinical 
academic paediatrician or a research physiotherapist using standardised definitions (1063).
Secondary outcomes were: 
1) cPVL, diagnosed by cranial ultrasound by a clinical academic neonatologist during 
the neonatal stay and defined using standard guidelines (i.e. echo-lucent cysts of ≥2 
mm diameter in the periventricular white matter) (4)
2) Griffiths aggregate general quotient (AGQ), assessing neurodevelopment at 2 years 
and administered by a psychologist (1064). The AGQ is derived from five subscales: 
personal and social, hearing and speech, locomotor, eye hand co-ordination and 
performance domains 
3) British Ability Scales score (BAS, 2nd Ed.), assessing cognitive skills at 5 years and 
administered by a psychologist (1065). The general conceptual ability score (GCA), 
an IQ estimate, is derived from verbal, non-verbal reasoning, and spatial skills 
subscales. 
Both the Griffiths DQ and BAS GCA have a standardised mean of 100 (± 15 SD) in 
the UK reference population, with lower scores indicating lower performance 
(Harding et al., 2004, Harding et al., 2005) 
4) Movement ABC Score (M-ABC, 1st Ed.), assessing manual dexterity, coordination 
and balance at 5 years and administered by a research nurse (216, 1066). The 
impairment score normalised to the reference UK population ranges from 0 to 40: 0-
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10 is classified as normal (>15th percentile), 10.5-16.5 as borderline (15th-5th 
percentile), 17-40 as definite movement impairment (<5th percentile)
Data on intraventricular haemorrhage was also available, with grading following the 
Papile classification (1067). Sensitivity analyses included additional measures of 
moderate white matter injury: persistent periventricular echodensities (echodensities 
present after 14 days of life not developing into cysts) and ventricular dilatation 
(ventricular size >97th percentile) (1068). 
2.3.4 Clinical covariates
Birth weight, gestational age and biological sex were considered a priori as possible 
mediators/effect modifiers and were used to generate z-scores standardised to the UK-WHO 
Preterm Growth Reference (1069). Newborns below the 10th birth centile (z-score ≤-1.28) 
were considered a priori as small for gestational age. Multiple births and a range of perinatal 
inflammatory exposures were also considered a priori as possible mediators/effect modifiers, 
including maternal infection/chorioamnionitis, early and late neonatal sepsis and necrotising 
enterocolitis. Ethnicity information was available only in the form of Caucasian/non-
Caucasian, with all ethnic minority groups grouped together. 
2.3.5 Statistical analysis
The complete cases cohort (n=202) was defined as the subset of newborns with genotype data 
for both glutamate transporter SNPs and at least one cytokine SNP, as well as primary CP 
outcome data. Analyses involving each variant independently or each EAAT2-cytokine pair 
had different complete cases subsets, and, as such, denominators vary throughout the study.
Allele frequencies in the complete cases cohort (n=202) were compared to those in the 
original APIP cohort (n=308) with a two-sample test of proportions. They were also 
compared to allele frequencies in the European population of the 1000 Genomes Project (see 
2.3.6). Hardy-Weinberg disequilibrium (HWD) was tested for all SNPs with a χ2 test and a 
threshold of p<0.05. 
Associations with neurodevelopmental outcomes were assessed for each variant 
independently with univariable tests of associations. Categorical outcomes were analysed by 
χ2 or Fisher’s exact test (if cell n<5). In post hoc analyses, genotypes with significantly 
different frequencies were identified as those with adjusted Pearson residuals >1.96 (i.e. more 
than two standard deviations from the mean). Continuous outcomes were analysed with one-
way ANOVA for variables with expected normal distribution and Kruskal Wallis test for 
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variables with expected skewed distribution. In post hoc analyses, the Dunnett’s test was used 
to compare the mean outcome for each of the two risk genotypes to that of the reference 
genotype. For categorical outcomes, effect sizes were estimated as odds ratios relative to the 
reference genotype (ORaa and ORAa). For continuous outcomes, effect sizes were expressed 
as mean differences (xĀA-x̄aa; xĀA-x̄Aa).
Following univariable analysis, multivariable regression analysis was planned to explore the 
interaction between the number of A alleles at EAAT2 -200/-181 (as a continuous variable) 
and each cytokine variant (as a categorical variable with three levels/genotypes), as well as to 
explore the effect of clinical covariates. Goodness of fit of increasingly complex models was 
tested and compared with the likelihood ratio test: baseline model vs univariate model, 
univariate model vs bivariate model (main effects), bivariate model (main effects) vs 
bivariate model (interaction). For the M-ABC score, which is positively skewed by 
definition, two approaches were considered: a linear regression with log transformed scores, 
or, in case of large departures from linear assumptions, a generalised linear model approach 
(gamma family, log link). 
Bonferroni correction was not applied in this exploratory hypothesis-driven study; however, 
all comparisons are reported. All analyses were performed using Stata 14 (Stata Corp, TX, 
USA).
2.3.6 Comparison with 1000 Genomes Project
To compare our data to that of a large reference sample, allele frequency and Hardy-
Weinberg data were obtained from the 1000 Genomes Project 
(http://www.internationalgenome.org). Allele frequency data was obtained from the most 
recent build (dbSNP build 153) of the dbSNP database of short genetic variations from the 
National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov/snp/). 
Hardy-Weinberg data was extracted from the latest release 1000 Genomes Phase 3 
(20130502 release) for the total sample, as well as the British subset and the CEU subset 
(Utah Residents with Northern and Western European Ancestry), which are both part of the 
larger European subset. Publicly available genotype data were downloaded from the FTP 
website (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/) in Variant Call Format (VCF) using the 
Data Slicer web tool (https://www.internationalgenome.org/data-slicer/) to filter and extract 
data by population. The downloaded VCF files were converted to suitable PED file format, 
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The complete cases cohort with data for both EAAT2 SNPs, at least one cytokine and CP 
outcome included 202 newborns. Complete cases cohorts were smaller for Griffiths (n=178), 
M-ABC (n=137) and BAS score (n=129). Individual complete cases cohorts for each EAAT2-
cytokine SNP pair included between 31% and 58% of the original APIP cohort (Table 2.2).
Table 2.2. Complete cases cohorts for each EAAT2 SNPs-cytokine SNP pair
Clinical Outcomes
Complete Cases Cohorts
CP cPVL Griffiths BAS M-ABC
TNFα -308 178 (58%) 175 (57%) 156 (51%) 114 (37%) 121 (39%)
IL1β -511 170 (55%) 167 (54%) 152 (49%) 109 (35%) 118 (38%)
IL6 -174 140 (45%) 137 (44%) 124 (40%) 89 (29%) 96 (31%)
Numbers are counts of children with genetic data for both EAAT2 SNPs, each cytokine SNP and 
relevant outcome
2.4.2 Distribution of alleles and genotypes
Genotype distributions of the five candidate SNPs are shown in Table 2.3. 
Table 2.3. Genotype distributions
































Total n 202 202 178 170 140
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Allele frequencies in the complete cases cohort were not significantly different from those in 
the original APIP cohort (Table 2.4). The TNFα -308 minor A allele was significantly more 
frequent in our cohort compared to the 1000 Genomes Project European subset (p<0.001). 
There was also some evidence that the EAAT2 variants were more frequent in our cohort (-
181: p=0.006; -200: p=0.006).






Vs Original APIP 
Cohort
Vs 1000 Genomes 
(EUR)
n n p* n p*




408 0.775 C: 0.61
A: 0.39
1006 0.006




408 >0.999 A: 0.59
C: 0.42
1006 0.006




414 0.516 G: 0.87
A: 0.13
1006 <0.001




402 0.770 C: 0.65
T: 0.35
1006 0.178




328 0.804 C: 0.42
G: 0.58
1006 >0.999
*Two-sample test of proportions vs complete cases cohort
Hardy-Weinberg equilibrium was tested for all SNPs. There was some evidence that the 
EAAT2 SNPs were in Hardy-Weinberg disequilibrium (-181: p=0.034; -200: p=0.029), i.e. 
the observed genotype frequencies were significantly different to the genotype frequencies 
expected from the observed allele frequencies under the Hardy-Weinberg assumptions. 
Specifically, excess heterozygotes were observed for both variants (Table 2.5). The EAAT2 
variants were also found to be in Hardy-Weinberg disequilibrium in the total 1000 Genomes 
Phase 3 sample, which includes genomic data for 2,504 individuals, as well as the British 
subset (n=91). However, in these two samples from the reference population, the direction 
was opposite with loss of heterozygotes. 
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Table 2.5. Hardy-Weinberg disequilibrium testing for the EAAT2 SNPs
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While the cytokine SNPs show very little non-random association (r2 = 0.01, D’ < 0.2), the 
EAAT2 SNPs were confirmed to be in strong but incomplete linkage disequilibrium (r2 = 0.8, 
D’ = 0.9). 
Figure 2.1. Linkage disequilibrium plots from Haploview. D’ (left) and r2 (right)
The SNPs appear to be on the same chromosome only because of the software output
 
The distributions of the 9 genotype combinations of EAAT2 -200 and -181 are shown in 
Table 2.6. 89% (n=180) children had concordant genotype combinations with 2 A alleles, i.e. 
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if -200 was homozygous (CC or AA), then -181 was also homozygous (AA or CC) and if -
200 was heterozygous (CA or AC) then -181 was also heterozygous (AC or CA). Over half 
of these children were heterozygote at both SNPs (genotype combination 2), followed by 
homozygote for major allele at both SNPs (genotype combination 1) and homozygote for the 
minor allele at both SNPs (genotype combination 3). Only 11% children had discordant 
genotype combinations, i.e. if -200 was homozygous then -181 was heterozygous or vice 
versa. Of these, 8% (n=16) of the children had 1 A allele (genotype combinations 6 and 9) 
and 3% (n=6) had 3 A alleles (genotype combinations 4 and 7). There were no children with 
the rarest genotype combinations 5 and 8 in this cohort (i.e. 4 As and 4 Cs).
Table 2.6. Distribution of the EAAT2 -200/-181 genotype combinations
No. A alleles at -200/-181 EAAT2 -200 EAAT2 -181 Frequency
0 CC CC 0 -
CC AC 9 (4.5%)
1
CA CC 7 (3.5%)
16 (8%)
CC AA 41 (20.3%)
CA AC 105 (52.0%)2
AA CC 34 (16.8%)
180 (89%)
CA AA 4 (2.0%)
3
AA AC 2 (1.0%)
6 (3%)
4 AA AA 0 -
Total 202
2.4.3 Characteristics of the cohort
Clinical and demographic characteristics of the complete cases cohort are shown in Table 2.7. 
There was no evidence that the children not included in the analyses due to missing genetic 
and/or CP data had different demographic/clinical characteristics compared to those in the 
complete cases cohort. 
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Table 2.7. Clinical and demographic characteristics of the cohort
Perinatal Characteristics Complete Cases Cohort Missing Subset p
n n
Male Sex 202 114 (56.4%) 106 63 (59.4%) 0.613
Birth Weight (g) 202 1432.4 (±387.9) 105 1444.5 (±391.3) 0.797
Gestational Age (weeks) 202 30 (29-32) 105 31 (29-32) 0.694
Small for Gestational Age 201 19 (9.5%) 105 11 (10.5%) 0.775
Multiple Birth 202 41 (20.3%) 106 17 (16.0%) 0.364
Maternal Infection 200 13 (6.5%) 104 6 (5.8%) 0.803
Neonatal Sepsis 202 69 (34.2%) 105 32 (30.5%) 0.515
Necrotising Enterocolitis 199 8 (4.0%) 101 4 (4.00%) 0.980
Caucasian Ethnicity 201 184 (91.5%) 104 95 (91.4%) 0.954
Within the complete cases cohort, 86% (n=173) of the children were born very preterm (28-
32 weeks) and 14% (n=29) extreme preterm (<28 weeks) (Table 2.8).  
Table 2.8. Distribution of gestational ages














Clinical and demographic characteristics of the complete cases cohort split by genotype are 
shown in Table 2.9, Table 2.10, Table 2.11, Table 2.12, Table 2.13 and Table 2.14. Ethnicity 
was strongly associated with the number of A alleles at EAAT2 -200/-181 (Table 2.11). In the 
post hoc analysis, it was found that, while the two EAAT2 SNPs did not differ by ethnicity in 
terms of minor allele frequency (-200, p>0.999; -181, p=0.373), non-Caucasian children were 
more likely to have discordant genotypes than Caucasian children (41.2% vs 8.2%, p<0.001). 
There was some evidence that IL1β -511 was associated with being small for gestational age 
(p=0.041) (Table 2.13), with more SGA in the reference CC genotype (adjusted Pearson 
residual = 2.57). There was very weak evidence of the following associations: EAAT2 -200 
and birth weight (p=0.068) (Table 2.9), TNFα -308 and gestational age (p=0.081) (Table 
2.12), and IL6 -174 and ethnicity (p=0.078) (Table 2.14). 





Total n n n
Male sex 202 28 (56.0%) 50 60 (51.7%) 116 26 (72.2%) 36 0.095







Gestational Age (wk) 202 31 (28-32) 50 30 (29-32) 116 31 (29.5-32) 36 0.354
Small for Gestational 
Age
201 4 (8.0%) 50 14 (12.1%) 116 1 (2.9%) 35 0.282
Multiple Birth 202 9 (18.0%) 50 24 (20.7%) 116 8 (22.2%) 36 0.880
Maternal Infection 200 3 (6.1%) 49 7 (6.0%) 116 3 (8.6%) 35 0.855
Neonatal Sepsis 202 16 (32.0%) 50 40 (34.5%) 116 13 (36.1%) 36 0.918
Necrotising 
Enterocolitis
199 0 (0.0%) 49 6 (5.2%) 115 2 (5.7%) 35 0.209
Caucasian ethnicity 201 45 (91.8%) 49 106 (91.4%) 116 33 (91.7%) 36 0.995
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Total n n n
Male sex 202 27 (60.0%) 45 60 (51.7%) 116 27 (65.9%) 41 0.252







Gestational Age (wk) 202 31 (28-32) 45 30 (29-31) 116 31 (29-32) 41 0.236
Small for Gestational 
Age
201 3 (6.7%) 45 15 (12.9%) 116 1 (2.5%) 40 0.140
Multiple Birth 202 6 (13.3%) 45 28 (24.1%) 116 7 (17.1%) 41 0.263
Maternal Infection 200 3 (6.7%) 45 7 (6.1%) 114 3 (7.3%) 41 0.928
Neonatal Sepsis 202 15 (33.3%) 45 39 (36.2%) 116 15 (36.6%) 41 0.934
Necrotising 
Enterocolitis
199 0 (0.0%) 45 6 (5.3%) 114 2 (5.0%) 40 0.293
Caucasian ethnicity 201 42 (95.5%) 44 107 (92.2%) 116 35 (85.4%) 41 0.227
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No. A alleles at EAAT2 -200/-181 p
1 2 3
Total n n n
Male sex 202 6 (37.5%) 16 104 (57.8%) 180 4 (66.7%) 6 0.256







Gestational Age (wk) 202 31 (29-31) 16 30 (29-32) 180 31 (30-32) 6 0.459
Small for Gestational 
Age
201 1 (6.3%) 16 18 (10.1%) 179 0 (0.0%) 6 >0.999
Multiple Birth 202 4 (25.0%) 16 35 (19.4%) 180 2 (33.3%) 6 0.497
Maternal Infection 200 0 (0.0%) 15 13 (7.2%) 180 0 (0.0%) 5 0.718
Neonatal Sepsis 202 4 (25.0%) 16 64 (35.6%) 180 1 (16.7%) 6 0.556
Necrotising 
Enterocolitis
199 0 (0.0%) 15 8 (4.5%) 178 0 (0.0%) 6 >0.999
Caucasian ethnicity 201 10 (62.5%) 16 169 (94.4%) 179 5 (83.3%) 6 <0.001
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Total n n n
Male sex 178 59 (59.0%) 100 35 (51.5%) 68 7 (70.0%) 10 0.429







Gestational Age (wk) 178 30 (28-32) 100 30 (29-31) 68 29 (26-30) 10 0.081
Small for Gestational 
Age
177 7 (7.0%) 100 8 (11.9%) 67 0 (0.0%) 10 0.418
Multiple Birth 178 22 (22.0%) 100 15 (22.1%) 68 2 (20.0%) 10 >0.999
Maternal Infection 177 8 (8.0%) 100 3 (4.5%) 67 1 (10.0%) 10 0.447
Neonatal Sepsis 178 37 (37.0%) 100 23 (33.8%) 68 5 (50.0%) 10 0.622
Necrotising 
Enterocolitis
175 2 (2.0%) 98 4 (6.0%) 67 1 (10.0%) 10 0.146
Caucasian ethnicity 177 90 (90.9%) 99 63 (92.7%) 68 9 (90.0%) 10 0.910
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Total n n n
Male sex 170 44 (52.4%) 84 41 (62.1%) 66 10 (50.0%) 20 0.419







Gestational Age (wk) 170 30 (29-32) 84 30 (29-32) 66 31 (28.5-32) 20 0.899
Small for Gestational 
Age
169 14 (16.9%) 83 3 (4.6%) 66 1 (5.0%) 20 0.041
Multiple Birth 170 15 (17.9%) 84 15 (22.7%) 66 4 (20.0%) 20 0.738
Maternal Infection 168 8 (9.6%) 83 1 (1.5%) 65 2 (10.0%) 20 0.092
Neonatal Sepsis 170 31 (36.9%) 84 21 (31.8%) 66 6 (30.0%) 20 0.742
Necrotising 
Enterocolitis
167 4 (4.8%) 83 2 (3.1%) 65 0 (0.0%) 19 0.854
Caucasian ethnicity 169 77 (91.7%) 84 58 (89.2%) 65 18 (90.0%) 20 0.878
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Total n n n
Male sex 140 31 (64.6%) 48 41 (61.2%) 67 12 (48.0%) 25 0.375







Gestational Age (wk) 140 30 (29-31) 48 31 (29-32) 67 30 (29-31) 25 0.906
Small for Gestational 
Age
139 3 (6.3%) 48 7 (10.6%) 66 2 (8.0%) 25 0.852
Multiple Birth 140 8 (16.7%) 48 13 (19.4%) 67 6 (24.0%) 25 0.752
Maternal Infection 139 1 (2.1%) 48 8 (12.1%) 66 1 (4.0%) 25 0.103
Neonatal Sepsis 140 22 (45.8%) 48 21 (31.3%) 67 7 (28.0%) 25 0.188
Necrotising 
Enterocolitis
139 3 (6.4%) 47 4 (6.0%) 67 0 (0.0%) 25 0.674
Caucasian ethnicity 139 41 (85.4%) 48 64 (97.0%) 66 23 (92.0%) 25 0.078
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2.4.4 Outcomes
Outcome distributions are shown in Table 2.15. There was no evidence that the children not 
included in the analyses due to missing genetic and/or CP data had different outcomes 
compared to those in the complete cases cohort. Within the complete cases cohort, children 
with missing data for the BAS score at 5 years were more likely to have had a CP diagnosis 
at 2 years (p=0.042). Similarly, children with missing M-ABC assessment at 5 years were 
more likely to have had a CP diagnosis (p=0.003). There was no significant evidence of an 
association between the Griffith score at 2 years and a missing BAS score (p=0.179) or M-
ABC score (p=0.273) at 5 years.
Table 2.15. Outcome distributions
Outcome Complete Cases Cohort Missing Subset p
n n
Cerebral Palsy 202 17 (8.4%) 106 13 (12.3%) 0.279
   Diplegia    8 (4.0%)    1 (0.9%)
   Quadriplegia    8 (4.0%)    4 (3.8%)
   Hemiplegia    1 (0.5%)    2 (1.9%)
   Hypotonia -    4 (3.8%)
   Mixed -    2 (1.9%)
cPVL 199 15 (7.5%) 95 8 (8.4%) 0.792
Griffiths 178 96.0 (±15.1) 89 93.73 (±19.5) 0.306
BAS 129 98.3 (±15.7) 68 101.82 (±16.3) 0.137
M-ABC 137 5 (2-12) 72 4.75 (1.75-9.5) 0.715
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Summary results of the univariable tests of associations are reported in Table 2.16 for the 
glutamate transporter variants and Table 2.17 for the cytokines variants. The results will also 
be presented by outcome in the relevant paragraphs. 
Table 2.16. Univariable tests of association between the EAAT2 SNPs and all outcomes 
Outcomes EAAT2 -200
CC CA AA p
Total n n n n
Cerebral Palsy 202 4 (8.0%) 50 10 (8.6%) 116 3 (8.3%) 36 >0.999
cPVL 199 3 (6.0%) 50 10 (8.8%) 114 2 (5.7%) 35 0.812
Griffith 178 96.7 (± 16.6) 46 95.7 (± 16.0) 99 95.7 (± 9.7) 33 0.936
BAS 129 99 (± 15) 34 100 (± 15) 71 92 (± 18) 24 0.084
M-ABC 137 3.5 (0.5-10) 35 5 (2 – 11.5) 81 7 (3 – 12.5) 21 0.440
EAAT2 -181
AA AC CC p
Total n n n n
Cerebral Palsy 202 5 (11.1%) 45 10 (8.6%) 116 2 (4.9%) 41 0.690
cPVL 199 3 (6.7%) 45 9 (8.0%) 113 3 (7.3%) 41 >0.999
Griffith 178 95.6 (±18.3) 42 96.2 (±15.5) 98 95.9 (±9.6) 38 0.978
BAS 129 98 (±18) 33 100 (±14) 69 93 (±17) 27 0.171
M-ABC 137 3.5 (2-12) 33 4.5 (2-9.5) 77 7.5 (3-14) 27 0.297
No. A alleles at EAAT2 -200/-181
1 2 3 p
Total n n n n
Cerebral Palsy 202 0 (0.0%) 16 15 (8.3%) 180 2 (33.3%) 6 0.085
cPVL 199 1 (6.3%) 16 14 (7.9%) 178 0 (0.0%) 5 >0.999
Griffiths 178 100.0 (±9.5) 15 95.6 (±15.3) 157 96.7 (±22.1) 6 0.555
BAS 129 99 (±11) 10 99 (±15) 113 88 (±29) 6 0.249




Table 2.17. Univariable tests of association between the cytokine SNPs and all outcomes 
TNFα -308
GG GA AA p
Total n n n n
Cerebral Palsy 178 6 (6.0%) 100 8 (11.8%) 68 3 (30.0%) 10 0.043
cPVL 175 6 (6.1%) 99 6 (9.1%) 66 3 (30.0%) 10 0.051
Griffith 156 96.5 (±16.2) 90 95.0 (±12.9) 57 92.4 (±25.5) 9 0.696
BAS 114 99 (±15) 62 95 (±16) 46 105 (±14) 6 0.191
M-ABC 121 4.5 (2.5-
11.5)
67 5 (1-11.5) 47 5 (4-27.5) 7 0.637
IL1β -511
CC CT TT p
Total n n n n
Cerebral Palsy 170 10 (11.9%) 84 5 (7.6%) 66 0 (0.0%) 20 0.272
cPVL 167 5 (6.0%) 83 4 (6.3%) 64 1 (5.0%) 20 >0.999
Griffith 152 93.9 (±16.0) 73 98.8 (±13.9) 63 97.1 (±13.9) 16 0.160
BAS 109 94 (±16) 53 103 (±14) 46 100 (±15) 10 0.017
M-ABC 118 6.75 (3.3-
12)
60 4 (1-9.5) 47 4.5 (3-12.5) 11 0.141
IL6 -174
GG GC CC p
Total n n n n
Cerebral Palsy 140 3 (6.3%) 48 6 (9.0%) 67 4 (16.0%) 25 0.426
cPVL 137 3 (6.4%) 47 2 (3.1%) 67 4 (16.0%) 25 0.082
Griffith 124 94.0 (±15.1) 44 96.6 (±16.9) 59 98.5 (±13.6) 21 0.519
BAS 89 96 (±18) 32 99 (±16) 40 104 (±14) 17 0.261
M-ABC 96 3.5 (2-11.5) 35 4 (0.5-11.5) 43 5.8 (2.5-9.5) 18 0.831
2.4.4.1 Cerebral Palsy
In the univariable tests (Table 2.18), there was some evidence that TNFα -308 was associated 
with CP (p=0.043). The odds ratio for the heterozygote GA genotype relative to the reference 
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GG genotype was 2.09 (95% CI 0.60-7.66), whereas the odds ratio for the homozygote AA 
genotype was 6.71 (95% CI 0.87-39.84). 3 out of 10 children with the TNFα -308 AA 
genotype had CP, which was higher than expected by chance in the post hoc analyses 
(adjusted Pearson residual = 2.27). Of these 3 children, one had diplegia, one had 
quadriplegia and one non-Caucasian child had hemiplegia. Analysis was repeated in the 
entire cohort with TNFα -308 data, regardless of availability of EAAT2 genetic data. 
However, all 29 additional children included in this larger cohort (n=207 vs 178) had the 
TNFα -308 GG reference genotype. 
There was no evidence that CP was associated with IL1β -511, IL6 -174, or either of the 
glutamate transporter variants individually. There was very weak evidence of an association 
with the number of A alleles at EAAT2 -200/-181 genotype combination (p=0.085), however 
numbers were very low in the rarest allele counts, with 2 out of 6 children with 3 A alleles 
having CP and none of the 16 children with 1 A allele.
Table 2.18. Univariable tests of association between all SNPs and cerebral palsy
Genetic Variant Cerebral Palsy - Univariable Tests of Association
Total 
n
n n n p














































In the multivariable interaction analyses, the cohort was subdivided into smaller subsets 
based on genotypes at both EAAT2 and cytokine SNPs (Table 2.19, Figure 2.2, Figure 2.3, 
Figure 2.4). Most children (89%) had 2 A alleles at EAAT2 -200/-181 genotype combination. 
Only a small number of children had 1 and 3 alleles at EAAT2, less than 20 when considering 
only the children with available CP and cytokine data. None of the children with 1 or 3 A 
alleles were also homozygote for the risk allele at the cytokine, except for one child with IL6 
-174 CC, and heterozygotes were also rare (n=6-12 depending on the SNP). This precluded 
assessment of the genotype combinations hypothesised a priori as carrying the highest risk. 
According to the widely used “Events Per Variable” (EPV) rule of thumb, at least 10 cases 
are needed for each predictor variable included in a model to avoid generating models that 
have poor predictive power and are too uncertain (1070-1072). The problems with fitting 
regression models with low number of events (i.e. CP cases) include inaccuracy of the logit 
coefficients due to small sample bias, with systematic overestimation of the associations, as 
well as the issue of separation, whereby a single predictor perfectly separates events from 
non-events. The current study features two genetic exposures (the number of A alleles at 
EAAT2 -200/-181 and a cytokine genotype) and their interaction and would therefore require 
at least 30 CP cases. This is far more than the 17 CP cases in the complete cases cohort. 
Moreover, separation is not perfect but substantial, with the vast majority of CP cases having 
2 A alleles at EAAT2 due to rarity of the other combinations with current sample size. On 
separated data, the maximum likelihood estimation procedure, which estimates the best 
fitting model of the observed data, can go through the iterations, and fail to converge on an 
estimate (1073). This was indeed observed when attempting to fit a multivariable regression 
model. As such, due to the rarity of both CP outcome and risk genetic variants, logistic 
regression was considered inappropriate with current sample size. 
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Table 2.19. Combined EAAT2-cytokine genotype distributions in relation to cerebral 
palsy
No. A alleles at EAAT2 -200/-181Cytokine Variant Genotype Cerebral Palsy
1 2 3
No 8 83 3
GG
Yes - 6 -
No 6 54 -
GA
Yes - 6 2
No - 7 -
TNFα -308
AA
Yes - 3 -
No 5 68 1
CC
Yes - 9 1
No 10 50 1
CT
Yes - 4 1
No - 20 -
IL1β -511
TT
Yes - - -
No 6 37 2
GG
Yes - 2 1
No 5 56 -
GC
Yes - 5 1
No - 20 1
IL6 -174
CC
Yes - 4 -
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Figure 2.2. Combined EAAT2-TNFα genotype distributions in relation to cerebral palsy
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Figure 2.3. Combined EAAT2-IL1β genotype distributions in relation to cerebral palsy
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Figure 2.4. Combined EAAT2-IL6 genotype distributions in relation to cerebral palsy
An example of how logistic regression could be carried out with a larger sample size is given 
for EAAT2 and TNFα in the Appendix (Table 8.2). Informally, it can be observed that none of 
the children with 1 A allele at EAAT2 have CP, whereas both children with 3 A alleles and 
CP also have the TNFα heterozygote genotype. Whilst in agreement with the a priori 
hypothesis, larger studies are needed with greater number of CP cases and rare genotype 
combinations before regression modelling can be applied with precision. As such, statistically 
sound inferences about the genetic interaction effects of the glutamate transporter and 
cytokine variants on CP risk cannot be drawn at this stage.
To assess potential effect modification, children with CP were stratified by both genotype and 
perinatal inflammatory exposures (Table 2.20). The number of children with CP does not 
always amount to 17 because of missing genetic and/or clinical data. Stratified numbers were 
too low for statistical testing of heterogeneity of effects across strata. Informally, it can be 
observed that two of the children with CP had multiple inflammatory exposures and multiple 
cytokine risk genotypes: one child with diplegia (indicated as *) had a history of both 
maternal infection and neonatal sepsis and had TNFα -308 AA, IL1β -511 CC and IL6 -174 
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GC. Another child with quadriplegia (indicated as ^) had a history of both necrotising 
enterocolitis and neonatal sepsis and had TNFα -308 AA and IL6 -174 GC genotype (missing 
data for IL1β -511). Both children had 2 A alleles at EAAT2 -200/-181. Stratification by SGA 
status was not appropriate in this cohort, as no children identified as small for gestational age 
in the complete cases cohort had CP. 
Table 2.20. Stratification of the children with cerebral palsy by both genotype and 
perinatal inflammatory exposures
Genotype Number of Children with CP and Perinatal Inflammatory 
Exposures
Maternal Infection Neonatal Infection Necrotising 
Enterocolitis
No Yes No Yes No Yes
TNFα -308
GG 5 1 3 3 6 -
GA 7 - 5 3 8 -
AA 2 1* - 3*^ 2 1^
IL1β -511
CC 8 2* 6 4* 10 -
CT 4 - 1 4 5 -
TT - - - - - -
IL6 -174
GG 3 - 1 2 3 -
GC 4 1* 3 3*^ 5 1^
CC 3 1 2 2 4 -
No. A alleles EAAT2 -
200/-181
1 - - - - - -
2 13 2* 6 9*^ 14 1^
3 1 - 2 - 2 -
* and ^ - two children with multiple inflammatory exposures
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2.4.4.2 Cystic Periventricular Leukomalacia
In the complete cases cohort, 17 children had CP and 15 newborns had cPVL at birth. 
Approximately half (n=8) of the children with CP had cPVL at birth. Of these, 3 (19%) also 
had severe intraventricular haemorrhage (IVH grade 3 or 4). Indeed, all CP cases with severe 
IVH also had cPVL in this cohort. Of the remaining 9 children with CP, one had moderate 
injury (persistent periventricular echodensities), 7 had normal ultrasound data and one had no 
ultrasound data.
In the univariable tests (Table 2.21), there was some evidence that TNFα -308 was associated 
with cPVL (p=0.051). The odds ratio for the heterozygote GA genotype relative to the 
reference GG genotype was 1.55 (95% CI 0.39-6.08), whereas the odds ratio for the 
homozygote AA genotype was 6.64 (95% CI 0.86-39.42). 3 out of 10 children with the TNFα 
-308 AA genotype had cPVL, which was higher than expected by chance in the post hoc 
analyses (adjusted Pearson residual = 2.49). These were the same 3 children with TNFα -308 
AA who had CP. All three children also had some form haemorrhage: one child developed 
quadriplegia and had severe intraventricular haemorrhage at birth (IVH grade 3 or 4); one 
child developed diplegia and had moderate IVH (grade 2) and one child with hemiplegia had 
a mild subependymal haemorrhage (grade 1). 
There was no evidence that cPVL was associated with IL1β -511 or the glutamate transporter 
variants in the univariate analyses. On the other hand, there was very weak non-significant 
evidence of an association with IL6 -174 (p=0.082). The complete cases cohort for IL6 -174 
and cPVL outcome was the smallest (n=137), with only 2-4 cPVL cases for each IL6 -174 
genotype. When the analysis was repeated in the whole cohort with IL6 -174 data, regardless 
of availability of EAAT2 genetic data (n=157), the number of children with cPVL for each 
genotype was still very low (n=3-4) and there was no longer any evidence of association. 
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Table 2.21. Univariable tests of association between all SNPs and cystic periventricular 
leukomalacia
Genetic Variant Cystic Periventricular Leukomalacia - Univariable Tests of Association
Total 
n
n n n p













































A sensitivity analysis was performed with a new variable describing any moderate to severe 
white matter injury detectable through ultrasound (Table 2.22). Alongside cPVL (n=23), this 
comprised persistent periventricular echodensities not evolving into cysts (n=10), and 
ventricular dilatation (n=11), which can be caused by atrophy of the periventricular white 
matter in diffuse white matter injury or with microscopic glial scars not visible with 
ultrasound. Inclusion of these more moderate forms of white matter injury did not affect the 
size of the complete cases cohort (n=157) but increased the number of cases (n=44). The 
association with TNFα -308 was no longer supported (p=0.631), whereas the evidence 
supporting IL6 -174 strengthened (p=0.052). Post hoc residual analysis suggested that the 
reference CC genotype was associated with a significantly higher proportion of moderate to 
severe white matter injury (37.5%, adjusted Pearson residual = 2.37).
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n n n p
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As for CP, cPVL is a rare outcome, and the study is especially underpowered for multivariate 
interaction analysis (Table 2.23). 
Table 2.23. Combined EAAT2-cytokine genotype distributions in relation to cystic 
periventricular leukomalacia
No. A alleles at EAAT2 -200/-181Cytokine Variant Genotype cPVL
1 2 3
No 7 83 3
GG
Yes 1 5 -
No 6 53 1
GA
Yes - 6 -
No - 7 -
TNFα -308
AA
Yes - 3 -
No 5 71 2
CC
Yes - 5 1
No 10 49 1
CT
Yes - 4 -
No - 19 -
IL1β -511
TT
Yes - 1 -
No 6 35 3
GG
Yes - 3 -
No 5 58
GC
Yes - 2 -
No - 20 1
IL6 -174
CC
Yes - 4 -
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2.4.4.3 Griffiths Neurodevelopmental Scales at 2y
In the univariable tests (Table 2.24), there was no evidence that any of the genetic variants 
was associated with the Griffiths aggregate general quotient, assessing movement, cognition, 
perception, and communication at 2 years of age. 
Table 2.24. Univariable tests of association between all SNPs and the Griffiths aggregate 
general quotient at 2 years
Genetic Variant Griffiths Developmental Score (2y) - Univariable Tests of Association
Total 
n
n n n p

















































Linear regression modelling the effect of the increasing number of A alleles at EAAT2 on the 
Griffiths score would assume a linear relationship between the two variables. However, the 
low number of children with 1 and 3 A alleles and the lack of children with 0 and 4 A alleles 
did not allow to reasonably make this assumption (Figure 2.5). Additionally, there were few 
children with available Griffiths data and non-reference EAAT2-cytokine genotype 
combinations (n<10) (Table 2.25). Therefore, progression to linear regression modelling was 
deemed inappropriate.
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Figure 2.5. Scatterplot of the Griffiths score at 2 years by the number of A alleles at 
EAAT2 -200/-181
Table 2.25. Combined EAAT2-cytokine genotype distributions in relation to the number 
of children with the Griffiths score at 2 years
EAAT2(#A) -200/-181Cytokine Genotype
1 2 3
GG 8 79 3
GA 5 50 2TNFα -308
AA - 9 -
CC 5 66 2
CT 9 52 2IL1β -511
TT - 16 -
GG 5 36 3
GC 5 53 1IL6 -174
CC - 20 1
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2.4.4.4 British Ability Scales Cognitive Score at 5y
Children with missing BAS cognitive data at 5 years were more likely to have had a CP 
diagnosis at 2 years (p=0.042), but not necessarily a lower Griffiths score (p=0.179).
In the univariable tests (Table 2.26), there was some evidence that the BAS score was 
associated with IL1β -511 (p=0.017). Post hoc analysis revealed that the BAS score was 
significantly lower in children with the reference CC genotype compared to the CT genotype 
(94 (±16) vs 103 (±14), p=0.003). Evidence was weaker for CC vs the rarest TT genotype 
(100 (±15), p=0.193). The difference in means between CT and CC was 8.93 (2.84-15.02) 
and the difference in means between TT and CC was 5.52 (-4.90-15.94). Repeating the 
analysis in the whole IL1β -511 complete cases cohort, regardless of availability of EAAT2 
genetic data, increased sample size (n=127 vs 109) and included 2 additional children with 
TT genotype. In this analysis, the evidence for a difference between CC and TT genotypes 
strengthened (p=0.078). There was also very weak evidence of an association between the 
BAS score and EAAT2 -200 (p=0.084).
Table 2.26. Univariable tests of association between all SNPs and the BAS score at 5y
Genetic Variant




n n n p














































A sensitivity analysis explored association between IL1β -511 and the EAAT2 variants and 
the BAS subscales, i.e. verbal ability, non-verbal reasoning ability and spatial ability (Table 
2.27). There was increasing evidence that IL1β -511 was associated with the non-verbal 
reasoning subscale (p=0.003). Specifically, children with the reference CC genotype had 
lower non-verbal reasoning scores than both the CT heterozygotes (p=0.013) and the TT 
homozygotes for the minor allele (p=0.008). There was also some evidence that EAAT2 -200 
and -181 were both associated with the verbal subscale (-200: p=0.030; -181: p=0.024). 
Specifically, having two copies of the minor allele at either variant was associated with a 
lower verbal subscale score than having one copy (-200: p=004; -181: p=0.002) or none (-
200: p=0.009; -181: p=0.013). There was no association with the number of A alleles at 
EAAT2, though all three subscale scores were nominally lower in the 6 children with 3 A 
alleles. 
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Table 2.27. Sensitivity analysis of the effects of IL1β -511, EAAT2 -200 and -181 on the 




n n n n
CC CT TT
IL1β -511 134
100 (±13) 65 103 (±14) 57 99 (±12) 12 0.339
CC CA AA
EAAT2 -200
102 (±12) 35 102 (±14) 78 94 (±15) 25 0.028
AA AC CC
EAAT2 -181




No. A alleles at 
EAAT2 -200/-181
138
100 (±10) 12 101 (±14) 120 96 (±19) 6 0.726
CC CT TTIL1β -511
129
94 (±15) 62 101 (±16) 55 110 (±20) 12 0.003
CC CA AAEAAT2 -200
100 (±15) 34 99 (±17) 73 92 (±15) 24 0.132
AA AC CCEAAT2 -181





No. A alleles at 
EAAT2 -200/-181
131
93 (±17) 11 99 (±15) 114 91 (±26) 6 0.199
CC CT TTIL1β -511
126
95 (±18) 61 99 (±17) 53 99 (±11) 12 0.399
CC CA AAEAAT2 -200
99 (±14) 33 97 (±16) 73 94 (±20) 23 0.641
AA AC CCEAAT2 -181




No. A alleles at 
EAAT2 -200/-181
129
102 (±10) 10 97 (±16) 113 84 (±29) 6 0.109
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As for the Griffiths score, progression to linear regression was deemed inappropriate due to 
the inability to assume linearity between the increasing number of A alleles at EAAT2 and the 
BAS score (Figure 2.6) and the small number of children with available BAS data and non-
reference EAAT2-cytokine genotype combinations (n<10) (Table 2.28).
An example of how linear regression could be carried out with a larger sample size and 
reasonable linear assumptions is given for EAAT2 and TNFα in the Appendix (Table 8.3). 
Plots of model predictions could be used to illustrate the predicted effect of the increasing 
number of A alleles at EAAT2 on the BAS score by cytokine risk genotypes (Figure 8.1).  
Figure 2.6. Scatterplot of the BAS score at 5 years by the number of A alleles at EAAT2 
-200/-181
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Table 2.28. Combined EAAT2-cytokine genotype distributions in relation to the number 
of children with the BAS score at 5 years
EAAT2(#A) -200/-181Cytokine Genotype
1 2 3
GG 5 54 3
GA 4 40 2TNFα -308
AA - 6 -
CC 3 48 2
CT 7 37 2IL1β -511
TT - 10 -
GG 4 25 3
GC 4 35 1IL6 -174
CC - 16 1
120
2.4.4.5 Movement Assessment Battery for Children Motor Score at 5y
Children with missing data for the M-ABC score at 5 years were more likely to have had a 
CP diagnosis at 2 years (p=0.003). This is in part explained by the fact that children with 
moderate/severe CP are not required to undertake the M-ABC assessment. Additionally, 
some of the children with moderate/severe impairments may have been lost-to-follow-up. In 
the univariable tests (Table 2.29), there was no evidence that any of the genetic variants was 
associated with the M-ABC score, assessing fine and gross motor skills, balance, and 
coordination at 5 years of age.
Table 2.29. Univariable tests of association between all SNPs and the M-ABC score at 5 
years
Genetic Variant
Movement Assessment Battery for Children (M-ABC) Impairment Score (5 y) 
- Univariable Tests of Association
Total 
n
n n n p
















































As for all other outcomes, regression modelling was deemed inappropriate due to the small 
number of children with M-ABC data and non-reference EAAT2-cytokine genotype 
combinations (n<10) (Table 2.30). With larger sample sizes, a generalised linear model with 
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gamma distribution (reflecting the positive skew of the impairment score) could be used to 
model univariable and multivariable associations (see Appendix, Table 8.4).
Table 2.30. Combined EAAT2-cytokine genotype distributions in relation to the M-ABC 
score at 5 years
No. A alleles at EAAT2 -200/-181Cytokine Genotype
1 2 3
GG 7 58 2
GA 4 42 1TNFα -308
AA - 7 -
CC 4 54 2
CT 8 38 1IL1β -511
TT - 11 -
GG 5 28 2
GC 5 38 -IL6 -174
CC - 17 1
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In the attempt to increase power, a sensitivity analysis was carried out including the 18 
children with CP at 2 years old who did not have a M-ABC score, by assigning them an 
arbitrary value of 17, i.e. the M-ABC threshold for definite movement impairment (1066). 
Univariable tests were repeated within each variant’s complete cases cohort (Table 2.31). 
Once again, there was no evidence of association between any of the variants and the M-ABC 
score.
Table 2.31. Sensitivity analysis of the SNP effects on the M-ABC score at 5 years
Genetic Variant
Movement Assessment Battery for Children (M-ABC) Impairment Score (5 y) 
- Univariable Tests of Association (sensitivity analysis including children 
with missing M-ABC and CP)
Total 
n
n n n p



















































This exploratory study set out to assess whether candidate genetic variants regulating the 
expression of key pro-inflammatory cytokines and glutamate transporter interact with each 
other and affect the risk of brain injury and neurodevelopmental impairment in newborns 
born at or before 32 weeks of gestation. Due to low frequencies of some of the genetic 
variants and relatively rare outcomes, SNP-SNP interaction analyses were not appropriate, 
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and the analysis was redesigned to univariable associations only, assessing the effect of each 
variant independently. The main finding was that genetic variants regulating the expression 
of key cytokines TNFα and IL1β may increase the risk of CP and cognitive impairment at 
pre-school age in children born very preterm. 
2.5.1 Genetic models
In exploratory genetic association studies, the underlying mode of inheritance is often not 
known and pragmatic decisions have to be made about reasonable assumptions in the choice 
of genetic models. A dominant model (Aa+aa vs AA) assumes that one copy of the minor 
allele is sufficient for an effect. A recessive model (aa vs Aa+AA) assumes that both copies 
are needed. A co-dominant additive genetic model (AA vs Aa vs aa) assumes that having two 
copies of the minor allele has twice the effect of having one copy; this model underlies the 
linear trend analysis used for the increasing number of A alleles at EAAT2 -200/-181. The 
genotypic analyses chosen here consider each genotype as a separate level, without requiring 
any assumptions about the mode of inheritance, which can instead be argued a posteriori for 
future work based on effect sizes (1074). 
One of the largest candidate SNP studies to date, assessing 39 candidate variants in 587 cases 
and 1154 controls from Australia, used allelic analyses (a vs A, assuming HWE), followed by 
dominant, recessive, and genotypic analyses whenever deviation from the additive model was 
observed (162). This leads to a further increase in multiple comparisons, in a study design 
already featuring multiple genetic exposures. Most candidate SNP studies of CP to date have 
used genotypic analyses, making the current study more directly comparable to the wider 
literature. By using a genotypic approach, we have also kept with recommendations made by 
the Human Genome Epidemiology Network (HuGENet), a global collaborative effort 
established by the U.S. Centers for Disease Control (CDC): “where possible, separate effect 
estimates for heterozygotes and for homozygotes be presented to allow readers to judge for 
themselves issues around the likely mode of inheritance and the choice of model” (1075). 
The downside of this approach is reduced power, which is best addressed by replicating any 
findings in a larger sample. 
2.5.2 Missing data
Missing genetic data can be due to missing blood spots or failure of the DNA extraction or 
amplification processes. The molecular methodologies used by the original authors have 
known strengths and weaknesses. Manual methods for DNA extraction, such as the boiling 
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method followed by phenol extraction used for the cytokine variants, are usually robust for 
simple PCR screening (1030). However, yield and purity can be more variable than with 
commercial kits used for the glutamate transporter variants (911). This may have contributed 
to the much smaller complete cases subsets for the cytokine variants compared to the 
glutamate transporter variants, especially for IL6 -174 and IL1β -511. Moreover, while both 
RFLP and pyrosequencing are relatively robust genotyping methods, comparative studies 
have reported higher accuracy for pyrosequencing (1076-1078). For example, 4 out of 46 
TNFα-308 GG homozygotes were misclassified as heterozygotes with RFLP compared to 
pyrosequencing in a cohort of traumatic and burn injury patients (1079). Accuracy of the 
pyrosequencing method used for the glutamate transporter variants was further supported by 
evidence of complete concordance with the 10% data re-genotyped by Sanger sequencing, 
which is the gold standard for sequencing accuracy in low throughput analyses (911). As 
such, cytokine data may be more likely not only to be missing but also to be less accurate 
compared to the glutamate transporter. This type of limitation is unavoidable when using 
historical data. For a future prospective study, pyrosequencing remains suitable when 
investigating multiple variants in the same region (e.g. the glutamate transporter variants) in 
small to medium-sized projects. As it is relatively time-, labour- and cost-intensive, other 
methods may be more suitable if looking at many independent variants in different regions of 
the genome (e.g. TaqMan fluorescent probes) (1080).
Outcome data were also incomplete, and data was not missing completely at random 
(MCAR), as children with missing motor and cognitive outcomes at 5 years were more likely 
to have had CP at 2 years. It is also possible that 5 year outcomes were missed for children 
diagnosed with CP at a later age (28). This suggests that the children with the most severe 
motor disabilities were more likely to have been lost to follow up, leading to sub-selection of 
the children with milder motor impairment. This means not only a loss of power but also 
likely underestimation of the genetic effects for the 5 year outcomes. The non-attendance for 
follow-up may be due to several reasons, including the socioeconomic status of the 
mother/family, poor parental health, maternal age, maternal education and distance to 
hospital; perinatal and developmental characteristics of the child may also affect retainment 
in the study, since it has been shown that parents of the sickest newborns may be more likely 
to attend follow-up visits and take part in relevant research in the long-term (223, 1081-
1084).
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Moreover, children with moderate/severe CP are not required to undertake the M-ABC 
assessment. Given the association between dependent outcome measures, children with 
missing M-ABC who were diagnosed with CP at 2 years were assigned an arbitrary value 
corresponding to the M-ABC threshold for “definite motor problems” (1066). This is a 
consistent approach with large population studies which have defined motor impairment as a 
diagnosis of CP and/or M-ABC score 17-40 (<5th centile) (215). A more refined approach 
would be to collect data from the Gross Motor Function Classification System (GMFCS) 
(1085, 1086). This would allow stratification by CP severity, with the maximum score 
assigned to children with the most severe forms of CP, who were not able to start or complete 
the M-ABC assessment. 
2.5.3 Characteristics of the study population
The rates of CP and cPVL (around 8%) are comparable to other studies carried out in the 90s 
(115, 1087-1089). Just under half of the children with CP had a normal ultrasound scan at 
birth, which is considerably higher than the 5-7% previously identified by Kapitanovic Vidak 
and colleagues (908) and De Vries and colleagues (96) and the third identified by Ancel and 
colleagues (350). In the future, serial ultrasound could be collected to assess development of 
injury in the neonatal period (595), alongside MRI data for a more comprehensive assessment 
of brain injuries (1090). The mean values for the neurodevelopmental outcomes are slightly 
lower than the expected population mean of 100, though within the normal range (+1SD). 
This is in line with finding from the original APIP study that very preterm newborns tend to 
have lower neurodevelopmental scores compared to the general population (275, 276). The 
trial arm allocation was not reported to confound any of the previous analyses (1030). 
The TNFα -308 minor A allele was significantly more frequent in this cohort compared to the 
1000 Genomes European subset. A potential explanation is that fetal TNFα -308 (or a variant 
in LD) increases the risk of preterm birth and is therefore more frequent in this selected very 
preterm cohort. Maternal TNFα -308 has previously been reported in association with preterm 
birth, including in combination with fetal -308 (1091-1094). However, findings have been 
inconsistent, with several studies, including a meta-analysis, reporting no association (1095-
1101) or association with two haplotypes containing the G allele rather than the minor A 
allele (1102). While association with -308 is controversial, other variants in TNFα and its 
receptors have been found to differ significantly by ethnicity and this has been proposed to 
contribute to ethnic disparities in rates of preterm birth (1103). This is an important aspect to 
consider when interpreting studies of CP since, for example, the higher prevalence of CP in 
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black newborns seems to be largely mediated by a disparity in the risk of preterm birth which 
cannot be explained solely by sociodemographic factors and access to healthcare (188, 1104-
1107).
Genetic differences across populations are at the basis of stratification by ethnicity in genetic 
association studies. This design has the benefit of allowing for both scenarios in which 
ethnicity is an effect modifier (i.e. the genetic effect is different depending on ethnicity) or a 
confounder (i.e. population stratification: the genetic effect is the same in all ethnicities and 
ethnicity is independently associated with both allele frequencies and disease outcomes), 
although confounding can also be handled by adjustment at the analysis stage (1108). 
Practically, it is difficult to distinguish between these two scenarios unless the risk alleles 
have been first robustly identified in non-stratified samples, which is not the typical scenario 
of exploratory studies. Additionally, in cohort studies, ethnicity is not uniformly distributed 
and post hoc stratification often lacks statistical power. Our study suggests that the discordant 
EAAT2 genotypes hypothesised to be detrimental are more frequent in non-Caucasians. As 
expected, the current sample does not allow a more in-depth analysis of ethnicity effects, as 
only 18 children were non-Caucasian, with no available detailed ethnicity information. Future 
studies on variants suspected to have different allele frequencies in different populations 
should be designed, where possible, to either focus on each population separately or to have 
sufficient power for post hoc stratification.
2.5.4 The study is underpowered to assess the combinations of glutamate transporter 
variants and their interaction with cytokine variants
GWAS of complex traits have highlighted that only a portion of heritability estimated by twin 
and family studies can be explained by additive genetic variance, i.e. the combined effect of 
each indiviual variant. The unexplained heritability has been attributed to multiple factors, 
including rare and structural variants, epigenetic factors, gene-environment and gene-gene 
interactions (1109, 1110). Exploring gene-gene interactions can get us closer to 
understanding the complex genomic architecture underpinning neurological and 
neurodevelopmental traits. However, these studies are known to be problematic in terms of 
both interpretation and power (1111-1113). 
The issue of interpretation is more obvious in GWAS designs, whereby the biological 
relevance of statistically significant interaction found by scanning throughout the genome 
without any prior hypothesis may be less clear. A statistical interaction is simply a 
mathematical deviation from linearity in a model of the effect of two exposures on the log-
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odds of disease, and does not carry biological relevance per se (1114). However, a substantial 
body of clinical and experimental evidence supports a biological mechanism of potentiation 
between glutamate excitotoxicity and inflammation, backing the hypothesis of genetic 
interactions. On the other hand, interaction studies typically suffer from power issues 
compared to main effects only analyses, since the sample is subdivided into more subsets, 
each with lower counts. This precluded assessment of the EAAT2 SNP-cytokine SNP 
interaction hypothesis in this study, due to the combination of three factors with a taxing 
effect on power:
 CP is a relatively rare binary outcome. This is an issue inherent to all studies of CP, 
which have historically suffered from power issues. Here, we have focused on a very 
preterm population since failing to assess different pathophysiologies of CP separately 
may also result in reduced power (1115). Despite the APIP cohort being one of the 
largest prospective very preterm cohorts with CP data, sample size remains limited, 
with 17 CP cases amongst 202 very preterm survivors
 Most (89%) children in the sample had 2 A alleles at the EAAT2 genotype 
combination, while all other EAAT2 genotype combinations were rare (16 children 
with 1 A allele, 6 children with 3 A alleles) or absent (no children with 0 and 4 A 
alleles). This translated in little variability in the glutamate genetic exposure and 
limited statistical power already at the univariable stage 
 The risk genotype combinations at the glutamate transporter were even more rarely 
found in combination with the risk genotypes at the cytokines, further exacerbating 
the power issue in multivariable analyses of interaction effects
Due to the power issue, the study was scaled down to univariable analyses, exploring the 
independent effect of each variant on neurodevelopmental outcomes. Statistical adjustment 
for multiple comparison was not considered necessary here, given that this is an exploratory 
study based on an a priori hypothesis for candidate pathways known to interact in the 
developing brain. False negatives are costly in exploratory studies and the best approach is to 
interpret with caution and replicate the findings in new datasets (1116). Similarly, other 
candidate gene studies have chosen to not correct for multiple comparison, while others have 
shown near total loss of significant findings after correction with even larger sample sizes 
(162, 901, 917, 1115). Notably, a large meta-analysis of 17 candidate SNPs previously 
implicated in CP with over 2,500 CP cases and 4,400 controls only confirmed an association 
with IL6 -174 (912). The best approaches to address the potential issues of false positives and 
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negatives and identify robust genetic associations in the future remain to increase sample size 
by recruitment and collaborations and replicate findings in independent cohorts. This will 
ideally include different ethnicities, since variable allele frequencies are known to contribute 
to power issues and poor replication (1117), and especially given the finding that EAAT2 
discordant genotypes may be more common in non-Caucasian ethnicies (911). Future studies 
focusing specifically on interaction effects should consider the known issue of scale when 
interpreting interactions, since an effect may appear larger in one group on the difference 
(additive) scale but smaller on the ratio (multiplicative) scale and therefore both should be 
reported for completeness (1118, 1119). 
2.5.5 TNFα -308 is associated with cPVL at birth and cerebral palsy at 2y 
The primary outcome of CP was associated with the TNFα -308 AA genotype, with 3 out of 
10 (30%) children with AA having CP compared to 6 in 100 (6%) children with GG. 
Previous smaller case-control studies found no association with CP in very preterm newborns 
(910) or a small protective effect, including in children with cPVL at birth (908). In larger 
South Australian case-control studies, the variant was reported to have both a protective 
effect in quadriplegia at all gestational ages and in moderately preterm newborns when 
analysed with a recessive model (AA vs GG + GA) (162, 917); on the other hand, the variant 
had a detrimental effect in hemiplegia in very preterm newborns for children with GA or AA 
genotypes vs reference GG genotype (906). This study did not have any neuroimaging data 
and their findings relating TNFα -308 to hemiplegia in very preterm newborns may point to a 
mechanism of injury involving unilateral vascular causes, rather than cPVL specifically. 
TNFα -308 A allele has previously been reported in association with IVH in preterm 
newborns (1120-1122), although not consistently (1123). In the current study, the children 
with cPVL and CP also had some degree of hemorrhage, ranging from mild to severe. cPVL 
and IVH do indeed co-occur, especially in the severe range (1124-1127). With such small 
numbers, it is not possible with to disentangle the effects of cPVL and IVH, and further 
insights may be gained by collecting MRI data. 
This study did not support previous association between IL1β -511 and CP in case-control 
studies of very preterm newborns with cPVL (908) and at all gestational ages (1028), or the 
protective effect in preterm newborns (1102). The large South Australian case-control study 
also reported a protective effect only in non-spastic CP when analysed as additive minor 
allele effects (162, 917). There was also no evidence supporting an association between CP 
and IL6 -174 (see 2.5.7). 
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2.5.6 IL1β -511 is associated with cognitive skills at 5y
This study produced first evidence of an association between IL1β -511 and cognitive skills at 
pre-school age, measured with the BAS score. The T allele has been previously reported in 
association with neurodevelopmental delay at 2 years old (Bayley Scales of Infant 
Development, mental and/or psychomotor development index <85 in the absence of CP) 
(905). Interestingly, in our study children with the CC genotype scored on average 
approximately 8 points less compared to children with the CT genotype (95% CI for the 
mean difference: 2.84-15.02). Evidence was weaker in relation to the rare TT genotype (95% 
CI for the mean difference: -4.90-15.94) though in the same direction. This apparent 
incongruence in direction of effect may be due to haplotype effects, which could not be 
investigated in the current study due to lack of genetic data on the surrounding genetic 
sequence (see 5.1.1). 
The mean score falls within the normal range of the BAS score, which is within 1 standard 
deviation from the population mean (85-115), with children below 3 standard deviations 
(<55) requiring special needs education and children with intermediate scores having variable 
requirements (1065). Notably, randomised controlled trials (RCTs) of neuroprotective 
strategies have previously proposed clinically meaningful minimum differences in cognitive 
scores ranging from half (i.e. 7.5 points) to a third (i.e. 5 points) of a standard deviation (276, 
1128, 1129). 
In the sensitivity analyses, a suggestive association emerged specifically with the non-verbal 
reasoning subscale. The subscales reflect the three main processing information systems in 
the Horn-Cattell model of structural intelligence, i.e. fluid intelligence, crystal intelligence 
and visuo-spatial intelligence (1130-1132). Fluid non-verbal reasoning is thought to be at the 
heart of the most complex cognitive processes and involve integration of different processing 
sub-systems, including visual and auditory (1133, 1134). The structural correlate for fluid 
reasoning/non-verbal ability is thought to be the frontal lobe (1135, 1136). This is also the 
last area to complete myelination, well into the second and third decade of life, consistent 
with the time course of maturation of cognitive functions in childhood and adolescence (101, 
1137-1139). Thus, developmental deficits involving the frontal lobe may become even more 
evident at a later stage and it would be interesting to re-assess the association at school age 
and during adolescence, as the complexity of cognitive tasks and potential interactions with 
environmental stressors increases. Additional cognitive outcomes could be assessed including 
the WISC-IQ (1140-1142) and the NEPSY, which has been previously used in the ELGAN 
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studies of extreme preterm newborns (606) and in combination with the BAS in studies of 
mild cognitive impairment in term newbors with encephalopathy (260).
IL1β -511 was not associated with the Griffiths score at 2 years. This is consistent with the 
known good specificity (accurate prediction of the absence of later impairment) but poor 
sensitivity (accurate prediction of later impairment) of 2 year outcomes in relation to school 
age outcomes. Assessment at 2 years is indeed good for predicting the more severe 
disabilities (e.g. CP, severe cognitive impairment, blindness, deafness), which tend to emerge 
earlier and remain stable over time (1143). However, predictive power for the milder range of 
disabilities is modest as developmental trajectories are highly variable, due to increasing 
exposure to different environmental factors and increasing complexity of cognitive tasks 
(1082, 1144-1150). In a meta-analysis with over 3,000 very preterm/very low birth weight 
children, almost half of the children developing some degree of cognitive impairment at 
school age were classified as having normal development at 2 years (1143).
Future studies should consider the issue of choice of control, since it has been shown that 
using the normative mean of the psychometric test leads to underestimating cognitive 
impairment compared to using a selected sample of control children (e.g. classmates or term-
born children) (28, 243, 1151).
2.5.7 IL6 -174 may be associated with cPVL at birth
There was suggestive evidence that IL6 -174 was associated with cPVL. This was the variant 
most affected by low power in the univariable analyses, since the complete cases was the 
smallest in the study (n=137). Inclusion of 20 newborns with moderate white matter injury 
(i.e. persistent periventricular echodensities not evolving into cysts and ventricular dilatation) 
in the sensitivity analyses strenghtened evidence. Interestingly, the CC genotype has also 
been found in association with MRI-defined volume loss in the deep grey matter in very 
preterm newborns (1031). Other studies have reported no association between IL6 -174 and 
cPVL (1032, 1152). Similarly, a large study of very low birth weight newborns produced no 
evidence of an association with brain injury or death (defined as IVH grade IV, PVL, 
ventricular-peritoneal-shunting or death) (1029). This would support the finding of elevated 
levels of TNFα and IL1β but not IL6 in post-mortem cPVL brains (579), though this may 
also be due to poor replication and different cytokine kinetics and temporal profiles during 
and after injury.
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The finding that IL6 -174 CC genotype may be associated with moderate to severe white 
matter injury but not with motor and cognitive impairment aligns with the original study 
using the APIP cohort (1030). On the other hand, a study reported an association with 
cognitive impairment (Griffith and Kaufmann assessments) in children with cPVL, proposing 
that rather than causing cPVL, the variant may modify the severity of neurodevelopmental 
impairment in children with cPVL (1032). 
Findings relating IL6 -174 and CP are also mixed: some studies did not find evidence of 
association in very preterm (908) and moderately preterm newborns (1032), and the current 
study did not produce evidence of an association either. On the other hand, associations have 
been reported with both quadriplegia and hemiplegia at all gestational ages (163, 918, 1027, 
1115). In a meta-analysis of 11 case-control studies with 17 SNPs previously implicated in 
CP, the C allele of IL-6 -174 was the only surviving association (912). A large South 
Australian case-control study reported that having one or two copies of the minor allele 
(dominant model) increased risk of CP both in the total sample and in the term subset (162, 
917). IL6 -174 has also been reported in association with neurodevelopmental impairment 
(Bayley <85) in the absence of CP (905). The inconsistent findings highlight the need for 
replication in independent samples.
2.5.8 EAAT2 variants are in Hardy-Weinberg disequilibrium
The EAAT2 gentoypes were found to be in Hardy-Weinberg disequilibrium (HWD), with 
more heterozygotes than expected based on the observed allele frequencies. Evidence of 
HWD suggests infringement of one or more HW assumptions due to technical artefacts or 
biological effects (1153-1155). Genotyping error is usually the main source of HWD, with 
population genetic causes (non-random mating, non-negligible migration and mutation rates, 
natural selection) usually playing a minor role in genetic association studies (1156).
Genotyping errors due to pyrosequencing seem unlikely due to the general robustness of this 
methodology (1157) and the positive evidence of complete concordance with the 10% of the 
sample re-sequenced by Sanger sequencing (911). Heterozygote excess may also be due to 
copy number variation encompassing the variant. A search in the Database of Genomic 
Variants (http://dgv.tcag.ca/dgv/app/home) revealed that EAAT2 lies within a CNV locus 
where both gains and losses of DNA segments have been recorded; however, CNVs in this 
region are extremely rare and have not been found in association with relevant phenotypes 
(e.g. neurodevelopmental delay, schizophrenia) (1158-1160) (Dr Reese E., Cardiff 
University, personal communication). SNPs in the primers can also cause HWD via 
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preferential amplification of one allele over the other (1161). Both PCR primers and the 
pyrosequencing primer were checked for SNPs using the UCSC BLAT alignment tool 
(dbSNP build 153) and several SNPs were found which were catalogued in the Genome 
Aggregation Database (gnomAD, https://gnomad.broadinstitute.org/) after publication of the 
study from Rajatileka and colleagues. The majority were very rare (minor allele frequency 
<0.0001), except for one variant in the pyrosequencing primer common in the African 
population (7%) but not found in Europeans, which represent the majority of this cohort. 
Therefore, there is no convinving evidence that HWD was due to SNPs in the primers. 
A possible explanation for HWD is selection bias for admission to the study (1162). 
Genotypes may have been systematically selected into the study because of unmeasured 
factors affecting inclusion or assessment, such as gestational age or demographics of the 
hospital. There is also a small chance that HWD is caused by an actual biological effect 
driven by natural selection, i.e. the EAAT2 genotypes may confer a selective 
advantage/disadvantage, affecting survival/mortality and therefore selection into the study. 
Indeed, the preterm newborns with the most severe brain injuries who died in the first days of 
life were not included in this study of a developmental intervention. Therefore, if the 
homozygous genotypes conferred a selective disadvantage, they could be missing from the 
cohort due to early death; if the heterozygote genotypes conferred a selective advantage, they 
could be overrepresented in the cohort. It is not possible to disentangle these effects without a 
prospective study collecting genotypes during pregnancy, so that data from stillbirths and 
early neonatal deaths is included. This may be achieved by extracting cell free fetal DNA 
(cffDNA) emanating from the placenta and circulating in maternal blood from as early as 5 
weeks of gestation (1163-1165). This method has been widely studied in the context of non-
invasive prenatal diagnosis of aneuploidies (1166-1168), and has been proposed as a tool for 
earlier identification of pregnancies at risk for adverse outcomes (e.g. pre-eclampsia and 
foetal growth restriction) (1169-1174)
Interestingly, the variants were in HWD also in the 1000 Genomes total and British but not 
CEU samples, but the direction of effect was opposite, with loss of heterozygotes. Common 
genotyping error sources of loss of heterozygotes include deletions, multi-allelic SNPs, and 
SNPs in the primers. It is difficult to make direct comparisons since the genotyping 
techniques used in the 1000 Genomes were different. However, the magnitude of the 
deviation was around 7% in both samples, with the level of evidence being relatively low in 
our sample, thus it remains to be seen whether these effects have any biological relevance. 
133
2.5.9 EAAT2 variants remain suitable candidates for future studies
Sensitivity analyses produced suggestive evidence of an association between the glutamate 
transporter variants and the verbal BAS subscale. Verbal skills at school age have been 
reported in association with the volume of the corpus callosum (1175). EAAT2 is 
dysregulated in the white matter lesions of cPVL brains (775), which may affect volume of 
the corpus callosum. It can be hypothesised that genetic influences on EAAT2 dysregulation 
may contribute to interindividual differences in vulnerability of white matter structures and 
related long-term functions. While the evidence remains suggestive in this study, the potential 
role of EAAT2 variants in long-term cognition and verbal skills certainly remains worth 
exploring in larger cohorts. This is of particular interest, since a GWAS of educational 
attainment with over 100,000 individuals in the discovery sample and 25,000 in an 
independent replication sample identified 3 non-coding SNPs near 4 genes involved in 
NMDA glutamatergic signalling (KNCMA1, NRXN1, POU2F3, and SCRT) (1176, 1177).
The EAAT2 variants remain good candidates for future genetic association studies, due to 
their large effect on gene expression in vitro. A construct with 2 copies of the minor allele at 
both EAAT2 variants (-200 AA/-181 CC, i.e. 2 A alleles at the genotype combination) 
showed a staggering 70-80% reduction in basal promoter activity compared to a construct 
with the reference genotypes (-200 CC/-181 AA) in fetal rat astrocytes (911). The increasing 
number of A alleles at the EAAT2 variants has also been reported in association with fMRI-
defined reduction in cortical connectivity (1178). It is not known whether the variants affect 
transcription via epigenetic effects (e.g. DNA methylation). Unfortunately, it is not 
straightforward to assess mQTL effects for these variants, since they belong to a list of 
flagged SNPs that Illumina advises to discard from any analyses due to technical limitations 
of their arrays, with type I probes hybridising poorly and unpredictably to regions containing 
SNPs 
(https://support.illumina.com/array/array_kits/infinium_humanmethylation450_beadchip_kit/
downloads.html) (1179). On the other hand, the -181 variant has been shown to alter 
transcription factor binding to the promoter of EAAT2, with the minor C allele abolishing the 
binding site for activator protein 2 (AP2) and creating one for the repressor transcription 
factor GC-binding factor 2 (GCF2) (1046). Therefore, preterm newborns with the major A 
allele may be less able to dynamically suppress EAAT2, which may be detrimental if 
transport activity becomes impaired, reverse transport is established and EAAT2 becomes a 
source of extracellular glutamate (668, 751, 753). To this end, these variants may be good 
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candidates for studies in growth-restricted preterm newborns exposed to chronic intrauterine 
hypoxia, where being unable to dynamically suppress EAAT2 may be detrimental if reverse 
transport is established (1180, 1181). On the other hand, having the minor C allele may be 
more detrimental following acute HI insults, when glutamate transport is lost in the acute 
phases (Figure 2.7). 
Figure 2.7. Proposed model for differential effects of EAAT2 genetic variants in acute 
and chronic hypoxia-ischaemia
2.5.10 Considerations on SNP-outcome and SNP-clinical covariate-outcome associations
The existence of linkage disequilibrium (LD) patterns in the human genome affects the 
interpretation of all genetic association studies. Any variant identified here may be causal or 
simply in LD with a non-genotyped causal variant (912). Moreover, the confounding effect of 
population stratification must be considered since it can lead to spurious associations and 
inflated estimates (1182). In this sample, non-Caucasian children were more likely to have 
discordant genotypes (1 or 3 A alleles) at the EAAT2 -200/-181 genotype combination. 
Population stratification bias may occur if ethnicity was also associated with the relevant 
outcome via mechanisms independent of the genetic effect. On one hand, larger studies 
sampling from different populations are required to assess whether discordant genotype 
combinations are indeed more common in non-Caucasian ethnicities. On the other hand, 
experimental studies more comprehensively assessing the effect of 0, 1, 3 and 4 A alleles on 
EAAT2 expression in vitro (e.g. via site-directed mutagenesis) may offer more insight into the 
functional path between genotype and phenotype (1183).
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Due to the low power issue, multivariable analyses including the clinical covariates could not 
be carried out. Published candidate SNP studies have previously adjusted genetic effects on 
CP by a range of perinatal factors, including these and others (e.g. maternal age, smoking) 
(917). However, from an epidemiological perspective none of these clinical covariates can be 
a confounder for these genetic effects because genetic variants are inherited randomly at 
meiosis (1184). Confounding may occur for example with genetic variants located on sex 
chromosomes and their effect on outcomes independently associated with sex. However, 
clinical covariates such as perinatal inflammation or gestational age cannot influence which 
autosomal variants are inherited by the foetus (Figure 2.8), making adjustment unnecessary 
(1184). 
Figure 2.8. Directed acyclic graph showing that clinical covariates cannot confound 
genetic effects on neurodevelopmental outcomes
On the other hand, clinical covariates could be analysed as mediators, interactions/effect 
modifiers via regression modelling in future larger studies. These concepts are interrelated 
but different, and the choice of the analytical framework will depend on the specific research 
question. For example, perinatal inflammatory exposures may lie on the causal pathway 
between these SNPs and neurodevelopmental outcomes as mediators (Figure 2.9). IL6 -174 
has been reported in association with histological chorioamnionitis and neonatal infection in 
preterm newborns (1098, 1185-1187), and high levels of IL6 have been found in histological 
chorioamnionitis  (628, 630). Similarly, the genetic variants may contribute to 
neurodevelopmental impairment also by directly affecting risk of preterm birth (1188).
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Figure 2.9. Directed acyclic graph of the SNP-cerebral palsy association with clinical 
covariates as mediators
In gene × environment interaction or effect modification analyses, no causal assumptions are 
made, instead the rationale is that genetic effects may vary with the covariate, e.g. newborns 
exposed to perinatal stresses (e.g. infection/inflammation) vs to those who are not. Effect 
modification analyses differ subtly from interaction analyses in that the focus is specifically 
on the genetic effect and whether it differs with the covariate (e.g. biological sex) (1189). 
Figure 2.10. Directed acyclic graph of the SNP-cerebral palsy association with clinical 
covariates as effect modifiers
If clinical covariates are neither confounders nor mediators nor effect modifiers but are 
known a priori to affect the outcome, adjusting has been proposed as a way to increase power 
by reducing residual variance in the outcome not due to the exposures under study (1190). 
This adjustment can only be done if the SNPs are not associated with the covariate, otherwise 
bias will be introduced inducing a spurious association between SNPs and outcome (1191). 
Maternal age (both young and advanced), maternal education and socioeconomic status are 
known risk factors for CP. Although this data was not available for the APIP cohort, future 
studies should aim to include this information for more complex modelling. 
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2.5.11 Strengths and limitations
This is one of the largest prospective birth cohorts where genetic associations with CP can be 
investigated in very preterm survivors. The target population is clinically relevant as very 
preterm newborns represent 85% of surviving very preterm infants and two thirds of preterm 
children with CP (33). The cohort design bypasses the issue of choice of suitable controls 
(e.g. all healthy newborns vs matched by gestational age) in case-control studies (162). 
Moreover, the study has the advantage of including secondary cognitive and motor outcomes 
at 2 and 5 years, assessed through standardised assessments well-established in the UK and 
used worldwide. Indeed, many children with CP suffer from multiple disabilities and motor 
and cognitive impairment can occur in addition to or in the absence of CP (146, 192).
The greatest limitation of this exploratory study is represented by low power and the related 
possibility of false negatives and inflated estimates. The power issue was especially severe 
for the multivariable SNP-SNP interaction analyses, for univariable analyses for SNPs with 
low minor allele frequencies (e.g. IL1β -511), for the rare binary outcomes (i.e. CP and 
cPVL) and for the 5 year outcomes subject to loss-to-follow up (i.e. BAS, M-ABC). The 
wide confidence intervals reflect the limited precision in effect estimates with limited sample 
size. With regard to the reported associations, we are unable to empirically distinguish 
between association (correlation) and causation. Moreover, the high number of multiple 
comparison rises the possibility that these may be false positives. All these limitations are 
best addressed by replication in independent clinically and ethnically homogeneous samples. 
Another important limitation of this study is the lack of direct quantification of circulating 
cytokine levels. Serial measurements from blood spanning the first two postnatal weeks 
would be ideal, since it has been shown that in extreme preterm newborns persistently high 
levels of cytokines over multiple days (i.e. sustained inflammation) have better predictive 
power for neurodevelopmental impairment than single measurements, and measurements at 
day 7 and especially day 14 have better predictive power than day 3 (604, 611, 612). 
Additionally, neuroimaging evidence was limited to cranial ultrasound, which has modest 
sensitivity for white matter injury. Ultrasound scans are likely to have missed less severe 
non-cystic forms of PVL, which can only be detected through more sensitive MRI scanning 
(113). Importantly, disorganisation of white matter tracts can affect white matter function and 
neurodevelopment in the absence of anatomical lesions and this can only be studied with 




In conclusion, subject to replication, the current study supports evidence that common 
regulatory genetic variants thought to influence circulating levels of key pro-inflammatory 
cytokines TNFα and IL1β contribute to risk of neurodevelopmental impairment in children 
born very preterm. This study replicated previous evidence of association between TNFα -
308, cPVL and CP in children born very preterm, and produced first evidence of an 
association between IL1β -511 and cognitive skills at 5 years of age. It also produced 
suggestive evidence of an association between IL6 -174 and moderate to severe white matter 
injury at birth, and between EAAT2 variants and the verbal skills cognitive subdomain at 5 
years of age. More broadly, the finding supports the role of inflammation as a key pathway of 
neurodevelopmental impairment, as well as the role of genetic make-up as a contributor to 
risk. 
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3 Transcriptional regulation of key pro-inflammatory cytokines 
and the glutamate transporter in a rat model of hypoxic-
ischemic brain injury at term
3.1 Introduction
Despite evidence of glutamate excitotoxicity as a key pathway to injury after acute HI, 
regulation of the glutamate transporter in HIE has largely been overlooked. More evidence is 
available supporting an altered cytokine response following HI, however the mechanisms of 
such changes in regulation are not known (see 1.5.3). While the consequences of in utero 
hypoxia on reprogramming of the foetal brain epigenome are starting to emerge (see 1.5.5), 
no studies have yet assessed the effects of an acute HI insult on the epigenome of the term 
brain. DNA methylation provides a suitable candidate mechanism due to its key biological 
roles for brain function and development, responsivity to early life environmental stresses 
and evidence of abnormalities associated with brain disorders (see 1.5.5). Moreover, DNA 
methylation from blood provides an ideal candidate biomarker of injury with potential 
clinical use translatable to newborns (see 1.5.5). In this study, the Rice Vannucci rat model of 
HIE was used to assess whether acute HI alters transcription (this chapter) and promoter 
DNA methylation (chapter 4) of the main glutamate transporter (Glt1) and three pro-
inflammatory cytokines (Tnfα, Il1β, Il6) in two of the most vulnerable brain regions, the 
cortex and hippocampus, as well as in blood. 
The Rice Vannucci rat model is the most established rodent model of HI brain injury in the 
term-equivalent newborn and has been used for the last 40 years (1192, 1193). The insult 
involves unilateral carotid artery ligation followed by exposure to a defined period of hypoxia 
in the P5-P10 (postnatal day 5-10) rat pup, leading to a combined unilateral HI injury which 
cannot be achieved with either of the insults alone (1193). The contralateral hemisphere 
exposed to hypoxia but not ischaemia serves as an internal control as it is largely undamaged 
upon histological examination (1194). In the ipsilateral hemisphere, HI causes neuronal and 
glial necrosis, microglial activation and astrogliosis, with brain injury typically affecting the 
cortex and hippocampus, followed by the basal ganglia, subcortical and periventricular white 
matter (1195, 1196). This reflects typical patterns of brain injury seen in HIE babies, which 
involve the deep grey matter (basal ganglia, thalamus, and hippocampus), somatosensory 
cortex, white matter, brain stem and cerebellum (79, 80, 82-88). Importantly, these rats 
140
develop neurobehavioural deficits including gross motor dysfunction and cognitive 
impairment (e.g. learning and memory), which are largely dependent on the HI parameters 
(502). Versions of this model and its extension to the P7-P9 mouse have provided valuable 
insights into the pathophysiology of HI brain injury and the molecular mechanisms involved 
(1197). One of the major characteristics of this model is the inherent variability in the extent 
of focal injury observed, so that within a sample of rats receiving the same insult some will 
have no injury and others will have mild to severe injury (1198, 1199). Our group developed 
a modified version of the P7 Rice Vannucci model with strict control of both core 
temperature and HI, which produces around 40% brain tissue loss in the ipsilateral 
hemisphere relative to the contralateral hemisphere one week after HI (1200). Alongside 
infarction, this model reproduces the reduction of cerebral blood flow, as well as the 
impairment of innate postural responses and fine motor dexterity seen in humans (1198, 
1200-1203). Importantly, this modified Rice Vannucci model was instrumental in the 
translational journey of therapeutic hypothermia from bench to bedside (702) and is being 
used for ongoing neuroprotection research for HIE (1199, 1202). The resemblance of short-
term brain injury patterns and long-term motor impairment make this model suitable for 
evaluation of regulatory changes affecting glutamate transport and inflammation in HIE.
3.2 Hypothesis
The hypotheses of this pilot study are that: 
1) acute hypoxia-ischaemia causes changes in mRNA transcription of the main glutamate 
transporter (Glt1) and three key pro-inflammatory cytokines (Tnfα, Il1β, Il6) in the term-
equivalent rat brain within the first 24 hours (this chapter)
2) any observed or latent transcriptional changes in Glt1 and Tnfα in the brain are at least in 
part mediated by DNA methylation changes in the respective gene promoters (chapter 4) 
3) DNA methylation of Glt1 and Tnfα in the brain correlates with DNA methylation in blood, 
which may be a clinically useful peripheral biomarker of injury (chapter 4)
3.3 Materials and methods
3.3.1 Study design
The experiments up to tissue collection were carried out at the University of Essen, Germany, 
in accordance with the Animal Research: Reporting of in vivo Experiments (ARRIVE) 
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guidelines with government approval by the State Agency of Nature, Environment and 
Consumer Protection North Rhine-Westphalia, Germany. Hemmen Sabir and Ela 
Chakkarapani assigned the pups to the different groups, and carried out 
anaesthesia/experimental HI, killing and tissue collection, in order to minimise operator-
related variability. I observed these procedures and, together with Hemmen Sabir, dissected 
the brains into regions of interest (left and right cortex including subcortical white matter, 
hippocampus, thalamus, a region enriched for the corpus callosum, cerebellum/brain stem). 
Brain and blood samples were transported to Cardiff University for downstream molecular 
analyses. 
4 litters (n=10, 12, 11, 10) were included, for a total of 43 P7-8 pups. The final sample size 
was 42, since the “sentinel” rat chosen to carry the rectal temperature probe died at the end of 
hypoxia. The experimental design included 3 time points (6h, 12h, 24h, n=14 for each time 
point), each of which featured 3 experimental groups: naïve (n=3), surgical sham (i.e. 
anaesthesia, n=3) and hypoxia-ischaemia (anaesthesia and surgical ligation of left carotid 
artery, followed by hypoxia, n=8), with a total of 9 groups (Figure 3.1). The design was 
therefore unbalanced, with a higher number in the HI group informed by previous experience 
from our research group and others of high variability and wide distribution of injury in the 
model. 
In terms of genes, mRNA expression was assessed for all candidate genes explored in chapter 
1, i.e. the main glutamate transporter in the brain (Glt1) and three key pro-inflammatory 
cytokines (Tnfα, Il1β, Il6). Two housekeeping genes (Hprt and B2m) with stable expression 
across all groups were included to normalise gene expression and account for differences in 
the starting amount of template. Hprt is an enzyme catalysing salvage and recycling of 
purines for building of DNA and RNA. B2m is a component of major histocompatibility 
complex class I molecules. Previous work with this model has shown that the ideal time to 
assess brain injury (brain volume loss) is 7 days post-HI (1199, 1200, 1202), which was not 
allowed by the early time points in this pilot study. To support validity of the model, gene 
expression of established markers of injury was also measured, i.e. Mbp for myelin injury, 
Map2 for neuronal injury, and Gfap for astrocyte activation. Markers of microglial activation 
(e.g. Iba1) and apoptotic cell death (e.g. caspase 3) could not be included since this project 
did not involve histological analyses, which are required to comment on density, 
morphology, and localisation of these markers. 
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Promoter DNA methylation analysis focused on Glt1 and Tnfα. Unfortunately, DNA 
methylation of Tnfα could not be assessed due to COVID-19-related disruptions in the final 
stages of the PhD. The imprinted gene Peg3 was also included as an internal control for the 
DNA methylation methodology, based on an expected methylation value of 40-60% (0% on 
one chromosome and 100% on the other chromosome). 
In terms of brain regions, priority was given to analysis of the ipsilateral cortex and 
hippocampus in the transcriptional analyses (brain: n=84). In the DNA methylation analyses, 
the ipsilateral cortex was assessed alongside peripheral blood (brain: n=42, blood: n=42). 
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Figure 3.1. Experimental design of the pilot study
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3.3.2 Rice Vannucci rat model of moderate hypoxic-ischemic brain injury at term
3.3.2.1 Preparation and anaesthesia
Dams and litters were cared for in the local in-house animal facility at Essen University. 
Between experiments, pups were kept in the animal facility with their dams under a 12h:12h 
dark:light cycle at 21°C room temperature. Dams had access to food and water ad libitum. 
The evening before the experiment, pups were temporarily separated from their dams, 
weighed, sexed, and randomly assigned a numerical ID. This was marked on their back, using 
a different colour marker for each litter. The 42 pups in the final sample belonged to 4 litters 
(n=10, n=12, n=11, n=9), 24 were male (57%) and mean birth weight was 15 g (±1.26). Pups 
were subsequently assigned to experimental groups and time points, ensuring balanced 
representation of litter, sex, and birth weight in each group to minimise confounding. The 
colour code and number allowed for rapid identification and allocation to treatment on the 
experimental days (Figure 3.2).
Figure 3.2. Marking of pups with numerical IDs for assignment to experimental groups 
On the day of the experiment (P7-8), rat pups from the sham and HI groups were kept in a 
box on top of a heated mat before and after anaesthesia and experimental HI. The set mat 
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temperature of 38.5°C was chosen based on previous experiments from our group showing 
that it keeps rat core temperature stable at 34-35°C (Hemmen Sabir, personal 
communication). The surgery station, including a dissecting microscope for left carotid 
ligation, is shown in Figure 3.3. 
Figure 3.3. Surgery station
Including: 1) box with the rat pups on a heated mat (38.5°C) 2) anaesthesia gases 
(isoflurane, NO2, O2) 3) ventilated anaesthesia chamber 4) dissecting microscope for 
carotid ligation, also served by the anaesthesia gases. The hypoxia chamber and the 
CritiCool temperature management system (not included in this picture) were located 






Anaesthesia was induced by placing the rat in a ventilated pre-filled anaesthesia chamber 
with 3% isoflurane in a 2:1 gas mixture of NO2/O2, with a gas flow of 1.2 l.. The average time 
for anaesthesia and ligation was 7 minutes (Figure 3.4). 
Figure 3.4. Anaesthesia chamber
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3.3.2.2 Ischaemia: left carotid artery ligation
After approximately 2 minutes of anaesthesia, the rat was placed under a dissecting 
microscope and immobilised to the platform underneath with paper tape. The regime of 
anaesthesia was maintained under the microscope through a face mask (Figure 3.5). 
Figure 3.5. Rat pup under the dissecting microscope
Reaching of an appropriate level of anaesthesia was verified by loss of the righting reflex and 
by pinching a paw. Buprenorphine was injected intracutaneously into the neck. A small 
incision was made on the left side of the neck. Forceps were used to dissect through the 
surrounding tissue and the left carotid artery was identified as bright red and pulsating, with a 
pale muscular wall. The artery was ligated with two sutures of 6-0 surgical silk and cut in the 
middle. The wound was subsequently closed with surgical silk and the rat was returned to the 
box on the heating mat with the other pups. After recovery from anaesthesia on the heated 
mat and regaining of the righting reflex, rat pups were returned to the dams for 30 min 
recovery period. Each ligation took no longer than 5 minutes. While Hemmen Sabir 
performed a ligation, Ela Chakkarapani or I placed the next rat in the anaesthesia chamber to 
ensure the time from ligation to hypoxia was kept within 2 hours. 
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3.3.2.3 Hypoxia
After 30 min recovery with the dam, the rat pups were placed randomly in individual cells 
within a custom designed metal chamber (1198, 1202). Medical air was delivered in parallel 
to each cell in the cage. During hypoxia, temperature was continuously monitored by 
assigning a “sentinel” rat to carry a calibrated rectal temperature probe, secured to the body 
with paper tape. As the 6 hours HI group included an extra rat compared to the other 
timepoints, the temperature probe rat was chosen from this group. The cage was placed in a 
hypoxic chamber on top of a water-filled mat providing constant temperature across all cells. 
The rectal temperature probe provided continuous measurements to the temperature 
management system (CritiCool, MTRE), which regulated the temperature of the water-filled 
mat accordingly to achieve a target of 36°C. This temperature was chosen based on previous 
studies from our group showing that rectal temperature correlates within 0.1°C with brain 
temperature and contributes to moderate brain injury (40% area loss in left vs right 
hemisphere) (702, 1200, 1202). After temperature was stabilised for 15 minutes, the gas 
supply was set to hypoxia at 8% O2 (92% N2). Oxygen concentration was measured 
continuously and monitored through the Oxycyler system. 8% hypoxia was maintained for 90 
minutes or until an animal died. As no animal had died at 90 min, hypoxia was prolonged to 
100 min, when the “sentinel” rat carrying the temperature probe died. At the end of hypoxia, 
gas supply was switched back to room air and temperature raised to 37°C. Rat pups destined 
for the 12h and 24h time points were returned to the dams in the animal facility, whereas rat 
pups destined for the 6h timepoint were transferred to the lab facility for killing. 
3.3.2.4 Killing and tissue collection
Animals were transported to the lab facilities just before killing and sacrificed to achieve 
mean time points of 6h, 12h and 24h. Schedule 1 killing was performed by rapid decapitation 
using surgical scissors. Blood was collected immediately after decapitation using capillary 
blood collection tubes pre-anticoagulated with K2EDTA, mixed by gentle inversion, and 
stored at 4°C. Brains were immediately removed from the skull and placed on a slicer matrix 
(Zivic Instruments) in a pre-specified orientation (Figure 3.6). The first blade allowed to 
separate cerebellum and brain stem from the cerebrum. A second blade was inserted 5 
grooves rostral from the first one to obtain a single 2.5 mm slice of similar composition 
across all rats, including portions of the cortex, hippocampus, basal ganglia, and thalamus. 
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Figure 3.6. Brain on slicer matrix
After separating the cerebellum/brain stem, the slice was transferred to an ice plate and 
further separated into left (injured) and right (uninjured) hemispheres. From each hemisphere, 
the following regions were dissected: a small slice (<0.5 mm) immediately proximal to the 
longitudinal fissure enriched for corpus callosum, followed by cortex (including subcortical 
white matter), thalamus and hippocampus. In total, 9 regions were collected for each animal, 
including the cerebellum/brain stem. All dissected regions were placed in pre-labelled tubes 
and immediately snap frozen in liquid nitrogen. Brain tissue was stored at -80°C and 
anticoagulated blood was stored at 4°C until the day of travel, then transported on dry ice to 
Cardiff University for downstream molecular analyses. 3 P7 spleens were subsequently 
obtained from Hemmen Sabir for optimisation of qPCR (quantitative polymerase chain 
reaction) cytokine primers since baseline expression is expected to be higher than in brain.
3.3.3 Downstream molecular analyses
Briefly, mRNA and genomic DNA were simultaneously extracted from left cortices and 
hippocampi, ensuring they originated from the same population of cells. Brain DNA was 
further processed and analysed alongside blood DNA in DNA methylation analyses (chapter 
4). mRNA was cleaned, reverse transcribed to complementary DNA (cDNA) and amplified 
via qPCR using an intercalating fluorescent dye. Real-time measurements of fluorescence 
allowed quantification of the transcript in each sample, normalised to endogenous controls 
(i.e. housekeeping/reference genes). Expression was compared across experimental groups 
and time points.
3.3.3.1 RNA extraction and clean-up
Genomic DNA and mRNA were simultaneously extracted from each brain sample using 
Trizol (protocol 1). The extracted mRNA was further cleaned using a column-kit and treated 
with DNase to avoid genomic DNA contamination (protocol 2). 
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3.3.3.1.1 Protocol 1: simultaneous DNA/RNA extraction from brain with TRIzol
Precipitation and separation of RNA and DNA
 Transfer samples from -80°C storage to wet ice
 Transfer tissue to FastPrep matrix tubes with lysing beads (MPBio, Matrix D for animal 
tissues) 
 Add 1 ml TRIzol (Invitrogen) per 50-100 mg sample
 Homogenise using FastPrep FP120 homogeniser (Thermo) (3 cycles at 5 m/sec for 15 
sec)
 Incubate at room temperature (RT) for 5 min
 Add 0.2 ml chloroform per 1 ml Trizol and shake by inversion for 15 sec
 Incubate at RT for 2-3 min
 Centrifuge at <4000 rpm, 4°C for 15 min with hinge facing outward 
 Transfer the colourless upper aqueous phase (containing mRNA) to a fresh tube 
 Store remaining sample (interphase containing DNA and organic pink phase containing 
proteins) at 4°C until DNA extraction
Washing and resuspending of RNA
 Add 0.5 ml isopropanol per 1 ml Trizol and gently mix by inversion
 Incubate at RT for 10 min 
 Centrifuge at <4000 rpm, 4°C for 10 min to pellet the RNA 
 Quickly remove and discard supernatant
 Add 1 ml 75% ethanol per 1 ml Trizol, mix by pipetting up and down and vortex to 
resuspend the pellet
 Centrifuge at <4000 rpm, 4°C for 5 min 
 Discard the supernatant
 Allow the RNA pellet to air dry (e.g. briefly on heat block with lid open) 
 Resuspend in 100 ml nuclease-free water and mix by pipetting up and down
 Incubate at 60°C on thermomixer on gentle shake for 10 min
 Quantify and check purity of RNA on Nanodrop (Nanodrop 8000, Thermo Fisher 
Scientific) (average at least 2 measurements, use water as blanking buffer)
 Store at -80°C
 Proceed with DNase I treatment (Ambion) and RNeasy MinElute column clean-up 
(Qiagen) 
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Washing and Resuspending of DNA
See chapter 4
3.3.3.1.2 Protocol 2: clean-up of RNA (DNase treatment and column clean-up)
 RNeasy MinElute column kit clean-up (Qiagen) (as per manufacturer instructions except 
for final elution volume)
o Adjust samples to 100 µl with supplied RNase-free water (i.e. 50 µl RNA + 5 µl 
DNase buffer + 1 µl DNase = 56 µl: add 44 ul water)
o Add 350 µl Buffer RLT and mix well by pipetting
o Add 250 µl 100% ethanol, mix well by pipetting (do not centrifuge and proceed 
immediately to the next step)
o Transfer the sample (700 µl) to a spin column and centrifuge at ≥ 8,000 xg (≥ 
10,000 rpm) for 15 s
o Discard the flow-through and place the column in a new 2 ml collection tube 
(supplied)
o Add 500 µl Buffer RPE
o Centrifuge at ≥ 8,000 xg (≥ 10,000 rpm) for 15 s
o Discard the flow-through and place the column in a new 2 ml collection tube (not 
supplied)
o Add 500 µl 80% ethanol
o Centrifuge at ≥ 8,000 xg (≥ 10,000 rpm) for 2 min
o Discard the flow-through and place the column in a new 2 ml collection tube 
(supplied)
o Write IDs on the side of the tubes, cut lids and keep 
o Centrifuge at full speed for 5 min, with the hinge facing outward 
o Centrifuge at full speed for 5 min, with the hinge facing inward 
o Discard the flow-through and place the column in a new 1.5 ml collection tube 
(not supplied)
o Elute in 20 µl in two steps (higher than 14 µl in single elution recommended by 
manufacturer)
 Add 10 µl RNase-free water directly to the centre of the membrane and put 
lid back on
 Centrifuge at full speed for 1 min and repeat step
 DNase I treatment (Ambion)
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o Transfer 50 µl RNA to a fresh tube (if concentration is > 200 µg/ml, dilute RNA 
to 10 µg/50 µl)
o Add 5 µl DNase I Buffer to the RNA sample (10X to 1X)
o Add 1 µl DNase I (2 U) and incubate at 37° C for 30 min (to remove up to 2 µg 
DNA)
o Incubate at 75° C for 5 min for heat inactivation of DNase I
 Quantify and check purity of RNA on Nanodrop 
3.3.3.2 Reverse transcription of mRNA to cDNA and qPCR
Cleaned mRNA was reverse transcribed to double stranded cDNA (protocol 3), which is 
more stable than mRNA and can be recognised by DNA polymerase. The RNA to cDNA 
EcoDry™ Premix (Double Primed) kit (Takara) contains a mixture of oligo(dT) and random 
primers. Oligo(dTs) are specific for poly(A) tails and allow reverse transcription of full-
length mRNAs, random primers are ideal for degraded mRNAs. 
Gene expression was measured by quantification of amplified cDNA in each brain sample by 
real-time qPCR using a fluorescent dye. The following genes were assessed: the four 
candidate genes (Glt1, Tnfα, Il1β, Il6), the three markers of brain injury (Mbp, Gfap and 
Map2) and two established housekeeping genes (Hprt and B2m). Inclusion of housekeeping 
genes with stable expression across groups and time points allows to account for non-
biological variation between samples (e.g. amount of input mRNA and PCR reagents, 
pipetting error, errors in sample quantification) which could otherwise be erroneously 
attributed to group differences (1204). 
qPCR was carried out using the SensiFAST SYBR Green No-ROX kit (Bioline), which 
includes the SYBR fluorescent dye, DNA polymerase and PCR buffers and enhancers. Each 
sample was run in triplicate, yielding 126 samples for each of the two brain regions, for each 
of the 9 genes (total n = 2,268). Three 100-wells qPCR plates/rings (Qiagen) were run for 
each gene. Each plate was designed to include representatives of all time points and 
experimental groups. cDNA samples were mixed with the SYBR Green premix and loaded 
on the rings using a PCR set-up robot (CAS-1200, Corbett) under supervision. The ring was 
heat sealed and transferred to the Rotor-Gene Q cycler (Qiagen) for qPCR (protocol 4). 
During exponential amplification, the fluorescent SYBR Green dye intercalates within the 
double stranded cDNA. Fluorescence is measured in real time on the Rotor-Gene Q and 
plotted against the number of cycles by the Rotor-Gene Q software, which automatically 
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applies quality control procedures (e.g. fluorophore-specific channel filters, removal of 
background noise). Fluorescence and number of cycles have an exponential relationship or 
log linear with log fluorescence. The resulting sigmoidal-shape plots (on a linear scale) allow 
to distinguish a log-linear phase of growth between a baseline phase (i.e. noise level in early 
cycles) and a plateau phase (i.e. PCR resource exhaustion). A threshold is arbitrarily chosen 
and set as a horizontal line within the log-linear region of growth of the amplification curve, 
where precision of the replicates is highest. Fluorescence is quantified as a cycle threshold 
(Ct), i.e. the cycle at which the amplification curve exceeds the set threshold (1205). A 
threshold of 0.4 was found to be suitable across all genes and plates. Raw Ct data were 
obtained in text format from the software for analysis.
Before running the experiments, all qPCR assays were optimised on the Rotor-Gene Q by 
testing different qPCR primer concentrations with constant temperature and number of 
cycles. Cytokine primers were optimised in spleen and all remaining primers were optimised 
in brain tissue. For optimisation, a good quality cDNA sample was run in triplicate with 9 
combinations of forward and reverse primer concentrations: 10 µM, 4.3 µM and 0.7 µM 
(final concentration in qPCR reaction: 700 nM, 300 nM, 50 nM). The combination of primer 
concentrations was chosen as the one producing the lowest Ct (i.e. earliest detectable change 
in fluorescence), highest technical replicate reproducibility and minimal noise in the non-
template control.
Initially, sample Ct values were found to differ systematically in different plates for the same 
genes. This was found to be due to a setting on the Rotor-Gene Q software automatically 
optimising the gain for the green channel at the beginning of quantitation for each plate. 
Plates were repeated after manually setting the green channel gain value to 8. Moreover, two 
spare samples were included on all plates as calibrator samples to evaluate consistency in 
gene expression quantification (1206). Housekeeping genes were quantified separately for 
each cDNA batch.
3.3.3.2.1 Primers
qPCR primers (Sigma-Aldrich) were designed for the four candidate genes (Glt1, Tnfα, Il1β, 
Il6), the three markers of brain injury (Mbp, Gfap and Map2) and two housekeeping genes 
(Hprt and B2m) (Table 3.1), using Primer3 software (http://bioinfo.ut.ee/primer3-
0.4.0/primer3/). All Primer3 parameters were kept to default settings except for product size 
(reduced to 80-200 bp) and primer melting temperature (reduced to 58-61°C). Moreover, 
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primers were forced to span exon boundaries, to ensure selective amplification of mRNA 
over genomic DNA. Published Glt1 primers were excluded as, upon inspection, it was found 
they did not span exon boundaries (1207-1209). Primers for the two housekeeping genes 
routinely used in mouse by the Cardiff Behavioural Genetics Group (i.e. Hprt and B2m) were 
redesigned for the rat genome. All primers were BLASTed on NCBI to check specificity 
(1210). 
Table 3.1. qPCR primers




























3.3.3.2.2 Protocol 3: cDNA Synthesis from mRNA 
 Transfer 1 µg mRNA to a fresh tube (measured on Nanodrop)
 Make up to 20 µl with nuclease-free water 
 Add mRNA to the premix (RNA to cDNA EcoDry™ Premix (Double Primed) kit, 
Takara) and mix by pipetting up and down
 Incubate on thermal cycler (Bio-Rad)
o 42°C for 60 min
o 70°C for 10 min
 Make up to 500 µl with nuclease-free water
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 Store at -20°C
 Proceed to qPCR
3.3.3.2.3 Protocol 4: qPCR
 Load PCR set-up robot (Corbett) with the total volume required for all cDNA samples 
and non-template controls (NTC) (Table 3.2)
Table 3.2. qPCR recipe
Reagent Volume (1 reaction)
SensiFAST SYBR Green 12.5 µl
Forward Primer 1.75 µl
Reverse Primer 1.75 µl
Nuclease-Free Water 4 µl
cDNA Template/NTC 5 µl
Total 25 µl
 Heat seal plate
 Load ring on RotorGene-Q and run qPCR (Table 3.3):
Table 3.3. qPCR protocol
PCR Cycle Step Temperature Time No. Cycles
Taq Heat Activation 95°C 10 min
Denaturation 95°C 20 sec
Annealing 60°C 20 sec
Extension 72°C 20 sec
x 40
3.3.4 Statistical analysis
The exposures in this study are experimental group (naïve, sham, hypoxia-ischaemia) and 
time (6h, 12h, 24h), while the outcome is normalised gene expression on the log scale 
(untransformed ΔCt values). At the analysis stage, the 2−ΔΔCT method was used (1211), with 
the following calculations: 
1) Mean sample Ct values obtained by averaging the three technical replicates for each 
sample. Batch differences were assessed by comparing mean sample Ct values by plate 
with a one-way ANOVA and plates were repeated where needed
Sample Ct = arithmetic mean of the Ct values for the 3 technical replicates 
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2) Untransformed sample ΔCt values (used for statistical analyses and plots), i.e. the log of 
gene expression normalised to the geometric mean of the housekeeping genes. The 
geometric mean controls better than the arithmetic mean for possible outliers and 
differences in abundance: 
Sample ΔCt = Ct(geometric mean of Hprt and B2m) – Ct(gene of interest)
This was adapted from the original 2−ΔΔCT method, whereby the subtraction was 
performed as (Ct(gene of interest) – Ct(reference gene)) leading to higher values on the 
plots indicating lower quantities relative to the housekeeping genes and vice versa; this 
adaptation does not affect the values but allows easier interpretation of the direction of 
effect on the plots
3) Untransformed mean group ΔCt values, obtained by averaging the biological replicates 
for each group (e.g. 6N, 12S, 24HI). A standard error of the mean was also calculated as 
(SD/SQRT(N))
Group ΔCt = arithmetic mean of the sample ΔCt values for each of the 9 group/time point 
combinations
4) Transformed 2ΔΔCt values (used for plots), i.e. fold-change in gene expression for each 
experimental group in relation its age-matched control group (i.e. naïve group at the same 
time point). This was achieved first by calculating untransformed ΔΔCt values:
ΔΔCt = group ΔCt – control group ΔCt (e.g. 12HI ΔCt – 12N ΔCt)
Back-transformation of logarithmic values (2ΔΔCt) allowed expression as fold-change for 
each group relative to its age-matched control (which takes a constant value of 1 
following subtraction to itself and transformation). The upper and lower limits of the 
standard error of the mean were calculated by adding and subtracting the standard error of 
the mean group ΔCt from the ΔΔCt. 
Gene expression data are often plotted as fold change (2ΔΔCt), since untransformed ΔCt values 
on the logarithmic scale are not necessarily intuitive for visualisation. However, it is useful to 
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plot raw data on the same scale as used for the analysis; moreover, fold-change can be more 
easily interpreted in treatment vs control designs than in 3 x 3 designs with a different control 
group for each time point. For these reasons, side-by-side plots were reported of both the 
untransformed ΔCt (on the logarithmic scale, scatterplots with means and standard errors) 
and the 2ΔΔCt fold change in relation to respective age-matched controls (on the linear scale, 
bar charts with potentiated means, asymmetric standard error bars and age-matched controls 
set as y=1). 
A two-way 3 x 3 factorial ANOVA was run separately on 42 left cortices and hippocampi to 
compare the main effects and interaction of experimental group (naïve, sham, hypoxia-
ischaemia) and time (6h, 12h, 24h) on normalised gene expression, i.e. untransformed ΔCt 
values, which are expected to have a normal distribution (1212). The Scheffe’s test was used 
for post hoc analyses to identify which pairs of means were significantly different. While 
affording less power than the Tukey’s and Fisher’s tests, it allows comparison of all possible 
pairs of three means as well as different number of observations per group. Effect sizes were 
expressed in terms of population (ω2, omega squared) rather than sample (η2, eta squared) 
effect sizes, as, though always smaller, they have been found to carry less sampling error bias 
in unbalanced designs with multiple groups (1213). 
Secondary analyses were planned to partially address the issue of limited power in this small 
pilot study. Differences were tested between naïve (n=3 per time point) and sham (n=3 per 
time point). If no differences were detected, the naïve (N) and sham (S) groups were 
collapsed into a single larger control group (n=6 per time point) and the ANOVA repeated in 
a 2 x 3 design (N/S vs HI). This type of analysis remains suggestive in terms of evidence 
level. Sensitivity analyses were carried out for the cytokines and Gfap based on the observed 
non-significant trends for interaction effects between group and time. These secondary 
analyses merged time points as well as groups in a 2 x 2 ANOVA design based on 
observations from the primary analyses.
Stringent multiple comparison correction for multiple independent tests (e.g. Bonferroni 
correction) may not be appropriate in exploratory pilot studies with limited power, whereby 
the cost of false negatives is potentially higher than that of false positives (1116). Moreover, 
some degree of correlation may be expected amongst genes that are co-regulated within the 
inflammatory and glutamatergic pathways and may therefore not represent independent tests. 
For this reason, uncorrected p-values were reported. The Benjamini Hochberg False 
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Discovery Rate (FDR) was applied as an alternative strategy for multiple comparison 
correction, since it does not assume independency of the tests and is less penalising in terms 
of power by setting an acceptable level of false discoveries (1214). An FDR of 7% was 
chosen, and it translates in accepting that 1 gene in one of the two brain regions may be a 
false positive (7% of 14 (n=7 genes per brain region) = 1). To apply the Benjamini Hochberg 
FDR correction, p-values were ranked from smallest to largest; a critical value was calculated 
for each p-value as (i/m)Q (i = rank; m = total number of tests; Q = chosen FDR); the largest 
p-value that was smaller than its Benjamini-Hochberg critical value was considered as 
significant after correction, alongside all of the p-values higher up in rank. The most suitable 
way to address the issue of false positives is to interpret results with caution until replication 
in larger experiments.
To explore co-regulation between genes, Pearson’s correlation coefficients were derived 
inferring the linear relationship between expression of each pair of genes. The coefficients 
with significant correlations (p≤0.05) were annotated on pairwise scatterplots without 
adjustment for multiple comparison. In sensitivity analyses, rats were ranked based on the 
normalised gene expression values (untransformed ΔCt) for each gene taking into 
consideration the expected direction of effect based on observed data from this study as well 
as the literature, e.g. ranking from lowest to highest gene expression for genes expected to be 
suppressed and highest to lowest for genes expected to be upregulated. The top 10 pups with 
the most extreme gene expression values for each gene were nominally compared across 
genes to make observations of suggestive value. 
Calculations from Ct values to 2ΔΔCt values were performed using Excel (Microsoft Corp, 
version for Microsoft 365). Statistical analyses with sample ΔCt and plots of sample ΔCt and 
2ΔΔCt were carried out and designed using Stata 14 (Stata Corp, TX, USA).
3.4 Results
3.4.1 Housekeeping genes
There was no evidence that the Ct values for housekeeping genes B2m and Hprt were 
affected by group (pB2m=0.227; pHprt=0.103) or time (pB2m=0.880; pHprt=0.272).  
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3.4.2 Cortex
3.4.2.1 Markers of injury
Descriptive statistics are reported in Table 3.4. Results from the primary analyses are 
reported in Table 3.5. Briefly, there was strong evidence of suppression of Mbp, a marker of 
myelin injury, and upregulation of Gfap, a marker of astrocyte activation, in the left cortex in 
the HI group. This effect was independent of time. There was no evidence of changes in 
neuronal marker Map2 with group or time. 
Table 3.4. Markers of Injury (Cortex): descriptive statistics
N: naïve; S: sham; HI: hypoxia-ischaemia; SD: standard deviation
Group Time (h) n Mbp Gfap Map2
Mean ΔCt SD Mean ΔCt SD Mean ΔCt SD
6 3 -0.23 0.38 0.09 0.25 0.62 0.39
12 3 -0.53 0.64 0.06 0.27 0.53 0.32N
24 3 0.22 0.59 0.09 0.45 0.19 0.41
6 3 0.21 0.38 0.28 0.34 0.72 0.62
12 3 0.27 0.37 0.27 0.08 0.86 0.32S
24 3 0.04 0.18 0.21 0.20 0.53 0.22
6 8 -1.12 0.87 0.80 0.37 0.54 0.32
12 8 -0.85 0.44 0.88 0.78 0.49 0.39HI
24 8 -0.78 0.58 1.73 1.37 0.61 0.29
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Table 3.5. Markers of injury (cortex): primary analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia
Gene Variable Levene’s 
p
df MS F p Effect 
size
Post hoc Scheffe’s 
p 
Group (N vs S 
vs HI)
2 4.55 13.04 0.0001 0.40
N (p=0.009) and S 
(p<0.0001) ≠ HI






4 0.25 0.71 0.589
0 (-
0.03)
Group (N vs S 
vs HI)
2 4.91 8.42 0.001 0.29
N (p=0.005) and S 
(p=0.021) ≠ HI






4 0.49 0.84 0.513
0 (-
0.02)
Group (N vs S 
vs HI)
2 0.15 1.18 0.320 0.01










More in detail, there was strong evidence of a group effect on Mbp expression (p=0.0001) 
independently of time, with a large effect size of 40%, i.e. 40% of the variation in Mbp 
expression was accounted for by group (Table 3.5). Post hoc analyses revealed that this was 
driven by the HI group, with no evidence of differences between naïve and sham. The plots 
of normalised expression and the plot of the fold change reflect this Mbp loss in the ipsilateral 
cortex in the HI group (Figure 3.7). The plot of fold-change shows that expression in the HI 
groups is 0.5-0.8 fold down (20-50% lower) compared to the age-matched naïve groups at the 
corresponding time points. In the secondary analyses merging naïve and sham groups, 
evidence of Mbp loss in the HI group strengthened (p<0.00001) and maintained a similar 
effect size (38%) (Table 3.6, Figure 3.10).
Figure 3.7. Mbp expression (cortex): plots
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There was also strong evidence of a group effect on Gfap expression independent of time 
(p=0.001), with a large effect size of 29%. As for Mbp, this was driven by the HI group, with 
no differences between naïve and sham in post hoc analyses (Table 3.5). Specifically, Gfap 
was upregulated in HI, with a distinct S-shaped bimodal distribution (Figure 3.8). The plot of 
the fold change shows that expression in the HI groups is 1.6-3.1 fold higher (160-310%) 
compared to the age-matched naïve groups. Within the HI group, there was a non-significant 
trend for higher expression at 24h compared to 6h and 12h, with a 3-fold higher expression 
compared to the naïve group at 24 h. In the secondary analyses merging naïve and sham 
groups, evidence of Gfap upregulation in the HI group strengthened (p=0.0001) and 
maintained a similar effect size (31%) (Table 3.6, Figure 3.11). 
Figure 3.8. Gfap expression (cortex): plots
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There were no differences in neuronal marker Map2 in the primary or secondary analyses, 
and effect sizes were also negligible (Table 3.5, Figure 3.9, Table 3.6, Figure 3.12). 
Figure 3.9. Map2 expression (cortex): plots
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Table 3.6. Markers of injury (cortex): secondary analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia




df MS F p Effect 
size
Group 1 0.55 2.75 0.123 0.11






2 0.37 1.83 0.202 0.10
Group 1 8.56 24.03 <0.00001 0.38







2 0.13 0.36 0.698
0 (-
0.03)
Group 1 0.13 1.59 0.231 0.04





2 0.04 0.05 0.955
0 (-
0.15)
Group 1 9.69 18.0 0.0001 0.31





2 0.97 1.80 0.180 0.03
Group 1 0.30 1.87 0.196 0.06




2 0.03 0.16 0.854
0 (-
0.13)
Group 1 0.01 0.07 0.799
0 (-
0.03)







2 0.21 1.60 0.216 0.03
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Figure 3.10. Mbp expression (cortex): plot of secondary analyses
Figure 3.11. Gfap expression (cortex): plot of secondary analyses 
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Figure 3.12. Map2 expression (cortex): plot of secondary analyses
Given the non-significant trend for late Gfap upregulation in 24h HI, a sensitivity analysis 
was carried out merging the 6h and 12h time points in an early (6h + 12h) vs late (24h) 
design comparing the HI group vs the control group (N/S) (Table 3.7). Evidence of 
interaction between group and time strengthened (p=0.060), with an effect size of 6% (Figure 
3.13. Gfap expression (cortex): plot of sensitivity analyses).
Table 3.7. Gfap expression (cortex): sensitivity analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia
Gene Variable Levene’s p df MS F P Effect size
Group (N/S vs HI) 1 11.54 22.61 <0.00001 0.35
Time (6h/12h vs 24h) 1 1.72 3.37 0.074 0.06Gfap
Group*Time
<0.00001
1 1.93 3.77 0.060 0.06
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Figure 3.13. Gfap expression (cortex): plot of sensitivity analyses
3.4.2.2 Inflammation
Descriptive statistics are reported in Table 3.8. Results from the primary analyses are 
reported in Table 3.9. Briefly, there was some evidence that all three pro-inflammatory 
cytokines (Tnfα, Il1β and Il6) were upregulated in the left cortex following HI, with a non-
significant trend for early upregulation (i.e. higher at 6h vs later time points). 
Table 3.8. Inflammation (Cortex): descriptive statistics
N: naïve; S: sham; HI: hypoxia-ischaemia; SD: standard deviation
Group Time n Tnfα Il1β Il6
Mean ΔCt SD Mean ΔCt SD Mean ΔCt SD
6 3 -8.03 0.25 -10.47 0.53 -10.27 0.14
12 3 -7.89 0.45 -10.49 0.51 -10.32 0.49N
24 3 -8.18 0.57 -10.49 0.27 -10.36 0.25
6 3 -8.16 0.44 -10.56 0.60 -10.24 0.51
12 3 -7.77 0.30 -10.29 0.34 -10.32 0.36S
24 3 -7.75 0.28 -10.95 0.13 -10.50 0.35
6 8 -6.48 1.10 -7.89 2.56 -8.01 1.37
12 8 -7.39 1.20 -9.85 1.17 -9.32 1.67HI
24 8 -7.17 0.72 -10.37 0.50 -9.17 1.29
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Table 3.9. Inflammation (cortex): primary analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia
Gene Variable Levene’s 
p
df MS F P Effect 
size
Post hoc Scheffe’s p 
Group (N vs S 
vs HI)
2 4.67 6.40 0.005 0.23
N (p=0.015) and S 
(p=0.040) ≠ HI






4 0.68 0.93 0.457
0 (-
0.01)
Group (N vs S 
vs HI)
2 7.07 3.92 0.030 0.14
N (p=0.178) and S 
(p=0.124) may be ≠ 
HI




4 2.80 1.56 0.209 0.06
Group (N vs S 
vs HI)
2 11.60 8.34 0.001 0.29
N (p=0.010) and S 
(p=0.008) ≠ HI






4 0.75 0.54 0.708
0 (-
0.05)
Evidence of a group effect was strong for both Tnfα (p=0.005) and Il6 (p=0.001), with large 
effect sizes of 23% and 29% respectively, i.e. 23% of the variation in Tnfα expression and 
29% of the variation in Il6 expression were accounted for by group (Table 3.9). Evidence was 
weaker but still significant for Il1β (p=0.030), with an effect size of 14% (Table 3.9). Post 
hoc analyses suggested that this was driven by the HI group for all cytokines, with no 
evidence of differences between naïve and sham. Such upregulation of the cytokines in the 
ipsilateral cortex is reflected by plots of normalised expression and fold change (Figure 3.14, 
Figure 3.15, Figure 3.16). There was no evidence of a time effect for any of the cytokines in 
the primary analyses. 
The plots of normalised expression show a trend for a bimodal distribution for all cytokines 
in the HI group. The plots of fold change show that Tnfα and Il6 are higher in the HI group at 
all time points compared to naïve rats at 6h, whereas Il1β upregulation in the HI group is 
mainly limited to the 6h time point. Indeed, despite the lack of significant interaction effects 
with current sample size and the high variability in the HI group at 6h (especially for Il1β and 
Il6), it can be observed that for all cytokines the largest increase seems to occur at 6h. 
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Specifically, the HI group at 6h had 3-fold (300%) higher expression of Tnfα, 4.8-fold higher 
expression of Il6 and 6-fold higher expression of Il1β compared to the naïve groups at the 
corresponding time points. For Tnfα and Il6, expression in the HI group at 12h and 24h was 
still 1.4-2.2 fold higher compared to the naïve groups at the corresponding time points. 
Figure 3.14. Tnfα expression (cortex): plots
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Figure 3.15. Il6 expression (cortex): plots
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Figure 3.16. Ilβ expression (cortex): plots
In the secondary analyses merging naïve and sham groups, evidence of upregulation in the HI 
group strengthened for both Tnfα (p=0.0007) and Il6 (p=0.0001), with similar effect sizes of 
25% and 31%. Additionally, some evidence an interaction effect emerged for Il1β (p=0.049), 
with an effect size of 10%, driven by the 6h time point (Table 3.10, Figure 3.17, Figure 3.18, 
Figure 3.19).
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Table 3.10. Inflammation (cortex): secondary analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia




df MS F p Effect 
size
Group 1 0.09 0.56 0.470 0 (-0.03)
Time 2 0.11 0.68 0.524 0 (-0.03)N vs S
Group*Time
0.03
2 0.12 0.74 0.496 0 (-0.04)
Group 1 9.24 13.66 0.0007 0.25





2 1.24 0.83 0.174 0 (-0.04)
Group 1 0.06 0.32 0.579 0 (-0.05)
Time 2 0.17 0.92 0.424 0 (-0.01)N vs S
Group*Time
<0.00001
2 0.16 0.86 0.446 0 (-0.02)
Group 1 14.07 8.47 0.006 0.16





2 5.44 3.28 0.049 0.10
Group 1 0.006 0.05 0.834 0 (-0.07)
Time 2 0.05 0.34 0.721 0 (-0.10)N vs S
Group*Time
0.16
2 0.01 0.09 0.915 0 (-0.14)
Group 1 23.19 18.17 0.0001 0.31





2 1.49 1.17 0.323 0.01
Figure 3.17. Tnfα expression (cortex): plot of secondary analyses
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Figure 3.18. Il1β expression (cortex): plot of secondary analyses
Figure 3.19. Il6 expression (cortex): plot of secondary analyses
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Given the non-significant trend for early upregulation of the cytokines in HI group at 6h, a 
sensitivity analysis was carried out merging the 12h and 24h time points in an early (6h) vs 
late (12h + 24h) design comparing the HI group vs control group (N/S) (Table 3.11, Figure 
3.20). Evidence for the interaction effect between group and time strengthened for Il1β 
(p=0.013) with an effect size of 13%. There was also a non-significant interaction effect for 
Tnfα (p=0.069), with an effect size of 6%, and weaker evidence for Il6 (p=0.133) and an 
effect size of 3%.
Table 3.11. Inflammation expression (cortex): sensitivity analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia
Gene Variable Levene’s p df MS F P Effect size
Group (N/S vs HI) 1 11.34 17.52 0.0002 0.29
Time (6h vs 12h/24h) 1 0.82 1.26 0.269 0.006Tnfα
Group*Time
0.005
1 2.27 3.50 0.069 0.06
Group (N/S vs HI) 1 21.47 13.33 0.0008 0.24
Time (6h vs 12h/24h) 1 11.70 7.26 0.010 0.14Il1β
Group*Time
0.01
1 10.83 6.72 0.013 0.13
Group (N/S vs HI) 1 26.05 21.49 <0.00001 0.34
Time (6h vs 12h/24h) 1 4.21 3.48 0.070 0.06Il6
Group*Time
0.03
1 2.86 2.36 0.133 0.03
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Figure 3.20. Inflammation expression (cortex): plots of sensitivity analyses
176
3.4.2.3 Glutamate transporter
Descriptive statistics are reported in Table 3.12. There were no significant changes in Glt1 
expression with group or time. On the other hand, an 8% effect was estimated and post hoc 
analyses produced very weak evidence of differences between the HI group and the sham 
group (p=0.098) (Table 3.13, Figure 3.21). In the secondary analyses merging naïve and 
sham, some evidence emerged that Glt1 may be lower in the HI group (p=0.036) with a small 
effect size of 9% (Table 3.14, Figure 3.22).
Table 3.12. Glt1 (cortex): descriptive statistics
N: naïve; S: sham; HI: hypoxia-ischaemia; SD: standard deviation
Group Time n Glt1
Mean ΔCt SD
6 3 1.90 0.30
12 3 2.15 0.39N
24 3 1.95 0.54
6 3 2.18 0.47
12 3 2.03 0.60S
24 3 2.25 0.14
6 8 1.70 0.58
12 8 1.89 0.40HI
24 8 1.73 0.41
Table 3.13. Glt1 (cortex): primary analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia
Gene Variable Levene’s 
p
df MS F p Effect 
size
Post hoc Scheffe’s 
p 
Group (N vs S vs 
HI)
2 0.52 2.50 0.098 0.08
S may be ≠ HI 
(p=0.094)




4 0.05 0.26 0.901 0 (-0.08)
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Figure 3.21. Glt1 expression (cortex): plots
Table 3.14. Glt1 (cortex): secondary analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia




df MS F p Effect 
size
Group 1 0.10 0.53 0.480 0 (-0.03)
Time 2 0.01 0.04 0.965 0 (-0.15)N vs S
Group*Time
0.18
2 0.08 0.44 0.657 0 (-0.08)
Group 1 0.95 4.74 0.036 0.09





2 0.03 0.13 0.874 0 (-0.05)
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Figure 3.22. Glt1 expression (cortex): plot of secondary analyses
3.4.2.4 Comparison across genes
Correlations between pairs of genes were tested with pairwise Pearson’s correlation 
coefficient and the significant coefficients (p≤0.05, not corrected for multiple comparisons) 
annotated on pairwise scatterplots (Figure 3.23). There was a strong positive correlation 
between all three cytokines (Pearson’s correlation coefficients ≥0.8), so that as expression of 
one cytokine increased so did expression of the others. The correlation was particularly 
strong between Tnfα and Il6 (Pearson’s correlation coefficients =0.9). There was a weak 
negative correlation between Glt1 and all cytokines (Pearson’s correlation coefficients ≤-0.4). 
In terms of markers of injury, Mbp showed a moderate positive correlation to Glt1 (Pearson’s 
correlation coefficients =0.6) and a weak/moderate negative correlation to the cytokines 
(Pearson’s correlation coefficients ≤-0.4). Gfap showed a moderate positive correlation to 
Tnfα and Il6 (but not Il1β) (Pearson’s correlation coefficients = 0.6) and a weak negative 
correlation to Glt1 and Mbp (Pearson’s correlation coefficients =-0.4). Map2 had a weak 
positive correlation with Glt1 only (Pearson’s correlation coefficients =0.3).
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Figure 3.23. Matrix of pairwise correlations in gene expression (ΔCt) (cortex)
Only correlation coefficients with p≤0.05 are reported.
In sensitivity analyses, the ten pups showing the most extreme normalised expression values 
(untransformed ΔCt) for each gene were reported in Table 3.15. “Extreme” referred to the 
highest expression values for Gfap and the cytokines, and lowest for Mbp, Map2 and Glt1, 
based on current findings and the direction of change expected from previous literature. 
Outliers, as seen in the plots, are indicated with a star. The rats with the most extreme 
expression for one gene (ranked 1st-2nd) tended to be amongst those with most extreme 
expression for at least 3 other genes (ranked 1st-10th). For example, the pup in the 6h HI 
group with highest expression of Il1β (outlier in Figure 3.16) is also the pup with highest 
expression of Il6 (outlier in Figure 3.15) and lowest expression of Glt1 and amongst the pups 
with highest Tnfα and lowest Mbp (in purple). Similarly, the pup with the highest Tnfα 
expression, from the 12h HI group, is amongst the pups with highest expression for Il6 
(outlier in Figure 3.15), Il1β and Gfap and lowest expression for Mbp, Map2 and Glt1. The 
pup with the lowest expression for Mbp (outlier in Figure 3.7), from the 6h HI  group, was 
also amongst the pups with highest cytokine levels and lowest Glt1 levels (in orange). Since 
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there was no indication that the outliers were technical artifacts, they were retained in the 
analyses.
With regard to Glt1, the pup with lowest expression (in purple) was from the 6h HI group and 
also amongst the pups with the highest cytokine levels and lowest Mbp and Map2. The 
second in rank for Glt1 (in yellow), also from the 6h HI group, also had high Il1β and low 
Map2. The third in rank (red) was from the HI 24h group and also had high Tnfα, Il6 and 
Gfap, and low Mbp and Map2. The fourth in rank, from the 6h HI group, also had high levels 
of all three cytokine and the lowest level of Mbp. Therefore, the four pups with lowest Glt1 
expression in the study all belonged to the HI groups and also had particularly extreme levels 
of at least one cytokine and injury marker compared to the other pups in the study. While 
some interesting patterns emerge from these data, these are sensitivity analyses from a small 
pilot study and must be interpreted with caution.
Table 3.15. Top 10 rats ranked by most extreme gene expression for each gene (cortex)
“Extreme”: the highest or lowest expression value within the sample, depending on the 
expected direction of change based on these findings and previous literature, i.e. highest 
to lowest expression for the cytokines and Gfap (▼); lowest to highest expression (▲) 
for Glt1, Mbp and Map2. 
Cell numbers are rat IDs (e.g. 6H5 is the 5th of one of the 8 rats from the hypoxia-
ischaemia group at 6h; N: naïve; S: sham; H: hypoxia-ischaemia). Each rat ID has been 
assigned one colour in the table (e.g. 6H5 is shown in orange). Outliers (see 
corresponding figures in the main text) are marked with *.
Mbp▲ Gfap▼ Map2▲ Tnfα▼ Il1β▼ Il6▼ Glt1▲ 
6H5* 24H2 12H4 12H4 6H2* 6H2* 6H2
24H8 24H4 24N3 6H2 6H8 12H4* 6H1
12H8 24H8 6H2 6H6 6H6 24H4 24H8
6H6 12H4 6S2 6H8 12H4 6H5 6H5
6H4 24H3 24N2 24H4 6H5 6H6 12H1
6H2 24H7 24H2 6H5 6H4 6H8 24H2
12H4 12H1 6N2 24H8 12H1 6H3 24N3
12H1 6H3 12N1 12H1 6H1 24H7 12S1
24H3 6H7 6H1 6H4 12H3 24H8 12H4
24H7 6H8 24H8 24H7 6N1 6H4 6N1
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3.4.3 Hippocampus
3.4.3.1 Markers of injury 
Descriptive statistics are reported in Table 3.16. Results from the primary analyses are 
reported in Table 3.17. Briefly, there was strong evidence of upregulation of Gfap, a marker 
of astrogliosis, in the HI group (independently of time). There was also strong evidence that 
Mbp was lower at 6h compared to 24h; this time effect was independent of group, although 
secondary analyses suggested that Mbp may be lost in the HI group compared to the 
naïve/sham control group. There was no evidence of changes in neuronal marker Map2 with 
group or time. 
Table 3.16. Markers of Injury (Hippocampus): descriptive statistics
N: naïve; S: sham; HI: hypoxia-ischaemia; SD: standard deviation
Group Time n Mbp Gfap Map2
Mean ΔCt SD Mean ΔCt SD Mean ΔCt SD
6 3 -0.54 1.05 0.80 0.30 0.14 0.32
12 3 0.52 0.86 0.90 0.54 -0.01 0.23N
24 3 0.56 1.68 0.48 0.58 0.04 0.43
6 3 -0.83 0.78 0.74 0.20 -0.07 0.12
12 3 -0.42 0.58 0.37 0.40 -0.11 0.39S
24 3 1.05 0.25 0.69 0.29 -0.19 0.25
6 8 -0.93 0.89 1.45 0.37 0.01 0.28
12 8 -0.66 0.89 1.15 0.66 -0.16 0.17HI
24 8 0.03 0.48 1.33 0.82 -0.26 0.14
Table 3.17. Markers of injury (hippocampus): primary analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia
Gene Variable Levene’s 
p
df MS F p Effect 
size
Post hoc Scheffe’s p 
Group (N vs S 
vs HI)
2 1.86 2.56 0.093 0.08
N (p=0.187) may be ≠ 
HI
Time 2 4.94 6.78 0.003 0.24
6h ≠ 24h (p=0.004); 





4 0.53 0.73 0.577
0 (-
0.03)
Group (N vs S 
vs HI)
2 2.17 6.70 0.004 0.24









Group*Time 4 0.13 0.41 0.803
0 (-
0.07)
Group (N vs S 
vs HI)
2 0.13 2.10 0.138 0.06
Time 2 0.08 1.34 0.277 0.02Map2
Group*Time
0.07
4 0.02 0.27 0.895
0 (-
0.08)
The naïve group showed particularly high variability for Mbp, indeed the highest variability 
amongst all genes in both brain regions (Figure 3.24). There was strong evidence of a time 
effect on Mbp expression (p=0.003), with a large effect size of 24%, i.e. 24% of the variation 
in Mbp expression was accounted for by time (Table 3.17). Post hoc analyses confirmed that 
expression was significantly lower at 6h compared to 24h independently of group, with 
weaker evidence for an intermediate effect of 12h. The evidence of a group effect was very 
weak (p=0.093), with an effect size of 8%. Post hoc analyses suggested that Mbp may be lost 
in the HI group compared to naïve rats. In the plot of normalised expression by group, a trend 
can be seen for lower Mbp expression in the sham and HI 6h groups compared to the 
corresponding 24h groups; this was more ambiguous for the naïve group (Figure 3.24). The 
time effect is more easily observed in a plot of normalised expression by time (Figure 3.25). 
Evidence of a time effect for Mbp persisted in the secondary analyses (N vs S: p=0.062; N/S 
vs HI: p=0.002), maintaining a similar effect size to the primary analyses (24-25%). 
Moreover, stronger evidence that Mbp may be lower in the HI group emerged when merging 
naïve and sham rats (p=0.035), also maintaining similar effect size (9%) (Table 3.18, 
Figure 3.28).
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Figure 3.24. Mbp expression (hippocampus): plots
Figure 3.25. Mbp expression (hippocampus): plot by time
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There was also strong evidence of a group effect on Gfap expression (p=0.004) independent 
of time, with a large effect size of 24%. This was driven by the HI group being different from 
both naïve and sham groups, as shown by post hoc analyses (Table 3.17). The upregulation of 
Gfap in the HI group is reflected in the plots of normalised expression and fold change. The 
latter shows that Gfap expression is 1.2-1.8-fold higher in the HI group at all time points 
compared to the naïve groups at the corresponding time points (Figure 3.26). A bimodal 
distribution in the HI group was less obvious in the hippocampus than in the cortex. Unlike in 
the cortex, in the hippocampus there was no obvious trend for higher expression at 24h in the 
HI group compared to 6h and 12h. In the secondary analyses merging naïve and sham groups, 
evidence of Gfap upregulation in the HI group strengthened (p=0.0007) and maintained a 
similar effect size (25%) (Table 3.18). 
Figure 3.26. Gfap expression (hippocampus): plots
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There were no differences in neuronal marker Map2 in the primary or secondary analyses, 
and effect sizes were also negligible (Table 3.17, Figure 3.27, Table 3.18, Figure 3.30). 
Figure 3.27. Map2 expression (hippocampus): plots
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Table 3.18. Markers of injury (hippocampus): secondary analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia




df MS F p Effect 
size
Group 1 0.28 0.30 0.594 0 (-0.05)
Time 2 3.35 3.54 0.062 0.25N vs S
Group*Time
0.22
2 0.77 0.82 0.465 0 (-0.02)
Group 1 3.44 4.79 0.035 0.09





2 0.29 0.41 0.669 0 (-0.03)
Group 1 0.07 0.43 0.526 0 (-0.04)
Time 2 0.06 0.34 0.720 0 (-0.10)N vs S
Group*Time
0.26
2 0.21 1.26 0.318 0.03
Group 1 4.27 13.73 0.0007 0.25





2 0.05 0.16 0.849 0 (-0.04)
Group 1 0.15 1.55 0.237 0.04
Time 2 0.02 0.22 0.808 0 (-0.12)N vs S
Group*Time
0.40
2 0.01 0.09 0.918 0 (-0.14)
Group 1 0.11 1.82 0.186 0.02
Time 2 0.13 2.19 0.127 0.06
Map2
N/S vs HI
Group*Time 2 0.02 0.41 0.666 0 (-0.03)
Figure 3.28. Mbp expression (hippocampus): plot of secondary analyses
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Figure 3.29. Gfap expression (hippocampus): plot of secondary analyses
Figure 3.30. Map2 expression (hippocampus): plot of secondary analyses
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3.4.3.2 Inflammation
Descriptive statistics are reported in Table 3.19. Results from the primary analyses are 
reported in Table 3.20. Briefly, there was some evidence that all three pro-inflammatory 
cytokines Tnfα, Il1β and Il6 were upregulated in the left hippocampus following HI, with a 
non-significant trend for early upregulation (i.e. higher at 6h vs 12h and 24h). 
Evidence of a group effect was strong for Il6 (p=0.001), with a large effect size of 29% 
(Table 3.20). Evidence was weaker but still significant for both Tnfα (p=0.054) and Il1β 
(p=0.027), with effect sizes of 11% and 14% respectively (Table 3.20). Post hoc analyses 
suggested that this was driven by the HI group for all cytokines, with no evidence of 
differences between naïve and sham. There was no evidence of a time effect for any cytokine 
in the primary analyses.
Table 3.19. Inflammation (hippocampus): descriptive statistics
N: naïve; S: sham; HI: hypoxia-ischaemia; SD: standard deviation
Group Time n Tnfα Il1β Il6
Mean ΔCt SD Mean ΔCt SD Mean ΔCt SD
6 3 -8.10 0.18 -10.24 0.33 -11.05 0.35
12 3 -7.96 0.18 -10.07 0.20 -10.66 0.12N
24 3 -7.78 0.17 -10.49 0.34 -10.57 0.22
6 3 -7.85 0.17 -10.77 0.41 -11.13 0.34
12 3 -8.10 0.21 -10.24 0.32 -11.28 0.83S
24 3 -7.97 0.23 -10.58 0.31 -10.95 0.15
6 8 -6.66 1.33 -8.08 2.44 -8.86 1.51
12 8 -7.57 0.96 -9.64 0.92 -10.05 1.21HI
24 8 -7.76 0.51 -10.26 0.31 -10.08 0.91
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Table 3.20. Inflammation (hippocampus): primary analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia
Gene Variable Levene’s 
p
df MS F P Effect 
size
Post hoc Scheffe’s p 
Group (N vs S 
vs HI)
2 2.03 3.18 0.054 0.11
N (p=0.179) and S 
(p=0.156) may be ≠ HI






4 0.70 1.09 0.376 0.01
Group (N vs S 
vs HI)
2 6.05 4.03 0.027 0.14
N (p=0.215) and S 
(p=0.085) may be ≠ HI




4 2.41 1.61 0.196 0.06
Group (N vs S 
vs HI)
2 8.66 8.40 0.001 0.29
N (p=0.036) and S 
(p=0.004) ≠ HI






4 1.23 1.20 0.331 0.02
The cytokine upregulation in the HI group is reflected in the plots of normalised expression 
and the plots of fold change (Figure 3.31, Figure 3.32, Figure 3.33). The former shows a 
bimodal distribution for all cytokines in the HI group. The latter show that Il6 is higher in the 
HI group at all time points compared to the age-matched controls, whereas Tnfα and Il1β 
upregulation is mainly limited to 6h. Indeed, despite the lack of significant interaction effects 
with current sample size and the high variability in the HI group at 6h (especially for Il1β and 
Il6), the largest increase occurs at 6h it for all cytokines. Specifically, the 6h HI group had 
2.7-fold (270%) higher expression of Tnfα, 4.5-fold higher expression of Il6 and 4.5-fold 
higher expression of Il1β compared to the 6h naïve group. For Il6, expression at 12h and 24h 
in the HI group was still 1.5-fold higher than the respective age-matched controls.
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Figure 3.31. Tnfα expression (hippocampus): plots
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Figure 3.32. Ilβ expression (hippocampus): plots
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Figure 3.33. Il6 expression (hippocampus): plots
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In the secondary analyses merging naïve and sham groups, evidence of upregulation 
strengthened for both Tnfα (p=0.013) and Il6 (p=0.0002), with similar effect sizes of 13% and 
30% respectively. Additionally, some evidence an interaction effect emerged for Il1β 
(p=0.044), with an effect size of 11%, driven by the 6h time point (Table 3.21, Figure 3.34, 
Figure 3.35, Figure 3.36).
Table 3.21. Inflammation (hippocampus): secondary analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia




df MS F p Effect 
size
Group 1 0.003 0.08 0.781 0 (-0.07)






2 0.09 2.36 0.136 0.15
Group 1 4.06 6.88 0.013 0.13





2 1.31 2.22 0.123 0.06
Group 1 0.31 2.91 0.114 0.12
Time 2 0.27 2.48 0.125 0.17N vs S
Group*Time
0.61
2 0.08 0.75 0.493 0 (-0.03)
Group 1 11.78 8.49 0.006 0.16





2 4.74 3.42 0.044 0.11
Group 1 0.58 3.48 0.087 0.15
Time 2 0.16 0.98 0.405 0 (-0.03)N vs S
Group*Time
0.01
2 0.11 0.67 0.528 0 (-0.05)
Group 1 16.73 17.30 0.0002 0.30





2 2.35 2.43 0.102 0.07
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Figure 3.34. Tnfα expression (hippocampus): plot of secondary analyses
Figure 3.35.Il1β expression (hippocampus): plot of secondary analyses
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Figure 3.36. Il6 expression (hippocampus): plot of secondary analyses
Given the non-significant trend for early upregulation of the cytokines in the 6h HI group, 
sensitivity analyses were carried out merging the 12h and 24h time points in an early (6h) vs 
late (12h + 24h) design comparing the HI group vs the control group (N/S) (Table 3.22, 
Figure 3.37). Evidence for the interaction effect between group and time strengthened for all 
cytokines, including Tnfα (p=0.045) with an effect size of 8%, Il1β (p=0.013) with an effect 
size of 13%, and Il6 (p=0.031) with an effect size of 9%. 
Table 3.22. Inflammation expression (hippocampus): sensitivity analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia
Gene Variable Levene’s p df MS F P Effect size
Group (N/S vs HI) 1 5.85 10.36 0.003 0.19
Time (6h vs 12h/24h) 1 2.24 3.97 0.054 0.07Tnfα
Group*Time
0.01
1 2.42 4.28 0.045 0.08
Group (N/S vs HI) 1 18.13 13.27 0.001 0.23
Time (6h vs 12h/24h) 1 6.66 4.88 0.033 0.08Il1β
Group*Time
0.001
1 9.39 6.87 0.013 0.13
Group (N/S vs HI) 1 20.90 22.73 <0.00001 0.35
Time (6h vs 12h/24h) 1 2.18 2.37 0.132 0.03Il6
Group*Time
0.02
1 4.61 5.01 0.031 0.09
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Figure 3.37. Inflammation expression (hippocampus): plots of sensitivity analyses
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3.4.3.3 Glutamate transporter
Descriptive statistics are reported in Table 3.23. There were no significant changes in Glt1 
expression with group or time in primary or secondary analyses, and effect sizes were also 
negligible (Table 3.24, Figure 3.38, Table 3.25, Figure 3.39).
Table 3.23. Glt1 (hippocampus): descriptive statistics
N: naïve; S: sham; HI: hypoxia-ischaemia; SD: standard deviation
Group Time n Glt1
Mean ΔCt SD
6 3 1.67 0.17
12 3 1.74 0.43N
24 3 1.87 0.24
6 3 1.93 0.16
12 3 1.76 0.28S
24 3 2.10 0.17
6 8 1.73 0.41
12 8 1.72 0.46HI
24 8 1.85 0.25
Table 3.24. Glt1 (hippocampus): primary analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia
Gene Variable Levene’s 
p




Group (N vs S vs 
HI)
2 0.10 0.83 0.445 0 (-0.01)




4 0.02 0.15 0.963 0 (-0.1)
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Figure 3.38. Glt1 expression (hippocampus)
Table 3.25. Glt1 (hippocampus): secondary analyses
df: degrees of freedom; MS: means squares; F: F ratio; N: naïve; S: sham; HI: hypoxia-
ischaemia




df MS F p Effect 
size
Group 1 0.13 1.91 0.192 0.06
Time 2 0.09 1.38 0.288 0.05N vs S
Group*Time
0.38
2 0.02 0.35 0.713 0 (-0.09)
Group 1 0.07 0.59 0.449 0 (-0.01)





2 0.01 0.10 0.908 0 (-0.05)
199
Figure 3.39. Glt1 expression (hippocampus): plot of secondary analyses
3.4.3.4 Comparison across genes
Correlations between pairs of genes were tested with pairwise Pearson’s correlation 
coefficient and the significant coefficients (p≤0.05, not corrected for multiple comparisons) 
annotated on pairwise scatterplots (Figure 3.40). There was a strong positive correlation 
between all three cytokines (Pearson’s correlation coefficients ≥0.8), so that as expression of 
one cytokine increased so did expression of the others. The correlation was particularly 
strong between Tnfα and both Il1β and Il6 (Pearson’s correlation coefficients =0.9) There was 
a weak negative correlation between Glt1 and all cytokines (Pearson’s correlation 
coefficients =-0.5). In terms of markers of injury, Mbp showed a weak positive correlation to 
Glt1 (Pearson’s correlation coefficient =0.3) and a weak negative correlation to the cytokines 
(Pearson’s correlation coefficients ≤-0.4). Gfap showed a moderate positive correlation to Il6 
(Pearson’s correlation coefficient = 0.7) and a weak positive correlation to Il1β (Pearson’s 
correlation coefficient = 0.5). Map2 was not correlated to any gene.
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Figure 3.40. Matrix of pairwise correlations in gene expression (ΔCt) (hippocampus)
Only correlation coefficients with p≤0.05 are reported 
In sensitivity analyses, the ten pups showing the most extreme normalised expression values 
(untransformed ΔCt) for each gene were reported in Table 3.26. “Extreme” referred to the 
highest expression values for Gfap and the cytokines, and lowest for Mbp, Map2 and Glt1, 
based on current findings and the direction of change expected from previous literature. 
Outliers, as seen in the plots, are indicated with a star. The rats with the most extreme 
expression for one gene (ranked 1st-2nd) tended to be amongst those with the most extreme 
expression for at least 3 other genes (ranked 1st-10th).
This was seen more consistently for the cytokines and Gfap and less so for Mbp, Map2 and 
Glt1, which showed weak or no group effects in the analyses. For example, the pup in 6h HI 
group with highest expression of Tnfα (outlier in Figure 3.31) is also the pup with highest 
expression of Il1β (outlier in Figure 3.32) and Il6 (outlier in Figure 3.33) and is amongst the 
pups with highest expression of Gfap and lowest expression of Glt1 (in purple). Similarly, the 
pup with lowest expression for Glt1 was also the pup with highest Gfap expression and 
amongst the pups with highest cytokine expression and lowest Mbp expression (in green). 
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The pup with lowest Mbp expression was also amongst the pups with highest cytokine 
expression (outliers in Figure 3.31, Figure 3.32, Figure 3.33) and lowest Glt1 expression (in 
orange). Since there was no indication that the outliers were artifacts, they were retained in 
the analyses.
With regard to Glt1, the pup with lowest Glt1 expression (in green) was from the 12h HI 
group and also amongst the pups with the highest cytokine levels and Gfap, and lowest Mbp. 
The second in rank for Glt1 (in yellow) was from the 6h HI group and also amongst the pups 
with highest cytokine levels. The third in rank for Glt1 (red) was from the 12h naïve group 
and did not feature amongst the pups with most extreme expression of any of the other genes. 
The fourth in rank was also from the 6h HI group, also had the highest cytokine levels across 
the entire sample and was amongst the pups with highest level of Gfap (in purple). Therefore, 
three of the four pups with lowest Glt1 expression were from the HI groups and also amongst 
the pups with the highest cytokine levels. While some interesting patterns emerge from these 
data, these are sensitivity analyses from a small pilot study and must be interpreted with 
caution.
Table 3.26. Top 10 pups ranked by most extreme gene expression for each gene 
(hippocampus)
“Extreme”: the highest or lowest expression value within the sample, depending on the 
expected direction of change based on these findings and previous literature, i.e. highest 
to lowest expression for the cytokines and Gfap (▼); lowest to highest expression (▲) 
for Glt1, Mbp and Map2. 
Cell numbers are rat IDs (e.g. 6H5 is the 5th of one of the 8 rats from the hypoxia-
ischaemia group at 6h; N: naïve; S: sham; H: hypoxia-ischaemia). Each rat ID has been 
assigned one colour in the table (e.g. 6H5 is shown in orange). Outliers (see 
corresponding figures in the main text) are marked with *.
Mbp▲ Gfap▼ Map2▲ Tnfα▼ Il1β▼ Il6▼ Glt1▲ 
6H5 12H4 12S2 6H2* 6H2* 6H2* 12H4
6H2 24H2 24H2 12H4* 6H5* 12H4* 6H1
6S3 24H4 24H8 6H5* 12H4* 6H5* 12N2
12H5 24H3 12H7 6H8 6H8 24H4 6H2
12H4 6H2 24S2 24H4 6H1 6H1 24H4
12H8 6H7 6H8 6H1 6H4 6H8 6H5
6H4 6H3 24H4 6H4 12H1 24H7 6N1
6N3 12H1 24H3 24H2 6H6 24H2 12H1
6H6 12N1 24S3 6H3 12H6 6H3 12S2
24N3 6H8 12H4 6H6 24H4 12H1 12H3
202
3.4.4 Comparison across regions
The marker of astrocyte activation Gfap was strongly increased after HI in both cortex and 
hippocampus, with approximately similar level of evidence and effect size (cortex: p=0.001, 
ω2=0.29; hippocampus: p=0.004, ω2=0.24). In the cortex but not the hippocampus, there was 
a non-significant trend for higher expression in the later phase (24h) compared to the earlier 
phases (6h and 12h), with 3-fold higher expression in the HI group compared to the naïve 
group at 24h. 
The marker of myelin injury Mbp was lost after HI in the left cortex (cortex: p=0.0001, 
ω2=0.40), with secondary analyses merging naïve and sham suggesting a slight reduction in 
the hippocampus too (hippocampus: p=0.035; ω2=0.09). In the hippocampus, there was a 
significant time effect whereby Mbp was lower in the early phase (6h) compared to the later 
phase (24h) in all groups. 
There was no evidence of changes in neuronal marker Map2 in either region. There was also 
no evidence of changes in Glt1 in either region. Secondary analyses merging naïve and sham 
suggested that Glt1 may be slightly reduced in the cortex after HI (cortex: p=0.036, ω2=0.09).
All three pro-inflammatory cytokines were elevated after HI in both brain regions. Effect size 
was the same in both regions for Il1β (cortex: p=0.030, ω2=0.14; hippocampus: p=0.027, 
ω2=0.14) and Il6 (cortex: p=0.001, ω2=0.29; hippocampus: p=0.001, ω2=0.29). Effect size for 
Tnfα was twice as large in the cortex vs hippocampus (cortex: p=0.005, ω2=0.23; 
hippocampus: p=0.054, ω2=0.11), i.e. group accounted for twice as much variation in Tnfα 
expression in the cortex compared to the hippocampus. In both regions, there was a non-
significant trend for higher expression in the early phases (6h) post-HI compared to the later 
phases (12h and 24h). In the secondary analyses assessing early (6h) vs late (12h + 24h) 
response in the HI group vs control group (N/S), evidence of an interaction effect with 
upregulation at 6h in the HI group reached significance for all cytokines in the hippocampus 
(Tnfα: p=0.045, ω2=0.08; Il1β: p=0.013, ω2=0.13; Il6: p=0.031, ω2=0.09) and for Il1β in the 
cortex (p=0.013, ω2=0.13), with a non-significant trend for Tnfα (p=0.069, ω2=0.06) and Il6 
(p=0.133, ω2=0.03) in the cortex.
To summarise findings within each brain region, there was a strong positive correlation 
between all three cytokines (Pearson’s correlation coefficients ≥0.8), especially between Tnfα 
and Il6 in the cortex and between Tnfα and both Il1β and Il6 in the hippocampus (Pearson’s 
correlation coefficients =0.9). There was also a weak negative correlation between Glt1 and 
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all cytokines (Pearson’s correlation coefficients ≤-0.4), with the weakest correlation seen for 
Glt1 and Tnfα in the cortex (Pearson’s correlation coefficient =-0.35). In terms of markers of 
injury, Mbp was positively correlated to Glt1, with stronger correlation in the cortex than in 
the hippocampus (Pearson’s correlation coefficients =0.6 vs 0.3). Mbp also showed a weak 
negative correlation with all cytokines in both regions, with a slightly stronger correlation for 
Tnfα and Il6 in the cortex than in the hippocampus (Pearson’s correlation coefficients =-0.5 
vs -0.35). Gfap showed a moderate positive correlation to Il6 in both regions (Pearson’s 
correlation coefficients ≥0.6), a moderate positive correlation to Tnfα but not Il1β in the 
cortex (Pearson’s correlation coefficients = 0.6), and a weak positive correlation to Il1β but 
not Tnfα in the hippocampus (Pearson’s correlation coefficient = 0.5). In the cortex, Gfap 
additionally showed a weak negative correlation to Glt1 and Mbp (Pearson’s correlation 
coefficients =-0.4). Map2 only showed a weak positive correlation with Glt1 in the cortex 
(Pearson’s correlation coefficients =0.3).
Between regions (Figure 3.41), there was a strong positive correlation of all of the cytokines 
as well as Gfap (Pearson’s correlation coefficients ≥0.76), so that if expression was high in 
the cortex it tended to be high in the hippocampus as well. Thus, pups with particularly high 
expression in the cortex tended to correspond with pups with particularly high expression in 
the hippocampus (and generally had very low/high levels of at least three other genes 
compared to the other pups). There was a weak positive correlation between left cortex and 
left hippocampus for Glt1 (Pearson’s correlation coefficients =0.46) and Mbp (Pearson’s 
correlation coefficients =0.31), i.e. as expression of Glt1 and Mbp in the cortex decreased, 
there was more variability in the hippocampus. There was no significant correlation between 
brain regions for Map2.
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Figure 3.41. Pairwise correlations (between bran regions)
After Benjamini-Hochberg False Discovery Rate correction, 9 findings from the primary 
analyses survived multiple comparison adjustment, with an accepted false discovery rate of 
7% (i.e. one gene in one of the two brain regions amongst 14 tests) (Table 3.27). The findings 
surviving FDR adjustment (shaded) included Mbp in the cortex, as well as Gfap and all 
cytokines in both brain regions.
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Table 3.27. Gene expression: findings surviving Benjamini-Hochberg False Discovery 
Rate (7%) correction (shaded)




Mbp Cortex 0.0001 1 0.007
Gfap Cortex 0.001 2 0.014
Il6 Cortex 0.001 3 0.021
Il6 Hippocampus 0.001 4 0.029
Gfap Hippocampus 0.004 5 0.036
Tnfα Cortex 0.005 6 0.043
Il1β Cortex 0.030 7 0.050
Il1β Hippocampus 0.027 8 0.057
Tnfα Hippocampus 0.054 9 0.064
Mbp Hippocampus 0.093 10 0.071
Glt1 Cortex 0.098 11 0.079
Map2 Hippocampus 0.138 12 0.086
Map2 Cortex 0.320 13 0.093
Glt1 Hippocampus 0.445 14 0.100
3.5 Discussion
This exploratory study used the Rice Vannucci model to assess whether acute HI alters 
transcription of three key pro-inflammatory cytokines (Tnfα, Il1β, Il6) and the glutamate 
transporter (Glt1) in two of the most vulnerable brain regions, the cortex and hippocampus. 
mRNA levels of the candidate genes were assessed with qPCR and normalised to two 
housekeeping genes (Hprt, B2m) to account for confounding differences in the starting 
amount of template. Since brain injury and survival could not be directly assessed in this 
study, gene expression of established markers of neuronal injury (Map2), myelin injury 
(Mbp) and astrogliosis (Gfap) was also assessed. Transcription of the neuronal marker was 
not affected, although post-translational regulation was not assessed and nor were other 
neuronal markers. Changes in the other markers support clinical relevance of the model, since 
they signal some of the most common neuropathological features seen in HIE, i.e. early onset 
of astrogliosis and myelin injury. All three cytokines were upregulated following HI in both 
brain regions, with a trend for peak upregulation at 6h, providing evidence of an early 
neuroinflammatory response. There was no evidence of significant changes for the glutamate 
transporter, other than suggestive evidence of lower expression in the HI group at the 
secondary analysis stage merging naïve and sham groups. This may be an artefact or flag an 
effect in the astrocyte compartment which the study is underpowered to detect with current 
sample size and bulk tissue.
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3.5.1 Hypoxia-ischaemia induces astrogliosis and myelin injury in both regions
Astrocytes can be directly injured and die via necrosis in the infarct area following HI. 
Additionally, surviving astrocytes nearby the injured tissue (‘the penumbra area’ or border 
zone) can become reactive due to the locally rising levels of danger associated molecular 
patterns, cytokines and reactive oxygen species released by injured neurons and glial cells 
(804, 1215).  During astrogliosis, astrocytes become hypertrophic, proliferate at an increased 
rate and alter their gene expression profiles (1216). One of the hallmarks of astrogliosis is 
rapid accumulation of intermediate filament protein GFAP (1217, 1218). Astrogliosis with 
GFAP staining has been shown in a model of severe HIE in nonhuman primates (1219). In 
the rodent brain, HI causes rapid upregulation of GFAP mRNA and protein in the cortex, 
hippocampus, striatum, thalamus, and corpus callosum, starting at 12h-72h and gradually 
increasing in the first two postnatal weeks (483, 1220-1222). Accordingly, we found that 
Gfap mRNA was upregulated rapidly after HI in both cortex and hippocampus, with a trend 
for peak upregulation at 24h which was especially obvious in the cortex. Of interest, 
accumulation of GFAP at the border zone corresponds to areas with loss of MAP2 protein 
and impaired neuronal growth (1221, 1223, 1224). In a similar rat model, Gfap accumulation 
switched location from the border zone at 12-72h to the infarct core, where it persisted until 
adolescence (1221). This highlights a potential chronic component to astrogliosis and 
suggests Gfap upregulation would have likely continued past 24h.
MBP is essential for the formation and maintenance of the myelin sheath, and the abundant 
transcripts provide an easily measurable marker of the amount of myelin and oligodendrial 
injury (1225, 1226). In rodents, loss of Mbp mRNA and oligodendrocyte death are observed 
as early as 3 hours post-HI and are obvious by 24-96h in the subcortical white matter, corpus 
callosum and deep grey matter (675, 1227-1229). Loss is sustained if injury is severe or can 
recover 2 weeks after HI, likely due to migration of new oligodendrocytes from the 
subventricular zone or maturation of spared pre-oligodendrocytes (1228, 1230-1232). Of 
note, therapeutic hypothermia protects against white matter injury measured as MBP loss 
(1233-1235). In this pilot study, HI caused Mbp loss in the ipsilateral cortex, signalling the 
onset of myelin and oligodendrial injury. This loss was detectable from the earliest 6h time 
point to latest 24h time point. In the hippocampus, Mbp was lower at 6h vs 24h regardless of 
experimental group. The weaker evidence here was likely due to high variability in the naïve 
group coupled with small sample size, and a trend for Mbp loss following HI was present. 
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Importantly, baseline Mbp levels are still low in both white matter and hippocampus at P7, 
increasing from the second postnatal week (1228).
MAP2 is a structural protein expressed in dendrites and an established marker of HI neuronal 
injury, with transient protein loss observed 1-72h post-HI in the hippocampus, cortex, and 
thalamus of newborn rats and piglets (684, 1236-1243). Loss of MAP2 correlates with 
histological evidence of neuronal injury, with complete loss in the ischemic core/infarct area 
and partial loss in the border area, detectable within the first 12h (684, 1240). Moreover, loss 
of MAP2 precedes microglial activation in the cortex, striatum and hippocampus of the 
newborn rat, whereas delayed loss coincides with delayed microglial activation in the 
thalamus (1244). MAP2 loss is also seen in the cortex and hippocampus of infants younger 
than 1 year of age with HI injuries (1245). Therefore, MAP2 protein appears to be an early 
and sensitive marker of the distribution, time course and severity of neuronal injury after HI. 
In this pilot study, we did not examine MAP2 protein or neuronal ischemic injury directly by 
immunohistochemistry, and we found no evidence of changes in Map2 mRNA. Rodent 
studies focusing on Map2 mRNA instead of protein are rarer, but nonetheless include 
evidence of loss after HI and correlation with neuronal injury in adults and after systemic 
inflammation in newborns (484, 1246). 
The lack of changes in Map2 mRNA levels may have arisen through technical error, with 
selective amplification of certain alternative splicing isoforms. However, qPCR primers for 
Map2 were designed to span exon 3 and 4, which belong to all known isoforms, and should 
therefore capture total mRNA expression. Alternatively, mRNA and protein levels may be at 
least in part uncoupled. This explanation is supported by the finding that MAP2 protein levels 
increase in the developing mouse from birth to P21, however mRNA levels remain more 
constant (1247). While qPCR detects the levels of mature mRNA transcripts (spliced, 
polyadenylated and capped), regulatory processes continue after transcription, and include 
transport to the cytoplasm, degradation, localisation to different cellular compartments and 
translation (1248). Protein assays could be used to assess MAP2 protein levels, however the 
most appropriate next step would be assessing mRNA levels of another established neuronal 
injury marker, NeuN. This marker is localised in and around the nucleus of most neurons and 
has been previously used in this and other relevant animal models, including in combination 
with MAP2 (1202, 1227, 1249-1251). 
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In conclusion, although brain tissue loss was not directly measured in this pilot study due to 
the early time points for sacrifice, the rat model appears clinically relevant since it reproduces 
some of the most common neuropathological features seen in HIE, i.e. early onset of 
astrogliosis and myelin injury. 
3.5.2 Hypoxia-ischaemia induces an early neuroinflammatory response in both regions
Transcription of three key pro-inflammatory cytokines (Tnfα, Il1β, Il6) was increased in both 
cortex and hippocampus following HI, with a trend for peak upregulation at 6h. This finding 
aligns with previous evidence of upregulation in similar rat models in the ipsilateral vs 
contralateral hemispheres starting as early as the first hour, peaking at 3-12h and returning to 
baseline by 24h (555, 1221, 1252). The finding also aligns with evidence of increased Tnfα 
and Il1β mRNA levels 3h post-HI in the ipsilateral hemisphere compared to sham rats, with 
simultaneous infiltration of peripheral neutrophils and microglial activation. A switch to anti-
inflammatory mechanisms was seen after 24h, with Tnfα levels remaining elevated at 24h 
(1253). In another study of combined inflammatory and HI insults, the group exposed to HI 
only (plus vehicle NaCl injection) showed only a mild upregulation of Il6 in the hippocampus 
but not the cortex, and no difference in Il1β in either region (Tnfα not investigated); however, 
the only time point included was at 24h, which may have led to missing any changes in gene 
expression at earlier time points (1254). The current study features three time points in the 
early phases of injury and adds a regional dimension rather than analysing hemispheres in 
bulk, with detection of a transient inflammatory response in two of the most vulnerable brain 
regions. These cytokines are known to interact and stimulate each other and are often 
expressed concurrently (1255, 1256). This was reflected by the correlation between cytokines 
within each region and across regions. Importantly, previous evidence exists that an increase 
in IL1β and IL6 protein levels and activity accompanies the increase in mRNA in relevant 
rodent models (555, 558). Protein assays should be employed in future studies to assess the 
correlation between mRNA and proteins over time and obtain a more complete picture of 
cytokine regulation following HI. While rapid de novo transcription of cytokine mRNA (e.g. 
via activation of NFκB and STAT3) is key in mediating the acute phases of inflammation, 
post-transcriptional regulation may be important for resolving inflammation after the acute 
phase, for example by degradation of mRNA transcripts or storage for translation at a later 
stage (1257-1259).
In terms of fold-change, the magnitude of upregulation in the HI vs naïve groups was highest 
for Il1β in the cortex (6-fold), followed by Il1β and Il6 in both regions (4- to 5-fold) and 
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finally Tnfα in both regions (3-fold). The values of the fold-changes need to be interpreted 
with caution since this was a small pilot study with low power and, as expected from the 
model, variability was relatively high for the HI group. Compared to fold-changes relative to 
the age-matched control groups, standardised effect sizes (ω2) take into account variability 
within the 3 x 3 design. Within this framework, the larger effect size was found for Il6 in both 
regions and Tnfα in the cortex (group effect accounting for 20-30% variation in gene 
expression) followed by Il1β in both regions and Tnfα in the hippocampus (group effect 
accounting for 10-15% variation in gene expression). The most appropriate way to estimate 
effect sizes more precisely will be via a follow-up experiment with larger sample sizes. 
Low power reduces the chance of detecting a true effect but also the likelihood that a detected 
effect is true (1260). This is likely to lead not only to missing important discoveries, but also 
to overestimate true effect sizes and poor reproducibility. Exploratory studies with 
particularly low power, such as this one, can only detect effects that are large and may 
overestimate smaller effects when detected. This is because statistical significance may not 
be reached unless effects that are by chance larger than the true effect size are detected. This 
leads to inflated effects in the initial studies (“winner’s curse”) which are followed by smaller 
effects in replication studies, as findings converge towards the true effect size. For this 
reason, replication studies should feature larger sample sizes. This is a high priority in light of 
recent evidence pointing to particularly severe power issues specific to this rat model. A 
study recently merged samples from multiple smaller studies with this model reaching a 
sample size of over 600 for the first time (1199). In this larger analysis, a bimodal distribution 
of injury (i.e. brain area loss or pathology scores) was observed. This suggests that there are 
two distinct population of rats with differences in underlying initial characteristics, for 
example in blood flow, which may contribute to differences in brain injury (1203, 1261). A 
bimodal distribution was indeed observed for the cytokines and Gfap, indicating that most 
rats had either high or low expression. The observations from the large study led to the 
suggestion that non-parametric analyses should be used in studies with this model. Moreover, 
it was acknowledged that most existing studies are markedly underpowered to detect true 
effects and much larger sample sizes are required to produce robust findings (1199). Despite 
the issue of low power, biological relevance in this pilot study is supported by the consistency 
in direction of effect and temporal profiles, the correlation within and between brain regions 
and the agreement with the existing literature. 
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In terms of time points, there was a non-significant trend for peak upregulation at 6h for all 
three cytokines; at subsequent time points, Il1β levels went back to baseline in both regions, 
alongside Tnfα in the hippocampus, whereas they were reduced but still 1.5- to 2-fold higher 
for Il6 in both regions and Tnfα in the cortex. Based on previous evidence, upregulation of 
these cytokines is likely to have started earlier than our first time point at 6h (555, 1221, 
1252). Increased power may be achieved in future work by considering two rather than three 
time points (e.g. 6h vs 24h, or 3h vs 6h). Assessing gene expression at earlier time points may 
provide more definitive evidence of the peak time of the early increase in transcription within 
this model; on the other hand, assessing later time points may provide insights into which 
cytokines tends to have a more sustained upregulation or biphasic patterns of expression. This 
has been shown for some inflammatory genes (including Il6 and NFκB) in HIE, suggesting 
that they might switch roles from mediators of injury to mediators of repair in the secondary 
phases (1262-1265). Exploring interaction with hypothermia treatment will also be of clinical 
interest, especially since evidence is emerging that it may alter cytokine expression and 
promote repair roles (1265-1267). 
3.5.3 Hypoxia-ischaemia may suppress Glt1 in the cortex
In this pilot study, there was no significant evidence of any changes in Glt1 expression in 
either cortex or hippocampus in the primary analyses. There was, however, very weak non-
significant evidence that expression in the cortex may be lower in the HI group vs sham 
group. When naïve and sham were merged, evidence suggesting that Glt1 may be lower in 
the HI group was stronger. It is not possible to know at this stage whether this is an artefact of 
data manipulation in the secondary analyses or a true biological effect which the study is 
underpowered to detect. Moreover, should this be a true biological effect, it is not currently 
possible to distinguish whether isoflurane upregulated Glt1, HI suppressed it or both. 
The low power may be due to both low sample size and use of bulk tissue. The latter may be 
an issue specifically for Glt1, which is expected to be expressed mainly by astrocytes at this 
gestational age. Transcriptional and DNA methylation changes may therefore be detectable 
only after isolating astrocytes. Moreover, differences in gene expression between left and 
right hemispheres have been observed empirically even in naïve brains (1200). Hence, it is 
possible that within-rat variability may have concealed between-rat variability. Ideally, future 
studies will assess both hemispheres and generate a ratio of gene expression for each rat 
including information about both brain hemispheres. Based on the existing in vitro and in 
vivo evidence of dysregulation of EAAT2/GLT1 following hypoxia or HI, the glutamate 
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transporter remains worthy of further attention (see 5.2.2). Moreover, transport activity 
should be assessed alongside expression since both mechanisms can contribute to failure of 
the glutamate transport system, and drug compounds exist that improve both (743). 
Importantly, Glt1 transcription may be affected by HI but not within these experimental 
conditions. For example, transcription of Glt1 may change after 24h post-HI, or it may 
change with more severe HI. The HI insult was sufficient to trigger the onset of astrogliosis 
and myelin injury, flagged by upregulation of Gfap and loss of Mbp respectively. 
Nonetheless, unlike previous studies, there was no evidence that HI caused significant 
neuronal injury in the first 24h. The lack of transcriptional changes in Map2 does not rule out 
changes at the protein level, and indeed transcription and translation of MAP2 have been 
shown to be at least in part uncoupled. However, another neuronal marker (e.g. NeuN) should 
be assessed to better assess the severity of the effects of HI on neuronal integrity. Glt1 
dysregulation may also be detectable at a later developmental stage (see 5.2.2). 
Any future studies should consider that the effects of isoflurane anaesthesia on Glt1 
expression in the P7 brain are not known. Isoflurane affects neuronal glutamate signalling in 
vitro and in adult rats, though changes in astrocytic expression have not been found (1268-
1277). Merging naïve and sham data in the secondary analyses assumes no effect, however 
there is not currently enough evidence to suggest whether this is appropriate. Careful 
examination of the sham group should always be included in future studies.
3.5.4 Methodological refinement for future studies
This study was limited by the use of bulk tissue and the inability to directly demonstrate the 
cellular sources of these cytokines. Future studies could sort and isolate relevant cell types, 
e.g. microglia and astrocytes, by fluorescent-activated (FACS) or magnetic-activated 
(MACS) cell sorting, before assessing gene expression and DNA methylation. While FACS 
is the gold standard for cell separation at high purity, it is time consuming and requires 
expensive specialist equipment not required by MACS (1278). Both techniques have been 
used in relevant animal models of newborn brain injuries (1254, 1279). 
There was no evidence that the housekeeping genes were affected by HI in this pilot study. 
Indeed, previous studies have reported stability of Hprt and B2m in different cell types 
following hypoxia in vitro (1280-1283). Choosing appropriate reference genes is essential 
since normalising to genes that are affected by the insult can lead to false positives. 
Conversely, the effect could be masked if the reference gene is expressed by a different cell 
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type than the gene of interest and the two cell types are differentially lost due to the insult. 
Software exist, such as GeNorm or Normfinder, that assist with identification of the most 
suitable housekeeping gene for certain experimental conditions. A study recently used this 
software to identify reference genes specifically in the cortex of the P7 rat exposed to HI. The 
study found that Hprt was the best candidate at 0h and B2m at 3h post-HI, with other genes 
being more suitable at 12h (e.g. Pgk1, Ppia, Rplpo) (1284). A study recently highlighted the 
impact of reference genes choice specifically in the neonatal rat brain cortex after intrauterine 
HI (1285). 5 candidate reference genes were ranked using different methods/tools (e.g. 
GeNorm, ΔCt method). Different methods not only proposed different candidates but also 
generated large differences in quantification of the gene of interest. A similar finding comes 
from studies in hypoxic cancer cell lines (1286), highlighting the need to validate reference 
genes separately for each experimental paradigm. A future study should empirically measure 
expression of a panel of candidate reference genes prior to the experiment to select the most 
appropriate genes in this Rice Vannucci model.
Finally, differences in qPCR efficiency between reference and target genes can distort 
differences in expression. The 2−ΔΔCT method assumes 100% qPCR efficiency however this 
should be experimentally assessed in a larger study. This can be done after assay optimisation 
by performing a series of cDNA dilutions and inferring efficiency from the observed 
expression values (1287, 1288). 
3.5.5 Strengths and limitations
A main advantage of this study is the use of an established rat model, which has supported 
and enabled the translational journey of therapeutic hypothermia from bench to bedside (702, 
1193, 1202, 1289, 1290). This modified Rice Vannucci model is currently being used within 
our research group for studies of hypothermia treatment (1199, 1202), and this pilot study 
provides information which is directly relevant. Nonetheless, this is a small pilot study with 
limited power and results must be interpreted with caution. Follow-up analyses collecting 
new data in larger samples are needed to address the chance of both false negatives and false 
positives, as well as to better estimate effect sizes. 
The study provides a good overview of the early changes occurring in the first 24h, however 
it did not include assessment after 24h, e.g. a 72h time point may have been particularly 
useful for the glutamate transporter. Moreover, the study did not include histological analyses 
of brain injury, data on survival or behavioural assessments. The study focused on two of the 
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most vulnerable brain regions (cortex and the hippocampus), however potentially important 
gene expression changes in other regions vulnerable to injury (e.g. thalamus) were not 
evaluated. Gene expression was not quantified in the right hemisphere although differences in 
gene expression may occur between hemispheres even in naïve rats. Gene expression analysis 
was limited to quantification of mRNA (and DNA methylation) and did not include protein 
assays. The study did not evaluate cellular sources and targets of the genes assessed. 
Expression of four inflammatory and glutamatergic genes was assessed in this candidate gene 
exploratory study, however many other genes, some of which unsuspected, are likely to be 
involved in HI injury.
3.6 Conclusion
While brain injury and survival could not be directly measured in this pilot study, validity of 
the model was supported by evidence of early changes (within 24h) in Gfap in both cortex 
and hippocampus and Mbp in the cortex, signalling onset of astrogliosis and myelin injury. 
No changes in neuronal marker Map2 were detected in either region, however it is not known 
whether protein was lost post-transcriptionally or if other neuronal markers were altered in 
the 24h post-HI. Another marker of neuronal injury (e.g. NeuN) should be assessed in future 
work, alongside markers of microglial activation (e.g. Iba1, Cox2) and apoptosis (e.g. 
Casp3).
The main finding of this study was that an acute HI insult causes an early inflammatory 
response in two of the most vulnerable brain regions in newborns with HIE. Specifically, 
transcription of three key pro-inflammatory cytokines (Tnfα, Il1β, Il6) was upregulated in the 
ipsilateral cortex and hippocampus, with a trend for early upregulation at 6h post-HI. All 
three cytokines were positively correlated across brain regions and to each other within each 
brain region, suggesting a synergistic co-regulation within the inflammatory response. The 
findings align with previous evidence of an early inflammatory response induced by acute HI 
(516).
There was no significant evidence of transcriptional changes in Glt1 in either region, 
although there was a non-significant trend for differences between sham and HI. In secondary 
analyses, there was suggestive evidence of suppression in the HI cortex compared to a control 
group merging naïve and sham rats. Should this be a true biological effect, it is not known 
whether isoflurane upregulated Glt1, HI suppressed it or both. To assess this, a follow-up 
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study should be set up with larger sample size and ideally assessing Glt1 regulation in 
isolated astrocytes.
4 Promoter DNA methylation at the glutamate transporter in a 
rat model of hypoxic-ischemic brain injury at term
4.1 Introduction
In the next part of the study, DNA methylation was assessed as an epigenetic mechanism 
potentially mediating the observed transcriptional changes. Importantly, it is worthwhile 
measuring DNA methylation changes even in the absence of obvious transcriptional changes 
since they could precede latent effects which may have been measurable after 24h. Due to 
funding and time limitations, DNA methylation analysis focused on the cortex and blood, and 
on Glt1 and Tnfα in terms of candidate genes, based on previous evidence of mutual 
interaction (see 1.5.3.3). Unfortunately, DNA methylation analyses could not be carried out 
for Tnfα due to COVID-19-related disruptions at the end of the PhD. 
DNA methylation of candidate promoter regions can be explored by bisulfite conversion of 
DNA followed by pyrosequencing. This technique allows accurate sequencing of short 
sequences (e.g. up to 60-80 bp), posing the requirement for careful selection of candidate 
regions. Three regions were selected for Glt1 based on published evidence: a region within 
the classic CpG island near the transcription start site (TSS), a proximal region, and a distal 
shore region outside the CpG island (Figure 4.1).
The rat Glt1 promoter has a classic CpG island in the 5’ UTR spanning approximately 560 bp 
upstream of the transcription start site (TSS) (1 in Figure 4.1) (1207-1209). Within the CpG 
island, a region was chosen that is homologous to the region overlapping the two EAAT2 -
200 (C>A) and -181 (A>C) SNPs associated with adverse neurodevelopmental outcomes in 
humans (911). Neither SNP corresponds to a CpG site in humans, however SNPs can still 
affect methylation by altering binding of chromatin remodelling proteins (931, 932). For -
200, the major allele is C in both humans and rats; for -181, the major allele is A in humans 
and C in rats, where it is also a CpG site, as identified from aligning the human and rat 
genomes with the Ensembl tool (human genome assembly GRCh37 with ENCODE 
annotations on DNA methylation, rat genome assembly Rrnor_5.0) (1291). Generally 
speaking, genetic variation cannot be extensively studied in inbred lab animals with limited 
genetic variability. However, it is still of interest to assess whether this region becomes 
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differentially methylated in rats following HI, since it can be hypothesised that these changes 
may interact with genetic influences and modify risk of injury in newborns. 
The second candidate region is a proximal promoter region approximately 1350 bp upstream 
of the TSS (2 in Figure 4.1). This region contains one of the CpG sites (cg21163960) 
identified as differentially methylated in a hypothesis-free epigenome-wide association study 
(EWAS) comparing methylation in saliva of very preterm and healthy term newborns (1292). 
Multiple CpG sites in this region were hypomethylated in preterm newborns, however 
pyrosequencing imposes a limit on sequence length and the region overlapping this particular 
CpG site was chosen because it is conserved in rats. 
The third candidate region is a distal shore approximately 1950 bp upstream of the TSS (3 in 
Figure 4.1). This sequence is upstream of the promoter CpG island, in a genomic region with 
lower GC content. It is more responsive to epigenetic changes including DNA methylation, 
responsivity which confers this region enhancer activity in reporter gene assays (1207). 
Differences in shore methylation in astrocytes of the cortex and cerebellum correlate with 
regional differences in baseline expression and in response to drugs (1207, 1208). 
Figure 4.1. Diagram of the candidate promoter regions in Glt1 chosen for DNA 
methylation analysis by bisulfite conversion followed by pyrosequencing
A region in the promoter of the Peg3 gene was also included as an internal control for the 
bisulfite conversion and pyrosequencing methodology. Peg3 is an imprinted gene encoding a 
zinc finger protein, with DNA methylation permanently silencing the maternal allele, 
resulting in expression of the paternal allele only (1293, 1294). As such, Peg3 is expected to 
be ~40-60% methylated (0% on one chromosome and 100% on the other chromosome in all 
cells), and positive evidence of this would indicate the ability to effectively measure 
methylation within each batch of bisulfite converted DNA (bcDNA). 
216
4.2 Hypothesis
The hypotheses of this pilot study are that: 
1) acute hypoxia-ischaemia causes changes in mRNA transcription of the main glutamate 
transporter (Glt1) and three key pro-inflammatory cytokines (Tnfα, Il1β, Il6) in the term-
equivalent rat brain within the first 24 hours (chapter 3)
2) any observed or latent transcriptional changes in Glt1 and Tnfα in the brain are at least in 
part mediated by DNA methylation changes in the respective gene promoters (this chapter) 
3) DNA methylation of Glt1 and Tnfα in the brain correlates with DNA methylation in blood, 
which may be a clinically useful peripheral biomarker of injury (this chapter)
4.3 Materials and methods
4.3.1 Study design
See chapter 3.
4.3.2 Rice Vannucci rat model of moderate hypoxic-ischemic brain injury at term
See chapter 3
4.3.3 Downstream molecular analyses
Briefly, genomic DNA and mRNA were simultaneously extracted from the ipsilateral 
cortices and hippocampi (protocol 1). Brain DNA was further cleaned (protocol 5) using the 
same column kit for blood DNA extraction and clean-up (protocol 6). DNA from both brain 
and blood was subjected to bisulfite conversion (protocol 7), which chemically alters DNA 
allowing differentiation between methylated and unmethylated cytosines at CpG islands. The 
candidate promoter regions in the bisulfite converted DNA (bcDNA) were then amplified and 
tagged with biotin via a two-step PCR (protocol 8). Presence of bcDNA both before and after 
amplification was checked by gel electrophoresis (protocol 9). Biotin-tagged strands were 
then isolated by binding to streptavidin beads and underwent pyrosequencing (protocol 10), 
which allows real time sequencing by synthesis. The pyrosequencing output is a percentage 
of DNA methylation at each CpG site, i.e. the percentage of methylated cytosines at the CpG 
site in all cells in the sample. An average DNA methylation value was then obtained from all 
CpG sites within each promoter region and compared across experimental groups and time 
points.
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4.3.3.1 DNA extraction and clean-up
4.3.3.1.1 Protocol 1: simultaneous DNA/RNA extraction from brain with TRIzol
4.3.3.1.1.1 Precipitation and separation of RNA and DNA
 Transfer samples from -80°C storage to wet ice
 Transfer tissue to FastPrep matrix tubes with lysing beads (MPBio, Matrix D for animal 
tissues) 
 Add 1 ml TRIzol (Invitrogen) per 50-100 mg sample
 Homogenise using FastPrep FP120 homogeniser (Thermo) (3 cycles at 5 m/sec for 15 
sec)
 Incubate at room temperature (RT) for 5 min
 Add 0.2 ml chloroform per 1 ml Trizol and shake by inversion for 15 sec
 Incubate at RT for 2-3 min
 Centrifuge at <4000 rpm, 4°C for 15 min with hinge facing outward relative to the rotor
 Transfer the colourless upper aqueous phase (containing mRNA) to a fresh tube 
 Store remaining sample (interphase containing DNA and organic pink phase containing 
proteins) at 4°C until DNA extraction
4.3.3.1.1.2 Washing and resuspending of RNA
See Chapter 3
4.3.3.1.1.3 Washing and resuspending of DNA
Refer to Invitrogen, TRIzol Reagent – Experimental Protocol for DNA Isolation
 Remove any remaining aqueous phase overlying the interphase (critical for DNA quality)
 Add 0.3 ml 100% ethanol per 1 ml Trizol and mix by gently inverting several times
 Incubate at RT for 3 min
 Transfer from matrix tubes to fresh 1.5 ml tubes
 Centrifuge at 2000 x g (4300 rpm) for 5 min to pellet the DNA
 Transfer the phenol-ethanol supernatant (containing proteins) to a fresh tube and store at -
80°C
 Precipitation in 0.1 M sodium citrate in 10% ethanol (repeat this step at least twice, or 
three times for large pellets > 200 µg)
o Resuspend the pellet in 1 ml of 0.1 M sodium citrate in 10% ethanol (pH 8.5) per 
1 ml Trizol and mix by pipetting up and down
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o Incubate on a tube roller for 30 min (DNA can be stored in sodium citrate for at 
least 2 hours)
o Centrifuge at 2000 x g (4300 rpm) for 5 min
o Discard the supernatant
 Resuspend the pellet in 1.5 ml 75% ethanol per 1 ml Trizol
 Incubate on a tube roller for 10-20 min (DNA can be stored in 75% ethanol for several 
months at 4°C)
 Centrifuge at 2000 xg (4300 rpm) for 5 min
 Discard the supernatant
 Air dry the DNA pellet (can invert with lid open on blotting paper)
 Resuspend the pellet in 0.3 ml of 8 mM NaOH and mix by pipetting up and down
 Centrifuge at 12,000 xg (10,600 rpm) for 10 min to remove insoluble materials
 Transfer supernatant to a new tube
 Quantify and check purity of DNA on Nanodrop (Nanodrop 8000, Thermo Fisher 
Scientific) (average at least 2 measurements, NaOH as blanking buffer)
 Store at -20°C 
 Proceed with DNeasy column clean-up (protocol 5)
4.3.3.1.2 Protocol 5: clean-up of brain DNA
 DNeasy Blood & Tissue kit column clean-up (Qiagen) (as per manufacturer instructions 
except for final elution volume)
o Add 200 µl Buffer AL, mix by vortexing
o Add 200 µl 100% ethanol, mix by vortexing
o Transfer sample in a spin column (supplied)
o Centrifuge at 6,000 xg (8,000 rpm) for 1 min
o Discard flow-through and place column in a new collection tube (supplied)
o Add 500 µl Buffer AW1
o Centrifuge at 6,000 xg (8,000 rpm) for 1 min
o Discard flow-through and place column in a new collection tube (supplied)
o Add 500 µl Buffer AW2
o Centrifuge at 20,000 xg (14,000 rpm) for 3 min
o Discard flow-through very carefully to avoid ethanol carryover and place column 
in a new collection tube with lid cut (not supplied, prepare 2 sets)
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o Elute in 100 µl Buffer AE in two steps (lower than 200 µl in single elution step as 
per manufacturer instructions)
 Add 50 µl Buffer AE directly on the membrane
 Incubate at RT for 2 min
 Centrifuge at 6,000 xg (8,000 rpm) for 1 min and repeat step
o Check DNA purity on Nanodrop (Nanodrop 8000, Thermo Fisher Scientific) and 
measure DNA concentration on Qubit (Thermo Fisher Scientific) using the Qubit 
Broad Range dsDNA kit 
o Proceed with bisulfite conversion (protocol 7)
4.3.3.1.3 Protocol 6: extraction and clean-up of blood DNA
 DNeasy Blood & Tissue kit column clean-up (Qiagen) (as per manufacturer instructions 
except for final elution volume)
o Add 20 µl proteinase K to a 1.5 ml tube
o Vortex defrosted anticoagulated blood briefly to mix plasma and cellular 
component
o Add 50 µl blood 
o Adjust volume to 220 µl with phosphate-buffered saline (add 170 µl)
o Add 200 µl Buffer AL, mix briefly by vortexing
o Incubate at 56°C for 10 min
o Continue with protocol 5 from step 2 (i.e. add 200 µl 100% ethanol)
4.3.3.2 Bisulfite conversion of genomic DNA from brain and blood
Bisulfite conversion requires a relatively precise input DNA concentration of 200-500 ng 
DNA. Precise measurements of DNA concentration required for downstream methylation 
analyses were obtained with the Qubit Fluorometer (Thermo Fisher Scientific) using the 
Qubit Broad Range dsDNA kit. DNA purity was checked with the Nanodrop (Nanodrop 
8000, Thermo Fisher Scientific). Cleaned DNA from both brain and blood was bisulfite-
converted (bcDNA) using the EZ DNA Methylation-Gold kit (Zymo Research). Bisulfite 
conversion chemically alters DNA and allows differentiation between methylated cytosines 
(protected) and unmethylated cytosines (converted to uracil). Presence of bcDNA was 
verified by agarose gel electrophoresis (protocol 8)
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4.3.3.2.1 Protocol 7: bisulfite conversion of genomic DNA
 Measure DNA concentration on Qubit using the Qubit Broad Range dsDNA kit (Thermo 
Fisher Scientific)
 Prepare 500 ng DNA in 20 µl nuclease-free water (optimal DNA input required for EZ 
DNA Methylation-Gold kit, Zymo Research) and follow manufacturer instructions
o Add 130 µl CT Conversion Reagent to 20 µl DNA, mix by pipetting up and down 
and spin down




4°C For optional storage up to 20 hours
 Check presence of bcDNA by gel electrophoresis (protocol 8)
 Amplify bcDNA immediately if possible, store remaining bcDNA at -20°C
4.3.3.2.2 Protocol 8: checking presence of bcDNA before and after PCR amplification 
by gel electrophoresis
 Prepare a 1% agarose gel in 0.5X TE Buffer (e.g. 2 g in 200 ml TE Buffer) with either 
ethidium bromide or GelRed (Biotium) (5 µl/100 ml gel) and leave at RT to set until 
opaque
 Mix 2 µl samples with 0.5 µl loading dye (Bioline)
 Place the gel cast in the electrophoresis tank and submerge with 0.5X TE Buffer
 Load a DNA sample into each well and at least one well per row with a 100 bp DNA 
ladder (Bioline)
 Run at 120 V for at least 1 hour or until DNA ladder bands of interest are sufficiently 
separated to allow for size determination
 Visualise on a UV transilluminator 
o For bcDNA before amplification: chill gel on ice for a few minutes before 
visualisation (as per manufacturer instructions); presence of bcDNA is confirmed 
by the presence of a smear of fragments with a range of lengths (100-1,500 bp)
o For bcDNA after amplification: strong and sharp DNA bands of expected size and 
minimal primer-dimer 
 Proceed to PCR amplification of bcDNA (protocol 9)
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4.3.3.3 PCR amplification and biotin-tagging of bcDNA from brain and blood
Typically, one of the primers used in PCR amplification (e.g. reverse primer) is tagged with 
biotin, which subsequently binds to streptavidin beads allowing isolation of the target DNA 
strands for pyrosequencing. Biotinylated primers are expensive. Moreover, the volume of 
source bcDNA is limited (10 µl as per bisulfite conversion protocol) and a single PCR may in 
turn offer a limited volume of amplified products, which may result in running out of source 
bcDNA if samples fail and need repeating. To avoid purchasing five biotin-tagged primers 
(i.e. one for each candidate promoter region in Glt1, one for Tnf and one for Peg3) and to 
produce larger volumes of amplified PCR products available for analysis, PCR amplification 
was divided in two steps. 
In the first step, the reverse primer for each region was designed to include an established 
common recognition sequence upstream of the primer sequence (Dr Kira Rienecker, personal 
communication), which is incorporated during amplification (Figure 4.2) (1295). In the 
second PCR, a biotinylated version of the common primer is used instead of the reverse 
primer, therefore allowing biotin tagging of the strand complementary to the target strand, 
which is further amplified. Three technical replicates were run for each sample in the second 
PCR. The target strand is subsequently synthesised and sequenced in real time during 
pyrosequencing. Alignment with the reference sequence reveals which cytosines have been 
protected (unmethylated) and which have been converted to uracils (unmethylated).
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Primers for both PCR amplification and pyrosequencing were designed using the Pyromark 
Assay Design 2.0 software (Qiagen). Sequences of PCR primers, pyrosequencing primers and 
common primer are reported in Table 4.1. Whenever possible, primers were designed to 
avoid overlapping CpG sites, since this can lead to preferential amplification of methylated or 
unmethylated DNA. Whenever this was not possible due to the nature of the sequence, a mix 
of primers containing all four bases (A+G+C+T=N) at the CpG site was used (in red in Table 
4.1), since this method has been previously shown to produce the least bias at similar melting 
temperatures (1296). The Pyromark Assay Design software outputs a quality score for each 
assay based on a range of in silico quality control analyses, with quality scores below 70 
generally not recommended. Due to the nature of the Glt1 promoter sequence, it was not 
possible to generate assays with a quality score above 70.
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Studies of the Peg3 differentially methylated region (DMR) (i.e. between maternal and 
paternal alleles) in the rat genome are scarce. In the mouse genome, the DMR has been 
studied more extensively, is approximately 4 kb long and spans the first exons of both Peg3 
and Usp29, another imprinted gene in the Peg3 imprinted domain (1297). The DMR of 
mouse and rat were aligned using the Ensembl genome browser (Ensembl release 101, 
(1291), GRCm38.p6 mouse genome assembly, Rnor_06 rat genome assembly). Alignment 
revealed similar though not identical genomic structure. The gene is located on chromosome 
7 in the mouse and chromosome 1 in the rat. The order of the genes in the Peg3 domain is the 
same, with opposite orientation. However, the first exon of Peg3 is over 200 kb from Usp29 
in the rat, making the boundaries of the target region in the DMR unclear. A published study 
previously identified a small discrete region in the mouse Peg3 DMR including 5 CpG sites 
and assessed it via bisulfite conversion and pyrosequencing (1298). BLASTing this sequence 
against the rat genome revealed that this region is approximately 12 kb upstream of the TSS 
and is conserved in the rat. Primers were designed to target this region. 
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Table 4.1. DNA methylation primers
These include forward (F) and reverse (R) PCR primers, and pyrosequencing (S) 
primer. Whenever it was not possible to avoid a CpG site, degenerate primers 
containing all four bases (N, in red) at the site were used. The common primer sequence 
is shown in blue. The quality score was automatically assigned by the Pyromark Assay 
Design 2.0 software
Primer Sequence PCR#2 Product 
Size
Score




















272 + 24 = 296
glt1_isl_S GGGGTTAAATTTTGTAATTTTT 
63




204 + 24 = 228









4.3.3.3.2 Protocol 9: two-step PCR amplification
All PCR assays were individually optimised prior to the experiment, and an annealing 
temperature of 57°C was found to be appropriate for all assays. The steps for the two PCRs 
are identical except for: 
1) The template was bcDNA in PCR#1, and a 1:6 dilution of PCR#1 products in PCR#2 
2) The gene/region-specific reverse primer was replaced with the biotinylated common 
primer in PCR#2 
3) Volumes were doubled in PCR#2 
4) Three technical replicates per sample were run in PCR#2
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 PCR#1
o Prepare master mix 
PCR Reagents Volume for one reaction Working Concentration
Water 6.175 µl
Buffer 1 µl 10X
dNTPs 0.8 µl 2 mM
F primer 0.3 µl 10 µM
R primer 0.3 µl 10 µM
HotStart Taq Polymerase 0.125 µl 5 U/µl
o Add 1 µl bcDNA sample or no-template control (NTC) to 9 µl master mix 
o Load on a thermal cycler (BioRad) with the following steps:
PCR Cycle Step Temperature Time No. Cycles
Taq Heat Activation 95°C 15 min
Denaturation 95°C 30 sec
Annealing 57°C 60 sec
Extension 72°C 40 sec
X 25
Final Extension 72°C 10 min
Hold 4°C Indefinitely
o Check amplification by gel electrophoresis (protocol 8)
 PCR#2
o Prepare master mix 
PCR Reagents Volume for one reaction Working Concentration
Water 12.35 µl
Buffer 3.6 µl 10X
dNTPs 1.6 µl 2 mM
F primer (same as PCR#1) 0.6 µl 10 µM
R primer (biotinylated common primer) 0.9 µl 10 µM
HotStart Taq Polymerase 0.25 µl 5 U/µl
o Add 1 µl of 1:6 dilution of PCR#1 product or no-template control (NTC) to 9 µl 
master mix 
o Load on a thermal cycler (BioRad) with the same steps as PCR#1
o Check amplification by gel electrophoresis (protocol 8)
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4.3.3.4 Pyrosequencing
Samples (PCR#2 products) were mixed with streptavidin beads to allow selective binding of 
the biotinylated DNA strands. These were subsequently transferred to a pyrosequencing plate 
containing the sequencing primer. Pyrosequencing was carried out with the Pyromark Q96 
system (Qiagen). During the automated pyrosequencing process, the sample is flushed with a 
pre-specified sequence of deoxyribonucleoside triphosphates (dNTPs); if the dNTP is 
complementary to the template strand, it is added by DNA polymerase (Figure 4.3). Every 
time a dNTP is incorporated, pyrophosphate (PPi) is released in a quantity that is equimolar 
to the number of incorporated nucleotides, i.e. twice as much pyrophosphate if the sequence 
includes two of the same dNTPs in a row. The enzyme sulfurylase converts pyrophosphates 
to ATP, while the enzyme apyrase degrades any unincorporated nucleotides. The enzyme 
luciferase converts ATP to a light signal, which is recorded by a camera in the Pyromark Q96 
and reported as a peak on a pyrogram. Peaks of different colours and lengths depending on 
the type and number of consecutive dNTPs allow to infer the target sequence. 
Figure 4.3. Pyrosequencing cascade as illustrated on the Pyromark Gold Q96 Reagents 
handbook (1299)
Prior to the experiment, all pyrosequencing assays were validated by running spare samples 
with various controls to rule out unwanted background signals, i.e. PCR reagents without 
template (duplexes between PCR primers), all pyrosequencing reagents minus the sequencing 
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primer (duplexes between PCR products), all pyrosequencing reagents minus the template 
and sequencing primer (duplexes or hairpins in the sequencing primer), all pyrosequencing 
reagents minus the template (duplexes between the sequencing and biotinylated reverse 
primer).
4.3.3.4.1 Protocol 10: Pyrosequencing
 Create an assay file for each target sequence by inputting information from the Pyromark 
Assay Design 2.0 software into the Pyromark Q96 software. This file allows the 
Pyromark Q96 software to calculate the appropriate volumes of enzyme, substrate, and 
nucleotides to load on the Pyromark Q96 cartridge (code 0016, Qiagen) depending on the 
number of samples on the 96-well pyrosequencing plate (Qiagen)
 Prepare Pyromark Gold reagents as per manufacturer instructions, i.e. add 620 ul water to 
both enzyme and substrate, swirl gently and leave at RT for 5-10 min; Pyromark Gold 
dNTPs are ready for use
 Prepare the streptavidin beads master mix (keep vortexing/inverting regularly to prevent 
the beads from settling at the bottom of the tube)
Streptavidin Beads Master Mix Reagents Volume for one reaction
Streptavidin Beads 1.5 µl
Pyromark Binding Buffer 40 µl
Water 18.5 µl
 Add 60 µl streptavidin beads master mix and 2 µl water to each sample (~18 µl after gel 
electrophoresis) in the 96-well PCR plate (final volume 80 µl)
 Agitate PCR plate on a plate shaker at 1400 rpm for 5-10 min to ensure binding of 
biotinylated primers to streptavidin beads
 Prepare 0.4 uM sequencing primer master mix 
0.4 uM Sequencing Primer Master Mix Reagents Volume for one reaction
Pyromark Annealing Buffer 38.4 µl
Sequencing Primer (10 uM Stock) 1.6 µl
 Add 40 µl to each well of a pyrosequencing plate (same layout as PCR#2 plate with three 
technical replicates)
 Set up Pyromark Vacuum Station according to manufacturer instructions, by placing the 
PCR plate, pyrosequencing plate and reservoirs in the specified orientation, and filling up 
the reservoirs with 70% ethanol, Pyromark Denaturation Buffer, Pyromark Wash Buffer, 
and nuclease-free water 
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 Use the Pyromark vacuum tool to transfer the beads from the PCR plate to the 
pyrosequencing plate with the sequencing primer
o With vacuum tool in parked position, switch ON vacuum machine and vacuum 
switch and flush all water in the reservoir 
o With vacuum ON, insert tool carefully into PCR plate wells to draw the beads to 
the filter probes of the vacuum tool, holding for 15 seconds and minimising any 
contact between the probes and the walls of the well 
o With vacuum ON, transfer the vacuum tool in the various stations in sequence:
 Ethanol for 5 sec 
 Denaturation Buffer for 5 sec
 Wash Buffer for 10 sec
 Turn the tool facing up past 90°C angle and hold for 5 sec to dry
 Align and hover over the pyrosequencing plate, turn vacuum machine off, 
remove hose, lower vacuum tool into the plate and agitate/tap for 15 
seconds
 Place the pyrosequencing plate on a pyrosequencing thermoplate (Qiagen), cover loosely 
(e.g. with a PCR plate seal) to avoid evaporation and place on a heat block at 80°C for 2 
minutes to allow annealing of the sequencing primer to the single strands of DNA; leave 
to cool at RT
 Load required volumes of Pyromark Gold reagents (enzyme, substrate, and dNTPs) on 
the Pyromark cartridge, load plate on the Pyromark Q96 and run pyrosequencing 
 Repeat samples identified by the software as low quality and colour-coded in red; 
manually inspect samples colour-coded in yellow and repeat if appropriate; include 
samples colour-coded in blue in the analysis
 For each CpG site, the Pyromark Q96 output is the percentage of methylated cytosines in 
the population of cells in the sample. For example, a CpG site that is 50% methylated 
followed by a non-CpG T will give a peak of 50% for C and 150% for T
4.3.4 Statistical analysis
The exposures in this study were experimental group (naïve, sham, hypoxia-ischaemia) and 
time (6h, 12h, 24h), while the outcome was the percentage DNA methylation at each of the 
promoter regions (three for Glt1 and one for Peg3) investigated in both left cortex and blood. 
The percentage methylation at each region was calculated by averaging methylation at 
multiple CpG sites included in each region. This is based on previous evidence that in 
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promoters there is strong correlation between neighbouring CpG within 1-2 kb regions in the 
same cell types, and measurements of DNA methylation tend to not be independent (1300-
1304). Differentially methylated regions composed of correlated CpG sites exist in the 
context of different tissues, developmental stages, disease and ageing (1305). Reducing data 
to regions can therefore increase power and reduce noise (1306). Single CpG sites were still 
examined in detail both graphically with scatterplots of raw DNA methylation data and at 
secondary analyses stage in case of significant findings at the region level. The number of 
CpG sites in each promoter region varies throughout the study, since it depends on the 
characteristics of each DNA sequence (CpG density and distance between sites) and on the 
limit in sequence length that can be studied by pyrosequencing (up to 60-80 bp).  
The percentage methylation at each CpG site is derived from all cells in the sample. While on 
a single DNA sequence on a single chromosome, methylation at a CpG site is binary (either 
0% or 100% methylated), each cell has two chromosomes, so that the same CpG site in a 
single cell can be 0%, 50% or 100% methylated. Each sample in this study is a section of 
bulk brain tissue or a specified volume of blood, containing DNA sequences from many 
thousands of cells, including different cell types with variable methylation status. Therefore, 
the percentage methylation at each CpG site in a sample will be a snapshot of methylation in 
all the cells in the sample, i.e. the meta-epigenome. As bisulfite conversion is not error-free, 
slightly looser thresholds were set arbitrarily to indicate methylation states: 0-10% range was 
considered as unmethylated, a 90-100% range was considered as fully methylated, whereas a 
10-90% range was considered as indicative of partial methylation. Thus, partial methylation 
may be due to methylation differences between the two chromosomes of a single cell, 
between cells of the same type, and between different types of cells. 
Firstly, the percentage methylation at each CpG site in each candidate region was plotted to 
graphically assess whether averaging to obtain a single methylation value per region was 
appropriate. The methylation across all CpG sites within each region was then averaged to 
obtain a single methylation value per region for each rat, which was used in the statistical 
analyses. A two-way 3 x 3 factorial ANOVA was run separately on 42 left cortices and 
related blood samples to compare the main effects and interaction of experimental group 
(naïve, sham, hypoxia-ischaemia) and time (6h, 12h, 24h) on percentage DNA methylation at 
each candidate region. The Scheffe’s test was used for post hoc analyses to identify which 
pairs of means were significantly different, since, although it affords less power than the 
Tukey’s and Fisher’s tests, it allows to compare all possible pairs of three means. Effect sizes 
231
were expressed in terms of population (ω2, omega squared) rather than sample (η2, eta 
squared) effect sizes, as, though always smaller, they have been found to be carry less 
sampling error bias in unbalanced designs with multiple groups (1213). 
Secondary analyses of suggestive value included:
 A 2 x 3 ANOVA collapsing naïve (n=3 per timepoint) and sham (n=3 per timepoint) into 
a single control group (n=6 per time point) to increase power, as long as no differences 
were found between naïve and sham. These analyses were carried out in the cortex and 
followed up in blood depending on the findings in the cortex
 A 3 x 3 ANOVA repeated for each individual CpG site in the region, whenever primary 
analyses yielded significant findings; this allowed to ascertain whether differences were 
driven by specific CpG sites within the region or the region as a whole
Uncorrected p-values are reported. A Benjamini Hochberg False Discovery Rate was applied 
for significant findings with a false discovery rate of 5% (1214). 
All statistical analyses and plots were carried out using Stata 14 (Stata Corp, TX, USA).
4.4 Results
4.4.1 Peg3
Methylation at the 5 CpG sites in the Peg3 promoter was between 45% and 51%, with very 
little variability and SD no larger than 3% (Table 4.2, Figure 4.4). When methylation was 
averaged across all 5 CpG sites, the mean percentage methylation across the Peg3 promoter 
was ~50% in both cortex and blood. 
Table 4.2. Peg3 – Percentage DNA methylation at individual CpG sites
Peg3: CpG Site n Cortex Blood
Mean % DNAm SD Mean % DNAm SD
1 42 48.13 1.52 46.78 1.90
2 42 46.95 1.50 45.10 1.72
3 42 49.43 1.57 48.03 2.29
4 42 50.75 2.03 50.95 2.91
5 42 51.10 1.37 50.83 1.85
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Figure 4.4. Peg3 – Percentage DNA methylation at individual CpG sites
4.4.2 Glutamate transporter
4.4.2.1 CpG island
The CpG island was largely unmethylated across all 7 CpG sites, with mean methylation for 
each CpG site below 3% in the cortex and below 6% in blood. Variability was higher in 
blood but still in the low range, with standard deviations no larger than 4% (Table 4.3, Figure 
4.5). Of note, CpG 7 coincides with the -181 SNP in humans, and is a CpG site only in rats. 
Table 4.3. Glt1 (CpG island) – Percentage DNA methylation at individual CpG sites
Glt1 (CpG island): CpG Site n Cortex Blood
Mean % DNAm SD Mean % DNAm SD
1 42 0.22 0.42 4.15 3.67
2 42 1.78 1.38 3.79 2.67
3 42 0.25 0.50 0.94 1.71
4 42 0.08 0.28 0.67 1.24
5 42 0.72 2.17 2.06 2.32
6 42 2.75 1.38 5.33 3.41
7 (EAAT2 -181) 42 0.36 0.68 2.58 2.97
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Figure 4.5. Glt1 (CpG island) – Percentage DNA methylation at individual CpG sites
234
When methylation was averaged across all 7 CpG sites (i.e. one methylation value across the 
entire region for each rat), the Glt1 CpG island region resulted unmethylated (< 5%) in both 
cortex and blood across all groups and time points (Table 4.4, Figure 4.6). There were no 
significant differences in percentage methylation at the CpG island between groups and time 
points in primary or secondary analyses (Table 4.5, Table 4.6). 
Table 4.4. Glt1 (CpG island): descriptive statistics
N: naïve; S: sham; HI: hypoxia-ischaemia; DNAm: DNA methylation; SD: standard 
deviation
Group Time n Glt1 – CpG island
Cortex Blood
Mean % DNAm SD Mean % DNAm SD
6 3 0.64 0.51 2.21 0.91
12 3 0.57 0.49 4.28 0.66N
24 3 1.00 0.49 3.21 0.10
6 3 1.21 1.52 3.29 0.40
12 3 0.81 0.58 3.48 0.70S
24 3 0.95 0.30 1.95 1.57
6 8 0.73 0.38 2.29 0.88
12 8 0.83 0.51 2.45 1.26HI
24 8 1.19 0.37 3.04 1.32
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Figure 4.6. Glt1 (CpG island) DNA methylation: plots
Table 4.5. Glt1 (CpG island): primary analyses
Gene Tissue Variable Levene’s 
p
df MS F p Effect Size 
(omega2)
Group (N vs S vs 
HI)
2 0.14 0.50 0.611 0 (-0.03)




4 0.12 0.46 0.767 0 (-0.07)
Group (N vs S vs 
HI)
2 1.15 1.05 0.367 0.003






4 2.14 1.96 0.133 0.12
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Table 4.6. Glt1 (CpG island): secondary analyses





df MS F p Effect 
size
Group
1 0.25 0.57 0.468 0 (-
0.04)
Time





2 0.12 0.26 0.773 0 (-
0.13)
Group
1 0.02 0.10 0.759 0 (-
0.03)








2 0.13 0.51 0.603 0 (-
0.03)
4.4.2.2 Proximal promoter
The proximal promoter was largely unmethylated across all 3 CpG sites in the cortex, with 
mean methylation for each CpG site below 6% and standard deviations no larger than 2%. 
Methylation in blood was higher but still in the low range, with mean percentage methylation 
for each CpG site below 18% and standard deviations no larger than 4% (Table 4.7, Figure 
4.7). Of note, CpG 3 coincides with a CpG site (cg21163960) that is differentially methylated 
in the saliva of very preterm newborns vs healthy term newborns in an EWAS (1292). 
Table 4.7. Glt1 (proximal promoter) – Percentage DNA methylation at individual CpG 
sites
Glt1 (proximal promoter): CpG Site n Cortex Blood
Mean % DNAm SD Mean % DNAm SD
1 42 5.52 1.09 13.74 2.57
2 42 4.95 1.27 11.52 2.92
3 (Differentially Methylated in (1292)) 42 2.29 1.53 17.90 3.11
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Figure 4.7. Glt1 (proximal promoter) – Percentage DNA methylation at individual CpG 
sites
When methylation was averaged across all 3 CpG sites, the Glt1 proximal promoter resulted 
unmethylated in the cortex (<5%) and hypomethylated in blood (<20%) across all groups and 
time points (Table 4.8, Figure 4.8). 
Table 4.8. Glt1 (proximal promoter): descriptive statistics
N: naïve; S: sham; HI: hypoxia-ischaemia; DNAm: DNA methylation; SD: standard 
deviation
Group Time n Glt1 – proximal promoter
Cortex Blood
Mean % DNAm SD Mean % DNAm SD
6 3 4.67 0.58 12.67 1.86
12 3 4.22 0.51 14.78 1.35N
24 3 5.11 1.39 13.11 2.04
6 3 2.56 2.27 12.56 1.84
12 3 4.11 0.51 16.78 1.07S
24 3 4.67 0.33 12.67 1.45
6 8 4.00 0.87 15.33 1.30
12 8 4.25 1.09 14.71 1.43HI
24 8 4.58 0.87 14.54 1.56
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Figure 4.8. Glt1 (proximal promoter) DNA methylation: plots
In the cortex, there was very weak evidence of a time effect that was independent of group 
(p=0.065), with post hoc analysis suggesting the difference may be between 6h and 24h 
(p=0.098) (Table 4.9). However, the difference in methylation was less than 1%. Therefore, 
similar to the CpG island, the proximal promoter was largely unmethylated across groups and 
time points.
In blood but not brain, there was a significant interaction between group and time on 
percentage methylation (p=0.018). Simple main effect analysis suggested that there were 
significant differences by group at 6h (p=0.004), with post hoc analysis suggesting that HI 
rats had higher methylation than both naïve and sham rats at 6h. The difference in means was 
less than 3% in both cases, with methylation therefore remaining in the low range. Any 
evidence of differences between groups disappeared at 12h (p=0.11) and 24h (p=0.12). 
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Table 4.9. Glt1 (proximal promoter): primary analyses
Gene Tissue Variable Levene’s 
p








Group (N vs 
S vs HI)
2 1.79 1.69 0.201 0.04
Time 2 3.13 2.94 0.067 0.10 6h may be 
≠ 24h 
(p=0.098)







4 1.07 1.01 0.419 0.001
Group (N vs 
S vs HI)
2 6.77 2.97 0.065 0.10


















At 6h, HI – 
N = 2.67% 
(-1.66-
6.99%)
At 6h, HI – 




In the secondary analyses collapsing naïve and sham groups, there was no significant 
evidence of differences in DNA methylation at the Glt1 proximal promoter in the cortex 
(Table 4.10). 
Table 4.10. Glt1 (proximal promoter): secondary analyses





df MS F p Effect 
size
Group 1 3.56 2.65 0.129 0.11
Time 2 2.46 1.84 0.201 0.10N vs S
Group*Time
0.01
2 1.72 1.29 0.312 0.04
Group
1 0.03 0.03 0.870 0 (-
0.03)








2 0.42 0.36 0.703
240
4.4.2.3 Distal shore
The distal promoter of Glt1 was hypomethylated at both CpG sites in the cortex, with mean 
percentage methylation for each CpG site around 15% and standard deviations no larger than 
4%. Methylation in blood was higher and in the mid-range, with a mean of 57% for one CpG 
site and 42% for the other CpG site, and standard deviations no larger than 6% (Table 4.11, 
Figure 4.9). 
Table 4.11. Glt1 (distal shore) – Percentage DNA methylation at individual CpG sites
Glt1 (distal promoter): CpG Site n Cortex Blood
Mean % DNAm SD Mean % DNAm SD
1 42 15.26 3.44 57.40 5.23
2 42 15.43 3.82 42.14 4.21
Figure 4.9. Glt1 (distal shore) – Percentage DNA methylation at individual CpG sites
When methylation was averaged across both CpG sites, the Glt1 distal promoter resulted 
hypomethylated in the cortex (<20%) and around 50% methylated in blood across all groups 
and time points (Table 4.12, Figure 4.10). 
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Table 4.12. Glt1 (distal shore): descriptive statistics
N: naïve; S: sham; HI: hypoxia-ischaemia; DNAm: DNA methylation; SD: standard 
deviation
Group Time n Glt1 – distal shore
Cortex Blood
Mean % DNAm SD Mean % DNAm SD
6 3 15.67 1.76 45.50 6.50
12 3 16.67 0.76 50.83 5.69N
24 3 21.17 8.55 48.17 1.53
6 3 12.50 5.89 48.67 2.02
12 3 14.00 1.32 48.17 3.55S
24 3 14.83 1.53 49.67 0.76
6 8 15.31 3.75 49.38 2.97
12 8 14.75 1.81 50.88 3.99HI
24 8 14.94 1.84 51.94 4.59
Figure 4.10. Glt1 (distal shore) DNA methylation: plots
In the cortex, there was significant evidence of a group effect (p=0.041, effect size: 12%), 
with post hoc analysis suggesting the difference was between naïve and sham rats only 
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(p=0.047) (Table 4.13). Specifically, sham rats had 4% lower methylation at the distal 
promoter compared to naïve rats. No group or time effects were detected in blood.
Table 4.13. Glt1 (distal shore): primary analyses
Gene Tissue Variable Levene’s 
p









Group (N vs 
S vs HI)
2 40.34 3.54 0.041 0.12 S ≠ N 
(p=0.047)
S – N = -
4.06% (-
8.07- -0.04)




4 10.92 0.96 0.444 0 (-
0.04)
Group (N vs 
S vs HI)
2 26.56 1.72 0.194 0.04





Group*Time 4 7.94 0.51 0.725 0 (-
0.05)
In the secondary analyses, the two individual CpG sites were analysed separately, and it was 
found that the level of evidence and the effect size were similar for both CpG sites (Table 
4.14). No group or time effects were detected in blood. 
Table 4.14. Glt1 (distal shore): secondary analyses













Group (N vs 
S vs HI)
2 36.30 3.37 0.047 0.12 S ≠ N 
(p=0.059)
S – N = -
3.78% (-
7.67-0.12)




4 12.53 1.16 0.345 0.02
Group (N vs 
S vs HI)
2 44.83 3.41 0.045 0.12 S ≠ N 
(p=0.050)
















None of the group effects survived Benjamini Hochberg correction (FDR 5%) (Table 4.15).
Table 4.15. DNA methylation: findings surviving Benjamini-Hochberg False Discovery 
Rate (5%) correction (none)
Glt1 Promoter 
Region




Distal Cortex 0.041 1 0.01
Proximal Blood 0.065 2 0.02
Distal Blood 0.194 3 0.04
Proximal Cortex 0.201 4 0.05
CpG Island Blood 0.367 5 0.06
CpG Island Cortex 0.611 6 0.07
4.5 Discussion
This exploratory study set out to assess whether hypoxia-ischaemia alters DNA methylation 
at the promoter of Glt1 and Tnfα, potentially mediating latent or observed gene expression 
changes in the cortex. Correlation with DNA methylation in blood was also assessed as a 
potential early biomarker of injury. Only Glt1 was assessed due to COVID-19-related 
disruptions. Overall, DNA methylation was not significantly altered in any of the three Glt1 
promoter regions assessed. Small methylation differences (<5%) of dubious biological 
relevance included: 1) proximal promoter in the cortex: higher methylation at 24h vs 6h; 2) 
proximal promoter in blood (but not cortex): higher methylation in HI rats at 6h 3) distal 
promoter in the cortex: lower methylation in sham vs naïve.
4.5.1 Peg3 data supports accuracy and precision of DNA methylation methodology
Bisulfite pyrosequencing is currently considered the gold standard method for candidate gene 
DNA methylation studies since it allows quantification at the individual cytosine level with 
relatively little bias (1307, 1308). With the progress in next-generation sequencing 
technologies this approach can be extended to the entire genome. However, it is a challenging 
methodology for multiple reasons. Firstly, bisulfite conversion chemically alters DNA to 
convert unmethylated cytosines to uracils, which are subsequently read as thymines during 
pyrosequencing. During this process DNA is fragmented, which can lead to chimeric 
products and interfere with sequencing of long sequences. Moreover, genome complexity is 
reduced to three nucleotides, which underlies the requirement for longer primers and may be 
an issue for sequence alignment in larger studies. Importantly, if conversion of unmethylated 
cytosines is incomplete, this can lead to misleading quantification of DNA methylation. 
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Peg3 belongs to a small group of 100-200 autosomal genes that are regulated by genomic 
imprinting in mammals, with DNA methylation permanently silencing one of the parental 
alleles. Specifically, Peg3 is maternally imprinted and paternally expressed (1297). Peg3 
DNA methylation has been studied more extensively in the mouse compared to the rat. At the 
time of the experiment, a literature search found only assays designed for the mouse genome 
(1297, 1309). After the experiment, one published assay for the rat genome was found 
(1310). 
In this pilot study, Peg3 methylation was found to be very close to the expected 50% value 
for all CpG sites assessed. This provided evidence that bisulfite conversion of DNA 
successfully discriminated between methylated and unmethylated cytosines, and 
pyrosequencing successfully sequenced these cytosines. Since the observed DNA 
methylation values are close to the true methylation values and there was little variability in 
the measurements, it can be reasonably concluded that the methodology had good accuracy 
and precision (bisulfite conversion, two-step PCR, pyrosequencing, analysis). This novel 
pyrosequencing assay will be valuable in future studies of Peg3 methylation in the rat 
genome, including studies requiring an internal control for the methodology.
4.5.2 There is no evidence that DNA methylation in the promoter of Glt1 is affected by 
hypoxia-ischaemia
Briefly, there was no evidence that HI altered DNA methylation in any of the candidate 
regions in Glt1 promoter in the ipsilateral cortex, other than very small (<5%) effects of 
dubious biological relevance. 
CpG islands are nearly always unmethylated (939, 968-972), with few exceptions (e.g. 
imprinted genes) (971). The Glt1 CpG island is indeed unmethylated in the P1 rat cortex and 
cerebellum, with established inducers of Glt1 leaving DNA methylation unaffected (1207, 
1208). On the other hand, hypermethylation of the EAAT2 CpG island has been previously 
reported in human glioma cell lines, with EAAT2 silencing (1311). In this study, the CpG 
island of the Glt1 promoter was found to be unmethylated in the P7 cortex, with no evidence 
of significant changes after HI. 
In humans, the region homologous to the proximal promoter was identified as differentially 
methylated in saliva-based EWAS studies of very preterm vs term newborns (1292) and 
term-born infants at 6 weeks of life vs 1 year (1312), potentially reflecting changes induced 
by the profound stress of prematurity but also age-dependent changes in methylation. 
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Multiple CpG sites across the EAAT2 CpG island and proximal promoter have also been 
reported in EWAS of bipolar disorder and addiction, coinciding with regions near consensus 
sequences for transcription factors (1313). In this pilot study, there was only evidence of a 
very small time effect in the proximal rat promoter, with 1% higher methylation at 24h vs 6h 
in all groups. There was also a very small effect in blood, whereby methylation was 
approximately 3% higher in HI rats vs naïve and sham but only at 6h. 
In epigenome-wide association studies (EWAS), it has been suggested that more confidence 
can be held in the biological relevance of effects larger than 10%, whereas effects smaller 
than 5% should be interpreted with great caution (1314, 1315). This is a small hypothesis-
driven pilot study with limited sample size and using bulk tissue with multiple cell types; due 
to the high cost of false negatives in exploratory studies, it can be argued that more subtle 
changes may be of interest and guide a follow-up experiment. However, these effects are very 
small and do not overcome the 5% detection limit of pyrosequencing (1306, 1316). 
Additionally, the change in blood disappeared after 6h and was not correlated to changes in 
the cortex. To my knowledge, there is no published evidence regarding DNA methylation in 
this region in the rat brain. A region further downstream in the rat proximal promoter (~-900 
bp) was shown to be unmethylated in P1 cortical astrocytes similar to the CpG island closer 
to the TSS (1208). This region was not followed up by the authors in subsequent work 
(1207). 
Shore regions are sequences located up to 2 kb from the TSS and outside typical CpG island 
promoters. They are characterised by lower CpG density, and indeed only 2 CpG sites could 
be assessed by bisulfite pyrosequencing in this study. DNA methylation is typically more 
dynamic in these regions and varies in a tissue- and region-specific way (974, 975, 1317, 
1318). The function of methylation in these regions is less clear: the correlation with 
transcriptional silencing is not well understood and it is not known whether it is a cause or a 
consequence of gene silencing or what other implications it may have (974, 976, 977). Other 
epigenetically regulated genes have CpG islands that are protected, while differential 
methylation occurs at more distal enhancer elements with methylation-dependent function 
(1319). Accordingly, the Glt1 shore region has been shown to have more dynamic DNA 
methylation patterns compared to the CpG island, responsible for differences in gene 
expression in different brain regions (cortex vs cerebellum) both at baseline and in response 
to established inducers of Glt1 (1207, 1208). This higher epigenetic plasticity allows the 
region to act as an epigenetically-regulated enhancer in the cortex, as confirmed by a reporter 
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gene study in rat astrocytes (1207, 1208). In this pilot study, there was no evidence that DNA 
methylation at the distal shore region was affected by HI. There was some evidence of a very 
small effect of anaesthesia, with the sham group showing approximately 4% lower 
methylation than the naïve group independently of time. Once again, the effect size is small 
and of dubious biological relevance and was not associated with any transcriptional change 
within the 24h. However, it would be worth following up this finding, perhaps in the context 
of larger analyses, since there is evidence that isoflurane can be both neuroprotective or 
neurotoxic (depending on duration of exposure) and it affects glutamate signalling (see 
5.2.2). Follow-up may be achieved by analysing DNA methylation in isolated astrocytes and 
including a later time point for transcriptional analysis (e.g. 72h). 
Crucially, the good quality Peg3 data suggests that a lack of significant DNA methylation 
changes for Glt1 reflects true negative findings with these experimental conditions and 
sample size rather than a technical failure to detect effects. 
Epigenetic mechanisms other than DNA methylation were not assessed in this pilot study. 
However, epigenetic mechanisms do not act independently but in concert with each other to 
alter chromatin structure and accessibility for transcription and translation (1320-1324). For 
example, synthetic corticosteroid dexamethasone induces Glt1 in the cortex and increases 
histone acetylation in the shore region in the absence of DNA methylation changes (1207). 
Compared to the relative stability of DNA methylation, histone modifications have a highly 
transient nature and can be thought as reflecting the dynamic regulation of transcription 
rather than long-term gene silencing (927). Perhaps the effects of the environmental stress of 
HI are reflected in more dynamic and transient histone modifications, which may be assessed 
at candidate genes with chromatin immunoprecipitation followed by PCR (1325). 
4.5.3 Strengths and limitations
A strength of this study was inclusion of the Peg3 methylation data, which allowed more 
confident interpretation of these findings as true negatives with current experimental 
conditions and sample size. Assessment of both brain and blood DNA methylation added 
clinical relevance to the study, enabling assessment of DNA methylation as a potential 
biomarker in newborns. 
Main limitations of the study include limited sample size and power. This issue may be 
exacerbated by the use of bulk tissue, where differential methylation across cell types may 
prevent detection of effects in individual cell populations (e.g. astrocytes). Moreover, the 
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study did not assess DNA methylation changes beyond 24h or in other vulnerable brain 
regions (e.g. hippocampus, thalamus). DNA methylation changes at other regions of the Glt1 
promoter and the cytokine promoters could not be evaluated, due to time and funding 
restrictions. Finally, histone modifications were not evaluated in this study and may represent 
a more dynamic epigenetic mechanism sensitive to the environmental stress of HI. 
4.6 Conclusion
There was no significant evidence of biologically meaningful DNA methylation changes at 
the Glt1 promoter in the cortex of P7 rats in the 24h following HI. This aligned with the lack 
of obvious transcriptional changes. The very weak non-significant evidence of lower 
expression in HI vs sham in primary analyses, which strengthened in secondary analyses 
merging naïve and sham groups, may be an artefact. It is not possible to assess this without 
increasing sample size and/or assessing DNA methylation and transcription of Glt1 in 
astrocytes in isolation. Assessing DNA methylation changes at the cytokine promoters 
remains of great interest given evidence of upregulation in the acute phases after HI in this 
pilot study and the wider literature.
5 General discussion
This project aimed to evaluate genetic and environmental influences on regulation of 
glutamate transport and inflammation in relation to two of the most clinically relevant 
perinatal brain injuries (cPVL and HIE) and subsequent motor and cognitive impairment in 
childhood. The project integrated epidemiological approaches in newborns and experimental 
approaches in animal models. Genetic, epigenetic, and transcriptional regulation was assessed 
for four candidate genes, i.e. the main glutamate transporter in the brain (EAAT2/Glt1) and 
three key pro-inflammatory cytokines (TNFα, IL1β and IL6). Table 5.1 contains a summary 
of the research questions and main findings of the project. In the general discussion, relevant 
genetic, epigenetic, and transcriptional approaches in newborns and in animal models will be 
discussed. 
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Table 5.1. Research questions and main findings of this project
Chapter Research Question Main Findings
2: SNP association 
study in very 
preterm newborns
Are regulatory variants in the 
4 candidate genes associated 
with risk of cPVL, motor and 
cognitive impairment in 
children born very preterm?
 Replicated previous evidence of 
association between TNFα -308 in 
children born very preterm with cPVL 
and CP
 First evidence of association between 
IL1β -511 and the British Ability 
Scales score assessing cognitive skills 
at 5 years of age, in particular the non-
verbal reasoning subscale
 Suggestive evidence of association 
between IL6 -174 and any moderate to 
severe white matter injury at birth
 Suggestive evidence of association 
between the linked EAAT2 -200 and -
181 variants and the verbal skills 
subscale of the British Ability Scales 
at 5 years of age
3: Gene expression 
study in a rat model 
of hypoxic-ischemic 
brain injury at term
Is transcription of the 4 
candidate genes altered in the 
cortex and hippocampus in the 
24h after acute hypoxia-
ischaemia?
 Hypoxia-ischaemia causes an early 
neuroinflammatory response in both 
regions with upregulation of all 3 
cytokines
 Hypoxia-ischaemia also causes 
changes in brain injury markers, 
signalling onset of astrogliosis and 
myelin injury
 Hypoxia-ischaemia may cause a small 
loss in Glt1 in the cortex and/or 
isoflurane may cause a small increase 
in Glt1 
4: DNA methylation 
study in a rat model 
of hypoxic-ischemic 
brain injury at term
Is DNA methylation at the 
promoter of 2 of the 4 
candidate genes (Glt1 and 
Tnfα) altered in the cortex and 
blood following acute 
hypoxia-ischaemia?
 Hypoxia-ischaemia does not cause any 
DNA methylation changes at 3 
candidate promoter regions of Glt1
 (Tnfα could not be assessed due to 
COVID-19-related disruptions)
5.1 Genomic studies of cerebral palsy and newborn brain injuries
If the genetic landscape of CP reveals itself to be similar to that of other neurodevelopmental 
disorders, multiple genes and types of genetic variants will be involved, e.g. SNPs, indels, 
rare single-base variants and large structural variations that are individually rare but 
cumulatively common (875-877, 1326-1328). Integration of different genetic technologies 
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(e.g. microarray, sequencing, in silico analyses), designs (candidate vs hypothesis-free 
approach) and outcomes (e.g. molecular, neuroimaging and disease outcomes) will be 
required to advance our understanding of the genetic architecture of CP. Moreover, 
integrating haplotype analyses alongside single-SNP analyses will allow a more in depth 
understanding of genetic effects.
5.1.1 Understanding genetic effects: from single SNP to haplotype analyses 
Single SNP association studies do not consider the genetic sequence surrounding the variant 
under study. Moreover, they do not consider the diploid nature of the genome, since they do 
not separate, or phase, alleles inherited from the mother and father (1329). An alternative way 
to analyse genetic associations is by haplotype-based analyses (1330). These carry more 
biological relevance since genetic variants are not inherited independently of one another but 
in haplotype structures based on linkage disequilibrium (LD). A haplotype is a set of genetic 
loci located on the same chromosome and co-inherited from a single parent. These co-
inherited variants are in LD often, but not exclusively, through physical proximity along the 
linear genome. New haplotypes are born from mutations arising and being passed on in the 
population, and are destroyed by meiotic recombination, with population genetic forces 
acting as modifying factors (1331). Hence, SNPs identified by genetic association studies 
may simply tag linked variant on the same haplotype. There may also be multiple functional 
variants on a haplotype jointly acting as a “super allele” with a larger effect on a trait (e.g. 
multiple variants affecting folding of proteins) (1330, 1332, 1333). 
Importantly, haplotype effects may underlie the commonly observed “flip-flop” phenomenon, 
whereby the direction of effect flips from protective to detrimental or vice versa in replication 
studies (1334, 1335). This was also observed when comparing our findings to the wider 
literature and does not invalidate findings. On the contrary, evidence from multiple 
independent samples supports evidence of genetic association, with the flip-flop effect 
pointing to potential population differences in underlying allele and haplotype structures and 
frequencies. This is also seen for functional studies, with higher expression reported with 
both IL6 -174 G allele (1053, 1056, 1058, 1336-1338) and IL6 -174 C allele (1059, 1339-
1342), IL1β -511 T allele (1052, 1343, 1344) and C allele (1345-1347). For example, the 
finding from Fishman and colleagues (1053) that the C allele was associated with lower 
plasma IL6 levels in healthy subjects may be due to the fact that the low-expression 
haplotypes containing the G allele were rare in the population. Of course, factors other than 
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haplotypes affect results from reporter gene assays, including choice of cell and inclusion of 
other regulatory sequences (e.g. 3’ UTR) (1348). 
Haplotype-based analyses should be a priority in the future, supported by the substantial 
evidence that haplotype effects govern cytokine expression in vitro. This has been 
extensively studied with reporter gene assays for variants in the IL1β promoter (1052). IL1β -
511 induces only a modest upregulation in IL1β when considered as an individual SNP, 
whereas upregulation is strong when the -31 variant is also present. Moreover, inclusion of 
two other variants (-1464 and -3737) substantially suppresses IL1β only if the minor allele is 
present at both -511 and -31. Interestingly, the highest expression haplotype (-1464G/-511T/-
31C) is the least common in Caucasians (6%) but over 7-fold more common in African-
Americans (46%). When assessing haplotype effects in gingival fluid specifically from a 
Caucasian sample (1346), it was found that three out of four pro-inflammatory haplotypes, 
present in over half of the sample and associated with 28-52% higher IL1β levels, featured 
IL1β -511 CC genotype rather than the minor T allele, and the fourth included the CT 
genotype. We found that children with IL1β -511 CC genotype have lower BAS general 
conceptual ability scores. The CC genotype has also been reported in association with 
increased risk of myocardial infarction and ischemic stroke in young patients, as well as 
higher levels of IL1β in LPS-stimulated blood cells (1347, 1349). Importantly, experimental 
evidence shows that variants other than -511 in the IL1β promoter (e.g. -31 or -3737) alter 
transcription factor binding (1052, 1350, 1351), suggesting that this variant may simply tag a 
non-genotyped functional variant. 
Similarly, other SNPs in the TNFα promoter (e.g. -857) have been shown to be functional 
(1352). Moreover, TNFα -308 may simply tag neighbouring causal genes in the MHC region 
(e.g. HLA antigens, TNFβ, CD14) (1034, 1121). For example, the variant belongs to a 
haplotype including a variant in TNFβ which alters expression of TNFβ (1353). This cytokine 
is involved in adult stroke and autoimmune disorders (1354-1356), and levels in serum are 
associated with gross motor impairment in school-aged children with neonatal 
encephalopathy (652). Importantly, etanercept, which has been used as anti-TNFα therapy in 
rodent models of newborn brain injury, also blocks TNFβ (1357). 
Haplotype effects on gene expression and relevant outcomes have also been shown for IL6 
(1058, 1358-1362). IL6 -174 belongs to a 7-SNP haplotype, with homozygotes at the entire 
haplotype having a higher risk of CP than homozygotes at any individual variant (918). 
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Importantly, IL6 -174 may tag a variant in intron 4 (+3331) disrupting a CpG methylation site 
(1363) and/or a string of As and Ts (-373AnTn) which may affect the 3D structure of DNA 
(1358). Haplotype effects on EAAT2 expression in vitro have not been assessed, and very few 
studies exist assessing haplotype effects on disease risk (e.g. schizophrenia) (1050). 
As well as carrying more biological relevance, haplotype-based analyses have been shown to 
improve power and robustness of genetic association studies of complex diseases (1330, 
1364, 1365). The main limitation is that haplotype phasing information is rarely available, 
including in the current study, and collection requires a substantial effort (1333). 
Experimental phasing is expensive and labour-intensive and tends to be limited to studies 
where accurate long-range haplotypes are needed and family data is not available (1366, 
1367). Computational estimation of haplotypes in unrelated individuals is cheaper and faster 
but requires knowledge of the LD patterns in the sequence surrounding the variant, which 
was not available for the current study. This information is used to estimate the probability of 
any given variant belonging to a set of possible haplotypes based on observed genotype 
frequencies (1367). 
In future genetic studies of newborn brain injuries and neurodevelopmental outcomes, 
haplotype analyses could be carried out by genotyping larger regions (e.g. 500 bp on each 
side of the variant) or estimating haplotype frequencies in a more widely genotyped reference 
population (e.g. ALSPAC) (see 5.1.2).
5.1.2 Choice of study design: from candidate gene to genome-wide approaches
Follow-up work to this project will involve assessing a larger selection of candidate 
inflammatory and glutamatergic variants in relation to a variety of neonatal and childhood 
adverse motor, cognitive, educational, and behavioural outcomes in the Bristol-based 
ALSPAC birth cohort (also known as “The Children of the 90s” cohort). This cohort provides 
a unique opportunity to validate and add to these findings in a large sample with genetic, 
epigenetic and phenotypic data collected longitudinally from birth to childhood (1368). 
Availability of parental data additionally offers opportunities to analyse parental-offspring 
gene-gene and gene-environment interactions, estimate haplotypes more accurately, and 
identify possible sources of bias in genetic studies with unrelated individuals. Information on 
LD patterns will also allow identification of SNPs tagging the EAAT2 SNPs, which are not 
present on any of the widely used lllumina microarrays and are therefore not directly 
genotyped in any GWAS studies. Epigenetic data is available for the ARIES subset of 
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ALSPAC, allowing exploration of genetic effects on DNA methylation (mQTL effects) 
(1369). 
For common variants, the candidate approach still represent the main genetic epidemiology 
approach in the field. The approach benefits from building on previous scientific evidence for 
formulation of the a priori hypothesis, however this can also be a limitation, since our 
understanding of disease pathophysiology is often limited. SNPs in other inflammatory genes 
have been implicated in CP in preterm newborns through a candidate approach (e.g. IL8, 
IL10, IL18, TNFβ, COX1, COX2, MBL, TLR4) (162, 654, 901, 906, 907, 910, 917, 1027, 
1115, 1370, 1371). Moreover, SNPs in other pathways have been involved in preterm brain 
injury, including developmental pathways (e.g. WNT/β-catenin) (1372), neuronal migration 
and lipid metabolism (1373). Importantly, some of the genes involved in newborn brain 
injuries and CP may not even be currently suspected and allowing for wider analyses beyond 
the traditionally studied genes (e.g. cytokines) will be key (1374). This was recently 
demonstrated by a study integrating human and mouse molecular and neuroimaging data at 
the genome level, which reported a role for the less known microglial DLG4 protein in 
preterm white matter injury (1279). 
GWAS of relevant perinatal data have only recently started to accumulate, including preterm 
birth, gestational duration, clinical chorioamnionitis, bronchopulmonary dysplasia, 
necrotising enterocolitis and growth restriction (1375-1382). Interestingly, fetal variants in 
pro-inflammatory cytokines (including IL1 family) emerged as associated with gestational 
duration (1383). The main barrier to GWAS studies of newborn brain injuries or the 
polygenic forms of CP is currently the lack of sufficiently large samples held by any 
individual research centre, especially if focusing on specific subpopulations (e.g. very 
preterm). The issue of sample size has been widely illustrated in the field of psychiatric 
disorder research, where GWAS have been used for the last 15 years (1384), with only a 
handful of variants identified for schizophrenia with samples in the order of hundreds (1385), 
raising to over 100 SNPs with a sample in the order of tens of thousands (1386). National and 
international collaborations such as the International Cerebral Palsy Genomics Consortium 
formed in 2017 will be paramount in achieving adequate sample sizes (839). In England, a 
further issue is represented by the lack of a national CP register and valuable approaches may 
involve machine learning methods identifying likely cases of CP based on linkage of 
prescription data, medical records and secondary care records (1387, 1388). 
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Insights gained from an initial GWAS of CP could help deciding whether to pursue whole 
exome and/or whole genome sequencing to uncover rare variants. For many complex traits, a 
combination of all three approaches (microarrays, WES and WGS) will be required, to 
identify associated genetic variants with a range of effect sizes and frequencies (858). 
Bioinformatic tools (e.g. UCSC Genome Browser, Ensembl Variant Effect Predictor, 
Polyphen2 software for coding non-synonymous variants) can help predict functional effects 
and support identification of true causal variants before proceeding to lab-based functional 
studies (1023, 1389-1392). RegulomeDB and HaploReg combine information from 
ENCODE and the Roadmap Epigenomics Project and can be useful to prioritise GWAS hits 
that may be causal to disease by affecting gene expression. RegulomeDB provides 
information on transcription factor binding sites, cell-specific chromatin states and eQTL data 
(1393). HaploReg increases the chance to identify causal variants that may be in LD with the 
query variant by estimating haplotypes using the 1000 Genomes Project population data 
(1394).  
Once robust GWAS data will start accumulating, more advanced genetic epidemiology 
approaches will become available, including Mendelian randomisation (MR) and polygenic 
risk scores which may be used for earlier identification of high risk newborns (1395). In MR 
approaches, genetic variants robustly associated with an environmental risk factor are used as 
proxies to evaluate whether the environmental risk factor has a causal effect on disease. 
These approaches exploit the random inheritance of genetic variants at conception, 
resembling random assignment to treatment arm in an RCT, conferring robustness to the 
issues of confounding and reverse causation (1184, 1396-1398). MR approaches have 
recently been used to assess the Barker’s hypothesis of developmental origins of disease, e.g. 
to assess whether the observational association between birth weight and a range of adult 
diseases is causal (1399, 1400). Several studies have reported a causal association between 
birth weight and cardiovascular diseases and type 2 diabetes (1401-1403), while the causal 
relationship with psychiatric disorders has been proposed to be due to confounders or small 
effect size (1404). MR approaches are relatively new and constantly evolving, including 
strategies to account for the interaction between parental and foetal genotypes, and are likely 
to become increasingly used in epidemiology (1405-1408). Chorioamnionitis represents an 
interesting example of a poorly understood pathophysiology which could benefit from this 
approach (397). While there is strong evidence of an association between chorioamnionitis 
and motor (including CP), cognitive and behavioural impairment (239, 387, 389, 390, 392, 
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393, 401, 414-419, 630, 1409-1414), it is not clear whether the effects on perinatal brain 
injuries are causal or due to other perinatal factors (e.g. preterm birth, z-scores) (395, 397, 
1415-1419). MR approaches could also help with prioritising targets for neuroprotective 
drugs or repurposing existing drugs before expensive trials are conducted. This has been 
recently shown in a study evaluating pharmacological blockade of the IL6 receptor for 
coronary heart disease (1420). Specifically, SNPs robustly associated with increased IL6 
gene expression were used to generate groups differing only by IL6 levels (which is 
compatible with pharmacological IL6 receptor blockade), allowing comparisons of disease 
outcomes and distinction between on- and off-target effects. 
5.1.3 Choice of outcomes: integrating short-term and long-term outcomes
Heritability has classically been measured in relation to disease outcomes. More recently, 
technology developments have expanded the range of phenotypes that can be explored to 
molecular phenotypes (e.g. gene expression, metabolites measured by mass spectrometry) 
and neuroimaging phenotypes (e.g. MRI brain scans). This broadens the insights that can be 
gained through genetic studies by shifting the focus to the core biological processes that may 
in turn impact disease risk itself. This is important, for example, for drug development as 
drugs act on protein targets and biological processes to create a change in phenotype and 
protect from disease. Inclusion of neuroimaging outcomes will allow exploration of any 
genetic effects on brain structure and function in the perinatal period, which may mediate 
later neurodevelopmental impairment. In terms of neuroimaging-genetic approaches, a key 
advancement in the field will be the creation of a biomedical resource linking and 
harmonising hundreds of neonatal MRI scans between each other and with genetic data. An 
example from adult studies is the Enhancing Neuroimaging Genetics through Meta-Analysis 
(ENIGMA) Consortium, a collaboration from 70 institutions worldwide which has allowed 
the first GWAS studies of adult brain volumes (1421, 1422). 
Even more proximal outcomes can be chosen, such as gene expression. A GWAS including 
over 8,000 Finns recently identified 27 SNPs associated with circulating levels of one or 
more cytokines, including 15 SNPs affecting gene expression (eQTL effects) in whole blood 
(1423). Three SNPs were linked to both gene expression and protein, supporting candidacy as 
drug targets in adult immune diseases. Neither of the variants studied here were amongst 
these genome-wide hits, although variants in genes interacting with these cytokines were 
identified (e.g. TNF-related apoptosis inducing ligand). It would be of great interest to carry 
255
out a similar GWAS in neonatal blood, including at baseline and after ex vivo immune 
challenge (1424). 
5.1.4 Translational value of genetic studies
Investigating the genetic contribution to disorders with clear environmental risk factors, such 
as newborn brain injuries and neurodevelopmental disorders including CP, is driven by three 
main motivations. Firstly, it can advance our understanding of the biological mechanisms of 
disease, both by identifying the key mediators and pathways leading to disease, and by 
offering a tool to explore the causal effects of environmental risk factors themselves 
(Mendelian randomisation). 
Secondly, drug targets with genetic support are twice as likely to succeed and genetic 
evidence is the second biggest predictor of drug success (after repurposing of drugs already in 
use) (1425). Even if the individual SNP effect is small, robust associations can point to 
attractive protein targets if manipulation of the protein itself has a large effect on disease. 
Genetic evidence can also help excluding unattractive drug targets, e.g. when manipulation of 
the protein has no effect on disease despite a large effect on protein levels. pQTL Mendelian 
randomisation approaches are emerging as particularly valuable for drug target discovery: 
SNP effects on protein levels (pQTL effects) robustly identified by GWAS can be exploited 
in MR approaches to evaluate the causal effects of such proteins on disease (1426).
Thirdly, knowledge of genetic risk can aid in risk prediction. As sample sizes increase and 
genetic variants are uncovered, the proportion of trait variance explained by genetic factors 
will also increase, improving the diagnostic power for polygenic forms of CP. Importantly, 
even if the genetic component is small compared to the environmental component, the 
clinical value could be substantial if it leads to meaningful differences in clinical 
management (e.g. earlier identification, diagnosis and treatment, and more tailored 
approaches). Genetic risk prediction can also aid researchers in the designs of clinical trials. 
Approximately half of phase 3 trials fail (1427-1429), and incorporating genetic information 
to identify high-risk individuals has been proposed as a way to reduce trial cost and duration 
(1430).
Finally, pharmacogenetics is an area that holds promise of a powerful impact in clinical 
management of perinatal brain injuries. Genetic background is one of the factors contributing 
to differences in drug responsiveness and adverse reactions (1431), since it can affect 
pharmacokinetics (e.g. variants affecting drug bioavailability) and pharmacodynamics (i.e. 
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variants affecting drug targets). Accordingly, it was recently shown that treatment with 
magnesium sulphate abrogated the detrimental associations between inflammatory SNPs (e.g. 
Il1β, IL6, MBL2) and adverse neurodevelopmental outcomes in children born preterm (919). 
Identifying the best dose of immunomodulatory therapies currently being developed may be 
essential in the future given the potential adverse effects. To this end, neonatal 
neuroprotection research may draw knowledge from studies of the adult stroke drug warfarin. 
Here, pharmacogenomic approaches have been key since patients with certain genetic 
variants require lower doses to avoid fatal bleeds (1431), and ongoing clinical trials are 
evaluating genotype-guided dosing. Technological advances now include handheld devices 
which genotype DNA in minutes and hold great promise for rapid pharmacogenetic profiling 
and a push toward a ‘right first time prescribing’ approach (1432, 1433). 
5.2 Epigenetic and transcriptional studies of hypoxic-ischemic brain 
injury
A modified Rice Vannucci model was used to model HI brain injury in the term newborn, 
with left carotid artery ligation followed by 30 min recovery and 100 min hypoxia at 8% 
oxygen at 36°C, instead of the original 3.5 h of 8% oxygen at 37°C (1196). These parameters 
have been previously shown to produce moderate brain injury with around 40% brain tissue 
loss in the ipsilateral hemisphere relative to the contralateral hemisphere one week after HI in 
the P7 rat (1200). Injury involves necrosis of neurons and glial cells, microgliosis and 
astrogliosis typically observed in the cortex, basal ganglia, hippocampus, subcortical and 
periventricular white matter, and reflects patterns observed in HIE (1196). 
5.2.1 Neuroinflammation in hypoxic-ischemic brain injury
5.2.1.1 Likely cellular sources and targets of cytokines
In this pilot study, three key pro-inflammatory cytokines were found to be upregulated at the 
transcriptional level in the ipsilateral cortex and hippocampus. Based on previous evidence, 
the main cellular sources of cytokines following HI are likely to be activated microglia, 
infiltrating peripheral immune cells (e.g. mast cells, monocytes/macrophages, neutrophils) 
and reactive astrocytes (375, 516, 807). 
Microglial activation has been demonstrated in the post-mortem hippocampus of newborns 
with HIE (1434). Following HI, cells damaged by excitotoxicity release danger associated 
molecular patterns (DAMPs) in the microenvironment (375, 805). DAMPs start activating 
microglia as early as 2-4h post-HI in the newborn rat brain (e.g. via IL1 receptor, Toll-like 
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receptors, cytoplasmic NOD-like receptors) (1221, 1222, 1244, 1435-1437). Activation 
involves changes in morphology, proliferation rate, gene expression and acquirement of new 
functions, including phagocytosis of dying neurons (514, 516, 1438-1440). Activated 
microglia can damage the developing neurons, not only by losing their homeostatic and 
developmental functions, but also by releasing pro-inflammatory cytokines, reactive oxygen 
species, death receptor agonists and glutamate, potentiating further release by astrocytes and 
contributing to disruption of the blood brain barrier (375, 512, 514, 573, 813, 1441-1444). 
NFκB seems to be key in this process, with different signalling pathways converging on 
upregulation of this mediator leading to cytokine release (98, 375, 480, 1445-1455).
The increased permeability of the blood brain barrier caused by HI allows peripheral immune 
cells to infiltrate from the cerebral blood vessels into the brain (375, 1456). Activated 
microglia and astrocytes release chemokines (e.g. MIP1α), which further attract peripheral 
immune cells to the area of ischemic injury (1221, 1457, 1458). Infiltration of myeloid cells 
peaks around 24h post-HI and involves mainly neutrophils, dendritic cells, and monocytes, 
which give rise to local macrophages with phagocytic and antigen-presenting properties (375, 
1459). Mast cells, which bridge innate and adaptive immunity, can not only infiltrate but also 
proliferate locally for weeks after injury, releasing increasing levels of pro-inflammatory 
cytokines, such as TNFα (375, 516, 1460, 1461). HI can also cause local activation of the 
complement system and antimicrobial peptides (1462). Moreover, HI can cause infiltration of 
antigen-presenting cells and T lymphocytes, which are found in the ipsilateral hemisphere 
months after HI (375, 1463). The roles of these peripheral cells and mediators in the injury 
process are subject of current research, including the chronic component of 
neuroinflammation and potential interference with repair mechanisms (375, 516, 804, 1221, 
1223, 1464). 
Reactive astrocytes represent an additional source of pro-inflammatory cytokines. Both 
astrogliosis and microgliosis have been reported to start as early as 3h post-HI in the injured 
hippocampus and corpus callosum, with microgliosis peaking in the first week and 
decreasing from day 14, and astrogliosis peaking at 14 days, with the glial scar still evident at 
day 100 (1223). Reactive astrocytes are thought to have dual neuroprotective and neurotoxic 
roles which are only partially understood, with the relative contribution probably depending 
on severity of the insult and time of recovery (516, 1465, 1466). Alongside allowing scar 
formation, they can promote anti-inflammatory mechanisms and dedifferentiate to newly 
available neural progenitor cells (1467). However, reactive astrocytes also contribute to the 
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HI injury process, not only by losing their homeostatic and developmental functions but also 
by becoming themselves sources of pro-inflammatory cytokines, glutamate, and reactive 
oxygen species (516, 738, 1216, 1256, 1468-1472). In the rat brain, reactive astrocytes have 
been shown to be both cellular sources and targets of cytokines (including TNFα and IL6). 
Inhibiting cytokines, for example by hypothermia, reduces not only neuronal injury but also 
astrogliosis (483, 1473).
This pilot study was limited by the inability to identify not only cellular sources but also the 
cellular targets of the cytokines, which are likely to include glial cells, neurons, peripheral 
immune cells, and endothelial cells (516, 1474). Cytokines may contribute to brain injury via 
multiple mechanisms, including disruption of the cerebral blood flow oxygen delivery due to 
their vasoactive properties; direct neuronal and astrocyte injury due to their cytotoxic effects; 
and potentiation of glutamate excitotoxicity, inflammation and oxidative stress in complex 
interactions of glial cells and neurons with vicious circles of cytokine and glutamate release 
(101, 532-534, 549, 552, 1475, 1476). With regard to potentiation of glutamate 
excitotoxicity, the specific mechanisms are largely unresolved, but they are thought to 
converge on accumulation of extracellular glutamate (e.g. via impaired astrocytic uptake and 
increased glutamate release by activated glial cells) and overactivation of glutamate receptors 
(e.g. via accumulation of extracellular glutamate, alteration of number and chemical 
composition of neuronal glutamate receptors and expression of glutamate receptors by 
reactive astrocytes) (494, 585, 811-813, 1477, 1478). 
Given the evidence of transcriptional changes following HI, assessment of epigenetic 
regulation of these cytokines in this Rice Vannucci model is of great interest. This may be 
achieved by serial bisulfite pyrosequencing as done here, with a higher number of tandem 
assays along the amplicon if required (1316). An even more comprehensive analysis could be 
carried out with the PacBio sequencer, which allows accurate sequencing of long-reads 
beyond 20 kb. This would enable detection of DNA methylation across the entire gene, 
including promoters, distal shores, gene bodies and 3’UTRs (974). 
Overall, preclinical evidence supports the notion that HI triggers an early inflammatory 
response which contributes to injury of neurons, axons, and oligodendrocytes depending on 
stage of brain development (1463, 1479, 1480). In humans, evidence of a causal relationship 
between HI and inflammation comes from observation that cerebral ischaemia induced by 
circulatory arrest during cardiac surgery in the newborn triggers a systemic inflammatory 
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response within minutes (1480). Existing evidence supports the concept of stratification of 
HIE newborns by inflammatory status at birth and further research into immunomodulatory 
therapies for neuroprotection (485, 557, 559, 1481). 
5.2.1.2 Targeting inflammation for neuroprotection of the vulnerable newborn
The mechanisms through which therapeutic hypothermia exerts neuroprotection are not fully 
understood, but are thought to include protection from glutamate excitotoxicity, 
inflammation, oxidative stress, and apoptosis (723, 1482). Hypothermia lowers cytokine 
levels in serum and CSF, and peripheral cytokine levels correlate with MRS-defined injury 
(341). Unsurprisingly, clinical studies assessing how cytokine levels are affected by 
hypothermia are starting to accumulate (640, 1265, 1483, 1484). 
Evidence of an early neuroinflammatory response has triggered interest in 
immunomodulatory therapies targeting cytokines directly. The most convincing evidence 
currently supports IL1 receptor blockade as a therapeutic approach, based on the 
neuroprotective effects seen with pharmacological or genetic inhibition in newborn rodents 
(555-563). Safety trials are required to assess the potential issue of broad immunosuppression 
observed in adults (1485). Cytokines have pleiotropic effects on a variety of targets and 
systems, including important homeostatic, developmental, growth and repair functions (1444, 
1486). Accordingly, genetic or pharmacological inhibition of TNFα after an acute HI insult or 
a combined inflammatory/excitotoxic insult is neuroprotective, reducing brain injury by half 
in some studies (485, 568-570), however mice lacking TNFα receptors are more susceptible 
to HI injury (576). In the preterm mouse, inflammatory genes are upregulated in pre-
oligodendrocytes as part of developmental programmes, suggesting that global suppression 
may not be a safe and effective neuroprotective strategy in the preterm newborn (1487). How 
different the scenario is for the more developmentally mature term brain is not known. 
Targeting multiple transcription factors at low doses and selectively blocking individual 
pathways (e.g. apoptotic but not anti-apoptotic TNF receptor pathway) might be better 
approaches than globally suppressing the inflammatory response. Local delivery to the brain 
might also be a safer and more desirable approach, e.g. via perispinal administration, 
engineered fusion proteins small enough to cross the blood brain barrier (as shown for the 
TNFα receptor) (1488, 1489), or intranasal administration of inhibitory peptides (as shown 
for NFκB) (1490). The effectiveness and safety of pharmacological cytokine modulation 
remains controversial even in adult models with more data available than for HIE (1444), and 
more neonatal data is needed.
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5.2.2 Glutamate transporter regulation following hypoxia-ischaemia remains worth 
further attention
In this pilot study, there was only very weak non-significant evidence of lower Glt1 
expression in the cortex in the HI group compared to the sham group, which strengthened in 
secondary analyses merging naïve and sham groups. There was no evidence that DNA 
methylation changes in the three candidate promoter regions preceded this potential 
transcriptional change. The lack of significant evidence of DNA methylation and 
transcriptional changes with these experimental conditions does not currently support follow-
up protein analyses for GLT1. This negative evidence does not align with previous in vitro 
and in vivo evidence of GLT1 dysregulation following hypoxia and hypoxia-ischaemia. 
GLT1 (both mRNA and protein) is lost in the adult rat cortex and hippocampus after 
ischaemia (1491-1494). GLT1 protein is also downregulated in astrocyte cultures from P6-8 
rats subjected to hypoxia (via NFκB) (1495). To my knowledge, only one study exists 
assessing GLT1 expression in the P7 rat, using similar but not identical experimental 
conditions (left carotid artery ligation, 2h recovery and 2h 8% hypoxia at 33°C) (1240). Here, 
GLT1 protein was lost together with GFAP and MAP2 in the injured cortex and hippocampus 
at 12h. Both GLT1 and GFAP recovered by 48h in the hippocampus but not the cortex. On 
the other hand, GLT1 was unchanged in the border zone, where GFAP increased signalling 
astrogliosis. The study was limited by very small sample size (e.g. 2 rats in the 12h group 
destined to histological analyses). Moreover, the authors show only micrographs at 24h 
despite reporting loss of GLT1 at 12h. Nonetheless, the study supports a loss of GLT1 at the 
protein level following HI. In the current study, Gfap was upregulated and not lost in both 
cortex and hippocampus between 6h and 24h. This aligns with the notion that astrogliosis is 
an early response to HI in the rodent brain (483, 1220-1222), whereas it seems to be an 
adaptive mechanism to the acute phases in the piglet brain (1496-1498). Perhaps the slightly 
longer duration of hypoxia, recovery period between ischaemia and hypoxia, or different 
temperature control contributed to more severe injury in the study by Fukamachi and 
colleagues. This may have led to astrocyte abnormalities with an initial loss of both GFAP 
and GLT1 in the ischemic core which did not occur in our study. Alternatively, loss of GLT1 
and/or GFAP in our pilot study may have occurred post-translationally and/or locally in the 
ischemic core but remained undetected when assessing total lysates from cortex and 
hippocampus, which do not differentiate between ischemic core, border zone and uninjured 
tissue. 
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GLT1 loss following HI has also been shown in the newborn piglet. Consistent with 
impairment of glutamate transport, extracellular glutamate concentration becomes elevated in 
the cortex, basal ganglia, and thalamus after hypoxia (1499). Acute HI causes neuronal injury 
in the piglet striatum, with initial simultaneous loss of astrocytic GLT1 and GFAP proteins at 
24h and recovery of GFAP but not astrocytic GLT1 by 96h (1497). The gradual near 
complete loss of astrocytic GLT1 in the injured regions was accompanied by upregulation in 
neurons, suggesting a compensatory mechanism in response to increasing extracellular 
glutamate levels. In a piglet model of severe hypoxia, loss of astrocytic GLT1 started as early 
as 6h and was extensive by 72h (1500). At the same time, the GLT1B splice variant, 
normally expressed by astrocytes (1501), was upregulated in neurons by 72h. Crucially, 
astrocytic GLT1 was lost only in the injured regions, including cortex and hippocampus but 
not the dentate gyrus, supporting a role in the injury process via glutamate excitotoxicity. 
It is possible that baseline expression at P7 is too low to detect any transcriptional changes. 
GLT1 acquires astrocyte selectivity and undergoes profound developmental upregulation 
throughout the central nervous system from the second postnatal week onwards, reaching 
adult levels by weeks 4-5 (761-766). This may explain why knockout mice develop normally 
for the first few weeks and develop seizures and brain injury during postnatal week 3, with 
many dying by week 4 (760, 1502). This is also consistent with EAAT2 appearing in 
astrocytes at 41 weeks gestation in newborns and progressively increasing in all layers of the 
cortex in the first 1.5 years, at least in part via post-translational mechanisms (748). An 
interesting approach would be to repeat the experiment in P10 rats. Most studies with the 
Rice Vannucci model to date have focused on P7 rats, as the patterns of injury recapitulate 
the patterns seen in newborns with HIE, with injury in the cortex, thalamus, basal ganglia, 
hippocampus and subcortical white matter, and development of cortical cysts in longer 
survival models (79, 80). Working with P7 rats also allows to time the injury to coincide with 
the brain growth spurt and active myelination phase which signals the transition from preterm 
to term patterns of injury (356, 1503, 1504). Importantly, therapeutic hypothermia was 
developed with P7 rats and has been successfully translated to humans, and other 
neuroprotective treatments (e.g. xenon, melatonin, erythropoietin) have been studied in the 
same model (702, 1198, 1505, 1506). Nonetheless, the P10 rat brain is more similar to the 
full-term human brain in terms of myelination, neurotransmission, and brain electrical 
activity, and the Vannucci group recently replicated their traditional model in P10 rats 
262
(1290). While the P7 Rice Vannucci model benefits from decades of published studies, the 
P10 model may be particularly relevant for studies of Glt1. 
5.2.3 Choice of study design: from candidate gene to genome-wide approaches
5.2.3.1 Transcriptomic studies
Transcriptome-wide analyses have not been carried out in this rat model, however findings 
from a mouse model of HI injury at term have highlighted the value of hypothesis-free 
designs. Of the nearly 150 inflammatory genes (1257) and over 300 non-inflammatory genes 
(1507) found to be differentially expressed in the cortex, hippocampus, thalamus, and 
striatum between 2h and 72h post-HI, at least 90% had not been previously described in the 
newborn brain. The vast majority (97%) of the inflammatory genes were upregulated, 
generally from 8h and progressively increasing until the latest assessed time point at 72h 
(1257). This is in alignment with the early neuroinflammatory response found in the current 
study. The same pattern of early upregulation was observed for genes involved in 
transcription, stress, apoptosis, and growth. Genes involved in metabolism, cytoskeleton (e.g. 
Gfap), transport, enzymes and inhibitors were largely upregulated at a later stage (24-72h). 
Genes related to ion and vesicular transport, neurotransmission (e.g. glutamate receptor 
ionotropic Nmda1) and signal transduction were largely suppressed, and this suppression 
generally occurred at a later stage after HI (24-72h) (1507). Given this evidence of loss of 
Nmda glutamate receptor after 24h, it may be that excitotoxic shutdown at the synapsis and 
loss of glutamate transporter may have also been detectable after 24h. 
With appropriate funding and resources, a hypothesis-free transcriptome wide study would 
provide great insight into global gene expression changes in this model. This could be 
designed as in a recent study with a rat model of combined inflammatory and HI insult 
(Hemmen Sebir, personal communication, manuscript in preparation), i.e.  1) by isolating a 
cell type of interest (e.g. microglia, astroglia) from regions of interest (e.g. cortex, 
hippocampus, thalamus); 2) by using RNA sequencing, which allows full sequencing of the 
entire transcriptome and, unlike microarrays, is sensitive to lowly expressed genes 3) by 
following up transcriptome-wide analyses with RT-qPCR and protein analyses. 
Transcriptome-wide analyses could also be carried out in the piglet, however adequate 
sample size for genome-wide analyses is considerably more difficult to obtain than in 
rodents. Nonetheless, the piglet brain is more similar to the human brain in terms of 
anatomical complexities, myelination, genome as well as development, contrary to the rodent 
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brain which has a major postnatal growth spurt (1504, 1508-1511). The HI insult is also more 
similar since it is global rather than focal (e.g. hypoxia combined with airway occlusion 
causing cardiac arrest followed by resuscitation) and the neurological and neurobehavioural 
impairment resemble those seen in humans (1512). 
In newborns with HIE, blood-based transcriptomic analyses have revealed widespread gene 
expression dysregulation compared to controls (1513). Major pathways include axonal 
development, adhesion and infiltration of peripheral granulocytes (e.g. neutrophils, mast 
cells), IL12 signalling and production in macrophages and HIF1α signalling. The overlap in 
gene expression differences with a subset of newborns with neonatal sepsis was relatively 
modest and effects largely had opposite direction. Thus, while both HIE and sepsis are 
associated with inflammation, the mechanisms of inflammation may be divergent.
Transcriptome-wide gene expression differences present in blood at birth are also associated 
with adverse outcomes at 18 months (Bayley scores, GMFCS scores, blindness, deafness) 
(1514). Major pathways include melatonin, which protects from free radicals, and polo-like 
kinase signalling, which triggers apoptosis following HI. Both of these pathways trigger 
HIF1α signalling, supporting the central role of this gene in HIE (see 5.2.3.2). Such 
transcriptomic analyses may provide a useful clinical tool for rapid stratification of HIE at 
birth and identification of candidate drug targets. Epigenomic analyses may complement such 
studies by examining epigenetic regulation affecting gene expression
5.2.3.2 Epigenomic studies
While no studies have assessed the effect of acute HI on global DNA methylation in HIE 
models, evidence is emerging from models of chronic hypoxia during pregnancy, either in 
isolation or in a multiple hit paradigm. These studies have provided evidence of global and 
long-lasting changes in DNA methylation and expression in the developing brain following 
chronic antenatal hypoxia, which sensitise the brain to a subsequent acute HI insult around 
term time (985, 1016, 1017). Such changes include, for example, upregulation of the 
Wnt/β‐catenin signalling pathway, which plays a key role in brain development and 
synaptogenesis and is dysregulated in neurodevelopmental and neurological disorders (1515-
1517). The glucocorticoid receptor, involved in the stress response, is also affected, with 
hypermethylation and gene silencing worsening injury induced by the second hit of HI 
(1518). This in vivo evidence is complemented by in vitro studies of hypoxia in rodent 
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hippocampal neurons, showing a tendency for promoters and CpG islands across the genome 
to remain hypomethylated long after the end of a mild and short hypoxic insult (1519). 
Hypoxia is thought to impact epigenetic regulation via multiple mechanisms. Firstly, 
hypomethylation and upregulation of HIF1α seems to be central to the sensitisation process. 
HIF1α is the key mediator of the cellular response to hypoxia. It regulates many genes 
downstream, enabling adaptation to a hypoxic environment in the long-term by modulating 
angiogenesis, iron and glucose metabolism and stem cell function. However, it also affects 
expression of genes which may contribute to injury in the early phases and/or the long-term, 
including Wnt signalling and matrix metalloproteinases affecting the blood brain barrier  
(985, 1016). Some evidence exists of a bidirectional relationship with pro-inflammatory 
cytokines in normoxia, hypoxia and inflammation (1520-1525) and the participation of 
HIF1α in inflammatory processes is emerging (1526), however more data specific to the 
developing brain is required. Moreover, HIF1α also affects epigenetic regulators, including 
miRNAs and histone methylases, further propagating the epigenetic effects downstream 
(1017, 1527-1532). The complex roles of HIF1α are evidenced by the fact that early 
inhibition after HI is neuroprotective while later inhibition or genetic deletion exacerbates 
injury (1533-1535). 
Evidence from adult stroke and cancer studies suggests that hypoxia also directly affects the 
“writers” (DNMTs) and “erasers” (TETs) of DNA methylation (1536-1539). For example, 
disruption of cell metabolism induced by hypoxia can reduce availability of substrates 
necessary for TET activity (e.g. α-ketoglutarate) and produce new metabolites that inhibit 
TET (1540, 1541). Reverse glutamate transport may exacerbate the reduced availability of α-
ketoglutarate, since when glutamate is depleted it can be rapidly synthesised de novo from α-
ketoglutarate (1540, 1542). 
Finally, adult model studies show that HI can additionally alter DNA methylation without 
requiring enzyme activity. Reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) can chemically alter cytosines directly, so that they mimic 5-mC and induce DNMTs 
improperly leading to gene silencing (1543). ROS and RNS can also promote processing of 
methylated cytosines to 5-hmC, which are not recognised by the “readers” of DNA 
methylation (e.g. MeCP2) and therefore fail to engage co-operative epigenetic mechanisms 
(1544, 1545). 
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Future work could assess global DNA methylation changes in this Rice Vannucci model 
alongside co-regulation of other epigenetic mechanisms. Of relevance, evidence is emerging 
that hypoxia and HI also alter histone marks and miRNAs (1530). In a preconditioning model 
assessing the mechanisms through which a mild and short hypoxic insult during pregnancy 
protects the brain from a more severe hypoxic insult at birth, upregulation of histone 
deacetylation seems to be central. Such upregulation, which promotes chromatin 
condensation and transcriptional repression, is indeed not seen without the preconditioning 
insult (1546, 1547). This suggests that the epigenetic and transcriptional profiles may be 
unique depending on the nature of the insult (hypoxia vs HI, acute vs chronic, global vs 
local), number of hits (single vs multiple) and severity. The nature of epigenetic changes 
following perinatal stresses is likely to depend not only on the type of insult but also on 
degree of brain maturity. For example, neuroinflammation in a mouse model of IL1β-induced 
preterm brain injury leaves chromatin accessibility unaffected in pre-oligodendrocytes, while 
taking advantage of chromatin regions already open during early development (1487).
Importantly, DNA methylation can now be manipulated in animal models, via optogenetic 
methods and the CRISPR-Cas9 technology (1548-1550). These methodologies will be 
helpful in studying the effects of DNA methylation changes in vivo once more robust 
evidence emerges for particular candidate genes. For example, the CRISPR-Cas9 technology 
could be used not only to edit the sequence of gene promoters and assess the effects of the 
regulatory SNPs on expression, but also activate or repress transcription by editing DNA 
methylation and histone acetylation status (1551).
In humans, no EWAS has yet assessed methylation in term newborns with HIE compared to 
term-born controls. With a prevalence of 2-3/1,000 newborns, reaching adequate sample size 
is a challenge. On the other hand, EWAS have so far pointed to widespread peripheral 
methylation differences in preterm vs term newborns, including genes involved in labour and 
delivery, brain development and immunity (1292, 1552-1559). Widespread peripheral 
methylation differences have also been found in sick preterm newborns vs healthy preterm 
newborns in the NICU, including at glutamate receptors in relation to cumulative scores for 
neurological morbidity (1560, 1561). Methylation differences have been shown to be present 
at birth in pairs of monozygotic twins (mostly preterm) who later became discordant for CP, 
including genes involved in responses to inflammation (e.g. TNFβ, NFκB) and hypoxia (e.g. 
HNRNPL) (1562). Another twin CP study measured DNA methylation in childhood rather 
than at birth, revealing differences in key biological processes, including the cytokine 
266
signalling pathway, cell transport, growth and death, and genetic processes (1563). 
Importantly, measuring DNA methylation in childhood gives a snapshot of DNA methylation 
differences but provides no mechanistic insights into timing and causes of DNA methylation 
changes. 
Compared to GWAS, EWAS are complicated by the fact that the epigenome is a phenotype, 
which varies with cell type, tissue, developmental stage, age, environmental exposures, 
genetic background and by chance (933, 1564, 1565). Access to the target tissue of disease, 
the brain, is generally not possible or difficult in humans. EWAS can be carried out in post-
mortem brain tissue (e.g. HIE and cPVL brains), however this does not offer insights into 
causation since methylation is measured after disease manifestation and possibly treatment, 
and DNA degrades with increasing post-mortem interval (1013, 1566, 1567). So far, most 
human epigenetic studies of brain-based disorders have assessed DNA methylation in 
peripheral tissues, taken additional steps to assess relevance to the brain and discussed 
inherent limitations. Several studies have shown a good degree of correlation between brain 
and blood methylation, especially at CpG islands compared to other promoter regions and 
gene bodies (1568, 1569). Recent evidence suggests saliva may be a better surrogate tissue in 
EWAS of brain disorders, likely due to the variety and mixed proportions of cell types in 
saliva compared to blood and buccal swabs (1540, 1570-1572).
If the goal of the EWAS is to gain mechanistic insights, further steps need to be undertaken to 
strengthen causal inferences from peripheral methylation. This is achieved by choosing study 
designs and analytical approaches that account as much as possible for observational issues 
(reverse causation, confounding, selection bias) and biological confounders (e.g. differences 
in cell composition in the sample, genetic differences affecting DNA methylation, genetically 
determined differences in transcription affecting DNA methylation) (933, 1184). This may 
include longitudinal designs in prospective birth cohorts (e.g. ALSPAC) minimising issues of 
reverse causation and confounding due to choice of controls, and allowing assessment of 
DNA methylation stability (933). Mendelian randomisation approaches can also be used to 
strengthen causal inferences for EWAS. This relies on robust associations for SNP-DNA 
methylation (mQTL effects) and SNP-outcome associations from GWAS studies (1018, 
1573). While mQTL data can be obtained from publicly available databases from GWAS of 
DNA methylation in foetal brain (http://epigenetics.essex.ac.uk/mQTL/) and adult brain 
(http://mostafavilab.stat.ubc.ca/xqtl), the main limiting factor for this type of analysis remains 
the lack of GWAS of newborn brain injuries and CP. The most comprehensive analytical 
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framework for assessment of DNA methylation as a causal mediator between perinatal 
exposures and brain injuries or CP would be a two-step MR analysis (1018). This approach 
has recently shown that DNA methylation is a mediator between prenatal vitamin B12 and 
cognitive abilities (1574). This type of analysis requires not only GWAS of relevant 
outcomes for the second step (effect of DNA methylation on outcome), but also GWAS of 
perinatal exposures for the first step (effect of the exposure on DNA methylation), which are 
also currently scarce. Relevant GWAS studies are therefore urgently needed, not only for 
investigation of the genetic architecture of brain injuries and CP, but also for understanding 
the role of epigenetic factors.
When the pathway to injury is thought to start from a methylation change in the brain which 
subsequently affects the periphery (or at the very least a common cause affecting both brain 
and periphery simultaneously), concordance between brain and blood methylation must also 
be considered before attempting causal interpretations (1019). Databases with matched pre-
mortem blood methylation and post-mortem brain methylation have been made available to 
the scientific community to evaluate concordance of any regions of interest in studies of adult 
brain disorders (1019, 1575). Such matched databases do not yet exist for newborns. Animal 
model studies are particularly useful in this scenario.
An entirely separate goal of EWAS studies is that of prediction. In the context of biomarker 
studies, as long as DNA methylation is robustly associated with the exposure or the disease, it 
does not matter whether it is causally involved or it simply reflects biological confounders 
(e.g. cell type composition of the sample) (933, 1576). To this end, cord blood DNA 
methylation is currently being assessed for association with a range of early life stresses (e.g. 
maternal depression and anxiety, neurotoxin exposure) (1577). This approach may have great 
clinical utility for identifying peripheral biomarkers for HIE, and for improving speed and 
accuracy of CP diagnoses. This was shown by an EWAS of unrelated teenagers with CP, 
whereby observed DNA methylation differences were used to build a model which predicted 
CP diagnoses with relatively good accuracy in an independent sample of 4 year old children 
(1578).
5.2.3.3 Single cell multi-omics studies
One of the main challenges in epigenetic studies is that, unlike the genome, the epigenome 
varies in different cells and tissues, and both brain and blood are heterogeneous collections of 
different cell types. This has implications for animal model studies such as this one, where 
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analyses are carried out in bulk tissue and can only detect aggregate measures of gene 
expression or DNA methylation. In future studies, astrocytes or neurons could be isolated by 
FACS, before separating DNA and mRNA from single cells for parallel sequencing of the 
genome, epigenome, and transcriptome (1579, 1580). Integration of genomic, transcriptomic, 
epigenomic and electrophysiological information from single neurons and glial cells would 
allow a true understanding of gene regulation and how it underpins cell-specific behaviour in 
health, disease, and development (1550, 1581). 
6 Conclusion
In this project, the role of genetic, transcriptional, and epigenetic regulation of astrocytic 
glutamate transport (EAAT2) and inflammation (TNFα, IL1β, IL6) was assessed in relation to 
newborn brain injuries (cPVL in preterm newborns and HIE in term newborns) and 
subsequent motor and cognitive impairment. 
Genetic variants associated with higher cytokine levels, and therefore potentially stronger 
inflammatory responses, were found to be more frequent in children with cPVL and cerebral 
palsy (TNFα -308) and in association with cognitive scores (British Ability Scales) at 5 years 
of age (IL1β -511), especially the non-verbal reasoning subscale. There was also suggestive 
evidence for variants in IL6 (-174) with moderate to severe white matter injury at birth, and 
variants in EAAT2 (-200/-181) with verbal skills at 5 years of age. 
In an established rat model of moderate hypoxic-ischemic brain injury at term, hypoxia-
ischaemia induced expression of all three cytokines in both cortex and hippocampus in the 
first 24h, with a trend for early peak at 6h. This neuroinflammatory response was 
accompanied by changes in brain injury markers suggesting onset of astrogliosis and myelin 
injury. DNA methylation at the promoter of these cytokines could not be assessed within the 
timeframe of the project. However, it remains a suitable candidate mechanism for mediation 
of these transcriptional changes and holds potential for clinical use as a biomarker of HIE in 
newborns when measured in blood. Accumulating evidence of neuroinflammation following 
hypoxia-ischaemia supports stratification of HIE newborns based on neuroinflammatory 
status at birth and research into the neuroprotective effects of drugs modulating 
inflammation.
Evidence of a potential suppression of the glutamate transporter following hypoxia-ischaemia 
in the cortex was weak, and it was not associated with DNA methylation changes in any of 
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the three promoter regions examined. Inclusion of good quality DNA methylation data for 
imprinted gene Peg3 strongly suggests that these findings are true negatives with these 
experimental conditions and sample size. More insights might be gained by purifying 
astrocytes, focusing on a later developmental stage, assessing more dynamic types of 
epigenetic mechanisms sensitive to the environment, as well as post-translational regulation.
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8 Appendix
Table 8.1. Literature review of candidate cytokine SNP-relevant outcome studies
Detrimental effects are highlighted in orange, protective effects in purple, no effects are not highlighted
Genetic Variant Study Design 
and Sample 
Size






27 <32 CP (HP) AA+GA vs GG 
(OR=2.38 (1.02-
5.58))
443 cases, 883 
controls




141 All CP (QP) A (OR=0.62 
(0.43-0.89)
(917)
82 32-36 CP AA vs GA+GG 
(OR=0.31 (0.14-
0.69))





282 All CP (QP) A (OR=0.63 
(0.44-0.90)
(162)
60 cases, 84 
controls









96 <32 CP AA vs GG 
(OR=0.43 (0.02-









138 ≥37 CP AA vs GG 
(OR=1.9 (0.04-















vs GG OR= 0.32 
(0.01-6.71); GA 
vs GG OR=1.22 
(0.61-2.42))
(905)




Not reported <32 Stillbirth/death within 1 















60 cases, 84 
controls
White Croatian 60 <32 CP TT vs CC 
(OR=1.85 (0.71-





35 <32 CP + cPVL TT vs CC 
(OR=3.22 (1.11-









100 All Bayley<85 in the 
absence of CP
OR not reported, 
manually 
calculated: TT 
vs CC (OR= 
3.58 (1.36-











Not reported <32 Stillbirth/death within 1 





50 cases, 50 
controls
Mixed Brasilian 50 All cPVL + Neonatal 
encephalopathy 




IL6 -174 C>G 60 cases, 84 
controls
White Croatian 60 <32 CP GG vs CC 
(OR=0.84 (0.31-









100 All Bayley<85 in the 
absence of CP
OR not reported, 
manually 
calculated: CC 
vs GG (OR= 
2.39 (0.45-
12.56)); CG vs 
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Not reported <32 Stillbirth/death within 1 
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443 cases, 883 
controls
White Australian




52 cases, 46 
controls
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controls
Han Chinese 56 All CP + cPVL in males OR not reported, 
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calculated for 
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(OR=4.1 (1.4–
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White British 148 ≤32
Any disability (motor, 
vision, hearing, and 
cognitive)
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+ <1,500 g









Finnish 153 <32 or 
<1,500g
Reduced volume of deep 
grey matter (basal 
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Table 8.2. Regression modelling of the EAAT2-TNFα SNP effects on cerebral palsy
Likelihood ratio test Unadjusted Analyses (n=178)Logistic Regression Model for 
Cerebral Palsy 
Genetic Exposures
p OR (95% CI) p





















(vs univariable - 
EAAT2) 
0.02 
(vs univariable - 
TNFα) 7.35 (1.47-16.76) 0.02
EAAT2 (No. A alleles) -200/-
181*TNFα(GA) 9.47e+07 (0) 1.00
Multivariable (Interaction)
EAAT2 (No. A alleles) -200/-
181*TNFα(AA)
0.04 
(vs multivariable - 
main effects)
Not estimable (no children with TNFα(AA) 
and 1 or 3 A alleles at EAAT2 -200/-181)
-
343
Table 8.3. Regression modelling of the EAAT2-TNFα SNP effects on the BAS cognitive score at 5 years
Likelihood ratio test Unadjusted Analysis (n=114)Linear Regression Model for the 
BAS Score
Genetic Exposures
p β (95% CI) p





















(vs univariable - 
EAAT2) 
0.07 
(vs univariable - TNFα) 6.16 (-6.66-18.99) 0.34




EAAT2 (No. A alleles) -200/-
181*TNFα(AA)
0.01 
(vs multivariable - main 
effects)
Not estimable (no children with 




Figure 8.1. Plots of model predictions of the effect of the increasing number of A alleles at EAAT2 -200/-181 on the BAS score by TNFα -
308 risk genotypes
345
Table 8.4. Generalised linear model of the EAAT2-TNFα SNP effects on the M-ABC motor score at 5 years
Likelihood ratio test Unadjusted Analysis (n=121)Generalised Linear Model for the 
M-ABC Score (gamma family, 
log link)
Genetic Exposures
p β (95% CI) p





















(vs univariable - 
EAAT2) 
0.18 
(vs univariable - TNFα) 0.39 (-0.45-1.22) 0.37




EAAT2 (No. A alleles) -200/-
181*TNFα(AA)
0.59 
(vs multivariable - main 
effects)
Not estimable (no children with 




Frontiers in Physiology | www.frontiersin.org 1 April 2019 | Volume 10 | Article 417
REVIEW




University of Gothenburg, Sweden
Reviewed by: 
Pierre Gressens, 
Institut National de la Santé et de la 
Recherche Médicale (INSERM), 
France
Changlian Zhu, 






This article was submitted to 
Embryonic and Developmental 
Physiology, 
a section of the journal 
Frontiers in Physiology
Received: 15 October 2018
Accepted: 27 March 2019
Published: 24 April 2019
Citation:
Pregnolato S, Chakkarapani E, 
Isles AR and Luyt K (2019) Glutamate 
Transport and Preterm Brain Injury.
Front. Physiol. 10:417.
doi: 10.3389/fphys.2019.00417
Glutamate Transport and Preterm 
Brain Injury
Silvia Pregnolato1*, Elavazhagan Chakkarapani1, Anthony R. Isles 2 and Karen Luyt 1
1Department of Neonatal Neurology, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, 
United Kingdom, 2Behavioural Genetics Group, MRC Centre for Neuropsychiatric Genetics and Genomics, School of 
Medicine, Cardiff University, Cardiff, United Kingdom
Preterm birth complications are the leading cause of child death worldwide and a top 
global health priority. Among the survivors, the risk of life-long disabilities is high, including 
cerebral palsy and impairment of movement, cognition, and behavior. Understanding the 
molecular mechanisms of preterm brain injuries is at the core of future healthcare 
improvements. Glutamate excitotoxicity is a key mechanism in preterm brain injury, 
whereby the accumulation of extracellular glutamate damages the delicate immature 
oligodendrocytes and neurons, leading to the typical patterns of injury seen in the 
periventricular white matter. Glutamate excitotoxicity is thought to be  induced by an 
interaction between environmental triggers of injury in the perinatal period, particularly 
cerebral hypoxia-ischemia and infection/inflammation, and developmental and genetic 
vulnerabilities. To avoid extracellular build-up of glutamate, the brain relies on rapid uptake 
by sodium-dependent glutamate transporters. Astrocytic excitatory amino acid transporter 
2 (EAAT2) is responsible for up to 95% of glutamate clearance, and several lines of 
evidence suggest that it is essential for brain functioning. While in the adult EAAT2 is 
predominantly expressed by astrocytes, EAAT2 is transiently upregulated in the immature 
oligodendrocytes and selected neuronal populations during mid-late gestation, at the 
peak time for preterm brain injury. This developmental upregulation may interact with 
perinatal hypoxia-ischemia and infection/inflammation and contribute to the selective 
vulnerability of the immature oligodendrocytes and neurons in the preterm brain. Disruption 
of EAAT2 may involve not only altered expression but also impaired function with reversal 
of transport direction. Importantly, elevated EAAT2 levels have been found in the reactive 
astrocytes and macrophages of human infant post-mortem brains with severe white 
matter injury (cystic periventricular leukomalacia), potentially suggesting an adaptive 
mechanism against excitotoxicity. Interestingly, EAAT2 is suppressed in animal models of 
acute hypoxic-ischemic brain injury at term, pointing to an important and complex role in 
newborn brain injuries. Enhancement of EAAT2 expression and transport function is 
gathering attention as a potential therapeutic approach for a variety of adult disorders 
and awaits exploration in the context of the preterm brain injuries.
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GLOBAL SIGNIFICANCE OF PRETERM 
BRAIN INJURIES
Perinatal care has advanced considerably in the last century 
and has improved survival of many vulnerable newborns, 
including those born preterm. The World Health Organization 
estimates that 15 million newborns (1  in 10 live births) are 
born preterm (<37  weeks of gestation) worldwide each year 
(World Health Organization, 2012). Despite global improvements, 
the United Nations Millennium Development Goal to reduce 
childhood mortality by two-thirds in 2015 was not achieved 
globally (United Nations, 2015) and 2.7 million children died 
in the first month of life worldwide in 2015. Of these babies, 
over 900,000 died due to preterm birth complications – the 
leading cause of death of newborns and children under 5 years 
old (Liu et  al., 2016). For the newborns who survive, the 
multi-organ damage can result in life-long disabilities. Globally, 
preterm birth complications represent the fourth leading cause 
of years of “healthy” life lost due to disability (i.e., over 102,000 
DALYs), above causes such as diarrheal diseases, diabetes, and 
HIV (World Health Organization, 2016).
Prematurity is a major risk factor for cerebral palsy, “a group 
of permanent disorders of the development of movement and 
posture, causing activity limitation, that are attributed to 
non-progressive disturbances that occurred in the developing 
fetal or infant brain” (Bax et al., 2005; Rosenbaum et al., 2007). 
Cerebral palsy is the most common physical disability in 
childhood and is a heterogeneous diagnosis, including different 
clinical types and brain imaging patterns, comorbidities, and 
multiple causes (Stanley et  al., 2000; Locatelli et  al., 2010; 
MacLennan et  al., 2015). Preterm birth is clearly an important 
risk factor and risk is 30 times higher in children born before 
33 weeks of gestation than in those born at term (Stanley, 1992; 
Himpens et  al., 2008; Beaino et  al., 2010; Mercier et  al., 2010; 
Tronnes et al., 2014; MacLennan et al., 2015; Stavsky et al., 2017). 
A recent meta-analysis estimated an increase in prevalence 
from 1.4/1,000 live births in children born at term (>36  weeks 
of gestation) to 6.8/1,000 live births in moderate to late preterm 
(32–36  weeks of gestation), rising to 43.2/1,000 live births in 
very preterm (28–31  weeks of gestation) and 82.3/1,000 live 
births in extremely preterm infants (<28  weeks of gestation) 
(Oskoui et  al., 2013; Hirvonen et  al., 2014). More than a third 
of the extremely preterm children with cerebral palsy are unable 
to walk (Moore et al., 2012), and many have multiple disabilities, 
which may further limit independence and quality of life 
(Litt et  al., 2005; Glass et  al., 2008, 2015; Soria-Pastor et  al., 
2008; Anderson et  al., 2011; Moore et  al., 2012). A systematic 
review of international cerebral palsy registers in high-income 
settings highlighted the extent of these comorbidities: around 
three quarters of children with cerebral palsy suffer from chronic 
pain; approximately half have intellectual disabilities (IQ, executive 
function, language ability); around a quarter have active epilepsy, 
hip dislocation, bladder control problems, behavioral problems, 
sleep disorders, and/or speech impairment; 11 and 4% have severe 
vision and hearing impairment, respectively (Novak et al., 2012). 
There are less data from low-income settings, but it is likely 
that comorbidities, as well as mortality, are higher (Khandaker 
et al., 2015). Preterm birth complications impose a considerable 
economic burden on the public sector, which was estimated 
around £2.9 billion in England and Wales in 2006 (Mangham 
et  al., 2009). While administration of magnesium sulfate as a 
preventative treatment to the mother during preterm labor 
has been shown to reduce risk of cerebral palsy by a third 
in very preterm infants (Doyle et  al., 2009), no postnatal 
therapy currently exists for preterm brain injury. This is a 
global health priority as the increase in both preterm birth 
and survival rates has not been matched by a decrease in 
long-term disability (Wilson-Costello et  al., 2005).
NEUROIMAGING AND 
NEUROPATHOLOGY OF PRETERM 
BRAIN INJURIES
Preterm birth is associated with smaller brain volumes (Peterson 
et  al., 2003; Inder et  al., 2005; Srinivasan et  al., 2007) as 
well as motor, cognitive, and behavioral problems at school 
age (Peterson et al., 2000, 2003; Abernethy et al., 2004; Nosarti 
et  al., 2005; Gimenez et  al., 2006; Anderson and Doyle, 2008; 
Kesler et  al., 2008; Aarnoudse-Moens et  al., 2009; Delobel-
Ayoub et  al., 2009; Soria-Pastor et  al., 2009; Anderson et  al., 
2017). Progress in neuroimaging techniques has been key in 
linking childhood neurodevelopmental outcomes to perinatal 
brain injuries and in advancing our knowledge of the underlying 
neuropathology (Volpe, 2009c; Back, 2017). Both MRI-defined 
preterm white matter injury (periventricular leukomalacia) 
and preterm birth are predictive of cerebral palsy (Constantinou 
et  al., 2007; Spittle et  al., 2008, 2009, 2018; Duerden et  al., 
2013). In a large European population study of cerebral palsy, 
white matter injury was the most common feature found in 
over 40% of the children (Bax et al., 2006). Originally, cranial 
ultrasound could only detect the most severe cystic type of 
white matter injury (cystic periventricular leukomalacia), 
characterized by focal macroscopic cysts of necrotic tissue 
in the deep white matter (de Vries et  al., 1992) and highly 
predictive of cerebral palsy (Leviton and Paneth, 1990; De 
Vries et  al., 2004; Serdaroglu et  al., 2004; Fetters and Huang, 
2007). Necrotic white matter injury can also evolve into 
microscopic glial scars, which may not be visible with traditional 
ultrasound. These are a more common type of injury and 
are sufficient to cause a loss in brain volume (Volpe, 2009c; 
Volpe et al., 2011). With the development of MRI techniques, 
a diffuse type of white matter injury has increasingly been 
recognized in the form of diffuse disturbances of myelination 
in the central white matter. This has emerged as the predominant 
type of white matter injury, accounting for over 90% of 
periventricular leukomalacia cases, as well as the predominant 
type of preterm brain injury altogether, occurring in 50% 
preterm newborns (Volpe, 2008). Importantly, while rates of 
the more severe cystic form have declined to less than 5% 
with advances in perinatal care, this has not been reflected 
for the diffuse forms (Maalouf et  al., 2001; Counsell et  al., 
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2003; Inder et al., 2003; Miller et al., 2003; Back et al., 2007b; 
Volpe, 2008). These could be  seen as different manifestations 
of an “encephalopathy of prematurity” (Volpe, 2009c) or even 
as distinct pathologies (Back and Rosenberg, 2014). In the 
last two decades, advanced MRI techniques have highlighted 
that injury is not limited to the white matter but it extends 
to the deep grey matter, cortex, and cerebellum, all of which 
contribute to the volume loss (Counsell and Boardman, 2005; 
Ball et  al., 2012). The cerebellum is gathering attention as a 
key target of injury. This region grows rapidly at the peak 
time for preterm birth and damage in the form of infarction, 
atrophy, and poor growth has been reported as common in 
very preterm infants developing cerebral palsy and long-term 
motor, cognitive, and behavioral impairment (Mercuri et  al., 
1997; Abraham et  al., 2001; Bodensteiner and Johnsen, 2005; 
Johnsen et  al., 2005; Limperopoulos et  al., 2005a,b, 2007; 
Nosarti et al., 2008; Parker et al., 2008; Lawrence et al., 2014). 
Indeed, there is a relationship between cerebellar volume loss 
and white matter injury, pointing to the existence of a common 
insult, such as hypoxia-ischemia and infection/inflammation, 
which are known to damage the developing cerebellum 
(Shah et  al., 2006; Volpe, 2009b; Hutton et  al., 2014).
Disentangling the spatial and temporal contributions of 
infection/inflammation and hypoxia-ischemia will be  key in 
understanding brain injuries across the perinatal spectrum. 
For example, while white matter injury is typical of the preterm 
newborn, it may be  present in a subset of newborns born at 
term who experienced in utero hypoxic-ischemic insults (e.g., 
placental insufficiencies) (Mallard et al., 1998; Rees et al., 1998; 
Zhu et al., 2016). Indeed, newborns born at term with hypoxic-
ischemic encephalopathy are also at high risk and up to 40% 
develop cerebral palsy (Gluckman et al., 2005; Shankaran et al., 
2005; Azzopardi et  al., 2009; Simbruner et  al., 2010; Jacobs 
et  al., 2011). Investigating the molecular basis for divergence 
between term and preterm injuries is paramount for development 
of age-appropriate pharmacological therapies.
PATHOGENESIS OF PRETERM  
BRAIN INJURIES
Brain injury is thought to be  more common in preterm than 
term newborns for several reasons, including developmental 
and genetic vulnerabilities and differential exposure to adverse 
perinatal environments. A considerable body of in vitro and 
in vivo evidence points two potential triggers of injury, hypoxia-
ischemia, and infection/inflammation (Volpe, 2008, 2009a; 
Deng, 2010; Volpe et  al., 2011; Back and Rosenberg, 2014; 
Back, 2017). These insults are thought to interact in the 
vulnerable immature brain and converge onto three downstream 
mechanisms of injury: inflammation, glutamate excitotoxicity, 
and ultimately free radical attack, which directly damages 
cell components as well as triggering delayed cell death by 
apoptosis. Severity and temporal profile of hypoxia-ischemia 
and infection/inflammation, degree of brain maturity, 
comorbidities, sex, and genetic background may all contribute 
to individual differences in pathogenesis, clinical presentation, 
and individual susceptibility to injury. We  will review the 
role of developmental vulnerabilities, infection/inflammation, 
and hypoxia-ischemia and bring the focus on the common 
downstream mechanism of glutamate excitotoxicity. We  will 
then review the evidence linking glutamate transport to 
excitotoxic preterm brain injuries and highlight the current 
evidence supporting excitatory amino acid transporter 2 
(EAAT2) as a potential therapeutic target.
Developmental Vulnerability
The brain undergoes rapid and critical developmental events 
during the peak time of premature brain injury (24–32 weeks), 
including neuronal migration, growth of axons and dendrites, 
synaptogenesis, development of the vascular system, and 
myelination. Interference with these natural trajectories 
determines selective cellular and regional vulnerabilities and 
may redirect subsequent development. Among their functions, 
oligodendrocytes are responsible for laying the highly specialized 
myelin membrane around axons and are therefore key for 
the development of the white matter. Myelination begins before 
birth and peaks in the first 2 years of postnatal life, with 
the intracortical fibers of the cortex being myelinated in the 
third decade. The process of myelination requires that 
oligodendrocytes first proliferate and develop into mature 
oligodendrocytes and then depose myelin around axons (Volpe, 
2008). Around the peak time of preterm brain injury 
(28–32  weeks of gestation), the pre-oligodendrocyte stage still 
represents the majority of the oligodendrial pool in the very 
preterm brain (Iida et  al., 1995; Back et  al., 2001). 
Pre-oligodendrocytes are more vulnerable than mature 
oligodendrocytes to hypoxia-ischemia, infection/inflammation, 
oxidative damage, and ultimately cell death (Back et  al., 1998, 
2002, 2005, 2007b; Fern and Moller, 2000; Baud et  al., 2004; 
Fragoso et  al., 2004; Segovia et  al., 2008; Volpe et  al., 2011). 
Indeed, a unique feature of periventricular white matter injury 
is an arrest in the development of oligodendrocytes at the 
pre-oligodendrocyte stage, leading to the abnormal myelination 
patterns typically seen through MRI (Back et al., 2007b; Volpe 
et  al., 2011). More severe necrotic injury extends to all the 
cell components, leading to cysts and exacerbating myelin 
injury via focal axonal degeneration (Laptook, 2016; Back, 
2017). Concurrent developmental vulnerabilities include the 
limited ability of the immature brain to synthesize appropriate 
amounts of growth factors needed for brain development and 
self-protection, and an immature immune system, potentially 
promoting an excessive and sustained inflammatory response 
(Gilles et  al., 2018).
Environmental Triggers of Injury: Hypoxia/
Ischemia and Infection/Inflammation
Alongside the intrinsic developmental vulnerability of the 
immature brain, the preterm newborn is exposed to a range 
of potentially harmful exposures in the perinatal period. 
Supported by mounting experimental and epidemiological 
evidence, perinatal infection/inflammation leading to an overly 
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intense inflammatory response, or a “cytokine storm”, has 
increasingly been recognized as a major risk factor not only 
for preterm birth but also for preterm white matter injury 
and long-term neurodisabilities (Yoon et al., 1996, 1997, 2000; 
Baud et  al., 1999; Duggan et  al., 2001; Dollner et  al., 2002; 
Heep et  al., 2003; Kaukola et  al., 2004, 2006; Ellison et  al., 
2005; Bi et  al., 2014). The preterm brain is often exposed 
to inflammation early during fetal development (e.g., maternal 
infections and chorioamnionitis) and usually for prolonged 
periods during postnatal life in the neonatal intensive care 
environment (e.g., neonatal infections, inflammatory 
comorbidities such as necrotizing enterocolitis), during critical 
phases of myelination and brain plasticity (Murphy et  al., 
1995; Grether and Nelson, 1997; Verma et al., 1997; Alexander 
et al., 1998; Dammann and Leviton, 1998, 2000, 2004; O’Shea 
et  al., 1998; Leviton et  al., 1999; Wu and Colford, 2000; 
Dammann et  al., 2002; Rezaie and Dean, 2002; Stoll et  al., 
2002; Wu, 2002; Schlapbach et al., 2011; Hagberg et al., 2015; 
Anblagan et al., 2016). A combination of multiple inflammatory 
hits, antenatally and postnatally, has been shown to increase 
risk of brain injury and disability compared to single hits 
(Korzeniewski et  al., 2014; van der Burg et  al., 2016; Yanni 
et  al., 2017). Indeed, pharmacological interventions targeting 
inflammation may have translational potential based on 
preclinical studies (Hagberg et  al., 2015).
The role of hypoxia-ischemia in preterm brain injury is 
more controversial. In term newborns with hypoxic-ischemic 
encephalopathy, defined and acute hypoxic-ischemic events 
before or during birth (e.g., placental abruption, cord occlusion, 
and uterine rupture) are usually recognized by the clinician 
and represent the first step of a diagnosis of hypoxic-ischemic 
encephalopathy, aided by objective clinical and neuroimaging 
criteria. In the preterm newborn, a sentinel event is rarely 
recognized, and hypoxia-ischemia is generally assumed to have 
a more complex temporal profile, with intermittent or 
chronic nature (Laptook, 2016; Ohshima et  al., 2016). 
However, it remains challenging to determine the individual 
contribution of hypoxia-ischemia among several coexistent 
factors, such as infection/inflammation, growth restriction, or 
hyperoxia (Gopagondanahalli et  al., 2016). Physiologically, it 
is conceivable that the preterm brain is vulnerable to hypoxia-
ischemia due to the anatomical and functional immaturity 
of the periventricular vasculature, which would make the 
periventricular white matter vulnerable to minor drops in 
cerebral perfusion (Takashima and Tanaka, 1978; Lou et  al., 
1979; De Reuck, 1984; Altman et  al., 1988; Pryds, 1991; 
Miyawaki et al., 1998; Inage et al., 2000; Volpe, 2008; Laptook, 
2016). The periventricular white matter has lower basal blood 
flow compared to grey matter regions in both humans (Greisen, 
1986; Pryds et  al., 1990) and the preterm fetal sheep 
(Szymonowicz et  al., 1988; Gleason et  al., 1989; Riddle et  al., 
2006). Further drops in blood flow are common in sick 
premature infants with respiratory disease due to lung 
immaturity (Soul et  al., 2007). Mechanical ventilation may 
contribute to ischemia due to the vasoconstrictive effect of 
the induced cumulative hypocarbia (Shankaran et  al., 2006). 
Perinatal hypoxic-ischemic episodes are also likely to play a 
key role, including ongoing placental pathologies, an overlapping 
risk factor for intrauterine growth restriction, low birthweight, 
and preterm birth. A meta-analysis recently reported an 
association between preterm brain injury and perinatal risk 
factors related to hypoxia-ischemia, including oligohydramnios, 
acidemia, low Apgar scores, apnea, respiratory distress syndrome, 
and seizures (Huang et  al., 2017). However, the link between 
regional differences in blood flow and vulnerability to severe 
white matter injury is not consistent, and even in moderate 
ischemia, some regions of white matter are spared. This suggests 
that ischemia is necessary but not sufficient in isolation (Riddle 
et  al., 2006; McClure et  al., 2008; Back, 2017). Indeed, it has 
been suggested that more consistent evidence is needed to 
ascertain the specific role of hypoxic and ischemic events in 
preterm brain injury altogether and that future research should 
take into account contributions and interactions with other 
biological processes, including infection/inflammation and 
developmental vulnerability (Gilles et  al., 2018). Importantly, 
the impact of hypoxia-ischemia on the cerebellum is also 
emerging, as shown by reports of volume loss and death of 
Purkinje cells and Bergmann glia in term newborns with 
hypoxic-ischemic encephalopathy and mid-late gestation fetal 
sheep exposed to asphyxia (Rees et  al., 1997; Inage et  al., 
1998; Castillo-Melendez et al., 2004; Biran et al., 2012; Hutton 
et al., 2014). In an established mouse model of chronic hypoxia 
recapitulating perinatal brain injuries, damage to the cerebellum 
was reported in terms of a significant loss of GABAergic 
interneurons and a delay in dendritic arborization of 
Purkinje cells, followed by motor impairment and cerebellar 
learning deficits (Chahboune et al., 2009; Zonouzi et al., 2015; 
Sathyanesan et  al., 2018).
Several experimental studies have shown that hypoxia-
ischemia and infection/inflammation lead to worse brain 
and behavioral outcomes when they interact, and insults 
that are individually insufficient to cause injury can lead 
to injury when combined (Dommergues et  al., 2000; Eklind 
et al., 2001; Lehnardt et al., 2003; Ikeda et al., 2004; Larouche 
et  al., 2005; Favrais et  al., 2007; Wang et  al., 2007, 2009, 
2010; Aden et  al., 2010; van Tilborg et  al., 2018). This has 
led to the multiple hit hypothesis of preterm brain injury, 
whereby a mild first event sensitizes the brain to subsequent 
insults (Leviton et  al., 2013; Van Steenwinckel et  al., 2014; 
Barnett et al., 2018). The current hypothesis is that hypoxia-
ischemia triggers an inflammatory response per se. This 
additional endogenous response combined with the inflammation 
triggered by infection leads to a pro-inflammatory “cytokine 
storm,” which is not matched by upregulation of anti-
inflammatory cytokines and neurotrophic factors. This in 
turn sensitizes the brain to hypoxic-ischemic injury by 
enhancing glutamate excitotoxicity and damaging the blood-
brain barrier (Hagberg et  al., 2015). Tertiary mechanisms 
of injury, mediated by epigenetic modifications, may 
sustain  the sensitization in the long term and interfere with 
remodeling and repair mechanisms (Dammann, 2007;  
Fleiss and Gressens, 2012).
A substantial body of experimental evidence suggests that 
glutamate excitotoxicity triggered by hypoxia-ischemia and/or 
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infection/inflammation plays a key role in the pathogenesis of 
preterm white matter injury (Hagberg et al., 2002; Johnston, 2005; 
Volpe, 2008; Deng, 2010; Volpe et  al., 2011).
GLUTAMATE EXCITOTOXICITY IN THE 
PRETERM BRAIN
Glutamate Homeostasis and Dysregulation
Glutamate is the main excitatory neurotransmitter in the 
mammalian brain (Meldrum, 2000). It is essential for brain 
function, orchestrating not only fast excitatory 
neurotransmission but also long-lasting neuronal changes 
necessary for memory, learning, and cognition. It is also 
fundamental during brain development, due to its role in 
regulating formation and elimination of synapses, as well 
as neuronal migration, proliferation, and viability. Glutamate 
is abundant inside the brain cells, and most neurons and 
glial cells have glutamate receptors distributed across most 
cellular elements, highlighting the importance of glutamatergic 
systems for normal function (Curtis and Johnston, 1974; 
Watkins and Evans, 1981; Bliss and Collingridge, 1993; 
Newcomer et  al., 2000; Platt, 2007). Stimulation of a 
glutamatergic neuron results in Ca2+-dependent release of 
glutamate in the synapse by vesicular exocytosis. Extracellular 
glutamate binds to and activates post-synaptic ionotropic 
(NMDA, AMPA, and kainate receptors) and metabotropic 
(mGluR) glutamate receptors, stimulating the post-synaptic 
neurons via Ca2+ or Na+ influx and inducing intracellular 
signaling cascades that lead to physiological cellular responses, 
such as regulation of transcription factors and DNA replication 
(Nicholls and Attwell, 1990; Danbolt, 2001).
Glutamatergic transmission is terminated when glutamate 
transporters, expressed predominantly by astrocytes, slowly take 
up glutamate from the synaptic space (30 glutamate molecules 
per second at Vmax) (Otis and Kavanaugh, 2000; Bergles et  al., 
2002; Grewer and Rauen, 2005; Takahashi et  al., 2015). In the 
preterm brain, glutamate transporters are also expressed by 
immature neurons and oligodendrocytes, although their significance 
is controversial, as reviewed below. In astrocytes, glutamate is 
converted to glutamine via glutamine synthetase. Glutamine is 
shuttled back into the pre-synaptic neuron, where it is converted 
into glutamate via glutaminase (Figure 1). The glutamate-glutamine 
cycle is not essential for supplying glutamate for neuronal release 
but is needed for normal glutamatergic transmission (Danbolt, 
2001; Takahashi et  al., 2015; Danbolt et  al., 2016).
The ubiquity of glutamate is a double-edged sword: when 
homeostasis is disrupted, glutamate can turn into a potent 
neurotoxin. If the concentration of glutamate in the extracellular 
space rises above physiological levels, post-synaptic glutamate 
receptors are overactivated. This excessive activation, or 
excitotoxicity, leads to cell death via activation of suicide cell 
programs (apoptosis) (Danbolt, 2001; Sattler and Tymianski, 
2001) (Figure 1). Since it was first proposed in the late 1960s 
(Olney, 1969), the concept of glutamate excitotoxicity has been 
implicated in several adult disorders, both acute (e.g., ischemic 
stroke and traumatic brain injury) and chronic (e.g., amyotrophic 
lateral sclerosis, Alzheimer’s, Parkinson’s, major depression, and 
addiction) (Doble, 1999; Takahashi et  al., 2015). Consistently, 
injection of glutamate agonists into the cortex, striatum, and 
A B
FIGURE 1 | The glutamate/glutamine cycle in (A) physiological conditions and (B) excitotoxic conditions in the immature brain. (A) In the mature healthy brain, 
glutamate is released by exocytosis from the pre-synaptic neuronal terminal into the synapse (1), and it binds to post-synaptic ionotropic (NMDA, AMPA, and kainate 
receptors) and metabotropic (mGluR) glutamate receptors, inducing Ca2+-mediated signaling cascades that result in cellular responses (2). Extracellular glutamate is 
taken up primarily by astroglial EAAT2 (3) and converted to glutamine (4), which is shuttled back to the pre-synaptic terminal via glutamine transporters (5). Here, 
glutamine is converted back to glutamate (6). (B) During excitotoxicity, a combination of increased neuronal release and decreased astroglial uptake lead to a rise of 
extracellular glutamate levels, leading to overactivation of the post-synaptic glutamate receptors, Ca2+ overload, and activation of apoptotic pathways. Reversal of 
transport of astroglial transporters may also contribute to the accumulation of extracellular glutamate. In the immature brain, upregulation of the glutamate 
transporters in underdeveloped neurons and oligodendrocytes may contribute to their selective vulnerability.
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periventricular white matter of newborn rodents, rabbits, and 
kittens produces patterns of perinatal brain injuries similar to 
those seen in humans (McDonald et  al., 1988; Innocenti and 
Berbel, 1991a,b; Marret et  al., 1995; Gressens et  al., 1996; 
Acarin et  al., 1999; Follett et  al., 2000). On the other hand, 
pharmacological inhibition of glutamate receptors before or 
immediately after an hypoxic-ischemic insult is neuroprotective 
in both preterm (Follett et  al., 2004; Manning et  al., 2008) 
and term (Hagberg et  al., 1994; Follett et  al., 2000) brain 
injuries. Indeed, one of the mechanisms through which 
magnesium sulfate is thought to exert neuroprotection is by 
preventing excitotoxic damage through NMDA receptor blockade 
(Lingam and Robertson, 2018).
In vivo Evidence of Glutamate Excitotoxicity
Evidence of in vivo disturbance of glutamate signaling has 
been produced for animal models of hypoxic-ischemic brain 
injury. In a rat model of mild white matter injury near term, 
a rise in extracellular glutamate is observed in the acute phase 
after hypoxia-ischemia, with oligodendrocytes and axons 
representing the major sources of extracellular glutamate and 
astrocytes failing to take up excess glutamate (Back et  al., 
2007a). Similarly, repeated umbilical cord occlusion in the 
near-term fetal sheep causes periventricular white matter injury, 
the extent of which correlates with extracellular local glutamate 
levels (Loeliger et  al., 2003). Notably, the largest increase in 
glutamate occurred over the hours after the insult, a delayed 
increase that suggested impaired glutamate transport. In a piglet 
model of hypoxic-ischemic encephalopathy at term, glutamate 
levels in the basal ganglia were shown to change in two phases: 
an early increase in the first 6  hours was followed by transient 
and slight recovery by 12  hours, possibly due to the self-
protective glutamate transport mechanisms and conversion to 
glutamine in astrocytes; a further increase occurred after a 
day, possibly through cells bursting due to reperfusion injury 
and reversal of glutamate transport in the late stages of disease 
(Dang et  al., 2017). In humans, elevated glutamate levels have 
been reported in the cerebrospinal fluid and basal ganglia of 
asphyxiated newborns (Riikonen et  al., 1992; Hagberg et  al., 
1993). Moreover, elevated glutamine levels have been found 
in MRI-defined punctate necrotic white matter lesions (Wisnowski 
et al., 2013). Glutamate is taken up into astrocytes for conversion 
into glutamine and shuttling back to neurons. The finding of 
elevated glutamine rather than glutamate may be  due at least 
in part to the temporal lag between insult and measurement. 
An important limitation of in vivo glutamate measurements 
in preterm newborns is that the peak window of glutamate 
changes is probably missed, because magnetic resonance 
measurements are likely to be  carried out long after the initial 
insults in newborns that have already become sick. As such, 
these findings suggest that disrupted glutamate homeostasis 
persists in the subacute phase in moderate necrotic white matter 
injury. Although a relatively small subset of the newborns 
with punctate lesions also had evidence of cysts, no studies 
to date have measured glutamatergic metabolism specifically 
in newborns with severe cystic white matter injury.
Glutamate Excitotoxicity Following 
Hypoxia-Ischemia
Glutamate homeostasis can be  disrupted by an acute hypoxic-
ischemic event, and the phases of the subsequent excitotoxic 
injury are well described. During the primary energy failure, 
oxygen and blood deprivation lead to impairment of ATP 
production due to failure of oxidative phosphorylation. Astrocytes, 
with their unique oxidative capacity and ability to upregulate 
ATP production, are central to maintaining energy metabolism 
during the first stage of ischemia (Dienel and Hertz, 2005). 
Impairment of the ATP-dependent Na+/K+ pumps leads to loss 
of the electrochemical gradient across the cell membrane. If the 
insult is severe, some cells may die at this early stage via necrosis, 
due to influx of ions and water, cell swelling, and bursting. 
Within hours, the necrotic injury due to severe energy failure 
leads to death of all cellular elements and develops into the 
white matter cysts (Back, 2017). Depolarization of the cell 
membrane activates Ca2+ channels in the pre-synaptic terminal, 
triggering vesicular release of glutamate in the synapse. In 
astrocytes, hypoxia-ischemia leads to a failure in the astrocytic 
glutamate uptake system, which also relies on Na+/K+ gradients. 
The combination of increased synaptic release and reduced 
astrocytic uptake leads to accumulation of glutamate in the 
synaptic space and overactivation of post-synaptic ionotropic and 
metabotropic glutamate receptors (Volpe, 2008). The subsequent 
intracellular Ca2+ influx triggers activation of phospholipases, 
endonucleases, proteases, and nitric oxide synthase, with 
degradation of cellular and extracellular structures, and generation 
of harmful free radicals and reactive oxygen and nitrogen species. 
Glutamate leaking outside the synapse activates extrasynaptic 
NMDA receptors, which, contrarily to the pro-survival action 
of synaptic NMDA receptors, promotes excitotoxic cell death 
even further (Parsons and Raymond, 2014). This excitotoxic-
oxidative cascade eventually leads to cell damage or death via 
necrosis, apoptosis, and autophagy in the secondary phase of 
injury (Olney, 1969; Benveniste et  al., 1984; McDonald and 
Johnston, 1990; Choi, 1992; Thornton et  al., 2012; Back, 2017; 
Descloux et  al., 2018) (Figure 1).
Glutamate Excitotoxicity Following 
Inflammation
In preterm brain injury, comorbidities stimulating inflammation 
are thought to contribute to disruption of glutamate homeostasis 
and potentiation of excitotoxicity. TNFα, for example, is one of 
the most studied cytokines and is emerging as a key link between 
inflammation and glutamate excitotoxicity (Olmos and Llado, 
2014). TNFα has both neuroprotective and neurotoxic effects 
depending on the different signaling pathways activated by the 
different receptors. In fact, pharmacological inhibition or genetic 
deletion after a combined inflammatory and excitotoxic insult 
is neuroprotective (Aden et  al., 2010; Kendall et  al., 2011), but 
knocking out TNFα receptors in the mouse increases susceptibility 
to hypoxic-ischemic injury (Bruce et al., 1996). TNFα potentiates 
glutamate excitotoxicity in vitro via complex and interacting 
mechanisms involving crosstalk between neurons and glial cells 
and leading to vicious cycles of glutamate and cytokine release. 
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In neurons, TNFα increases the excitatory strength at the synapse 
by increasing cell surface expression of glutamate receptors and 
their permeability to Ca2+, while also decreasing expression of 
inhibitory GABAA receptors (Olmos and Llado, 2014). In microglia, 
TNFα stimulates autocrine release of TNFα and glutamate by 
upregulating glutaminase and from hemichannels of gap junctions 
(Takeuchi et al., 2006). In astrocytes, TNFα stimulates glutamate 
release via prostaglandin E2 and exacerbates impairment of 
glutamate transport (Bezzi et  al., 1998). Cheung et  al. (1998) 
suggested that glutamate concentration may be key in determining 
the pathways of cell death, with higher glutamate concentrations 
preferentially triggering necrosis and lower concentrations leading 
to apoptosis. Either way, even transient excess of glutamate can 
start a number of events that ultimately cause death or damage 
of vulnerable cell populations (Ottersen et  al., 1996).
Glutamate Excitotoxicity and Perinatal 
Brain Injuries
The patterns of excitotoxic injury tend to be  different in the 
preterm and term brain. Experimental evidence suggests that 
the main cellular target of excitotoxic injury in the preterm 
brain is pre-oligodendrocytes (Volpe et  al., 2011). Glutamate 
is highly toxic to pre-oligodendrocytes in cell culture and leads 
to cell death via free radical attack (Oka et  al., 1993). The 
white matter in the rat is much more vulnerable to hypoxia-
ischemia at preterm-equivalent age, when pre-oligodendrocytes 
are predominant, than at term-equivalent age, when mature 
oligodendrocytes are the major form (Back et  al., 2002; Craig 
et al., 2003; Dean et al., 2011). Indeed, the patterns of hypoxic-
ischemic white matter injury seem to be  determined primarily 
by the timing of appearance (Buser et  al., 2010) and spatial 
distribution (Riddle et al., 2006) of pre-oligodendrocytes rather 
than severity of ischemia itself. Pre-oligodendrocytes are strikingly 
more vulnerable than immature neurons of the cortex and 
caudate nucleus in moderate global ischemia in the preterm 
fetal sheep (Dean et al., 2013; McClendon et al., 2014). Immature 
neurons are also vulnerable, as NMDA receptors are functionally 
upregulated, more permeable to calcium and less sensitive to 
magnesium block (Jantzie et  al., 2015).
In physiological conditions, the abundance of glutamate 
receptors in the white matter is key during early neuronal 
development, contributing to rapid growth and myelination. 
However, their abundance also confers increased vulnerability 
in excitotoxic conditions (Kaindl et  al., 2009). Indeed, the 
selective vulnerability of subplate neurons compared to cortical 
neurons observed in a preterm model of hypoxia-ischemia 
has been suggested to originate from an increase of glutamate 
receptors in these neurons associated with early maturation 
(McQuillen et  al., 2003). Similarly, it has been suggested that 
selective vulnerability of the deep grey matter and sensorimotor 
cortex in term hypoxic-ischemic encephalopathy could be related 
to peaking NMDA receptor expression and proximity to 
developing glutamatergic circuits (Rocha-Ferreira and Hristova, 
2016). As such, developmental expression of key glutamatergic 
genes in the grey and white matter may contribute to the 
different patterns of excitotoxic injury (Volpe, 2008).
Overall, the potential sources of extracellular glutamate in 
the white matter include pre-oligodendrocytes, astrocytes, 
neurons, ependymal cells, and cells of the choroid plexus (Back 
and Rosenberg, 2014). While therapies targeting excitotoxicity 
have so far mostly focused on glutamate receptor blockade, 
targeting glutamate transport is gathering interest as a potential 
avenue for neuroprotection by counteracting glutamate 
accumulation in the first place (Tilleux and Hermans, 2007; 
Kim et  al., 2011; Fontana, 2015; Takahashi et  al., 2015).
GLUTAMATE TRANSPORT: FOCUS  
ON EAAT2/GLT-1
Maintaining the baseline extracellular glutamate concentrations 
in the nanomolar range is essential to avoid extracellular 
glutamate build-up. The brain has no known enzymatic 
mechanism to metabolize glutamate in the extracellular space, 
and simple diffusion over short distances is thought to bring 
only a minor contribution. Hence, the brain relies substantially 
on intracellular glutamate uptake, and astrocytes provide by 
far the largest contribution to preventing excitotoxicity through 
expression of glutamate transporters (Danbolt, 2001; Tzingounis 
and Wadiche, 2007; Vandenberg and Ryan, 2013). Given their 
crucial role, it is not surprising that expression of astrocytic 
glutamate transporters is constitutively high (Zhou and Danbolt, 
2013). Crosstalk between neurons and glia relies on tightly 
controlled extracellular glutamate homeostasis, and it is becoming 
increasingly evident that neuron-glia interactions are central 
to both the kinetics of glutamatergic synaptic activity in 
physiological (Fontana, 2015) and excitotoxic conditions 
(Carmignoto, 2000). Glutamate is released by astrocytes in 
immature rat optic nerve in ischemia in vitro (Wilke et  al., 
2004). Moreover, glutamate transport has been observed in 
immature axons (Arranz et  al., 2008), and impairment has 
been reported in pre-oligodendrocytes during hypoxia-ischemia, 
providing a potential mechanism of excitotoxic vulnerability 
(Oka et  al., 1993; Domercq et  al., 1999; Fern and Moller, 
2000; Deng et  al., 2003; Desilva et  al., 2007, 2009). The 
importance of glutamate transport to the integrity of 
oligodendrocytes and white matter is supported by evidence 
of extensive excitotoxic injury in oligodendrocytes and axons 
with experimental inhibition of glutamate transport in the optic 
nerve in vivo (Domercq et  al., 2005).
The five members of the excitatory amino acid transporter 
(EAAT) family carry out most of the glutamate clearance in 
the central nervous system (Anderson and Swanson, 2000), 
especially EAAT1 (SLC1A3, rodent orthologue Glast) and EAAT2 
(SLC1A2, rodent orthologue Glt-1) (Bristol and Rothstein, 1996). 
EAAT2 is the major glutamate transporter in the forebrain, 
except in the cerebellum, circumventricular organs, and retina, 
where EAAT1 is prevalent. In physiological conditions, both 
EAAT1 and EAAT2 are expressed predominantly by astrocytes 
and localized to the cellular membrane in the adult brain 
(Danbolt, 2001; Roberts et  al., 2014; Takahashi et  al., 2015). 
The high concentration (1  mg/g rat brain tissue), ubiquity 
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(1% of total CNS protein in the adult brain), and high degree 
of conservation across mammalian species are all indications 
of physiological importance of EAAT2/Glt-1 (Danbolt, 2001; 
Fontana, 2015; Danbolt et al., 2016). Unsurprisingly, it is expressed 
at high density near glutamatergic synapses in developing 
hippocampal astrocytes, with density and vicinity increasing 
with neuronal activity (Benediktsson et  al., 2012). This 
transmembrane transporter carries out glutamate uptake through 
a high affinity energy-dependent process driven by Na+ and 
K+ gradients. Specifically, glutamate and aspartate are 
co-transported inside the brain cells with 3 Na+ and 1 H+ for 
the antiport of 1  K+. EAAT2 is also a selective anion channel, 
transporting Cl− anions during intermediate conformations, 
uncoupled from the flux of glutamate (Fontana, 2015).
Several lines of evidence support the central role of EAAT2 
expression/function in maintaining extracellular glutamate 
homeostasis. Pharmacological inhibition of glutamate transport, 
including EAAT2, leads to rapid extracellular glutamate increase 
in vitro (Jabaudon et  al., 1999) and extended post-synaptic 
activation mediated by NMDA receptors (Lozovaya et al., 1999). 
Genetic deletion of Glt-1 via constitutive knockout in the 
mouse leads to lower body weight, seizures, acute cortical 
injury in the forebrain, and increased mortality from the second/
third postnatal week (Tanaka et  al., 1997). Brain tissue from 
this mouse shows much lower (5%) glutamate transport activity 
than wild-type, suggesting that Glt-1 is responsible for up to 
95% of glutamate transport. This is confirmed by the ability 
of Glt-1 antibodies to remove 90% of the transport activity 
in forebrain tissue (Haugeto et al., 1996). Other Glt-1 knockouts 
have confirmed the obvious phenotype, with lower life span, 
lower body and brain weight, mild loss of CA1 neurons in 
the hippocampus, and severe focal neuronal loss in layer II 
of the neocortex and focal gliosis (Kiryk et  al., 2008). A 
conditional knockout mouse with selective deletion of Glt-1 
reproduces this phenotype while ruling out developmental 
adaptations (Zhou et  al., 2014). Heterozygote knockouts, on 
the other hand, show halved concentrations of Glt-1, but no 
apparent morphological brain changes, despite an increased 
risk of traumatic spinal cord injury (Kiryk et  al., 2008; Lepore 
et  al., 2011). Inhibition with antisense oligonucleotides in vitro 
and in vivo induces a rise in extracellular glutamate, excitotoxic 
injury, and progressive paralysis (Rothstein et  al., 1996). On 
the other hand, selective overexpression in astrocytes is 
neuroprotective during ischemia (Chao et  al., 2010).
Studies of EAAT2 expression point to different patterns 
depending on cell type, region, developmental age, species, 
and methodology used (DeSilva et  al., 2012). In the adult rat, 
Glt-1 is expressed in the forebrain, especially in the hippocampus, 
cortex, striatum, and thalamus as well as in fibrous astrocytes 
in the white matter (Lehre et  al., 1995). The transporter is 
expressed predominantly by astrocytes but also pre-synaptic 
axon terminals in the rodent hippocampus and somatosensory 
cortex (Danbolt, 2001; Chen et  al., 2004; Furness et  al., 2008; 
Melone et  al., 2009; de Vivo et  al., 2010; Danbolt et  al., 2016). 
Neuronal EAAT2 represents no more than 10–20% total EAAT2 
(Furness et  al., 2008; Danbolt et  al., 2016), and while being 
implicated in adult neuropsychiatric disorders (O’Donovan 
et al., 2017), neuronal knockout barely affects total Glt-1 protein 
levels and mouse development (Petr et  al., 2015). Conversely, 
astrocytic knockout leads to a reduction of protein levels to 
a fifth in the forebrain, lower body weight and increased 
epilepsy and mortality.
Developmental Expression of EAAT2
The scenario may be  at least in part different in the preterm 
brain, where transient but more prominent neuronal and 
pre-oligodendrial expression is observed. During development, 
dynamic and species-specific changes in both cellular and 
regional expression have been observed, suggesting that 
glutamate transporters may be both regulated by and involved 
in brain development (e.g., participation in the development 
of the topographic organization). As expected, these changes 
in rodent Glt-1 expression correspond to changes in total 
glutamate uptake activity (Ullensvang et  al., 1997). Briefly, 
Glt-1 expression is low until after birth, except for a transient 
peak of expression in developing axons and oligodendrocytes 
around mid-late gestation. Glt-1 is expressed in vivo in rat 
pre-oligodendrocytes, whereas it is no longer detectable in 
mature oligodendrocytes (DeSilva et  al., 2009). Transient 
neuronal expression is also seen around mid-late gestation 
in the mouse (Sutherland et  al., 1996; Yamada et  al., 1998), 
rat (Furuta et  al., 1997), and sheep (Northington et  al., 1998). 
In the fetal rat, Glt-1 is expressed in the amygdala and 
hippocampus, as well as white matter tracts interconnecting 
neocortex, basal ganglia, and thalamus (Furuta et  al., 1997). 
In the fetal sheep, Glt-1 is found not only in white matter 
tracts but also in neuronal bodies and extended to the subplate, 
cranial nerve nuclei, basal ganglia, and cerebellar cortex, 
highlighting potential species differences in cellular expression 
during development (Furuta et  al., 1997; Northington et  al., 
1998, 1999). In the newborn rat at P1, Glt-1 levels are the 
highest in the spinal cord and moderate in the hippocampus 
and hypothalamus. Expression increases dramatically from the 
second postnatal week throughout the central nervous system, 
especially in the cortex, striatum, caudate nucleus, and 
hippocampus, reaching adult levels by weeks 4–5 (Rothstein 
et  al., 1994; Levy et  al., 1995; Shibata et  al., 1996; Sutherland 
et  al., 1996; Furuta et  al., 1997; Ullensvang et  al., 1997). 
Astrocyte selectivity is established in the postnatal period in 
rodents and around mid-late gestation in sheep (Furuta et  al., 
1997; Takasaki et al., 2008). Nonetheless, Glt-1 is still detected 
in immature axons at P14–17 (Arranz et  al., 2008). The 
significant developmental changes in Glt-1 after birth may 
explain why the Glt-1 knockout mice seem to develop normally 
for the first few weeks and develop seizures and brain injury 
during postnatal week 3, with many dying by week 4 
(Tanaka et  al., 1997; Takasaki et  al., 2008).
A limited number of studies have investigated developmental 
regulation of EAAT2  in humans. DeSilva et  al. (2012) found 
that, among EAAT1–3, expression of EAAT2 undergoes 
particularly prominent maturational changes in post-mortem 
cortex tissue of preterm and term newborns without neurological 
disease, all the way into childhood. Consistent with animal 
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studies, EAAT2 expression is generally low until birth and is 
limited to glia limitans, layer I-III fine astrocytes, and some 
neuron populations. EAAT2 was found not only in axons but 
also in the cell body and dendrites of certain neuron populations 
from as early as 23 gestational weeks up until term and, in 
some cases, until 8 postnatal months. These neuron populations 
are layer V pyramidal neurons, layer I neurons (putative Cajal-
Retzius cells), and subplate neurons (DeSilva et  al., 2012). A 
great proportion of these neuronal populations is glutamatergic, 
and it has been suggested that this transient neuronal EAAT2 
expression is critical for establishing and orchestrating excitatory 
transmission during maturation and migration of cortical 
neurons. Similarly, it could also provide the basis for selective 
vulnerability to premature excitotoxic injury due to expression 
of glutamate transporters, which may reverse transport and 
become sources of extracellular glutamate (Takasaki et al., 2008; 
DeSilva et  al., 2012), as discussed below. This is supported by 
evidence of selective vulnerability of layer V pyramidal neurons 
and subplate neurons in human and rat preterm white matter 
injury (McQuillen et  al., 2003; Andiman et  al., 2010). The 
same group reported EAAT2 expression in pre-oligodendrocytes 
in human fetal white matter at 32  weeks of gestation, during 
the peak time for premature brain injury, but not at 7  months 
old, consistent with rat studies (Desilva et  al., 2007). EAAT2 
expression appeared in the astrocytes of the developing cortex 
at 41 postconceptional weeks, increasing steeply in the first 
1.5  years (DeSilva et  al., 2012). Taken together, these findings 
suggest that the expression of EAAT2/Glt-1 undergoes substantial 
changes during development and that these changes may 
contribute to the selective vulnerability of cellular (e.g., immature 
oligodendrocytes and neurons) and regional (e.g., white matter 
tracts, hippocampus) targets in preterm brain injury.
EAAT2 and Preterm Brain Injury
Following severe energy failure, the dissipation of the 
transmembrane gradient impairs astrocytic EAAT2, which relies 
on transmembrane Na+/K+ gradients. This disruption may involve 
both quantity and quality of transport activity, i.e., it can manifest 
as decreased expression and/or impairment of glutamate transport 
function with establishment of reverse transport. Reverse transport 
has an outward direction and is driven by the transmembrane 
gradient of excitatory amino acids independently of ATP and 
Ca2+ (Nicholls and Attwell, 1990; Szatkowski et  al., 1990; Levi 
and Raiteri, 1993). In this scenario, glutamate transporters 
become themselves a major source of extracellular glutamate, 
potentially turning into key contributors of excitotoxic injury 
in any cells expressing them (Domingues et al., 2010) (Figure 1). 
While its significance to preterm brain injuries remains to 
be  explored, the importance of reverse transport is supported 
by evidence that ischemic cell death in the rat striatum can 
be  blocked by an inhibitor of reverse Glt-1 transport (Seki 
et  al., 1999). Moreover, knockout mice lacking Glt-1 are more 
vulnerable to neuronal death after a short, severe episode of 
ischemia than wild-type mice, suggesting that Glt-1 is essential 
for neuroprotection when ischemia is acute; on the other hand, 
wild-type mice expressing Glt-1 are more vulnerable to neuronal 
death than mice lacking Glt-1 during extended, chronic ischemia, 
suggesting that Glt-1 (via reverse transport) becomes neurotoxic 
when ischemia is prolonged (Mitani and Tanaka, 2003).
Consistent with impairment of glutamate transport, a decrease 
in glutamate uptake is seen in the hippocampus of rat pups 
exposed to intrauterine hypoxia following caesarean delivery 
(Frizzo et  al., 2010) and in the cortex, basal ganglia and 
thalamus of newborn piglets exposed to hypoxia (Jantzie et al., 
2010). Loss of Glt-1 expression and/or function has been 
reported in astrocyte cultures during hypoxia (Dallas et  al., 
2007) as well as in the adult rat cortex and hippocampus after 
ischemia (Torp et  al., 1995; Rao et  al., 2001a,b). In a small 
study of term-equivalent rats, astrocytic Glt-1 was suppressed 
in the initial 12  hours in the ischemic core of both the 
hippocampus and the neocortex, recovered after 48 hours only 
in the hippocampus, followed by astrogliosis at 72  hours 
(Fukamachi et al., 2001). In a piglet model of hypoxic-ischemic 
encephalopathy at term, canonical suppression of Glt-1 in 
astrocytes of the striatum and hippocampus was accompanied 
by upregulation in neurons of the striatum (Martin et  al., 
1997b; Danbolt, 2001; Pow et  al., 2004; Desilva et  al., 2007, 
2012). The striatum is known to be  selectively vulnerable to 
excitotoxicity at term, and this may suggest a potential neuronal 
response to locally increasing extracellular glutamate levels 
(Martin et  al., 1997a). In P6 rats, exposure to hypoxic 
preconditioning led to upregulation of Glt-1  in the cortex and 
suppression in the striatum, with no detectable changes in the 
hippocampus (Cimarosti et al., 2005). Glt-1 was also suppressed 
in the white matter in a preterm mouse model of chronic 
hypoxia, although this model was not subjected to ischemia 
and showed no sign of reactive astrogliosis (Raymond et  al., 
2011). Moreover, hypoxia has been found to alter the expression 
of Glt-1 splice variants in mouse brain and neurons of newborn 
pigs (Munch et  al., 2003; Pow et  al., 2004).
Exposure of mouse astrocytes, rat microglia, and human 
blood macrophages to the bacterial endotoxin lipopolysaccharide 
(LPS) and the pro-inflammatory cytokine TNFα has been found 
to enhance EAAT2 expression and glutamate uptake function 
in vitro (Rimaniol et  al., 2000; Persson et  al., 2005; O’Shea 
et al., 2006). On the other hand, TNFα suppresses both glutamate 
uptake and EAAT2  in a dose-dependent manner (via NF-κB) 
in human fetal astrocytes (Fine et  al., 1996; Liao and Chen, 
2001; Su et  al., 2003). TNFα also selectively suppresses EAAT2 
via NF-κB during hypoxia in vitro (Boycott et  al., 2008).
An important finding is that EAAT2 is upregulated in the 
reactive astrocytes and macrophages of post-mortem human 
brain tissue from preterm babies with white matter injury 
compared to controls, suggesting a possible response to hypoxia-
ischemia and/or inflammation in the preterm brain (Desilva 
et  al., 2008). Pre-oligodendrocytes in both cases and controls 
expressed EAAT2, with no qualitative differences in expression, 
although function was not measured. Upregulation of EAAT2 in 
reactive astrocytes and macrophages in preterm white matter 
injury may be an adaptive mechanism to counteract excitotoxicity, 
or it could be  a secondary mechanism due to gliosis. 
Whether in chronic white matter injury, this upregulation 
contributed to excitotoxicity via transport reversal remains to 
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be  established. Further studies are needed to elucidate how 
perinatal hypoxia-ischemia and infection/inflammation affect 
EAAT2 homeostasis, separately and in combination. Interestingly, 
genome-wide gene expression analysis of reactive astrocytes 
in two adult mouse models of ischemic stroke and LPS-induced 
neuroinflammation revealed that at least half of the altered 
gene expression is specific on the insult, with indication that 
reactive astrocytes may be  neuroprotective in ischemia but 
detrimental in neuroinflammation (Zamanian et  al., 2012). 
Overall, candidacy of EAAT2 is supported by the fact that 
dysregulation is implicated in several neurological, 
neurodegenerative, and psychiatric disorders thought to involve 
glutamate excitotoxicity (i.e., transient cerebral ischemia, 
ischemic stroke, epilepsy, traumatic brain injury, amyotrophic 
lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, chronic 
pain, Huntington’s disease, HIV-associated cognitive disorder, 
glioma, major depression, schizophrenia, and addiction) 
(Danbolt, 2001; Beart and O’Shea, 2007; Fontana, 2015;  
Karki et  al., 2015; Takahashi et  al., 2015; Verkhratsky et  al., 
2016; Zhang et  al., 2016; Zhou et  al., 2016; Goodwani et  al., 
2017; O’Donovan et al., 2017; Assefa et al., 2018; Fogarty, 2018; 
Kim et  al., 2018; Parkin et  al., 2018).
A better understanding of the role of glutamate transport 
in preterm brain injuries will require further investigations of 
EAAT1 in the cerebellum. EAAT1 is highly expressed in cerebellar 
astrocytes, particularly Bergmann’s glia (Lehre et  al., 1995; 
Danbolt, 2001). The processes of these cells ensheath the Purkinje 
cell synapses, which have been suggested to be  selectively 
vulnerable to excitotoxicity induced by hypoxia-ischemia (Harding 
et  al., 1984; Shibata et  al., 1996). Indeed, EAAT1 is 
developmentally upregulated from 23  weeks gestation, possibly 
in conjunction with the maturation of the Purkinje cells. 
Importantly, EAAT1 undergoes rapid changes in hypoxic-ischemic 
encephalopathy at term, with a decrease in the molecular layer 
and an increase in the Purkinje and inner granule cell layer 
at an early stage. This increase becomes marked at a later 
stage, potentially pointing to an adaptive neuroprotective 
mechanism against excitotoxicity (Inage et  al., 1998).
Mechanisms leading to loss of expression and/or function 
are likely to be  complex. Ying’s (1997) “deleterious network 
hypothesis” (1997) suggests that glutamate build-up may lead 
to detrimental vicious cycles. For example, receptor overactivation 
may lead to increased energy consumption and oxidative damage, 
which is known to impair glutamate transporters’ activity and 
expression, potentially leading to reverse transport with further 
glutamate release. Ion flux may cause cell swelling, leading to 
impaired energy metabolism (Danbolt, 2001). Inflammation 
may further potentiate the risks of excitotoxicity via glutamate 
transport suppression, including selective effects on EAAT2 
(Aden et  al., 2010; Kapitanovic Vidak et  al., 2012). Evidence 
to date supports the concept of suicide loops in 
pre-oligodendrocytes, which could provide both the source and 
the target for excitotoxic injury in the preterm brain. In this 
context, the combination of developmental upregulation of 
EAAT2 and establishment of reverse transport in the context 
of an energy failure could increase vulnerability of 
pre-oligodendrocytes to excitotoxic death (Back and Rosenberg, 
2014). Similarly, transient expression in neuronal populations 
could feed into suicide loops and explain the loss of layer V 
pyramidal neurons accompanying necrotic PVL (Andiman et al., 
2010). This is a different mechanism to that hypothesized in 
the mature brain, where the sources of glutamate killing neurons 
are thought to be other cells, including astrocytes and excitatory 
terminals (Lipton and Rosenberg, 1994) or, alternatively, 
retrograde degeneration from axonal injury. Astrocytes may 
have a delayed response due to their unique ability to use 
glycogen as a metabolic fuel during the initial stages of energy 
deprivation. In this scenario, extracellular glutamate 
concentrations may rise significantly only after depletion of 
glycogen stores in astrocytes (Grewer et  al., 2008), with a 
subsequent steep rise in extracellular glutamate and excitotoxic 
cell death (Gouix et  al., 2009). In chronic white matter injury, 
upregulation of astrocytic EAAT2 may be  detrimental when 
accompanied by establishment of reverse transport. Experimental 
data are needed to evaluate these hypotheses.
POTENTIAL FUTURE DEVELOPMENTS
In summary, it is plausible that both up- and downregulation 
of EAAT2 contribute to disease, depending on animal model, 
developmental stage, type and severity of the insult, and 
comorbidities. Regulation and dysregulation of EAAT2 may 
occur at the level of transcription (including epigenetic 
regulation), translation, trafficking, transport, and degradation 
(Karki et al., 2015; Takahashi et al., 2015). Accordingly, treatments 
aiming at restoring EAAT2 expression are a current area of 
research in neuroprotection, alongside enhancement of the 
transport function (Fontana, 2015). Ceftriaxone, a licensed 
β-lactam antibiotic safe and tolerable for humans, enhances 
EAAT2 expression and has been shown to be  neuroprotective 
in animal models of several adult excitotoxic disorders. Although 
no significant effects have been seen in clinical trials for 
amyotrophic lateral sclerosis and adult stroke, it is already 
widely used for the treatment of CNS infections in newborns 
and would therefore be a feasible drug to explore in the context 
of preterm neuroprotection. Guanosine enhances EAAT2 
transport function and has shown neuroprotective effects in 
rat models of hypoxic-ischemic encephalopathy (Moretto et al., 
2005, 2009) and adult cortical focal ischemia, via multiple 
mechanisms including prevention of free radical attack and 
pro-inflammatory response (Hansel et  al., 2014, 2015). Several 
other expression and function enhancers of EAAT2 are currently 
gathering attention as a potential therapeutic approach for a 
variety of adult disorders and await exploration in the context 
of the newborn brain (Fontana, 2015). It is currently unknown 
whether EAAT2 enhancers would restore glutamate uptake or 
exacerbate reverse transport in the preterm brain. Combination 
therapies targeting different mechanisms and therapeutic windows 
will also need exploring, including more established (i.e., 
magnesium sulfate) and more exploratory therapies (e.g., anti-
inflammatory treatment) (Ofek-Shlomai and Berger, 2014).
Genetic risk stratification and pharmacogenomic approaches 
focusing on interindividual differences in treatment response 
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are gathering interest and, as our healthcare systems develop, 
the integration of genomic data in clinical care seems an 
increasingly achievable goal (Rehm, 2017). Exploratory studies 
have implicated several functional genetic variants involved in 
glutamate excitotoxicity and inflammation in neurodevelopmental 
impairment, including as a sequelae of perinatal brain injuries 
(O’Callaghan et al., 2009, 2012, 2013; Wu et al., 2011; Kapitanovic 
Vidak et  al., 2012). Among these, common genetic variants 
altering EAAT2 expression have been reported in association 
with cerebral palsy and neurodevelopmental delay in very 
preterm newborns (Rajatileka et al., 2017). Replication in larger 
samples, genome-wide designs and comparison with term brain 
injuries are needed to consolidate and expand the finding. 
Identification of panels of genetic variants that collectively 
increase risk of injury may be  integrated with other types of 
clinical information and help identify high-risk pregnancies. 
Moreover, integration of genetic information has the potential 
to contribute to a more personalized approach to the care of 
the preterm newborn, with recent studies focusing on the 
interactions between genetic variants and responsiveness to 
antenatal magnesium sulfate therapy (Costantine et  al., 2012; 
Clark et  al., 2018). EAAT2 variants remain to be  evaluated 
in this context.
Future in vivo studies will need to explore whether 
dysregulation of the main glutamate transporter, EAAT2, is 
central to the pathogenesis of preterm brain injuries or if it 
is a secondary process and whether the different cellular effects 
represent destructive or compensatory mechanisms. As explained 
by Danbolt (2001), “as long as one variable is not extreme, 
it will be the combination of several factors that will determine 
whether the ship will sink,” and several different primary events/
changes may share a final common pathway. Well-designed 
animal model studies will be  needed to provide mechanistic 
evidence. Human post-mortem studies can provide insights 
into patterns of dysregulation of expression, function, and 
localization specific to the different types of perinatal brain 
injuries, though limited by confounding factors, post-mortem 
artifacts, reproducibility, and sample size. Promising preliminary 
findings on the neuroprotective effects of EAAT2 suggest that 
this is certainly an avenue worth exploring.
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